{"PMC4004714": [], "cdeec304237d77e5d23d268daedf008099b9ae43": [["\u00bb Fewer barriers to licensure and credentialing would reduce administrative costs and streamline telemedicine implementation across state and institutional boundaries.", [["administrative costs", "TREATMENT", 61, 81], ["streamline telemedicine implementation", "TREATMENT", 86, 124]]]], "PMC7242698": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)3 is a positive-sense RNA virus and the causative agent of coronavirus disease 2019 (COVID-19) (1, 2).", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["SARS-CoV-2)3", "CHEMICAL", 61, 73], ["coronavirus disease", "DISEASE", 131, 150], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2)3", "ORGANISM", 61, 73], ["coronavirus", "ORGANISM", 131, 142], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2)3", "SPECIES", 61, 73], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["a positive-sense RNA virus", "PROBLEM", 77, 103], ["coronavirus disease", "PROBLEM", 131, 150], ["COVID", "TEST", 157, 162], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["coronavirus disease", "OBSERVATION", 131, 150]]], ["Antiviral treatments are urgently needed to relieve the burden on healthcare systems worldwide.", [["Antiviral treatments", "TREATMENT", 0, 20]]], ["Effective therapeutics are expected to reduce mortality and hospitalizations.", [["Effective therapeutics", "TREATMENT", 0, 22]]], ["In the absence of a vaccine, antiviral therapeutics could also be utilized prophylactically to protect vulnerable populations, including those who are frequently exposed to the virus.", [["a vaccine", "TREATMENT", 18, 27], ["antiviral therapeutics", "TREATMENT", 29, 51], ["the virus", "PROBLEM", 173, 182]]], ["Despite the earlier outbreaks of SARS in 2003 and Middle East respiratory syndrome (MERS) in 2012, coronavirus-specific antivirals have yet to advance into clinical trials.", [["SARS", "DISEASE", 33, 37], ["Middle East respiratory syndrome", "DISEASE", 50, 82], ["coronavirus", "ORGANISM", 99, 110], ["SARS", "PROBLEM", 33, 37], ["Middle East respiratory syndrome", "PROBLEM", 50, 82], ["coronavirus", "PROBLEM", 99, 110], ["specific antivirals", "TREATMENT", 111, 130], ["Middle", "ANATOMY_MODIFIER", 50, 56], ["respiratory syndrome", "OBSERVATION", 62, 82]]], ["At this point, the focus is on compounds with a demonstrated broad spectrum of antiviral activities and on drugs developed for other therapeutic purposes with evidence of acting also against coronaviruses.", [["coronaviruses", "ORGANISM", 191, 204], ["antiviral activities", "TREATMENT", 79, 99], ["drugs", "TREATMENT", 107, 112], ["coronaviruses", "PROBLEM", 191, 204], ["antiviral activities", "OBSERVATION", 79, 99]]], ["Several of these compounds are currently being assessed in randomized controlled clinical trials, including remdesivir (RDV; formerly GS-5734) (4).IntroductionRDV is a phosphoramidate prodrug of a 1\u2032-cyano-substituted nucleotide analogue (5).", [["remdesivir", "CHEMICAL", 108, 118], ["RDV", "CHEMICAL", 120, 123], ["GS-5734", "CHEMICAL", 134, 141], ["IntroductionRDV", "CHEMICAL", 147, 162], ["1\u2032-cyano-substituted nucleotide", "CHEMICAL", 197, 228], ["remdesivir", "CHEMICAL", 108, 118], ["RDV", "CHEMICAL", 120, 123], ["GS-5734", "CHEMICAL", 134, 141], ["phosphoramidate", "CHEMICAL", 168, 183], ["1\u2032-cyano-substituted nucleotide", "CHEMICAL", 197, 228], ["remdesivir", "SIMPLE_CHEMICAL", 108, 118], ["1\u2032-cyano-substituted nucleotide", "SIMPLE_CHEMICAL", 197, 228], ["a phosphoramidate prodrug", "TREATMENT", 166, 191], ["compounds", "OBSERVATION", 17, 26]]], ["Its triphosphate form (RDV-TP) resembles ATP and is used as a substrate of several viral RNA-dependent RNA polymerase (RdRp) enzymes or complexes (6\u20139).", [["triphosphate", "CHEMICAL", 4, 16], ["RDV-TP", "CHEMICAL", 23, 29], ["ATP", "CHEMICAL", 41, 44], ["triphosphate", "CHEMICAL", 4, 16], ["RDV-TP", "CHEMICAL", 23, 29], ["ATP", "CHEMICAL", 41, 44], ["triphosphate", "SIMPLE_CHEMICAL", 4, 16], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 23, 29], ["ATP", "SIMPLE_CHEMICAL", 41, 44], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 89, 117], ["RDV", "PROTEIN", 23, 26], ["TP", "PROTEIN", 27, 29], ["viral RNA-dependent RNA polymerase (RdRp) enzymes", "PROTEIN", 83, 132], ["6\u20139", "PROTEIN", 147, 150], ["ATP", "PROBLEM", 41, 44], ["several viral RNA-dependent RNA polymerase", "PROBLEM", 75, 117], ["RdRp) enzymes", "TEST", 119, 132], ["viral RNA", "OBSERVATION", 83, 92]]], ["The compound has shown broad-spectrum in vitro and in vivo antiviral activity against nonsegmented negative-sense RNA viruses of the Filoviridae (e.g. Ebola virus (EBOV)) (5, 8) and Paramyxoviridae (e.g. Nipah virus (NiV)) families (7, 10, 11), as well as in vitro activity against viruses in the Pneumoviridae (e.g. respiratory syncytial virus (RSV)) family (10).", [["Ebola virus (EBOV))", "DISEASE", 151, 170], ["respiratory syncytial virus (RSV))", "DISEASE", 317, 351], ["Filoviridae", "ORGANISM", 133, 144], ["Ebola virus", "ORGANISM", 151, 162], ["EBOV", "ORGANISM", 164, 168], ["Paramyxoviridae", "ORGANISM", 182, 197], ["Nipah virus", "ORGANISM", 204, 215], ["NiV", "ORGANISM", 217, 220], ["Pneumoviridae", "ORGANISM", 297, 310], ["e.g. respiratory syncytial virus", "ORGANISM", 312, 344], ["RSV", "ORGANISM", 346, 349], ["Ebola virus", "SPECIES", 151, 162], ["Nipah virus", "SPECIES", 204, 215], ["respiratory syncytial virus", "SPECIES", 317, 344], ["Ebola virus", "SPECIES", 151, 162], ["EBOV", "SPECIES", 164, 168], ["Nipah virus", "SPECIES", 204, 215], ["NiV", "SPECIES", 217, 220], ["respiratory syncytial virus", "SPECIES", 317, 344], ["RSV", "SPECIES", 346, 349], ["vitro", "TREATMENT", 41, 46], ["the Filoviridae (e.g. Ebola virus", "TREATMENT", 129, 162], ["Paramyxoviridae (e.g. Nipah virus (NiV)", "TREATMENT", 182, 221], ["the Pneumoviridae", "TREATMENT", 293, 310], ["respiratory syncytial virus", "PROBLEM", 317, 344], ["broad", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syncytial", "ANATOMY", 317, 338]]], ["Antiviral activity against a broad spectrum of coronaviruses, including SARS-CoV and MERS-CoV, was subsequently demonstrated both in vitro and in animal models (6, 12\u201315).", [["coronaviruses", "ORGANISM", 47, 60], ["SARS-CoV", "ORGANISM", 72, 80], ["MERS-CoV", "ORGANISM", 85, 93], ["SARS-CoV", "SPECIES", 72, 80], ["MERS-CoV", "SPECIES", 85, 93], ["Antiviral activity", "TREATMENT", 0, 18], ["coronaviruses", "PROBLEM", 47, 60], ["SARS", "PROBLEM", 72, 76], ["coronaviruses", "OBSERVATION", 47, 60]]], ["No in vitro inhibition was reported for several segmented negative-sense RNA viruses of the Arenaviridae family (e.g. Lassa virus (LASV)) and the Bunyavirals order (formerly the family Bunyaviridae; e.g. Crimean Congo hemorrhagic fever virus) (10).", [["Bunyaviridae", "DISEASE", 185, 197], ["Crimean Congo hemorrhagic fever", "DISEASE", 204, 235], ["Arenaviridae", "GENE_OR_GENE_PRODUCT", 92, 104], ["Lassa virus", "ORGANISM", 118, 129], ["LASV", "ORGANISM", 131, 135], ["Crimean Congo hemorrhagic fever virus", "ORGANISM", 204, 241], ["Lassa virus", "SPECIES", 118, 129], ["Congo hemorrhagic fever virus", "SPECIES", 212, 241], ["Lassa virus", "SPECIES", 118, 129], ["LASV", "SPECIES", 131, 135], ["Crimean Congo hemorrhagic fever virus", "SPECIES", 204, 241], ["Lassa virus (LASV)", "TREATMENT", 118, 136], ["Crimean Congo hemorrhagic fever virus", "PROBLEM", 204, 241]]], ["RDV was also recently tested in a randomized controlled trial during the 2019 Ebola outbreak in the Democratic Republic of the Congo (16).", [["RDV", "CHEMICAL", 0, 3], ["Ebola", "DISEASE", 78, 83], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["RDV", "SPECIES", 0, 3]]], ["Although two antibody-based treatments showed superior efficacy, mortality in the RDV arm was lower than the overall mortality rate of the outbreak, and human safety data are now available (16).", [["human", "ORGANISM", 153, 158], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["two antibody", "TEST", 9, 21], ["based treatments", "TREATMENT", 22, 38], ["mortality in the RDV arm", "PROBLEM", 65, 89], ["human safety data", "TEST", 153, 170], ["superior", "OBSERVATION_MODIFIER", 46, 54]]], ["Inhibition of MERS-CoV replication and therapeutic efficacy of RDV was also demonstrated in mouse and rhesus macaque models (13, 15).IntroductionProgress has been made in elucidating the mechanism of action of RDV-TP.", [["RDV", "CHEMICAL", 63, 66], ["RDV", "CHEMICAL", 210, 213], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["RDV", "SIMPLE_CHEMICAL", 63, 66], ["mouse", "ORGANISM", 92, 97], ["macaque", "ORGANISM", 109, 116], ["RDV", "SIMPLE_CHEMICAL", 210, 213], ["RDV", "PROTEIN", 63, 66], ["mouse", "SPECIES", 92, 97], ["rhesus macaque", "SPECIES", 102, 116], ["RDV", "SPECIES", 63, 66], ["mouse", "SPECIES", 92, 97], ["rhesus macaque", "SPECIES", 102, 116], ["MERS", "PROBLEM", 14, 18], ["CoV replication", "TREATMENT", 19, 34], ["RDV", "PROBLEM", 63, 66], ["rhesus macaque", "OBSERVATION", 102, 116]]], ["RDV-TP competes with ATP for incorporation by the EBOV RdRp complex composed of the L protein and VP35 (9).", [["RDV-TP", "CHEMICAL", 0, 6], ["ATP", "CHEMICAL", 21, 24], ["RDV-TP", "CHEMICAL", 0, 6], ["ATP", "CHEMICAL", 21, 24], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 0, 6], ["ATP", "SIMPLE_CHEMICAL", 21, 24], ["EBOV", "ORGANISM", 50, 54], ["VP35", "GENE_OR_GENE_PRODUCT", 98, 102], ["RDV", "PROTEIN", 0, 3], ["TP", "PROTEIN", 4, 6], ["EBOV RdRp complex", "PROTEIN", 50, 67], ["L protein", "PROTEIN", 84, 93], ["VP35 (9)", "PROTEIN", 98, 106], ["ATP", "TREATMENT", 21, 24], ["incorporation", "TREATMENT", 29, 42], ["the L protein and VP35", "TREATMENT", 80, 102]]], ["Steady-state kinetics reveal that incorporation of ATP is slightly more efficient compared with RDV-TP.", [["ATP", "CHEMICAL", 51, 54], ["ATP", "CHEMICAL", 51, 54], ["ATP", "SIMPLE_CHEMICAL", 51, 54], ["incorporation of ATP", "PROBLEM", 34, 54]]], ["In contrast to classic chain terminators, inhibition is not seen immediately following the incorporated RDV-TP, and the existence of a 3\u2032-OH group allows the nucleophilic attack on the next incoming nucleotide.", [["RDV-TP", "CHEMICAL", 104, 110], ["3\u2032-OH", "CHEMICAL", 135, 140], ["nucleotide", "CHEMICAL", 199, 209], ["RDV-TP", "CHEMICAL", 104, 110], ["3\u2032-OH", "CHEMICAL", 135, 140], ["nucleotide", "CHEMICAL", 199, 209], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 104, 110], ["3\u2032-OH", "SIMPLE_CHEMICAL", 135, 140], ["the nucleophilic attack", "PROBLEM", 154, 177], ["not seen", "UNCERTAINTY", 56, 64]]], ["Studies with EBOV RdRp, RSV RdRp, and NiV RdRp have indicated that RNA synthesis is terminated after a few more nucleotide incorporation events (7, 9).", [["nucleotide", "CHEMICAL", 112, 122], ["nucleotide", "CHEMICAL", 112, 122], ["EBOV RdRp", "ORGANISM", 13, 22], ["RSV RdRp", "ORGANISM", 24, 32], ["NiV RdRp", "ORGANISM", 38, 46], ["EBOV RdRp", "PROTEIN", 13, 22], ["RSV RdRp", "PROTEIN", 24, 32], ["NiV RdRp", "PROTEIN", 38, 46], ["EBOV RdRp", "SPECIES", 13, 22], ["RSV", "SPECIES", 24, 27], ["NiV RdRp", "SPECIES", 38, 46], ["Studies", "TEST", 0, 7], ["EBOV RdRp", "TREATMENT", 13, 22], ["RSV RdRp", "TREATMENT", 24, 32], ["NiV RdRp", "TREATMENT", 38, 46], ["RNA synthesis", "PROBLEM", 67, 80], ["a few more nucleotide incorporation events", "PROBLEM", 101, 143], ["EBOV RdRp", "OBSERVATION", 13, 22], ["RSV RdRp", "OBSERVATION", 24, 32], ["NiV RdRp", "OBSERVATION", 38, 46]]], ["RDV-TP incorporation at position i commonly yields delayed chain termination between positions i+3 and i+5.", [["RDV-TP", "CHEMICAL", 0, 6], ["RDV-TP", "CHEMICAL", 0, 6], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 0, 6], ["i+3", "GENE_OR_GENE_PRODUCT", 95, 98], ["RDV", "PROTEIN", 0, 3], ["TP incorporation", "TREATMENT", 4, 20], ["TP incorporation", "OBSERVATION", 4, 20]]], ["We have recently expressed and purified an active complex composed of MERS nonstructural proteins nsp8 and nsp12 (17).", [["MERS", "GENE_OR_GENE_PRODUCT", 70, 74], ["nsp8", "GENE_OR_GENE_PRODUCT", 98, 102], ["nsp12 (17)", "GENE_OR_GENE_PRODUCT", 107, 117], ["MERS nonstructural proteins", "PROTEIN", 70, 97], ["nsp8", "PROTEIN", 98, 102], ["nsp12 (17)", "PROTEIN", 107, 117], ["nsp12", "TEST", 107, 112], ["active", "OBSERVATION_MODIFIER", 43, 49]]], ["With the limitations of steady-state kinetic measurements, we showed that incorporation of RDV-TP is more efficient than ATP, and delayed chain termination is observed specifically at position i+3.", [["RDV-TP", "CHEMICAL", 91, 97], ["ATP", "CHEMICAL", 121, 124], ["RDV-TP", "CHEMICAL", 91, 97], ["ATP", "CHEMICAL", 121, 124], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 91, 97], ["ATP", "SIMPLE_CHEMICAL", 121, 124], ["RDV", "PROTEIN", 91, 94], ["RDV", "TEST", 91, 94], ["TP", "PROBLEM", 95, 97], ["ATP", "TEST", 121, 124], ["delayed chain termination", "PROBLEM", 130, 155], ["more efficient", "OBSERVATION_MODIFIER", 101, 115]]], ["Potential inhibitory effects of RDV-TP on SARS-CoV RdRp or on SARS-CoV-2 RdRp have not been studied.", [["RDV-TP", "CHEMICAL", 32, 38], ["RDV-TP", "CHEMICAL", 32, 38], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 32, 38], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["RdRp", "ORGANISM", 73, 77], ["RDV", "PROTEIN", 32, 35], ["SARS-CoV RdRp", "PROTEIN", 42, 55], ["SARS-CoV-2 RdRp", "DNA", 62, 77], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV-2 RdRp", "SPECIES", 62, 77], ["RDV", "TREATMENT", 32, 35], ["TP", "PROBLEM", 36, 38], ["SARS", "PROBLEM", 42, 46], ["CoV RdRp", "PROBLEM", 47, 55], ["SARS", "PROBLEM", 62, 66], ["CoV-2 RdRp", "TREATMENT", 67, 77]]], ["Active SARS-CoV RdRp was shown to form a complex composed of nsp7, nsp8, and nsp12, whereby nsp7 and nsp8 were connected with a linker (18).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 7, 15], ["nsp7", "GENE_OR_GENE_PRODUCT", 61, 65], ["nsp8", "GENE_OR_GENE_PRODUCT", 67, 71], ["nsp12", "GENE_OR_GENE_PRODUCT", 77, 82], ["nsp7", "GENE_OR_GENE_PRODUCT", 92, 96], ["nsp8", "GENE_OR_GENE_PRODUCT", 101, 105], ["SARS-CoV RdRp", "PROTEIN", 7, 20], ["nsp7", "PROTEIN", 61, 65], ["nsp8", "PROTEIN", 67, 71], ["nsp12", "PROTEIN", 77, 82], ["nsp7", "PROTEIN", 92, 96], ["nsp8", "PROTEIN", 101, 105], ["linker (18)", "PROTEIN", 128, 139], ["SARS-CoV", "SPECIES", 7, 15], ["Active SARS", "PROBLEM", 0, 11], ["CoV RdRp", "PROBLEM", 12, 20], ["a complex composed of nsp7", "PROBLEM", 39, 65], ["nsp8", "PROBLEM", 67, 71], ["nsp12", "PROBLEM", 77, 82], ["nsp8", "PROBLEM", 101, 105], ["SARS", "OBSERVATION", 7, 11], ["CoV RdRp", "OBSERVATION", 12, 20]]], ["Structures of complexes with the three subunits were recently determined using cryo-EM (19).IntroductionHere, we expressed SARS-CoV and SARS-CoV-2 RdRp complexes in insect cells and monitored RNA synthesis on short model primer/templates during elongation.", [["cells", "ANATOMY", 172, 177], ["SARS-CoV", "ORGANISM", 123, 131], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["insect cells", "CELL", 165, 177], ["SARS-CoV and SARS-CoV-2 RdRp complexes", "PROTEIN", 123, 161], ["insect cells", "CELL_TYPE", 165, 177], ["SARS-CoV", "SPECIES", 123, 131], ["cryo-EM", "TEST", 79, 86], ["SARS", "PROBLEM", 123, 127], ["CoV", "TEST", 128, 131], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144], ["RdRp complexes in insect cells", "TREATMENT", 147, 177], ["RNA synthesis", "TREATMENT", 192, 205], ["short model primer/templates", "TREATMENT", 209, 237], ["complexes", "OBSERVATION", 14, 23], ["elongation", "OBSERVATION_MODIFIER", 245, 255]]], ["We demonstrate that RDV-TP inhibits SARS-CoV RdRp and SARS-CoV-2 RdRp with the same potency and mechanism of action.", [["RDV-TP", "CHEMICAL", 20, 26], ["RDV-TP", "CHEMICAL", 20, 26], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 20, 26], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["RdRp", "ORGANISM", 65, 69], ["SARS-CoV RdRp", "PROTEIN", 36, 49], ["SARS-CoV-2 RdRp", "PROTEIN", 54, 69], ["SARS-CoV", "SPECIES", 36, 44], ["RDV", "TEST", 20, 23], ["TP", "TEST", 24, 26], ["SARS", "PROBLEM", 36, 40], ["CoV RdRp", "TREATMENT", 41, 49], ["SARS", "PROBLEM", 54, 58], ["CoV-2 RdRp", "TREATMENT", 59, 69]]], ["The ability to efficiently compete with the natural counterpart ATP is a favorable property of RDV-TP.", [["ATP", "CHEMICAL", 64, 67], ["ATP", "CHEMICAL", 64, 67], ["ATP", "SIMPLE_CHEMICAL", 64, 67], ["RDV", "SIMPLE_CHEMICAL", 95, 98]]], ["We have tested in the same context several other nucleotide analogues and commonly observe that incorporation of the natural nucleotide is considerably preferred.", [["nucleotide", "CHEMICAL", 49, 59], ["nucleotide", "CHEMICAL", 125, 135], ["nucleotide", "CHEMICAL", 49, 59], ["nucleotide", "CHEMICAL", 125, 135], ["nucleotide analogues", "TREATMENT", 49, 69]]], ["Favorable selectivity for the RDV-TP over ATP and delayed chain termination at position i+3 are key elements of a refined mechanism of inhibition observed with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes.Expression of SARS-CoV and SARS-CoV-2 RdRp complexes ::: ResultsWe have recently generated recombinant MERS-CoV RdRp from a bacmid containing nsp5, -7, -8, and -12 (17).", [["RDV-TP", "CHEMICAL", 30, 36], ["ATP", "CHEMICAL", 42, 45], ["RDV-TP", "CHEMICAL", 30, 36], ["ATP", "CHEMICAL", 42, 45], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 30, 36], ["ATP", "SIMPLE_CHEMICAL", 42, 45], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 160, 168], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 170, 178], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 184, 194], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 224, 232], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 237, 247], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 313, 321], ["nsp5", "GENE_OR_GENE_PRODUCT", 352, 356], ["RDV", "PROTEIN", 30, 33], ["TP", "PROTEIN", 34, 36], ["SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes", "PROTEIN", 160, 209], ["SARS-CoV and SARS-CoV-2 RdRp complexes", "PROTEIN", 224, 262], ["recombinant MERS-CoV RdRp", "PROTEIN", 301, 326], ["bacmid containing nsp5, -7, -8, and -12 (17)", "DNA", 334, 378], ["SARS-CoV", "SPECIES", 160, 168], ["MERS-CoV", "SPECIES", 170, 178], ["SARS-CoV", "SPECIES", 224, 232], ["SARS-CoV", "SPECIES", 237, 245], ["MERS-CoV RdRp", "SPECIES", 313, 326], ["the RDV", "TREATMENT", 26, 33], ["TP over ATP", "TREATMENT", 34, 45], ["delayed chain termination", "TREATMENT", 50, 75], ["SARS", "PROBLEM", 160, 164], ["CoV", "TEST", 165, 168], ["MERS", "TEST", 170, 174], ["CoV", "TEST", 175, 178], ["SARS", "TEST", 184, 188], ["CoV", "TEST", 189, 192], ["SARS", "PROBLEM", 224, 228], ["SARS", "PROBLEM", 237, 241], ["SARS", "OBSERVATION", 224, 228]]], ["Expression of this construct in insect cells resulted in the nsp5-7-8-12 polyprotein processed by the nsp5 protease.", [["cells", "ANATOMY", 39, 44], ["insect cells", "CELL", 32, 44], ["nsp5-7-8-12", "GENE_OR_GENE_PRODUCT", 61, 72], ["nsp5 protease", "GENE_OR_GENE_PRODUCT", 102, 115], ["insect cells", "CELL_TYPE", 32, 44], ["nsp5-7-8-12 polyprotein", "PROTEIN", 61, 84], ["nsp5 protease", "PROTEIN", 102, 115], ["this construct in insect cells", "PROBLEM", 14, 44], ["the nsp5-7-8-12 polyprotein", "TREATMENT", 57, 84], ["the nsp5 protease", "TREATMENT", 98, 115]]], ["Nickel-nitrilotriacetic acid affinity chromatography yielded an active binary nsp8/12 RdRp complex.", [["Nickel-nitrilotriacetic acid", "CHEMICAL", 0, 28], ["Nickel-nitrilotriacetic acid", "CHEMICAL", 0, 28], ["Nickel-nitrilotriacetic acid", "SIMPLE_CHEMICAL", 0, 28], ["nsp8/12", "GENE_OR_GENE_PRODUCT", 78, 85], ["nsp8/12 RdRp complex", "PROTEIN", 78, 98], ["Nickel-nitrilotriacetic acid affinity chromatography", "TEST", 0, 52], ["active", "OBSERVATION_MODIFIER", 64, 70], ["binary nsp8/12", "OBSERVATION", 71, 85], ["RdRp complex", "OBSERVATION", 86, 98]]], ["We therefore expressed SARS-CoV and SARS-CoV-2 RdRp from bacmids containing the equivalent nsp5, -7, -8, and -12 sequences.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["SARS-CoV-2", "ORGANISM", 36, 46], ["RdRp", "ORGANISM", 47, 51], ["bacmids", "CANCER", 57, 64], ["nsp5", "GENE_OR_GENE_PRODUCT", 91, 95], ["7", "GENE_OR_GENE_PRODUCT", 98, 99], ["-8", "GENE_OR_GENE_PRODUCT", 101, 103], ["SARS-CoV and SARS-CoV-2 RdRp", "DNA", 23, 51], ["bacmids", "DNA", 57, 64], ["equivalent nsp5, -7, -8, and -12 sequences", "DNA", 80, 122], ["SARS-CoV", "SPECIES", 23, 31], ["SARS-CoV-2 RdRp", "SPECIES", 36, 51], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["bacmids", "TREATMENT", 57, 64]]], ["This approach yielded binary complexes with nsp8 and nsp12, as described previously for MERS-CoV (17).", [["nsp8", "GENE_OR_GENE_PRODUCT", 44, 48], ["nsp12", "GENE_OR_GENE_PRODUCT", 53, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["nsp8", "PROTEIN", 44, 48], ["nsp12", "PROTEIN", 53, 58], ["MERS-CoV", "SPECIES", 88, 96], ["nsp8", "TREATMENT", 44, 48], ["nsp12", "TREATMENT", 53, 58], ["binary complexes", "OBSERVATION", 22, 38]]], ["We also expressed mutant enzymes with amino acid substitutions in the conserved motif C of nsp12 (SDD to SNN) to inactivate the catalytic site (Fig. 1A).", [["amino acid", "CHEMICAL", 38, 48], ["amino acid", "CHEMICAL", 38, 48], ["amino acid", "AMINO_ACID", 38, 48], ["nsp12", "GENE_OR_GENE_PRODUCT", 91, 96], ["mutant enzymes", "PROTEIN", 18, 32], ["nsp12", "PROTEIN", 91, 96], ["SNN", "PROTEIN", 105, 108], ["catalytic site", "PROTEIN", 128, 142], ["Fig. 1A", "PROTEIN", 144, 151], ["mutant enzymes", "TEST", 18, 32], ["amino acid substitutions", "TREATMENT", 38, 62], ["nsp12", "TREATMENT", 91, 96]]], ["WT and mutant enzymes were tested for RNA synthesis on short model primer/templates mimicking a random elongation complex.", [["WT", "ORGANISM", 0, 2], ["mutant enzymes", "PROTEIN", 7, 21], ["random elongation complex", "PROTEIN", 96, 121], ["WT", "TEST", 0, 2], ["mutant enzymes", "TEST", 7, 21], ["RNA synthesis", "PROBLEM", 38, 51], ["short model primer/templates", "PROBLEM", 55, 83], ["a random elongation complex", "PROBLEM", 94, 121]]], ["Incorporation of a radiolabeled nucleotide allows gel-based detection of reaction products.", [["nucleotide", "CHEMICAL", 32, 42], ["nucleotide", "CHEMICAL", 32, 42], ["nucleotide", "SIMPLE_CHEMICAL", 32, 42], ["a radiolabeled nucleotide", "TREATMENT", 17, 42], ["reaction products", "TREATMENT", 73, 90]]], ["Whereas WT SARS-CoV and SARS-CoV-2 RdRp complexes were able to synthesize RNA from a 4-mer primer and a 14-mer template, the corresponding active-site mutants showed no template-base\u2013specific nucleotide incorporation (Fig. 1B).", [["nucleotide", "CHEMICAL", 192, 202], ["nucleotide", "CHEMICAL", 192, 202], ["WT SARS-CoV", "ORGANISM", 8, 19], ["SARS-CoV-2", "ORGANISM", 24, 34], ["RdRp", "ORGANISM", 35, 39], ["WT SARS-CoV and SARS-CoV-2 RdRp complexes", "PROTEIN", 8, 49], ["4-mer primer", "DNA", 85, 97], ["14-mer template", "DNA", 104, 119], ["active-site mutants", "DNA", 139, 158], ["SARS-CoV", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 24, 32], ["WT SARS", "TEST", 8, 15], ["CoV", "TEST", 16, 19], ["SARS", "PROBLEM", 24, 28], ["CoV", "TEST", 29, 32], ["RdRp complexes", "TREATMENT", 35, 49], ["a 4-mer primer", "TREATMENT", 83, 97], ["a 14-mer template", "TREATMENT", 102, 119], ["template-base\u2013specific nucleotide incorporation", "PROBLEM", 169, 216], ["no", "UNCERTAINTY", 166, 168]]], ["These data confirm that RNA synthesis activity is mediated by nsp12.Selectivity measurements of RDV-TP with related and distant RdRp enzymes ::: ResultsThe ratio of Michaelis\u2013Menten steady-state kinetic parameters Vmax/Km for a single incorporation of a natural nucleotide over a nucleotide analogue defines the selectivity.", [["K", "CHEMICAL", 219, 220], ["nucleotide", "CHEMICAL", 262, 272], ["nucleotide", "CHEMICAL", 280, 290], ["RDV-TP", "CHEMICAL", 96, 102], ["nucleotide", "CHEMICAL", 262, 272], ["nucleotide", "CHEMICAL", 280, 290], ["nsp12", "GENE_OR_GENE_PRODUCT", 62, 67], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 96, 102], ["Km", "GENE_OR_GENE_PRODUCT", 219, 221], ["nsp12", "PROTEIN", 62, 67], ["RDV", "PROTEIN", 96, 99], ["RdRp enzymes", "PROTEIN", 128, 140], ["These data", "TEST", 0, 10], ["RNA synthesis activity", "PROBLEM", 24, 46], ["Selectivity measurements", "TEST", 68, 92], ["RDV", "TEST", 96, 99], ["distant RdRp enzymes", "TEST", 120, 140], ["The ratio", "TEST", 152, 161], ["Michaelis", "TEST", 165, 174], ["a natural nucleotide", "TREATMENT", 252, 272], ["distant RdRp", "OBSERVATION", 120, 132]]], ["With the limitations of a steady-state approach, a selectivity value lower than 1 suggests that the analogue is incorporated more efficiently than the natural NTP.", [["NTP", "CHEMICAL", 159, 162], ["NTP", "CHEMICAL", 159, 162], ["NTP", "SIMPLE_CHEMICAL", 159, 162], ["a selectivity value", "TEST", 49, 68]]], ["Conversely, a selectivity value higher than 1 suggests that the analogue is incorporated less efficiently than the natural NTP.", [["NTP", "CHEMICAL", 123, 126], ["NTP", "CHEMICAL", 123, 126], ["NTP", "SIMPLE_CHEMICAL", 123, 126], ["a selectivity value", "TEST", 12, 31], ["the analogue", "PROBLEM", 60, 72]]], ["This approach enables comparisons of data with different enzymes and different nucleotide analogues.", [["nucleotide", "CHEMICAL", 79, 89], ["nucleotide", "CHEMICAL", 79, 89], ["enzymes", "PROTEIN", 57, 64], ["different enzymes", "TEST", 47, 64], ["different nucleotide analogues", "TREATMENT", 69, 99]]], ["This approach does not provide distinct information on inhibitor binding, catalysis, or enzyme dissociation from its nucleic acid substrate.", [["nucleic acid", "CHEMICAL", 117, 129], ["inhibitor binding", "TEST", 55, 72], ["enzyme dissociation", "PROBLEM", 88, 107], ["its nucleic acid substrate", "PROBLEM", 113, 139]]], ["To measure selectivity for RDV-TP incorporation, we determined the steady-state kinetic parameters for single nucleotide incorporations compared with ATP (Fig. S1 and Table 1).", [["RDV-TP", "CHEMICAL", 27, 33], ["nucleotide", "CHEMICAL", 110, 120], ["ATP", "CHEMICAL", 150, 153], ["RDV-TP", "CHEMICAL", 27, 33], ["nucleotide", "CHEMICAL", 110, 120], ["ATP", "CHEMICAL", 150, 153], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 27, 33], ["ATP", "SIMPLE_CHEMICAL", 150, 153], ["RDV-TP incorporation", "TREATMENT", 27, 47], ["single nucleotide incorporations", "PROBLEM", 103, 135], ["ATP (Fig", "TREATMENT", 150, 158]]], ["Previously, we reported a selectivity value of 0.35 for RDV-TP incorporation with MERS-CoV RdRp (17).", [["RDV-TP", "CHEMICAL", 56, 62], ["RDV-TP", "CHEMICAL", 56, 62], ["RDV-TP", "SIMPLE_CHEMICAL", 56, 62], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["MERS-CoV", "SPECIES", 82, 90], ["a selectivity value", "TEST", 24, 43], ["RDV", "TEST", 56, 59], ["TP incorporation", "TREATMENT", 60, 76], ["MERS-CoV RdRp", "TREATMENT", 82, 95]]], ["SARS-CoV and SARS-CoV-2 also showed low values in a similar range (0.32 and 0.26, respectively).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 13, 23], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 0, 4], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["low values", "PROBLEM", 36, 46], ["low values", "OBSERVATION_MODIFIER", 36, 46]]], ["For EBOV, RSV, and LASV enzymes, we measured higher values (4.0, 2.7, and 23, respectively).", [["EBOV", "ORGANISM", 4, 8], ["RSV", "ORGANISM", 10, 13], ["LASV", "ORGANISM", 19, 23], ["EBOV, RSV, and LASV enzymes", "PROTEIN", 4, 31], ["EBOV", "SPECIES", 4, 8], ["RSV", "SPECIES", 10, 13], ["LASV", "SPECIES", 19, 23], ["EBOV", "PROBLEM", 4, 8], ["RSV", "TEST", 10, 13], ["LASV enzymes", "TEST", 19, 31], ["higher", "OBSERVATION_MODIFIER", 45, 51]]], ["Because the RNA template used to measure selectivity in this study differs from the sequence previously used to study inhibition of EBOV and RSV RdRp (9), we repeated these experiments with EBOV and the current RNA template.", [["EBOV", "ORGANISM", 132, 136], ["RSV RdRp", "ORGANISM", 141, 149], ["EBOV", "ORGANISM", 190, 194], ["EBOV", "SPECIES", 132, 136], ["RSV", "SPECIES", 141, 144], ["EBOV", "SPECIES", 190, 194], ["the RNA template", "TREATMENT", 8, 24], ["this study", "TEST", 56, 66], ["EBOV", "PROBLEM", 132, 136], ["RSV RdRp", "TREATMENT", 141, 149], ["EBOV", "TREATMENT", 190, 194], ["the current RNA template", "TREATMENT", 199, 223], ["RSV RdRp", "OBSERVATION", 141, 149]]], ["The observed selectivity value of 4 is in good agreement with our previous measurement of 3.8 (9).", [["our previous measurement", "TEST", 62, 86], ["selectivity", "OBSERVATION_MODIFIER", 13, 24]]], ["LASV RdRp showed the highest selectivity value for RDV-TP of 23-fold, which provides evidence for target specificity.", [["LASV", "ORGANISM", 0, 4], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 51, 57], ["LASV RdRp", "PROTEIN", 0, 9], ["RDV", "PROTEIN", 51, 54], ["LASV", "SPECIES", 0, 4], ["LASV RdRp", "TEST", 0, 9], ["RDV", "TEST", 51, 54], ["TP", "TEST", 55, 57], ["highest selectivity", "OBSERVATION_MODIFIER", 21, 40], ["evidence for", "UNCERTAINTY", 85, 97]]], ["The combined results suggest that the ability of RDV-TP to compete with ATP is most pronounced with the coronavirus RdRp complexes.Selectivity of other nucleotide analogues against SARS-CoV-2 RdRp ::: ResultsWe determined selectivity values for various other nucleotide analogue inhibitors to provide a limited structure-activity relationship analysis with focus on SARS-CoV-2 RdRp (Fig. 2).", [["RDV-TP", "CHEMICAL", 49, 55], ["ATP", "CHEMICAL", 72, 75], ["nucleotide", "CHEMICAL", 152, 162], ["SARS", "DISEASE", 181, 185], ["nucleotide", "CHEMICAL", 259, 269], ["RDV-TP", "CHEMICAL", 49, 55], ["ATP", "CHEMICAL", 72, 75], ["nucleotide", "CHEMICAL", 152, 162], ["nucleotide", "CHEMICAL", 259, 269], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 49, 55], ["ATP", "SIMPLE_CHEMICAL", 72, 75], ["coronavirus RdRp", "ORGANISM", 104, 120], ["SARS-CoV-2", "ORGANISM", 181, 191], ["RdRp", "ORGANISM", 192, 196], ["RDV", "PROTEIN", 49, 52], ["TP", "PROTEIN", 53, 55], ["coronavirus RdRp complexes", "PROTEIN", 104, 130], ["SARS-CoV-2 RdRp", "PROTEIN", 366, 381], ["SARS-CoV", "SPECIES", 181, 189], ["RDV-TP", "TREATMENT", 49, 55], ["ATP", "PROBLEM", 72, 75], ["the coronavirus RdRp complexes", "PROBLEM", 100, 130], ["other nucleotide analogues", "TEST", 146, 172], ["SARS", "PROBLEM", 181, 185], ["various other nucleotide analogue inhibitors", "TREATMENT", 245, 289], ["SARS", "TEST", 366, 370], ["CoV", "TEST", 371, 374], ["most pronounced", "OBSERVATION_MODIFIER", 79, 94], ["coronavirus RdRp", "OBSERVATION", 104, 120]]], ["Selectivity for dATP, which lacks the 2\u2032\u03b1-hydroxyl group, 2\u2032-C-methylated compounds, and the broad-spectrum antivirals favipiravir and ribavirin were included in these studies (Table 2).", [["dATP", "CHEMICAL", 16, 20], ["2\u2032\u03b1-hydroxyl", "CHEMICAL", 38, 50], ["2\u2032-C-methylated", "CHEMICAL", 58, 73], ["favipiravir", "CHEMICAL", 119, 130], ["ribavirin", "CHEMICAL", 135, 144], ["dATP", "CHEMICAL", 16, 20], ["2\u2032\u03b1-hydroxyl", "CHEMICAL", 38, 50], ["2\u2032-C", "CHEMICAL", 58, 62], ["favipiravir", "CHEMICAL", 119, 130], ["ribavirin", "CHEMICAL", 135, 144], ["dATP", "SIMPLE_CHEMICAL", 16, 20], ["2\u2032\u03b1-hydroxyl", "SIMPLE_CHEMICAL", 38, 50], ["2\u2032-C-methylated compounds", "SIMPLE_CHEMICAL", 58, 83], ["favipiravir", "SIMPLE_CHEMICAL", 119, 130], ["ribavirin", "SIMPLE_CHEMICAL", 135, 144], ["dATP", "TEST", 16, 20], ["C-methylated compounds", "TREATMENT", 61, 83], ["the broad-spectrum antivirals favipiravir", "TREATMENT", 89, 130], ["ribavirin", "TREATMENT", 135, 144], ["these studies", "TEST", 162, 175]]], ["A high selectivity value of \u223c950-fold was measured for dATP, which shows that the enzyme efficiently discriminates against dNTPs as one would expect for an RNA polymerase.", [["dATP", "CHEMICAL", 55, 59], ["dNTPs", "CHEMICAL", 123, 128], ["dATP", "CHEMICAL", 55, 59], ["dNTPs", "CHEMICAL", 123, 128], ["dATP", "SIMPLE_CHEMICAL", 55, 59], ["dNTPs", "SIMPLE_CHEMICAL", 123, 128], ["RNA polymerase", "PROTEIN", 156, 170], ["A high selectivity value", "TEST", 0, 24], ["dATP", "TEST", 55, 59], ["the enzyme", "TEST", 78, 88], ["dNTPs", "TREATMENT", 123, 128], ["an RNA polymerase", "PROBLEM", 153, 170], ["high selectivity", "OBSERVATION_MODIFIER", 2, 18]]], ["Similarly, the 2\u2032\u03b2-hydroxyl in ara-ATP also translates in a high selectivity value (>1000-fold).", [["2\u2032\u03b2-hydroxyl", "CHEMICAL", 15, 27], ["ara-ATP", "CHEMICAL", 31, 38], ["2\u2032\u03b2-hydroxyl", "CHEMICAL", 15, 27], ["2\u2032\u03b2-hydroxyl", "SIMPLE_CHEMICAL", 15, 27], ["ara-ATP", "SIMPLE_CHEMICAL", 31, 38], ["high selectivity", "OBSERVATION_MODIFIER", 60, 76]]], ["2\u2032-CMe-ATP contains a 2\u2032\u03b2-methyl group, which shows a value of \u223c170.", [["2\u2032-CMe", "CHEMICAL", 0, 6], ["ATP", "CHEMICAL", 7, 10], ["2\u2032\u03b2-methyl", "CHEMICAL", 22, 32], ["2\u2032-CMe-ATP", "CHEMICAL", 0, 10], ["2\u2032\u03b2-methyl", "CHEMICAL", 22, 32], ["2\u2032-CMe-ATP", "SIMPLE_CHEMICAL", 0, 10], ["2\u2032\u03b2-methyl", "SIMPLE_CHEMICAL", 22, 32], ["ATP", "TEST", 7, 10]]], ["2-Deoxy-2\u2032fluoro-CTP has been shown to exhibit antiviral activity against several RNA viruses (20\u201323).", [["2-Deoxy-2\u2032fluoro-CTP", "CHEMICAL", 0, 20], ["2-Deoxy-2\u2032fluoro-CTP", "CHEMICAL", 0, 20], ["2-Deoxy-2\u2032fluoro-CTP", "SIMPLE_CHEMICAL", 0, 20], ["Deoxy", "TEST", 2, 7], ["CTP", "PROBLEM", 17, 20], ["antiviral activity", "TREATMENT", 47, 65], ["several RNA viruses", "PROBLEM", 74, 93]]], ["The selectivity value of 25 is relatively low compared with the aforementioned compounds and suggests that the 2\u2032\u03b1-fluoro is largely tolerated by the enzyme.", [["2\u2032\u03b1-fluoro", "CHEMICAL", 111, 121], ["2\u2032\u03b1-fluoro", "CHEMICAL", 111, 121], ["2\u2032\u03b1-fluoro", "SIMPLE_CHEMICAL", 111, 121], ["enzyme", "PROTEIN", 150, 156], ["The selectivity value", "TEST", 0, 21], ["the 2\u2032\u03b1-fluoro", "TREATMENT", 107, 121], ["the enzyme", "TEST", 146, 156], ["selectivity", "OBSERVATION_MODIFIER", 4, 15], ["relatively", "OBSERVATION_MODIFIER", 31, 41], ["low", "OBSERVATION", 42, 45]]], ["Sofosbuvir (SOF) is a uridine analogue that is approved for the treatment of hepatitis C virus (HCV) infection.", [["Sofosbuvir", "CHEMICAL", 0, 10], ["uridine", "CHEMICAL", 22, 29], ["hepatitis C virus (HCV) infection", "DISEASE", 77, 110], ["Sofosbuvir", "CHEMICAL", 0, 10], ["uridine", "CHEMICAL", 22, 29], ["Sofosbuvir", "SIMPLE_CHEMICAL", 0, 10], ["SOF", "SIMPLE_CHEMICAL", 12, 15], ["uridine", "SIMPLE_CHEMICAL", 22, 29], ["hepatitis C virus", "ORGANISM", 77, 94], ["HCV", "ORGANISM", 96, 99], ["hepatitis C virus", "SPECIES", 77, 94], ["hepatitis C virus", "SPECIES", 77, 94], ["HCV", "SPECIES", 96, 99], ["Sofosbuvir (SOF)", "TREATMENT", 0, 16], ["a uridine analogue", "TREATMENT", 20, 38], ["hepatitis C virus (HCV) infection", "PROBLEM", 77, 110], ["hepatitis", "OBSERVATION", 77, 86], ["infection", "OBSERVATION", 101, 110]]], ["The drug inhibits HCV RdRp (24).", [["HCV RdRp", "ORGANISM", 18, 26], ["HCV", "SPECIES", 18, 21], ["The drug inhibits HCV RdRp", "TREATMENT", 0, 26]]], ["It contains a fluoro group at the 2\u2032\u03b1-position and a methyl group at the 2\u2032\u03b2-position.", [["fluoro", "CHEMICAL", 14, 20], ["methyl", "CHEMICAL", 53, 59], ["fluoro", "CHEMICAL", 14, 20], ["methyl", "CHEMICAL", 53, 59], ["methyl", "SIMPLE_CHEMICAL", 53, 59], ["2\u2032\u03b1-position", "PROTEIN", 34, 46], ["2\u2032\u03b2-position", "PROTEIN", 73, 85], ["a fluoro group", "TREATMENT", 12, 26], ["a methyl group", "TREATMENT", 51, 65]]], ["Here we measured a high selectivity value (\u223c1000-fold), which suggests that the 2\u2032\u03b2-position may be the primary constraint for nucleotide incorporation by SARS-CoV-2 RdRp.", [["nucleotide", "CHEMICAL", 127, 137], ["nucleotide", "CHEMICAL", 127, 137], ["nucleotide", "SIMPLE_CHEMICAL", 127, 137], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 155, 165], ["2\u2032\u03b2", "PROTEIN", 80, 83], ["SARS-CoV-2 RdRp", "PROTEIN", 155, 170], ["a high selectivity value", "PROBLEM", 17, 41], ["nucleotide incorporation", "PROBLEM", 127, 151], ["SARS", "TEST", 155, 159], ["CoV", "TEST", 160, 163], ["high selectivity", "OBSERVATION_MODIFIER", 19, 35]]], ["The active triphosphate forms of favipiravir and ribavirin serve as substrates for several RdRp enzymes and mimic ATP and GTP (25\u201330).", [["triphosphate", "CHEMICAL", 11, 23], ["favipiravir", "CHEMICAL", 33, 44], ["ribavirin", "CHEMICAL", 49, 58], ["ATP", "CHEMICAL", 114, 117], ["GTP", "CHEMICAL", 122, 125], ["triphosphate", "CHEMICAL", 11, 23], ["favipiravir", "CHEMICAL", 33, 44], ["ribavirin", "CHEMICAL", 49, 58], ["ATP", "CHEMICAL", 114, 117], ["GTP", "CHEMICAL", 122, 125], ["triphosphate", "SIMPLE_CHEMICAL", 11, 23], ["favipiravir", "SIMPLE_CHEMICAL", 33, 44], ["ribavirin", "SIMPLE_CHEMICAL", 49, 58], ["ATP", "SIMPLE_CHEMICAL", 114, 117], ["GTP", "SIMPLE_CHEMICAL", 122, 125], ["RdRp enzymes", "PROTEIN", 91, 103], ["favipiravir", "TREATMENT", 33, 44], ["ribavirin", "TREATMENT", 49, 58], ["several RdRp enzymes", "TEST", 83, 103], ["ATP", "TEST", 114, 117], ["GTP", "TEST", 122, 125], ["active", "OBSERVATION_MODIFIER", 4, 10], ["triphosphate forms", "OBSERVATION", 11, 29]]], ["To compare efficiency of incorporation with RDV-TP, we measured selectivity values for incorporation opposite template uridine.", [["RDV-TP", "CHEMICAL", 44, 50], ["uridine", "CHEMICAL", 119, 126], ["RDV-TP", "CHEMICAL", 44, 50], ["uridine", "CHEMICAL", 119, 126], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 44, 50], ["uridine", "SIMPLE_CHEMICAL", 119, 126], ["incorporation", "PROBLEM", 25, 38], ["RDV", "PROBLEM", 44, 47], ["TP", "TREATMENT", 48, 50], ["incorporation opposite template uridine", "TREATMENT", 87, 126]]], ["High values of \u223c500 and \u226b1000, respectively, indicate that effective competition of these compounds with ATP is unlikely.Structural model of nucleotide binding by SARS-CoV-2 RdRp ::: ResultsTo provide plausible explanations for our experimental measurements, we generated a model of an elongating SARS-CoV-2 RdRp complex (Fig. 3).", [["ATP", "CHEMICAL", 105, 108], ["nucleotide", "CHEMICAL", 141, 151], ["SARS", "DISEASE", 297, 301], ["ATP", "CHEMICAL", 105, 108], ["nucleotide", "CHEMICAL", 141, 151], ["ATP", "SIMPLE_CHEMICAL", 105, 108], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 297, 307], ["SARS-CoV-2 RdRp", "DNA", 163, 178], ["elongating SARS-CoV-2 RdRp complex", "PROTEIN", 286, 320], ["Fig. 3", "PROTEIN", 322, 328], ["High values", "TEST", 0, 11], ["ATP", "PROBLEM", 105, 108], ["our experimental measurements", "TEST", 228, 257], ["an elongating SARS", "PROBLEM", 283, 301]]], ["This model is based on the cryo-EM structure of the apo SARS-Co RdRp complex composed of nsp7, nsp8, and nsp12 (19).", [["apo", "GENE_OR_GENE_PRODUCT", 52, 55], ["nsp7", "GENE_OR_GENE_PRODUCT", 89, 93], ["nsp8", "GENE_OR_GENE_PRODUCT", 95, 99], ["nsp12", "GENE_OR_GENE_PRODUCT", 105, 110], ["apo SARS-Co RdRp complex", "PROTEIN", 52, 76], ["nsp7", "PROTEIN", 89, 93], ["nsp8", "PROTEIN", 95, 99], ["nsp12 (19)", "PROTEIN", 105, 115], ["the apo SARS", "PROBLEM", 48, 60], ["Co RdRp complex", "PROBLEM", 61, 76], ["nsp7", "TEST", 89, 93], ["nsp8", "TEST", 95, 99], ["nsp12", "TEST", 105, 110]]], ["The active site is similar to other enzymes, for which ternary structures have been determined by X-ray crystallography, including HCV RdRp (Fig. 3A), norovirus, and poliovirus RdRp (24, 31, 32).", [["Fig. 3A", "GENE_OR_GENE_PRODUCT", 141, 148], ["norovirus", "ORGANISM", 151, 160], ["poliovirus RdRp", "ORGANISM", 166, 181], ["enzymes", "PROTEIN", 36, 43], ["HCV RdRp", "PROTEIN", 131, 139], ["poliovirus RdRp", "PROTEIN", 166, 181], ["HCV", "SPECIES", 131, 134], ["poliovirus RdRp", "SPECIES", 166, 181], ["other enzymes", "TEST", 30, 43], ["X-ray crystallography", "TEST", 98, 119], ["HCV RdRp", "PROBLEM", 131, 139], ["norovirus", "PROBLEM", 151, 160], ["poliovirus RdRp", "TREATMENT", 166, 181], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION", 11, 15], ["norovirus", "OBSERVATION", 151, 160], ["poliovirus RdRp", "OBSERVATION", 166, 181]]], ["The catalytic metal ions in SARS-CoV-2 nsp12 are coordinated by a trio of aspartates, Asp-618, Asp-760, and Asp-761, and the substrate \u03b2-phosphate is stabilized by Arg-555.", [["Asp-618", "CHEMICAL", 86, 93], ["Asp-760", "CHEMICAL", 95, 102], ["Asp-761", "CHEMICAL", 108, 115], ["\u03b2-phosphate", "CHEMICAL", 135, 146], ["Arg-555", "CHEMICAL", 164, 171], ["aspartates", "CHEMICAL", 74, 84], ["Asp", "CHEMICAL", 86, 89], ["Asp", "CHEMICAL", 95, 98], ["Asp-761", "CHEMICAL", 108, 115], ["\u03b2-phosphate", "CHEMICAL", 135, 146], ["Arg-555", "CHEMICAL", 164, 171], ["SARS-CoV-2 nsp12", "GENE_OR_GENE_PRODUCT", 28, 44], ["aspartates", "SIMPLE_CHEMICAL", 74, 84], ["Asp-618", "SIMPLE_CHEMICAL", 86, 93], ["Asp-760", "AMINO_ACID", 95, 102], ["Asp-761", "AMINO_ACID", 108, 115], ["substrate \u03b2-phosphate", "SIMPLE_CHEMICAL", 125, 146], ["Arg-555", "SIMPLE_CHEMICAL", 164, 171], ["The catalytic metal ions", "TREATMENT", 0, 24], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["Asp", "TEST", 86, 89], ["Asp", "TEST", 95, 98], ["Asp", "TEST", 108, 111], ["the substrate \u03b2-phosphate", "TEST", 121, 146], ["metal ions", "OBSERVATION", 14, 24]]], ["Converting Asp-760 and Asp-761 into Asn-760 and Asn-761 rendered the enzyme inactive (Fig. 1).", [["Asp-760", "CHEMICAL", 11, 18], ["Asp-761", "CHEMICAL", 23, 30], ["Asn-760", "CHEMICAL", 36, 43], ["Asn-761", "CHEMICAL", 48, 55], ["Asp-760", "CHEMICAL", 11, 18], ["Asp-761", "CHEMICAL", 23, 30], ["Asn", "CHEMICAL", 36, 39], ["Asn-761", "CHEMICAL", 48, 55], ["Asp-760", "AMINO_ACID", 11, 18], ["Asp-761", "AMINO_ACID", 23, 30], ["Asn-760", "AMINO_ACID", 36, 43], ["Asn-761", "AMINO_ACID", 48, 55], ["Converting Asp", "TEST", 0, 14], ["Asp", "TEST", 23, 26], ["Asn", "TEST", 36, 39], ["Asn", "TEST", 48, 51], ["the enzyme", "TEST", 65, 75]]], ["Of particular note, the residues Asp-623, Ser-682, and Asn-691 involved in 2\u2032-OH recognition of the incoming nucleotide are conserved.", [["Asp-623", "CHEMICAL", 33, 40], ["Asn-691", "CHEMICAL", 55, 62], ["2\u2032-OH", "CHEMICAL", 75, 80], ["nucleotide", "CHEMICAL", 109, 119], ["Asp", "CHEMICAL", 33, 36], ["Ser", "CHEMICAL", 42, 45], ["Asn", "CHEMICAL", 55, 58], ["2\u2032-OH", "CHEMICAL", 75, 80], ["nucleotide", "CHEMICAL", 109, 119], ["Asp-623", "AMINO_ACID", 33, 40], ["Ser-682", "AMINO_ACID", 42, 49], ["Asn-691", "AMINO_ACID", 55, 62], ["2\u2032-OH", "SIMPLE_CHEMICAL", 75, 80], ["the residues Asp", "TEST", 20, 36], ["Ser", "TEST", 42, 45], ["Asn", "TEST", 55, 58]]], ["However, whereas HCV, norovirus, and poliovirus RdRps use these serine and asparagine residues to coordinate the 2\u2032-OH during incorporation, nsp12 appears to rely on an additional threonine residue (Thr-680) not present in the others enzymes (Fig. 3B).", [["asparagine", "CHEMICAL", 75, 85], ["2\u2032-OH", "CHEMICAL", 113, 118], ["nsp12", "CHEMICAL", 141, 146], ["threonine", "CHEMICAL", 180, 189], ["Thr-680", "CHEMICAL", 199, 206], ["serine", "CHEMICAL", 64, 70], ["asparagine", "CHEMICAL", 75, 85], ["2\u2032-OH", "CHEMICAL", 113, 118], ["threonine", "CHEMICAL", 180, 189], ["Thr", "CHEMICAL", 199, 202], ["HCV, norovirus", "ORGANISM", 17, 31], ["poliovirus RdRps", "ORGANISM", 37, 53], ["serine", "AMINO_ACID", 64, 70], ["asparagine", "AMINO_ACID", 75, 85], ["2\u2032-OH", "SIMPLE_CHEMICAL", 113, 118], ["nsp12", "GENE_OR_GENE_PRODUCT", 141, 146], ["Thr-680", "AMINO_ACID", 199, 206], ["nsp12", "PROTEIN", 141, 146], ["enzymes", "PROTEIN", 234, 241], ["Fig. 3B", "PROTEIN", 243, 250], ["HCV", "SPECIES", 17, 20], ["norovirus", "SPECIES", 22, 31], ["poliovirus", "SPECIES", 37, 47], ["HCV", "PROBLEM", 17, 20], ["norovirus", "PROBLEM", 22, 31], ["poliovirus RdRps", "TREATMENT", 37, 53], ["these serine", "TREATMENT", 58, 70], ["asparagine residues", "PROBLEM", 75, 94], ["an additional threonine residue", "TREATMENT", 166, 197], ["norovirus", "OBSERVATION", 22, 31]]], ["This interaction has the effect of pulling the substrate deeper into the pocket.", [["pocket", "OBSERVATION_MODIFIER", 73, 79]]], ["The lower positioning of the NTP in the active site is also seen in the interaction of the 3\u2032-OH with the protein.", [["NTP", "CHEMICAL", 29, 32], ["3\u2032-OH", "CHEMICAL", 91, 96], ["NTP", "CHEMICAL", 29, 32], ["3\u2032-OH", "CHEMICAL", 91, 96], ["NTP", "SIMPLE_CHEMICAL", 29, 32], ["3\u2032-OH", "SIMPLE_CHEMICAL", 91, 96], ["the NTP", "TREATMENT", 25, 32], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["positioning", "OBSERVATION_MODIFIER", 10, 21], ["NTP", "OBSERVATION", 29, 32], ["active", "OBSERVATION_MODIFIER", 40, 46], ["site", "OBSERVATION", 47, 51]]], ["In HCV RdRp, 3\u2032-OH forms a hydrogen bond to the Asp-225 backbone NH, whereas in the coronaviruses, the model instead suggests that the \u03b2-phosphate coordinates to the analogous Asp-623 NH.", [["3\u2032-OH", "CHEMICAL", 13, 18], ["Asp-225", "CHEMICAL", 48, 55], ["\u03b2-phosphate", "CHEMICAL", 135, 146], ["Asp-623 NH", "CHEMICAL", 176, 186], ["3\u2032-OH", "CHEMICAL", 13, 18], ["hydrogen", "CHEMICAL", 27, 35], ["Asp", "CHEMICAL", 48, 51], ["NH", "CHEMICAL", 65, 67], ["\u03b2-phosphate", "CHEMICAL", 135, 146], ["Asp", "CHEMICAL", 176, 179], ["NH", "CHEMICAL", 184, 186], ["HCV RdRp", "ORGANISM", 3, 11], ["3\u2032-OH", "SIMPLE_CHEMICAL", 13, 18], ["NH", "AMINO_ACID", 65, 67], ["\u03b2-phosphate", "SIMPLE_CHEMICAL", 135, 146], ["\u03b2-phosphate coordinates", "PROTEIN", 135, 158], ["HCV", "SPECIES", 3, 6], ["the Asp", "TEST", 44, 51], ["HCV RdRp", "OBSERVATION", 3, 11]]], ["As a consequence of this repositioning of the substrate, the activity of various inhibitors across the coronaviruses is expected to diverge from that seen with other polymerases.", [["coronaviruses", "ORGANISM", 103, 116], ["polymerases", "PROTEIN", 166, 177], ["this repositioning of the substrate", "TREATMENT", 20, 55], ["various inhibitors", "TREATMENT", 73, 91], ["the coronaviruses", "PROBLEM", 99, 116], ["coronaviruses", "OBSERVATION", 103, 116]]], ["The preference for 2\u2032-OH > 2\u2032d2\u2032F \u226b 2\u2032deoxy is evident from the nature of the polar residues coordinating that position and is similar to the other enzymes.", [["2\u2032-OH", "CHEMICAL", 19, 24], ["2\u2032-OH", "CHEMICAL", 19, 24], ["2\u2032d2\u2032F \u226b 2\u2032deoxy", "CHEMICAL", 27, 43], ["2\u2032-OH", "SIMPLE_CHEMICAL", 19, 24], ["2\u2032d2\u2032F \u226b 2\u2032deoxy", "SIMPLE_CHEMICAL", 27, 43], ["enzymes", "PROTEIN", 148, 155], ["the other enzymes", "TEST", 138, 155], ["polar residues", "OBSERVATION", 78, 92]]], ["In contrast, SOF-TP and 2\u2032-CMe-ATP have increased clashes between the 2\u2032\u03b2-Me and Asp-623 and Ser-682 (Fig. 3C).", [["2\u2032-CMe", "CHEMICAL", 24, 30], ["ATP", "CHEMICAL", 31, 34], ["2\u2032\u03b2-Me", "CHEMICAL", 70, 76], ["Asp-623", "CHEMICAL", 81, 88], ["Ser-682", "CHEMICAL", 93, 100], ["SOF-TP", "CHEMICAL", 13, 19], ["2\u2032-CMe", "CHEMICAL", 24, 30], ["ATP", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 81, 84], ["Ser-682", "CHEMICAL", 93, 100], ["SOF-TP", "SIMPLE_CHEMICAL", 13, 19], ["2\u2032-CMe-ATP", "SIMPLE_CHEMICAL", 24, 34], ["2\u2032\u03b2-Me", "SIMPLE_CHEMICAL", 70, 76], ["Asp-623", "SIMPLE_CHEMICAL", 81, 88], ["Ser-682", "GENE_OR_GENE_PRODUCT", 93, 100], ["SOF", "TEST", 13, 16], ["TP", "TEST", 17, 19], ["ATP", "PROBLEM", 31, 34], ["increased clashes", "PROBLEM", 40, 57], ["Asp", "TEST", 81, 84], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["clashes", "OBSERVATION", 50, 57]]], ["This is partially relieved by a conformational change in Ser-682, but overall, the poorer incorporation efficiencies of the 2\u2032\u03b2-Me\u2013substituted inhibitors is likely due to these putative steric clashes.", [["Ser-682", "CHEMICAL", 57, 64], ["2\u2032\u03b2-Me\u2013substituted", "CHEMICAL", 124, 142], ["Ser", "CHEMICAL", 57, 60], ["Ser-682", "AMINO_ACID", 57, 64], ["2\u2032\u03b2-Me\u2013substituted", "SIMPLE_CHEMICAL", 124, 142], ["a conformational change", "PROBLEM", 30, 53], ["the poorer incorporation efficiencies", "PROBLEM", 79, 116], ["the 2\u2032\u03b2-Me\u2013substituted inhibitors", "TREATMENT", 120, 153], ["these putative steric clashes", "PROBLEM", 171, 200], ["relieved", "OBSERVATION_MODIFIER", 18, 26], ["likely due to", "UNCERTAINTY", 157, 170], ["steric clashes", "OBSERVATION", 186, 200]]], ["In contrast, RDV-TP (Fig. 3D) is recognized at the 2\u2032-OH in a manner similar to ATP, and the 1\u2032-CN modification is well-positioned in a pocket formed between Thr-687 and Ala-688.", [["RDV-TP", "CHEMICAL", 13, 19], ["ATP", "CHEMICAL", 80, 83], ["Thr-687", "CHEMICAL", 158, 165], ["Ala-688", "CHEMICAL", 170, 177], ["2\u2032-OH", "CHEMICAL", 51, 56], ["ATP", "CHEMICAL", 80, 83], ["1\u2032-CN", "CHEMICAL", 93, 98], ["Thr", "CHEMICAL", 158, 161], ["Ala-688", "CHEMICAL", 170, 177], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 13, 19], ["2\u2032-OH", "SIMPLE_CHEMICAL", 51, 56], ["ATP", "SIMPLE_CHEMICAL", 80, 83], ["1\u2032-CN", "GENE_OR_GENE_PRODUCT", 93, 98], ["Thr-687", "AMINO_ACID", 158, 165], ["Ala-688", "AMINO_ACID", 170, 177], ["RDV", "PROTEIN", 13, 16], ["TP", "PROTEIN", 17, 19], ["CN", "PROTEIN", 96, 98], ["RDV", "TEST", 13, 16], ["ATP", "TEST", 80, 83], ["the 1\u2032-CN modification", "TREATMENT", 89, 111], ["Thr", "TEST", 158, 161], ["Ala", "TEST", 170, 173], ["TP", "ANATOMY", 17, 19], ["pocket", "OBSERVATION_MODIFIER", 136, 142]]], ["The high efficiency of incorporation reported here is consistent with this model.Patterns of inhibition of RNA synthesis by RDV-TP ::: ResultsThe incorporation of a nucleotide analogue into the growing RNA chain does not necessarily translate into inhibition.", [["nucleotide", "CHEMICAL", 165, 175], ["RDV-TP", "CHEMICAL", 124, 130], ["nucleotide", "CHEMICAL", 165, 175], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 124, 130], ["growing RNA chain", "PROTEIN", 194, 211], ["RNA synthesis", "PROBLEM", 107, 120], ["a nucleotide analogue", "TREATMENT", 163, 184], ["high efficiency", "OBSERVATION_MODIFIER", 4, 19], ["consistent with", "UNCERTAINTY", 54, 69], ["RNA synthesis", "OBSERVATION", 107, 120]]], ["To determine the patterns of inhibition of RNA synthesis, we devised two RNA templates that contain single or multiple sites of incorporation (template uridines) (Fig. 4A).", [["uridines", "CHEMICAL", 152, 160], ["uridines", "SIMPLE_CHEMICAL", 152, 160], ["RNA synthesis", "TREATMENT", 43, 56], ["two RNA templates", "TREATMENT", 69, 86], ["incorporation (template uridines", "TREATMENT", 128, 160], ["RNA synthesis", "OBSERVATION", 43, 56], ["multiple", "OBSERVATION_MODIFIER", 110, 118]]], ["These sequences were used to compare the inhibitory effects of RDV-TP against MERS-CoV, SARS-CoV, SARS-CoV-2, and LASV RdRp.", [["RDV-TP", "CHEMICAL", 63, 69], ["RDV-TP", "CHEMICAL", 63, 69], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 63, 69], ["MERS-CoV", "ORGANISM", 78, 86], ["SARS-CoV", "ORGANISM", 88, 96], ["SARS-CoV-2", "ORGANISM", 98, 108], ["LASV RdRp", "ORGANISM", 114, 123], ["SARS-CoV, SARS-CoV-2, and LASV RdRp", "PROTEIN", 88, 123], ["MERS-CoV", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 98, 106], ["LASV RdRp", "SPECIES", 114, 123], ["These sequences", "TEST", 0, 15], ["RDV", "TEST", 63, 66], ["TP", "TEST", 67, 69], ["MERS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["LASV RdRp", "TREATMENT", 114, 123], ["LASV RdRp", "OBSERVATION", 114, 123]]], ["The latter enzyme showed a significantly higher selectivity value for RDV-TP (Table 1), and RDV does not show antiviral activity against LASV (10).", [["RDV-TP", "CHEMICAL", 70, 76], ["RDV", "CHEMICAL", 92, 95], ["RDV-TP", "CHEMICAL", 70, 76], ["RDV", "CHEMICAL", 92, 95], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 70, 76], ["RDV", "SIMPLE_CHEMICAL", 92, 95], ["LASV", "ORGANISM", 137, 141], ["LASV", "SPECIES", 137, 141], ["The latter enzyme", "TEST", 0, 17], ["RDV", "TEST", 70, 73], ["antiviral activity", "OBSERVATION", 110, 128]]], ["For CoV RdRp complexes with templates allowing multiple incorporations, we observe termination of RNA synthesis at positions i+3 and i+4.", [["CoV", "ORGANISM", 4, 7], ["CoV RdRp complexes", "PROTEIN", 4, 22], ["CoV RdRp", "SPECIES", 4, 12], ["CoV RdRp complexes", "TREATMENT", 4, 22], ["multiple incorporations", "TREATMENT", 47, 70], ["RNA synthesis", "PROBLEM", 98, 111], ["RNA synthesis", "OBSERVATION", 98, 111]]], ["A faint band representing the full-length product suggests low levels of read-through (Fig. 4B).", [["full-length product", "PROTEIN", 30, 49], ["A faint band", "PROBLEM", 0, 12], ["low levels", "PROBLEM", 59, 69], ["faint", "OBSERVATION_MODIFIER", 2, 7], ["band", "OBSERVATION_MODIFIER", 8, 12], ["full-length", "OBSERVATION_MODIFIER", 30, 41], ["low levels", "OBSERVATION_MODIFIER", 59, 69]]], ["On a template that allows only a single RDV-TP incorporation, termination is seen solely at position i+3.", [["RDV-TP", "CHEMICAL", 40, 46], ["TP", "GENE_OR_GENE_PRODUCT", 44, 46], ["RDV", "DNA", 40, 43], ["a single RDV-TP incorporation", "TREATMENT", 31, 60]]], ["Full-length product formation is generally more pronounced under these conditions, following the order MERS-CoV RdRp > SARS-CoV RdRp > SARS-CoV-2 RdRp.", [["SARS-CoV", "ORGANISM", 119, 127], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["MERS-CoV RdRp", "PROTEIN", 103, 116], ["SARS-CoV RdRp", "PROTEIN", 119, 132], ["SARS-CoV-2 RdRp", "PROTEIN", 135, 150], ["RdRp", "TEST", 112, 116], ["SARS-", "TEST", 119, 124], ["RdRp", "TEST", 128, 132], ["CoV", "TEST", 140, 143], ["more pronounced", "OBSERVATION_MODIFIER", 43, 58]]], ["For LASV RdRp, RNA synthesis patterns in the presence or absence of the nucleotide analogue are very similar.", [["nucleotide", "CHEMICAL", 72, 82], ["nucleotide", "CHEMICAL", 72, 82], ["LASV RdRp", "ORGANISM", 4, 13], ["LASV RdRp", "PROTEIN", 4, 13], ["LASV", "SPECIES", 4, 8], ["LASV RdRp", "TREATMENT", 4, 13], ["RNA synthesis patterns", "TREATMENT", 15, 37], ["the nucleotide analogue", "PROBLEM", 68, 91], ["RdRp", "OBSERVATION", 9, 13], ["RNA synthesis", "OBSERVATION", 15, 28], ["nucleotide analogue", "OBSERVATION", 72, 91], ["very", "OBSERVATION_MODIFIER", 96, 100], ["similar", "OBSERVATION_MODIFIER", 101, 108]]], ["Chain termination or delayed chain termination is not evident.", [["Chain termination or delayed chain termination", "TREATMENT", 0, 46], ["delayed", "OBSERVATION_MODIFIER", 21, 28], ["chain", "OBSERVATION_MODIFIER", 29, 34], ["not evident", "UNCERTAINTY", 50, 61]]], ["To further investigate the possibility of long-range effect of RDV-TP incorporation, we used a 26-mer RNA template and did not observe any change in the pattern of RNA synthesis (Fig. S3).", [["RDV-TP", "CHEMICAL", 63, 69], ["RDV-TP", "CHEMICAL", 63, 69], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 63, 69], ["RDV", "PROTEIN", 63, 66], ["RDV", "PROBLEM", 63, 66], ["TP incorporation", "TREATMENT", 67, 83], ["a 26-mer RNA template", "TREATMENT", 93, 114], ["RNA synthesis", "PROBLEM", 164, 177], ["RNA synthesis", "OBSERVATION", 164, 177]]], ["Hence, LASV L protein is likely not inhibited by RDV-TP.Patterns of inhibition of RNA synthesis by RDV-TP ::: ResultsExamination of the structural model suggests that the primer with the incorporated RDV can translocate without obstruction to position i+1 (Fig. 5, A and B).", [["RDV-TP", "CHEMICAL", 49, 55], ["RDV-TP", "CHEMICAL", 99, 105], ["RDV", "CHEMICAL", 200, 203], ["RDV-TP", "CHEMICAL", 49, 55], ["RDV-TP", "CHEMICAL", 99, 105], ["LASV L", "GENE_OR_GENE_PRODUCT", 7, 13], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 49, 55], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 99, 105], ["RDV", "GENE_OR_GENE_PRODUCT", 200, 203], ["LASV L protein", "PROTEIN", 7, 21], ["RDV", "PROTEIN", 99, 102], ["RDV", "PROTEIN", 200, 203], ["LASV", "SPECIES", 7, 11], ["LASV L protein", "TEST", 7, 21], ["RNA synthesis", "PROBLEM", 82, 95], ["the primer", "PROBLEM", 167, 177], ["obstruction", "PROBLEM", 228, 239], ["LASV", "OBSERVATION", 7, 11], ["likely not", "UNCERTAINTY", 25, 35], ["RNA synthesis", "OBSERVATION", 82, 95], ["without", "UNCERTAINTY", 220, 227], ["obstruction", "OBSERVATION", 228, 239]]], ["Similarly, no obstructions can be discerned at the i+2 (Fig. 5C) or i+3 (Fig. 5D).", [["obstructions", "PATHOLOGICAL_FORMATION", 14, 26], ["obstructions", "PROBLEM", 14, 26], ["no", "UNCERTAINTY", 11, 13], ["obstructions", "OBSERVATION", 14, 26]]], ["This would allow the incorporation of three subsequent nucleotides, in agreement with our experimental data.", [["nucleotides", "CHEMICAL", 55, 66]]], ["However, at position i+4 (Fig. 5, E and F), a steric clash is seen between the 1\u2032-CN substituent of RDV and residue Ser-861.", [["Ser-861", "CHEMICAL", 116, 123], ["1\u2032-CN", "CHEMICAL", 79, 84], ["RDV", "CHEMICAL", 100, 103], ["Ser", "CHEMICAL", 116, 119], ["1\u2032-CN", "SIMPLE_CHEMICAL", 79, 84], ["RDV", "SIMPLE_CHEMICAL", 100, 103], ["residue", "AMINO_ACID", 108, 115], ["Ser-861", "AMINO_ACID", 116, 123], ["RDV", "PROTEIN", 100, 103], ["residue Ser", "TEST", 108, 119], ["steric clash", "OBSERVATION", 46, 58]]], ["The serine O is only 1.7 \u212b from the 1\u2032-CN N. The short distance is expected to lead to a significant distortion of the positioning of the RNA, hampering translocation to the i+4 position.Overcoming of the delayed chain termination by incorporated RDV ::: ResultsRead-through at a site of delayed chain termination may reduce the inhibitory effect of RDV-TP.", [["RDV", "CHEMICAL", 350, 353], ["serine", "CHEMICAL", 4, 10], ["O", "CHEMICAL", 11, 12], ["RDV", "CHEMICAL", 247, 250], ["serine O", "SIMPLE_CHEMICAL", 4, 12], ["CN", "PROTEIN", 39, 41], ["RDV", "PROTEIN", 247, 250], ["The serine O", "TEST", 0, 12], ["a significant distortion of the positioning of the RNA", "PROBLEM", 87, 141], ["delayed chain termination", "TREATMENT", 288, 313], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["distortion", "OBSERVATION", 101, 111], ["positioning", "OBSERVATION_MODIFIER", 119, 130], ["RNA", "ANATOMY", 138, 141], ["delayed", "OBSERVATION_MODIFIER", 205, 212], ["chain", "OBSERVATION_MODIFIER", 213, 218]]], ["We therefore tested whether termination of RNA synthesis could be overcome with time or with increasing concentrations of nucleotide pools (Fig. 6).", [["nucleotide", "CHEMICAL", 122, 132], ["nucleotide", "CHEMICAL", 122, 132], ["RNA synthesis", "TREATMENT", 43, 56], ["nucleotide pools", "TREATMENT", 122, 138]]], ["In the presence of equivalent concentrations of RDV-TP and UTP (0.1 \u03bcm), which is the next nucleotide to be incorporated following the RDV-TP incorporation site and also following the site of delayed chain termination, the full-length product formation is negligible.", [["RDV-TP", "CHEMICAL", 48, 54], ["UTP", "CHEMICAL", 59, 62], ["nucleotide", "CHEMICAL", 91, 101], ["RDV-TP", "CHEMICAL", 48, 54], ["UTP", "CHEMICAL", 59, 62], ["nucleotide", "CHEMICAL", 91, 101], ["RDV-TP", "CHEMICAL", 135, 141], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 48, 54], ["UTP", "SIMPLE_CHEMICAL", 59, 62], ["TP", "GENE_OR_GENE_PRODUCT", 139, 141], ["RDV-TP incorporation site", "DNA", 135, 160], ["equivalent concentrations of RDV", "PROBLEM", 19, 51], ["UTP", "TEST", 59, 62], ["the RDV-TP incorporation site", "TREATMENT", 131, 160], ["delayed chain termination", "PROBLEM", 192, 217], ["equivalent", "OBSERVATION_MODIFIER", 19, 29], ["concentrations", "OBSERVATION_MODIFIER", 30, 44], ["TP", "ANATOMY", 52, 54], ["UTP", "OBSERVATION_MODIFIER", 59, 62], ["delayed", "OBSERVATION_MODIFIER", 192, 199], ["chain", "OBSERVATION_MODIFIER", 200, 205], ["negligible", "OBSERVATION_MODIFIER", 256, 266]]], ["The signal for delayed chain termination is not alleviated with time, which provides more evidence for a bona fide termination site and not enzyme pausing (Fig. 6A, left).", [["bona fide termination site", "DNA", 105, 131], ["enzyme", "PROTEIN", 140, 146], ["delayed chain termination", "PROBLEM", 15, 40], ["a bona fide termination site", "PROBLEM", 103, 131], ["enzyme pausing", "PROBLEM", 140, 154], ["left", "ANATOMY_MODIFIER", 165, 169]]], ["In contrast, full-length product formation is time-dependent when ATP replaces RDV-TP in the reaction mixture (Fig. 6A, middle).", [["ATP", "CHEMICAL", 66, 69], ["RDV-TP", "CHEMICAL", 79, 85], ["ATP", "CHEMICAL", 66, 69], ["RDV-TP", "CHEMICAL", 79, 85], ["ATP", "SIMPLE_CHEMICAL", 66, 69], ["RDV-TP", "SIMPLE_CHEMICAL", 79, 85], ["RDV", "PROTEIN", 79, 82], ["full-length product formation", "TREATMENT", 13, 42], ["ATP", "TEST", 66, 69], ["RDV", "TEST", 79, 82], ["TP", "PROBLEM", 83, 85], ["the reaction mixture", "TREATMENT", 89, 109]]], ["As expected, the omission of both ATP and RDV-TP prevents RNA synthesis beyond product 5, thus controlling for C:U and U:U misincorporations under the present reaction conditions (Fig. 6A, right).", [["ATP", "CHEMICAL", 34, 37], ["RDV-TP", "CHEMICAL", 42, 48], ["ATP", "CHEMICAL", 34, 37], ["RDV-TP", "CHEMICAL", 42, 48], ["ATP", "SIMPLE_CHEMICAL", 34, 37], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 42, 48], ["C:U", "GENE_OR_GENE_PRODUCT", 111, 114], ["U:U", "GENE_OR_GENE_PRODUCT", 119, 122], ["both ATP", "TREATMENT", 29, 37], ["RDV", "TREATMENT", 42, 45], ["TP", "TREATMENT", 46, 48], ["RNA synthesis", "TREATMENT", 58, 71], ["U misincorporations", "TREATMENT", 121, 140], ["right", "ANATOMY_MODIFIER", 189, 194]]], ["However, delayed chain termination can be overcome with higher NTP concentrations.", [["NTP", "CHEMICAL", 63, 66], ["NTP", "CHEMICAL", 63, 66], ["NTP", "SIMPLE_CHEMICAL", 63, 66], ["delayed chain termination", "PROBLEM", 9, 34], ["higher NTP concentrations", "TREATMENT", 56, 81]]], ["In the presence of increasing concentrations of UTP, the signal at i+3 decreases concomitantly with an increase in the full-length product.", [["UTP", "CHEMICAL", 48, 51], ["UTP", "CHEMICAL", 48, 51], ["UTP", "SIMPLE_CHEMICAL", 48, 51], ["full-length product", "PROTEIN", 119, 138], ["increasing concentrations of UTP", "PROBLEM", 19, 51], ["increasing", "OBSERVATION_MODIFIER", 19, 29], ["concentrations", "OBSERVATION_MODIFIER", 30, 44], ["UTP", "OBSERVATION", 48, 51], ["decreases", "OBSERVATION_MODIFIER", 71, 80], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["full-length", "OBSERVATION_MODIFIER", 119, 130]]], ["UTP concentrations that are \u223c100-fold higher than RDV-TP can cause significant reductions in delayed chain termination (Fig. 6B).DiscussionRDV is an investigational nucleotide analogue with a broad spectrum of antiviral activities against several RNA viruses, including filoviruses and coronaviruses (5, 8, 10, 12\u201314).", [["UTP", "CHEMICAL", 0, 3], ["RDV-TP", "CHEMICAL", 50, 56], ["DiscussionRDV", "CHEMICAL", 129, 142], ["nucleotide", "CHEMICAL", 165, 175], ["filoviruses", "DISEASE", 270, 281], ["UTP", "CHEMICAL", 0, 3], ["RDV-TP", "CHEMICAL", 50, 56], ["nucleotide", "CHEMICAL", 165, 175], ["UTP", "SIMPLE_CHEMICAL", 0, 3], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 50, 56], ["UTP concentrations", "TEST", 0, 18], ["RDV", "TEST", 50, 53], ["significant reductions in delayed chain termination", "PROBLEM", 67, 118], ["an investigational nucleotide analogue", "TREATMENT", 146, 184], ["antiviral activities", "TREATMENT", 210, 230], ["several RNA viruses", "PROBLEM", 239, 258], ["filoviruses", "PROBLEM", 270, 281], ["coronaviruses", "PROBLEM", 286, 299], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["reductions", "OBSERVATION_MODIFIER", 79, 89], ["RNA viruses", "OBSERVATION", 247, 258]]], ["Studies in mice and rhesus macaques have helped to assess the therapeutic potential of this drug against EBOV, SARS-CoV, and MERS-CoV (8, 13\u201315).", [["SARS-CoV", "DISEASE", 111, 119], ["mice", "ORGANISM", 11, 15], ["rhesus macaques", "ORGANISM", 20, 35], ["EBOV", "ORGANISM", 105, 109], ["SARS-CoV", "ORGANISM", 111, 119], ["MERS-CoV", "ORGANISM", 125, 133], ["mice", "SPECIES", 11, 15], ["rhesus macaques", "SPECIES", 20, 35], ["mice", "SPECIES", 11, 15], ["rhesus macaques", "SPECIES", 20, 35], ["EBOV", "SPECIES", 105, 109], ["SARS-CoV", "SPECIES", 111, 119], ["MERS-CoV", "SPECIES", 125, 133], ["Studies", "TEST", 0, 7], ["this drug", "TREATMENT", 87, 96], ["EBOV", "PROBLEM", 105, 109], ["SARS", "PROBLEM", 111, 115], ["CoV", "TEST", 116, 119]]], ["Antiviral activity of RDV has also been demonstrated against SARS-CoV-2 in cell culture (33), whereas data from animal models and clinical trials are pending.", [["cell culture", "ANATOMY", 75, 87], ["RDV", "CHEMICAL", 22, 25], ["RDV", "CHEMICAL", 22, 25], ["RDV", "SIMPLE_CHEMICAL", 22, 25], ["SARS-CoV-2", "ORGANISM", 61, 71], ["cell culture", "CELL", 75, 87], ["RDV", "PROTEIN", 22, 25], ["RDV", "SPECIES", 22, 25], ["SARS-CoV", "SPECIES", 61, 69], ["Antiviral activity of RDV", "PROBLEM", 0, 25], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["cell culture", "TEST", 75, 87], ["animal models", "TEST", 112, 125], ["clinical trials", "TEST", 130, 145]]], ["Moreover, it remains to be seen whether the mechanism of inhibition described for EBOV RdRp and MERS RdRp is also relevant for SARS-CoV-2.", [["EBOV RdRp", "ORGANISM", 82, 91], ["MERS", "GENE_OR_GENE_PRODUCT", 96, 100], ["RdRp", "ORGANISM", 101, 105], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 127, 137], ["EBOV RdRp", "PROTEIN", 82, 91], ["MERS RdRp", "PROTEIN", 96, 105], ["EBOV", "SPECIES", 82, 86], ["SARS-CoV", "SPECIES", 127, 135], ["EBOV RdRp", "TREATMENT", 82, 91], ["MERS RdRp", "TREATMENT", 96, 105], ["SARS", "PROBLEM", 127, 131]]], ["Here, we expressed and purified active SARS-CoV-2 RdRp to study RNA synthesis and its inhibition by RDV-TP.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["SARS-CoV-2 RdRp", "PROTEIN", 39, 54], ["CoV", "TEST", 44, 47], ["RNA synthesis", "TREATMENT", 64, 77]]], ["Based on our biochemical data, we propose a unifying, refined mechanism of inhibition of SARS-CoV, MERS-CoV, and SARS-CoV-2 (Fig. 7).DiscussionCo-expression of SARS-CoV-2 nsp5, nsp7, nsp8, and nsp12 in insect cells yields an active RdRp complex composed of nsp8 and nsp12.", [["cells", "ANATOMY", 209, 214], ["SARS", "DISEASE", 89, 93], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 113, 123], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 160, 170], ["nsp5", "GENE_OR_GENE_PRODUCT", 171, 175], ["nsp7", "GENE_OR_GENE_PRODUCT", 177, 181], ["nsp8", "GENE_OR_GENE_PRODUCT", 183, 187], ["nsp12", "GENE_OR_GENE_PRODUCT", 193, 198], ["insect cells", "CELL", 202, 214], ["nsp8", "GENE_OR_GENE_PRODUCT", 257, 261], ["nsp12", "GENE_OR_GENE_PRODUCT", 266, 271], ["SARS-CoV-2 nsp5", "DNA", 160, 175], ["nsp7", "PROTEIN", 177, 181], ["nsp8", "DNA", 183, 187], ["nsp12", "DNA", 193, 198], ["insect cells", "CELL_TYPE", 202, 214], ["RdRp complex", "PROTEIN", 232, 244], ["nsp8", "PROTEIN", 257, 261], ["nsp12", "PROTEIN", 266, 271], ["SARS-CoV", "SPECIES", 89, 97], ["MERS-CoV", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 113, 121], ["our biochemical data", "TEST", 9, 29], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["MERS", "TEST", 99, 103], ["CoV", "TEST", 104, 107], ["SARS", "TEST", 113, 117], ["CoV", "TEST", 118, 121], ["SARS", "PROBLEM", 160, 164], ["CoV", "TEST", 165, 168], ["nsp7", "PROBLEM", 177, 181], ["nsp8", "PROBLEM", 183, 187], ["nsp12 in insect cells", "PROBLEM", 193, 214], ["nsp12", "TREATMENT", 266, 271], ["active RdRp", "OBSERVATION", 225, 236]]], ["The same data were obtained with MERS-CoV and SARS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["SARS-CoV", "ORGANISM", 46, 54], ["MERS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 46, 54]]], ["RNA synthesis was monitored on short primer/templates that mimic the elongation stage (Fig. 7, step 1).", [["RNA synthesis", "PROBLEM", 0, 13], ["short primer/templates", "TREATMENT", 31, 53], ["the elongation stage", "PROBLEM", 65, 85], ["elongation", "OBSERVATION_MODIFIER", 69, 79]]], ["We initially compared the efficiency of incorporation of RDV-TP with its natural counterpart ATP (Fig. 7, step 2).", [["RDV-TP", "CHEMICAL", 57, 63], ["ATP", "CHEMICAL", 93, 96], ["RDV-TP", "CHEMICAL", 57, 63], ["ATP", "CHEMICAL", 93, 96], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 57, 63], ["ATP", "SIMPLE_CHEMICAL", 93, 96], ["RDV", "PROBLEM", 57, 60], ["TP", "TREATMENT", 61, 63]]], ["A steady-state kinetic approach was employed to translate our findings into quantitative terms and to facilitate comparisons among the various enzymes and compounds tested.", [["enzymes", "PROTEIN", 143, 150], ["the various enzymes", "TEST", 131, 150]]], ["Efficiency of incorporation of the natural nucleotide over the nucleotide analogue defines selectivity.", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 63, 73], ["the natural nucleotide", "TREATMENT", 31, 53], ["incorporation", "OBSERVATION", 14, 27]]], ["For RDV-TP, we measured selectivity values of \u223c0.3 with SARS-CoV, SARS-CoV-2, and previously also with MERS-CoV RdRp.", [["RDV-TP", "GENE_OR_GENE_PRODUCT", 4, 10], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 66, 74], ["MERS-CoV", "SPECIES", 103, 111], ["RDV", "TEST", 4, 7], ["selectivity values", "TEST", 24, 42], ["\u223c", "TEST", 46, 47], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["TP", "ANATOMY", 8, 10]]], ["SARS-CoV and SARS-CoV-2 both belong to the betacoronaviruses of the B lineage, and the nsp 12-amino acid sequences of the two viruses are 96% identical.", [["B lineage", "ANATOMY", 68, 77], ["SARS", "DISEASE", 0, 4], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 94, 104], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 13, 23], ["B lineage", "CELL", 68, 77], ["amino acid", "AMINO_ACID", 94, 104], ["B lineage", "CELL_TYPE", 68, 77], ["nsp 12-amino acid sequences", "DNA", 87, 114], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 0, 4], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["the nsp", "TEST", 83, 90], ["amino acid sequences", "TEST", 94, 114]]], ["In contrast, MERS-CoV belongs to the betacoronaviruses of the C lineage and is only 71% identical with SARS-CoV-2.", [["C lineage", "ANATOMY", 62, 71], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["C lineage", "CELL", 62, 71], ["SARS-CoV-2", "ORGANISM", 103, 113], ["MERS", "PROTEIN", 13, 17], ["C lineage", "CELL_TYPE", 62, 71], ["MERS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 103, 111], ["SARS", "TEST", 103, 107]]], ["Despite greater sequence variations, RdRp motifs that play important roles in substrate binding and catalysis are highly conserved among the three coronaviruses (Fig. S2).", [["RdRp motifs", "DNA", 37, 48], ["S2", "PROTEIN", 167, 169], ["greater sequence variations", "PROBLEM", 8, 35], ["RdRp motifs", "TREATMENT", 37, 48], ["catalysis", "TREATMENT", 100, 109]]], ["Hence, interactions with nucleotide analogue inhibitors are expected to be similar, and our selectivity data provide experimental evidence for this notion.", [["nucleotide", "CHEMICAL", 25, 35], ["nucleotide", "CHEMICAL", 25, 35], ["nucleotide analogue inhibitors", "TREATMENT", 25, 55]]], ["In contrast, selectivity values for RDV-TP against EBOV and RSV RdRp are between 2 and 5, and LASV RdRp shows even higher selectivity values of \u223c20.", [["RDV-TP", "GENE_OR_GENE_PRODUCT", 36, 42], ["EBOV", "ORGANISM", 51, 55], ["RSV RdRp", "ORGANISM", 60, 68], ["LASV", "ORGANISM", 94, 98], ["RDV", "PROTEIN", 36, 39], ["RSV RdRp", "PROTEIN", 60, 68], ["LASV RdRp", "PROTEIN", 94, 103], ["EBOV", "SPECIES", 51, 55], ["RSV", "SPECIES", 60, 63], ["LASV", "SPECIES", 94, 98], ["selectivity values", "TEST", 13, 31], ["RDV", "TEST", 36, 39], ["TP", "PROBLEM", 40, 42], ["EBOV", "PROBLEM", 51, 55], ["RSV RdRp", "PROBLEM", 60, 68], ["LASV RdRp", "TEST", 94, 103], ["RSV RdRp", "OBSERVATION", 60, 68], ["higher selectivity", "OBSERVATION", 115, 133]]], ["Whereas the active sites of EBOV and RSV enzymes still share a number of key residues within the classic polymerase motifs, LASV RdRp shows substantial differences when these motifs are compared with EBOV and RSV and also with SARS-CoV, SARS-CoV-2, and MERS-CoV (Fig. S2).DiscussionWe have evaluated several other nucleotide analogues using the same protocol with a focus on SARS-CoV-2 RdRp (Fig. 2 and Table 2).", [["nucleotide", "CHEMICAL", 314, 324], ["nucleotide", "CHEMICAL", 314, 324], ["EBOV", "ORGANISM", 28, 32], ["RSV", "ORGANISM", 37, 40], ["LASV RdRp", "ORGANISM", 124, 133], ["EBOV", "ORGANISM", 200, 204], ["RSV", "ORGANISM", 209, 212], ["SARS-CoV", "ORGANISM", 227, 235], ["SARS-CoV-2", "ORGANISM", 237, 247], ["MERS-CoV", "ORGANISM", 253, 261], ["EBOV and RSV enzymes", "PROTEIN", 28, 48], ["classic polymerase motifs", "PROTEIN", 97, 122], ["LASV RdRp", "PROTEIN", 124, 133], ["EBOV", "SPECIES", 28, 32], ["RSV", "SPECIES", 37, 40], ["LASV", "SPECIES", 124, 128], ["EBOV", "SPECIES", 200, 204], ["RSV", "SPECIES", 209, 212], ["SARS-CoV", "SPECIES", 227, 235], ["SARS-CoV", "SPECIES", 237, 245], ["MERS-CoV", "SPECIES", 253, 261], ["EBOV", "PROBLEM", 28, 32], ["RSV enzymes", "TEST", 37, 48], ["key residues", "PROBLEM", 73, 85], ["LASV RdRp", "TREATMENT", 124, 133], ["EBOV", "TEST", 200, 204], ["RSV", "TEST", 209, 212], ["SARS", "TEST", 227, 231], ["CoV", "TEST", 232, 235], ["SARS", "TEST", 237, 241], ["CoV", "TEST", 242, 245], ["MERS", "TEST", 253, 257], ["nucleotide analogues", "TREATMENT", 314, 334], ["the same protocol", "TREATMENT", 341, 358], ["SARS", "TEST", 375, 379], ["CoV", "TEST", 380, 383], ["active", "OBSERVATION_MODIFIER", 12, 18], ["sites", "OBSERVATION_MODIFIER", 19, 24], ["EBOV", "OBSERVATION", 28, 32], ["substantial", "OBSERVATION_MODIFIER", 140, 151]]], ["The selectivity of ATP over dATP is \u223c1000, which shows that the enzyme effectively discriminates against deoxyribonucleotides that are substrates for DNA polymerases.", [["ATP", "CHEMICAL", 19, 22], ["dATP", "CHEMICAL", 28, 32], ["ATP", "CHEMICAL", 19, 22], ["dATP", "CHEMICAL", 28, 32], ["ATP", "SIMPLE_CHEMICAL", 19, 22], ["dATP", "SIMPLE_CHEMICAL", 28, 32], ["deoxyribonucleotides", "SIMPLE_CHEMICAL", 105, 125], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["deoxyribonucleotides", "PROTEIN", 105, 125], ["DNA polymerases", "PROTEIN", 150, 165], ["ATP over dATP", "TEST", 19, 32], ["the enzyme", "TEST", 60, 70], ["deoxyribonucleotides", "TREATMENT", 105, 125], ["DNA polymerases", "PROBLEM", 150, 165]]], ["Similar results were obtained with the broad spectrum antivirals favipiravir and ribavirin (26, 27, 30).", [["favipiravir", "CHEMICAL", 65, 76], ["ribavirin", "CHEMICAL", 81, 90], ["favipiravir", "CHEMICAL", 65, 76], ["ribavirin", "CHEMICAL", 81, 90], ["favipiravir", "SIMPLE_CHEMICAL", 65, 76], ["ribavirin", "SIMPLE_CHEMICAL", 81, 90], ["the broad spectrum antivirals favipiravir", "TREATMENT", 35, 76], ["ribavirin", "TREATMENT", 81, 90]]], ["These compounds show high selectivity values of \u223c500 and \u223c10,000 in favor of ATP.", [["ATP", "CHEMICAL", 77, 80], ["ATP", "CHEMICAL", 77, 80], ["ATP", "SIMPLE_CHEMICAL", 77, 80], ["These compounds", "TEST", 0, 15], ["ATP", "PROBLEM", 77, 80], ["high selectivity", "OBSERVATION", 21, 37]]], ["Compounds with modifications at the 2\u2032\u03b2-position are also associated with high selectivity values in favor of the natural nucleotide.", [["nucleotide", "CHEMICAL", 122, 132], ["nucleotide", "CHEMICAL", 122, 132], ["2\u2032\u03b2-position", "DNA", 36, 48], ["high selectivity values", "PROBLEM", 74, 97], ["the natural nucleotide", "TREATMENT", 110, 132]]], ["SOF-TP and 2\u2032-CMe-ATP show selectivity values of \u223c1000 and \u223c170 in favor of UTP and ATP, respectively.", [["2\u2032-CMe", "CHEMICAL", 11, 17], ["ATP", "CHEMICAL", 18, 21], ["UTP", "CHEMICAL", 76, 79], ["ATP", "CHEMICAL", 84, 87], ["SOF-TP", "CHEMICAL", 0, 6], ["2\u2032-CMe-ATP", "CHEMICAL", 11, 21], ["UTP", "CHEMICAL", 76, 79], ["ATP", "CHEMICAL", 84, 87], ["SOF-TP", "SIMPLE_CHEMICAL", 0, 6], ["2\u2032-CMe-ATP", "SIMPLE_CHEMICAL", 11, 21], ["UTP", "SIMPLE_CHEMICAL", 76, 79], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["TP", "TEST", 4, 6], ["selectivity values", "TEST", 27, 45], ["UTP", "TEST", 76, 79], ["ATP", "TEST", 84, 87]]], ["Selectivity of ATP over ara-ATP is likewise high (\u223c1000).", [["ATP", "CHEMICAL", 15, 18], ["ATP", "CHEMICAL", 15, 18], ["ATP", "SIMPLE_CHEMICAL", 15, 18], ["ara-ATP", "SIMPLE_CHEMICAL", 24, 31], ["ATP over ara-ATP", "TEST", 15, 31], ["high", "OBSERVATION_MODIFIER", 44, 48]]], ["A homology model of SARS-CoV-2 points to a putative steric clash of 2\u2032\u03b2-modifications with residues Asp-623 and Ser-682.", [["SARS", "DISEASE", 20, 24], ["Asp-623 and Ser-682", "CHEMICAL", 100, 119], ["Asp", "CHEMICAL", 100, 103], ["Ser", "CHEMICAL", 112, 115], ["Asp-623", "AMINO_ACID", 100, 107], ["Ser-682", "AMINO_ACID", 112, 119], ["2\u2032\u03b2", "PROTEIN", 68, 71], ["SARS", "PROBLEM", 20, 24], ["a putative steric clash", "TREATMENT", 41, 64], ["residues Asp", "TEST", 91, 103], ["Ser", "TEST", 112, 115], ["steric clash", "OBSERVATION", 52, 64]]], ["With the limitations of a steady-state approach, we are unable to ascribe differences in selectivity measurements solely to inhibitor binding; however, whereas the model is not based on structural data of SARS-CoV-2 RdRp, it provides a plausible explanation for our experimental observations.DiscussionRDV-TP is a nonobligate chain terminator, which contains a 3\u2032-hydroxyl group that may still form a phosphodiester bond with the next incoming nucleotide.", [["DiscussionRDV-TP", "CHEMICAL", 292, 308], ["3\u2032-hydroxyl", "CHEMICAL", 361, 372], ["nucleotide", "CHEMICAL", 444, 454], ["3\u2032-hydroxyl", "CHEMICAL", 361, 372], ["phosphodiester", "CHEMICAL", 401, 415], ["nucleotide", "CHEMICAL", 444, 454], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 205, 215], ["DiscussionRDV-TP", "GENE_OR_GENE_PRODUCT", 292, 308], ["3\u2032-hydroxyl", "SIMPLE_CHEMICAL", 361, 372], ["SARS-CoV-2 RdRp", "PROTEIN", 205, 220], ["TP", "DNA", 306, 308], ["nonobligate chain terminator", "DNA", 314, 342], ["SARS", "PROBLEM", 205, 209], ["a 3\u2032-hydroxyl group", "TREATMENT", 359, 378], ["a phosphodiester bond", "TREATMENT", 399, 420], ["the next incoming nucleotide", "TREATMENT", 426, 454]]], ["Indeed, as demonstrated for RdRp enzymes from RSV, EBOV, NiV, and MERS, delayed chain termination provides a likely mechanism of action (7\u20139, 17).", [["RSV", "ORGANISM", 46, 49], ["EBOV", "ORGANISM", 51, 55], ["NiV", "ORGANISM", 57, 60], ["MERS", "GENE_OR_GENE_PRODUCT", 66, 70], ["RdRp enzymes", "PROTEIN", 28, 40], ["NiV", "PROTEIN", 57, 60], ["MERS", "PROTEIN", 66, 70], ["RSV", "SPECIES", 46, 49], ["EBOV", "SPECIES", 51, 55], ["RdRp enzymes", "TEST", 28, 40], ["RSV", "PROBLEM", 46, 49], ["EBOV", "TEST", 51, 55], ["NiV", "TREATMENT", 57, 60], ["delayed chain termination", "PROBLEM", 72, 97]]], ["For all three coronavirus RdRp complexes, we observe a specific termination site at position i+3 (Fig. 7, step 3).", [["coronavirus", "ORGANISM", 14, 25], ["coronavirus RdRp complexes", "PROTEIN", 14, 40], ["all three coronavirus RdRp complexes", "PROBLEM", 4, 40], ["a specific termination site", "PROBLEM", 53, 80], ["coronavirus RdRp", "OBSERVATION", 14, 30]]], ["At i+4, our model predicts a steric clash between the 1\u2032-CN substituent of the incorporated RDV and residue Ser-861.", [["Ser-861", "CHEMICAL", 108, 115], ["1\u2032-CN", "CHEMICAL", 54, 59], ["RDV", "CHEMICAL", 92, 95], ["Ser", "CHEMICAL", 108, 111], ["1\u2032-CN", "SIMPLE_CHEMICAL", 54, 59], ["RDV", "SIMPLE_CHEMICAL", 92, 95], ["Ser-861", "AMINO_ACID", 108, 115], ["RDV", "PROTEIN", 92, 95], ["steric clash", "OBSERVATION", 29, 41]]], ["This model is consistent with the observed termination at i+3 and the inability of the enzyme to translocate a single position further downstream to accommodate the next nucleotide.", [["nucleotide", "CHEMICAL", 170, 180], ["nucleotide", "CHEMICAL", 170, 180], ["enzyme", "PROTEIN", 87, 93], ["the next nucleotide", "TREATMENT", 161, 180], ["consistent with", "UNCERTAINTY", 14, 29]]], ["Sequences extracted from GenBankTM reveal that this serine residue is conserved across all alpha-, beta-, and deltacoronaviruses.DiscussionTermination of RNA synthesis can be overcome by higher concentrations of the natural nucleotide pools (Fig. 7, step 4).", [["nucleotide", "CHEMICAL", 224, 234], ["serine", "CHEMICAL", 52, 58], ["nucleotide", "CHEMICAL", 224, 234], ["GenBankTM", "GENE_OR_GENE_PRODUCT", 25, 34], ["serine", "AMINO_ACID", 52, 58], ["alpha-", "GENE_OR_GENE_PRODUCT", 91, 97], ["beta-", "GENE_OR_GENE_PRODUCT", 99, 104], ["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 110, 128], ["GenBankTM", "DNA", 25, 34], ["alpha-, beta-, and deltacoronaviruses", "PROTEIN", 91, 128], ["this serine residue", "PROBLEM", 47, 66], ["RNA synthesis", "TREATMENT", 154, 167], ["the natural nucleotide pools", "TREATMENT", 212, 240]]], ["NTP can reach low millimolar concentrations (34, 35).", [["NTP", "CHEMICAL", 0, 3], ["millimolar", "CHEMICAL", 18, 28], ["NTP", "CHEMICAL", 0, 3], ["NTP", "SIMPLE_CHEMICAL", 0, 3], ["NTP", "TREATMENT", 0, 3], ["low millimolar", "OBSERVATION_MODIFIER", 14, 28], ["concentrations", "OBSERVATION_MODIFIER", 29, 43]]], ["The intracellular concentration of RDV-TP can vary between low and high micromolar levels in relevant cell cultures (8, 14), and high ratios of NTP/RDV-TP are likely detrimental to inhibition.", [["intracellular", "ANATOMY", 4, 17], ["cell cultures", "ANATOMY", 102, 115], ["RDV-TP", "CHEMICAL", 35, 41], ["NTP", "CHEMICAL", 144, 147], ["RDV-TP", "CHEMICAL", 35, 41], ["NTP", "CHEMICAL", 144, 147], ["RDV-TP", "CHEMICAL", 148, 154], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 35, 41], ["cell cultures", "CELL", 102, 115], ["NTP", "SIMPLE_CHEMICAL", 144, 147], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 148, 154], ["RDV", "PROTEIN", 148, 151], ["The intracellular concentration", "TEST", 0, 31], ["RDV", "TEST", 35, 38], ["TP", "PROBLEM", 39, 41], ["low and high micromolar levels", "PROBLEM", 59, 89], ["relevant cell cultures", "TEST", 93, 115], ["high ratios of NTP/RDV", "PROBLEM", 129, 151], ["TP", "PROBLEM", 152, 154], ["concentration", "OBSERVATION_MODIFIER", 18, 31], ["low", "OBSERVATION_MODIFIER", 59, 62], ["high micromolar", "OBSERVATION_MODIFIER", 67, 82], ["cell cultures", "OBSERVATION", 102, 115]]], ["However, the efficient incorporation of RDV-TP into the growing RNA chain may also provide a mechanism that counteracts reduced termination in the presence of high NTP concentrations.", [["RDV-TP", "CHEMICAL", 40, 46], ["NTP", "CHEMICAL", 164, 167], ["RDV-TP", "CHEMICAL", 40, 46], ["NTP", "CHEMICAL", 164, 167], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 40, 46], ["NTP", "SIMPLE_CHEMICAL", 164, 167], ["RDV", "PROTEIN", 40, 43], ["TP", "PROTEIN", 44, 46], ["growing RNA chain", "PROTEIN", 56, 73], ["RDV-TP", "TREATMENT", 40, 46], ["high NTP concentrations", "PROBLEM", 159, 182], ["growing", "OBSERVATION_MODIFIER", 56, 63], ["RNA chain", "OBSERVATION", 64, 73], ["may also provide", "UNCERTAINTY", 74, 90], ["reduced", "OBSERVATION_MODIFIER", 120, 127], ["high", "OBSERVATION_MODIFIER", 159, 163], ["NTP concentrations", "OBSERVATION", 164, 182]]], ["Our data confirm that consecutive and/or multiple sites of incorporation of RDV-TP increase termination and in turn inhibition; however, the efficiency of this effect remains to be determined (Fig. S2B).", [["RDV-TP", "CHEMICAL", 76, 82], ["RDV-TP", "CHEMICAL", 76, 82], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 76, 82], ["RDV", "PROTEIN", 76, 79], ["Our data", "TEST", 0, 8], ["incorporation of RDV", "TREATMENT", 59, 79], ["TP increase termination", "TREATMENT", 80, 103]]], ["Another factor that can reduce the potency of nucleotide analogues is the 3\u2032-5\u2032 exonuclease activity of nsp14 (6, 36\u201338).", [["nucleotide", "CHEMICAL", 46, 56], ["nucleotide", "CHEMICAL", 46, 56], ["nucleotide analogues", "SIMPLE_CHEMICAL", 46, 66], ["nsp14", "PROTEIN", 104, 109], ["nucleotide analogues", "TREATMENT", 46, 66]]], ["This enzyme displays proofreading activity in conjunction with nsp10 (36, 37, 39).", [["nsp10", "GENE_OR_GENE_PRODUCT", 63, 68], ["This enzyme", "TEST", 0, 11], ["nsp10", "TEST", 63, 68], ["proofreading activity", "OBSERVATION", 21, 42]]], ["In this context, we have recently proposed that the additional three nucleotides that follow the incorporated RDV may provide protection from excision (17, 40).", [["RDV", "CHEMICAL", 110, 113], ["nucleotides", "CHEMICAL", 69, 80], ["RDV", "GENE_OR_GENE_PRODUCT", 110, 113], ["RDV", "DNA", 110, 113], ["the additional three nucleotides", "TREATMENT", 48, 80], ["excision", "TREATMENT", 142, 150], ["excision", "OBSERVATION", 142, 150]]], ["Future studies that take into account rates of nucleotide incorporation, rates of excision of multiple nucleotides, and the likelihood of RDV-TP reincorporation will be required to address this problem.DiscussionSeveral independent examples point to a significant correlation between the efficiency of selective incorporation of a given nucleotide analogue and the corresponding antiviral effect measured in cell culture.", [["cell culture", "ANATOMY", 408, 420], ["nucleotide", "CHEMICAL", 47, 57], ["nucleotide", "CHEMICAL", 337, 347], ["nucleotide", "CHEMICAL", 47, 57], ["nucleotides", "CHEMICAL", 103, 114], ["nucleotide", "CHEMICAL", 337, 347], ["nucleotide", "SIMPLE_CHEMICAL", 47, 57], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 138, 144], ["cell culture", "CELL", 408, 420], ["Future studies", "TEST", 0, 14], ["nucleotide incorporation", "TREATMENT", 47, 71], ["excision of multiple nucleotides", "TREATMENT", 82, 114], ["RDV", "PROBLEM", 138, 141], ["TP reincorporation", "TREATMENT", 142, 160], ["this problem", "PROBLEM", 189, 201], ["selective incorporation", "TREATMENT", 302, 325], ["nucleotide analogue", "TREATMENT", 337, 356], ["the corresponding antiviral effect", "PROBLEM", 361, 395], ["cell culture", "TEST", 408, 420], ["multiple nucleotides", "OBSERVATION", 94, 114]]], ["Half-maximal effective concentrations (EC50) of RDV against coronaviruses and filoviruses are in the submicromolar range, which is unusually low for a compound with a broad spectrum of antiviral activity (8, 10, 12, 14, 41).", [["RDV", "CHEMICAL", 48, 51], ["RDV", "SIMPLE_CHEMICAL", 48, 51], ["coronaviruses", "ORGANISM", 60, 73], ["RDV", "SPECIES", 48, 51], ["RDV", "PROBLEM", 48, 51], ["coronaviruses", "PROBLEM", 60, 73], ["filoviruses", "PROBLEM", 78, 89], ["antiviral activity", "TREATMENT", 185, 203], ["filoviruses", "OBSERVATION", 78, 89], ["submicromolar range", "OBSERVATION_MODIFIER", 101, 120], ["low", "OBSERVATION_MODIFIER", 141, 144], ["antiviral activity", "OBSERVATION", 185, 203]]], ["High potency in cell culture correlates with highly effective incorporation of RDV-TP with EBOV RdRp and, even more so, with the three coronavirus enzymes.", [["cell culture", "ANATOMY", 16, 28], ["RDV-TP", "CHEMICAL", 79, 85], ["cell", "CELL", 16, 20], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 79, 85], ["EBOV", "ORGANISM", 91, 95], ["RdRp", "ORGANISM", 96, 100], ["cell culture", "CELL_LINE", 16, 28], ["RDV", "PROTEIN", 79, 82], ["EBOV RdRp", "PROTEIN", 91, 100], ["coronavirus enzymes", "PROTEIN", 135, 154], ["EBOV", "SPECIES", 91, 95], ["cell culture", "TEST", 16, 28], ["RDV", "PROBLEM", 79, 82], ["TP", "PROBLEM", 83, 85], ["EBOV RdRp", "TREATMENT", 91, 100], ["the three coronavirus enzymes", "TEST", 125, 154], ["potency", "OBSERVATION_MODIFIER", 5, 12], ["cell culture", "OBSERVATION", 16, 28], ["EBOV RdRp", "OBSERVATION", 91, 100]]], ["Conversely, RDV shows a weak antiviral effect against LASV (10), and our biochemical data revealed low rates of incorporation by LASV RdRp.", [["RDV", "CHEMICAL", 12, 15], ["RDV", "SIMPLE_CHEMICAL", 12, 15], ["LASV", "ORGANISM", 54, 58], ["LASV RdRp", "ORGANISM", 129, 138], ["RDV", "PROTEIN", 12, 15], ["LASV RdRp", "PROTEIN", 129, 138], ["RDV", "SPECIES", 12, 15], ["LASV", "SPECIES", 54, 58], ["LASV RdRp", "SPECIES", 129, 138], ["a weak antiviral effect", "PROBLEM", 22, 45], ["our biochemical data", "TEST", 69, 89], ["low rates of incorporation", "PROBLEM", 99, 125], ["LASV RdRp", "TREATMENT", 129, 138], ["weak", "OBSERVATION_MODIFIER", 24, 28], ["antiviral", "OBSERVATION", 29, 38], ["low rates", "OBSERVATION", 99, 108], ["LASV RdRp", "OBSERVATION", 129, 138]]], ["In this context, it is also important to note that our previous measurements with human mitochondrial RNA polymerase revealed high selectivity of ATP over RDV-TP (9), which is consistent with low levels of cytotoxicity of RDV (8, 14).", [["mitochondrial", "ANATOMY", 88, 101], ["ATP", "CHEMICAL", 146, 149], ["RDV-TP", "CHEMICAL", 155, 161], ["RDV", "CHEMICAL", 222, 225], ["ATP", "CHEMICAL", 146, 149], ["RDV-TP", "CHEMICAL", 155, 161], ["RDV", "CHEMICAL", 222, 225], ["human", "ORGANISM", 82, 87], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["ATP", "SIMPLE_CHEMICAL", 146, 149], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 155, 161], ["RDV", "SIMPLE_CHEMICAL", 222, 225], ["human mitochondrial RNA polymerase", "PROTEIN", 82, 116], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["our previous measurements", "TEST", 51, 76], ["human mitochondrial RNA polymerase", "TEST", 82, 116], ["cytotoxicity of RDV", "PROBLEM", 206, 225], ["high selectivity", "OBSERVATION", 126, 142], ["consistent with", "UNCERTAINTY", 176, 191], ["low levels", "OBSERVATION_MODIFIER", 192, 202], ["cytotoxicity", "OBSERVATION_MODIFIER", 206, 218]]], ["Favipiravir-TP and ribavirin-TP are also less well-incorporated by SARS-CoV-2 RdRp.", [["Favipiravir", "CHEMICAL", 0, 11], ["TP", "CHEMICAL", 12, 14], ["ribavirin", "CHEMICAL", 19, 28], ["TP", "CHEMICAL", 29, 31], ["Favipiravir-TP", "CHEMICAL", 0, 14], ["ribavirin-TP", "CHEMICAL", 19, 31], ["Favipiravir-TP", "GENE_OR_GENE_PRODUCT", 0, 14], ["ribavirin-TP", "SIMPLE_CHEMICAL", 19, 31], ["SARS-CoV-2 RdRp", "ORGANISM", 67, 82], ["SARS-CoV-2 RdRp", "PROTEIN", 67, 82], ["SARS-CoV", "SPECIES", 67, 75], ["Favipiravir", "TREATMENT", 0, 11], ["TP", "TREATMENT", 12, 14], ["ribavirin", "TREATMENT", 19, 28], ["TP", "TREATMENT", 29, 31]]], ["This is also evident with a template that offers multiple incorporation sites (Fig. S2B).", [["a template", "TREATMENT", 26, 36], ["multiple incorporation sites", "PROBLEM", 49, 77], ["multiple", "OBSERVATION_MODIFIER", 49, 57], ["incorporation sites", "OBSERVATION", 58, 77]]], ["In cell culture, these inhibitors often show EC50 values in the higher micromolar range depending on the nature of the RNA virus (26, 41, 42).", [["cell culture", "ANATOMY", 3, 15], ["cell", "CELL", 3, 7], ["cell culture", "TEST", 3, 15], ["these inhibitors", "TEST", 17, 33], ["EC50 values", "TEST", 45, 56], ["the RNA virus", "PROBLEM", 115, 128], ["cell culture", "OBSERVATION", 3, 15], ["EC50 values", "OBSERVATION", 45, 56], ["higher micromolar", "OBSERVATION_MODIFIER", 64, 81], ["RNA virus", "OBSERVATION", 119, 128]]], ["High concentrations of favipiravir and ribavirin were also required to reduce infection with SARS-CoV-2 (EC50 = 109.50 \u03bcm and EC50 = 61.88 \u03bcm, respectively) (33).", [["favipiravir", "CHEMICAL", 23, 34], ["ribavirin", "CHEMICAL", 39, 48], ["infection", "DISEASE", 78, 87], ["SARS", "DISEASE", 93, 97], ["favipiravir", "CHEMICAL", 23, 34], ["ribavirin", "CHEMICAL", 39, 48], ["favipiravir", "SIMPLE_CHEMICAL", 23, 34], ["ribavirin", "SIMPLE_CHEMICAL", 39, 48], ["SARS-CoV", "SPECIES", 93, 101], ["favipiravir", "TREATMENT", 23, 34], ["ribavirin", "TREATMENT", 39, 48], ["infection", "PROBLEM", 78, 87], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["EC50", "TEST", 105, 109], ["EC50", "TEST", 126, 130], ["infection", "OBSERVATION", 78, 87]]], ["Moreover, ribavirin does not seem to provide clinical benefits in the context of SARS-CoV and MERS-CoV infection (41), 2\u2032-CMe-ATP is not utilized as a substrate by EBOV RdRp, and 2\u2032-C-methylated compounds show no significant antiviral effects in mini-genome replicons of EBOV (43).", [["ribavirin", "CHEMICAL", 10, 19], ["SARS", "DISEASE", 81, 85], ["infection", "DISEASE", 103, 112], ["ATP", "CHEMICAL", 126, 129], ["ribavirin", "CHEMICAL", 10, 19], ["ATP", "CHEMICAL", 126, 129], ["ribavirin", "SIMPLE_CHEMICAL", 10, 19], ["SARS-CoV", "ORGANISM", 81, 89], ["MERS-CoV", "ORGANISM", 94, 102], ["2\u2032-CMe-ATP", "SIMPLE_CHEMICAL", 119, 129], ["EBOV RdRp", "ORGANISM", 164, 173], ["2\u2032-C-methylated compounds", "SIMPLE_CHEMICAL", 179, 204], ["EBOV", "ORGANISM", 271, 275], ["SARS-CoV", "SPECIES", 81, 89], ["MERS-CoV", "SPECIES", 94, 102], ["EBOV", "SPECIES", 164, 168], ["EBOV", "SPECIES", 271, 275], ["ribavirin", "TREATMENT", 10, 19], ["SARS", "PROBLEM", 81, 85], ["CoV", "PROBLEM", 86, 89], ["MERS", "PROBLEM", 94, 98], ["CoV infection", "PROBLEM", 99, 112], ["EBOV RdRp", "TEST", 164, 173], ["C-methylated compounds", "TREATMENT", 182, 204], ["significant antiviral effects", "PROBLEM", 213, 242], ["no", "UNCERTAINTY", 210, 212], ["significant", "OBSERVATION_MODIFIER", 213, 224], ["antiviral effects", "OBSERVATION", 225, 242]]], ["Equivalent studies are not yet available for coronaviruses; however, the high selectivity for the natural nucleotides over SOF-TP and 2\u2032-CMe-ATP would not predict a potent antiviral effect.DiscussionIn conclusion, the combined data provide evidence for a unifying mechanism of inhibition of RDV-TP against coronavirus RdRp.", [["SOF-TP", "CHEMICAL", 123, 129], ["2\u2032-CMe", "CHEMICAL", 134, 140], ["ATP", "CHEMICAL", 141, 144], ["RDV-TP", "CHEMICAL", 291, 297], ["nucleotides", "CHEMICAL", 106, 117], ["SOF-TP", "CHEMICAL", 123, 129], ["2\u2032-CMe-ATP", "CHEMICAL", 134, 144], ["coronaviruses", "ORGANISM", 45, 58], ["SOF-TP", "SIMPLE_CHEMICAL", 123, 129], ["2\u2032-CMe-ATP", "SIMPLE_CHEMICAL", 134, 144], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 291, 297], ["coronavirus RdRp", "ORGANISM", 306, 322], ["RDV", "PROTEIN", 291, 294], ["coronavirus RdRp", "PROTEIN", 306, 322], ["coronavirus", "SPECIES", 306, 317], ["coronavirus RdRp", "SPECIES", 306, 322], ["Equivalent studies", "TEST", 0, 18], ["coronaviruses", "PROBLEM", 45, 58], ["the natural nucleotides", "PROBLEM", 94, 117], ["TP", "TEST", 127, 129], ["ATP", "TREATMENT", 141, 144], ["a potent antiviral effect", "PROBLEM", 163, 188], ["inhibition of RDV", "PROBLEM", 277, 294], ["TP", "TREATMENT", 295, 297], ["coronavirus RdRp", "PROBLEM", 306, 322], ["potent", "OBSERVATION_MODIFIER", 165, 171], ["antiviral effect", "OBSERVATION", 172, 188]]], ["Favorable selectivity for the nucleotide analogue over its natural counterpart ATP and delayed chain termination at position i+3 are key elements of inhibition observed with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes.", [["nucleotide", "CHEMICAL", 30, 40], ["ATP", "CHEMICAL", 79, 82], ["nucleotide", "CHEMICAL", 30, 40], ["ATP", "CHEMICAL", 79, 82], ["ATP", "SIMPLE_CHEMICAL", 79, 82], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 174, 182], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 184, 192], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 198, 208], ["SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes", "PROTEIN", 174, 223], ["SARS-CoV", "SPECIES", 174, 182], ["MERS-CoV", "SPECIES", 184, 192], ["the nucleotide analogue", "TREATMENT", 26, 49], ["delayed chain termination", "PROBLEM", 87, 112], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["MERS", "TEST", 184, 188], ["CoV", "TEST", 189, 192], ["SARS", "TEST", 198, 202], ["CoV", "TEST", 203, 206]]], ["The availability of human safety data along with the antiviral studies in cell culture and in animal models as well as a clear mechanism of action provide a large body of evidence to justify the ongoing clinical trials with RDV for the treatment of COVID-19 (8, 10, 12\u201317, 33).", [["cell culture", "ANATOMY", 74, 86], ["RDV", "CHEMICAL", 224, 227], ["COVID-19", "CHEMICAL", 249, 257], ["human", "ORGANISM", 20, 25], ["cell culture", "CELL", 74, 86], ["RDV", "SIMPLE_CHEMICAL", 224, 227], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["human safety data", "TEST", 20, 37], ["the antiviral studies", "TEST", 49, 70], ["cell culture", "TEST", 74, 86], ["RDV", "TREATMENT", 224, 227], ["COVID", "TEST", 249, 254]]], ["The refined biochemical mechanism described in this study characterizes RDV as a direct-acting antiviral (DAA).", [["RDV", "CHEMICAL", 72, 75], ["RDV", "CHEMICAL", 72, 75], ["RDV", "SIMPLE_CHEMICAL", 72, 75], ["DAA", "SIMPLE_CHEMICAL", 106, 109], ["RDV", "SPECIES", 72, 75], ["this study", "TEST", 47, 57], ["biochemical mechanism", "OBSERVATION", 12, 33]]], ["This term was previously introduced to describe newer classes of HCV drugs that target a specific process in the viral life cycle (44), as opposed to older treatments with interferon and ribavirin that have been associated with multiple possible mechanisms (45).", [["interferon", "CHEMICAL", 172, 182], ["ribavirin", "CHEMICAL", 187, 196], ["ribavirin", "CHEMICAL", 187, 196], ["HCV", "ORGANISM", 65, 68], ["interferon", "GENE_OR_GENE_PRODUCT", 172, 182], ["ribavirin", "SIMPLE_CHEMICAL", 187, 196], ["interferon", "PROTEIN", 172, 182], ["HCV", "SPECIES", 65, 68], ["HCV drugs", "TREATMENT", 65, 74], ["interferon", "TREATMENT", 172, 182], ["ribavirin", "TREATMENT", 187, 196]]], ["Compounds that are currently considered as potential treatments for COVID-19 include drugs approved for other conditions, repurposed drugs, and inhibitors with a broad spectrum of antiviral activities.", [["COVID-19", "CHEMICAL", 68, 76], ["COVID-19", "CHEMICAL", 68, 76], ["COVID-19", "SIMPLE_CHEMICAL", 68, 76], ["COVID", "TREATMENT", 68, 73], ["drugs", "TREATMENT", 85, 90], ["other conditions", "PROBLEM", 104, 120], ["repurposed drugs", "TREATMENT", 122, 138], ["inhibitors", "TREATMENT", 144, 154], ["antiviral activities", "TREATMENT", 180, 200], ["antiviral activities", "OBSERVATION", 180, 200]]], ["Research into underlying mechanisms is needed to classify any of these compounds as a DAA.Nucleic acids and chemicals ::: Experimental proceduresAll RNA primers and templates used for in this study were 5\u2032-phosphorylated and purchased from Dharmacon (Lafayette, CO).", [["Nucleic acids", "CHEMICAL", 90, 103], ["Nucleic acids", "SIMPLE_CHEMICAL", 90, 103], ["a DAA", "TREATMENT", 84, 89], ["Experimental procedures", "TREATMENT", 122, 145], ["All RNA primers", "TREATMENT", 145, 160], ["this study", "TEST", 187, 197], ["RNA primers", "OBSERVATION", 149, 160]]], ["2\u2032-CMe-ATP, RDV-TP, and SOF-TP were provided by Gilead Sciences (Foster City, CA).", [["ATP", "CHEMICAL", 7, 10], ["RDV", "CHEMICAL", 12, 15], ["2\u2032-CMe", "CHEMICAL", 0, 6], ["ATP", "CHEMICAL", 7, 10], ["RDV-TP", "CHEMICAL", 12, 18], ["SOF-TP", "CHEMICAL", 24, 30], ["2\u2032-CMe-ATP", "SIMPLE_CHEMICAL", 0, 10], ["RDV-TP", "SIMPLE_CHEMICAL", 12, 18], ["SOF-TP", "GENE_OR_GENE_PRODUCT", 24, 30], ["ATP", "TEST", 7, 10], ["RDV", "TEST", 12, 15], ["TP", "TEST", 16, 18]]], ["Ara-ATP, 2\u2032deoxy-2\u2032fluoro-CTP was purchased from TriLink (San Diego, CA).", [["Ara-", "CHEMICAL", 0, 4], ["ATP", "CHEMICAL", 4, 7], ["2\u2032deoxy-2\u2032fluoro-CTP", "CHEMICAL", 9, 29], ["ATP", "CHEMICAL", 4, 7], ["2\u2032deoxy-2\u2032fluoro-CTP", "CHEMICAL", 9, 29], ["Ara-", "SIMPLE_CHEMICAL", 0, 4], ["ATP", "SIMPLE_CHEMICAL", 4, 7], ["2\u2032deoxy-2\u2032fluoro-CTP", "SIMPLE_CHEMICAL", 9, 29], ["Ara-ATP", "TEST", 0, 7], ["deoxy", "TEST", 11, 16], ["CTP", "TEST", 26, 29]]], ["Ribavirin-TP was purchased from Jena Bioscience (Jena, Germany).", [["Ribavirin", "CHEMICAL", 0, 9], ["TP", "CHEMICAL", 10, 12], ["Ribavirin-TP", "CHEMICAL", 0, 12], ["Ribavirin-TP", "SIMPLE_CHEMICAL", 0, 12], ["Ribavirin", "TREATMENT", 0, 9], ["TP", "TREATMENT", 10, 12]]], ["Favipiravir-TP was purchased from Toronto Research Chemicals (North York, Ontario, Canada).", [["Favipiravir", "CHEMICAL", 0, 11], ["TP", "CHEMICAL", 12, 14], ["Favipiravir-TP", "CHEMICAL", 0, 14], ["Favipiravir-TP", "GENE_OR_GENE_PRODUCT", 0, 14], ["Favipiravir", "TREATMENT", 0, 11]]], ["NTPs and dATP were purchased from GE Healthcare. [\u03b1-32P]GTP was purchased from PerkinElmer Life Sciences.Protein expression and purification ::: Experimental proceduresThe pFastBac-1 (Invitrogen, Burlington, Ontario, Canada) plasmid with the codon-optimized synthetic DNA sequences (GenScript, Piscataway, NJ) coding for a portion of 1ab polyproteins of SARS-CoV (NCBI: AAP33696.1) and SARS-CoV-2 (NCBI: QHD43415.1) containing only nsp5, nsp7, nsp8, and nsp12 were used as a starting material for protein expression in insect cells (Sf9, Invitrogen).", [["cells", "ANATOMY", 526, 531], ["NTPs", "CHEMICAL", 0, 4], ["dATP", "CHEMICAL", 9, 13], ["[\u03b1-32P", "CHEMICAL", 49, 55], ["GTP", "CHEMICAL", 56, 59], ["SARS", "DISEASE", 354, 358], ["NTPs", "CHEMICAL", 0, 4], ["dATP", "CHEMICAL", 9, 13], ["[\u03b1-32P]GTP", "CHEMICAL", 49, 59], ["NTPs", "SIMPLE_CHEMICAL", 0, 4], ["dATP", "SIMPLE_CHEMICAL", 9, 13], ["[\u03b1-32P]GTP", "SIMPLE_CHEMICAL", 49, 59], ["pFastBac-1", "GENE_OR_GENE_PRODUCT", 172, 182], ["Invitrogen", "ORGANISM", 184, 194], ["DNA", "CELLULAR_COMPONENT", 268, 271], ["NJ", "GENE_OR_GENE_PRODUCT", 306, 308], ["SARS-CoV", "ORGANISM", 354, 362], ["SARS-CoV-2", "ORGANISM", 386, 396], ["nsp5", "GENE_OR_GENE_PRODUCT", 432, 436], ["nsp7", "GENE_OR_GENE_PRODUCT", 438, 442], ["nsp8", "GENE_OR_GENE_PRODUCT", 444, 448], ["nsp12", "GENE_OR_GENE_PRODUCT", 454, 459], ["insect cells", "CELL", 519, 531], ["Sf9", "CELL", 533, 536], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 538, 548], ["pFastBac-1 (Invitrogen, Burlington, Ontario, Canada) plasmid", "DNA", 172, 232], ["codon-optimized synthetic DNA sequences", "DNA", 242, 281], ["GenScript", "DNA", 283, 292], ["Piscataway", "DNA", 294, 304], ["NJ", "DNA", 306, 308], ["nsp5", "DNA", 432, 436], ["nsp7", "DNA", 438, 442], ["nsp8", "DNA", 444, 448], ["nsp12", "DNA", 454, 459], ["insect cells", "CELL_TYPE", 519, 531], ["Sf9", "PROTEIN", 533, 536], ["SARS-CoV", "SPECIES", 354, 362], ["SARS-CoV", "SPECIES", 386, 394], ["NTPs", "TREATMENT", 0, 4], ["dATP", "TREATMENT", 9, 13], ["Experimental procedures", "TREATMENT", 145, 168], ["The pFastBac", "TEST", 168, 180], ["plasmid", "TREATMENT", 225, 232], ["the codon-optimized synthetic DNA sequences", "TREATMENT", 238, 281], ["SARS", "PROBLEM", 354, 358], ["SARS-CoV", "TEST", 386, 394], ["nsp8", "TEST", 444, 448], ["nsp12", "TREATMENT", 454, 459], ["protein expression in insect cells", "PROBLEM", 497, 531]]], ["We employed the MultiBac (Geneva Biotech, Indianapolis, IN) system for protein expression in insect cells (Sf9, Invitrogen) according to published protocols (46, 47).", [["cells", "ANATOMY", 100, 105], ["Sf9", "ANATOMY", 107, 110], ["insect cells", "CELL", 93, 105], ["Sf9", "CELL", 107, 110], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 112, 122], ["insect cells", "CELL_TYPE", 93, 105], ["Sf9", "CELL_LINE", 107, 110], ["protein expression in insect cells", "PROBLEM", 71, 105]]], ["SARS-CoV and SARS-CoV-2 protein complexes were purified using nickel-nitrilotriacetic acid affinity chromatography of the nsp8 N-terminal 8-histidine tag according to the manufacturer's specifications (Thermo Scientific).", [["SARS", "DISEASE", 0, 4], ["nickel-nitrilotriacetic acid", "CHEMICAL", 62, 90], ["nsp8 N-terminal 8-histidine", "CHEMICAL", 122, 149], ["nickel-nitrilotriacetic acid", "CHEMICAL", 62, 90], ["N", "CHEMICAL", 127, 128], ["8-histidine", "CHEMICAL", 138, 149], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["nickel-nitrilotriacetic acid", "SIMPLE_CHEMICAL", 62, 90], ["SARS-CoV and SARS-CoV-2 protein complexes", "PROTEIN", 0, 41], ["nsp8 N-terminal 8-histidine tag", "PROTEIN", 122, 153], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["SARS", "PROBLEM", 13, 17], ["CoV-2 protein complexes", "TEST", 18, 41], ["nickel", "TEST", 62, 68], ["nitrilotriacetic acid affinity chromatography", "TEST", 69, 114], ["terminal 8-histidine tag", "TREATMENT", 129, 153]]], ["Expression and purification of EBOV RdRp complex were performed as described previously (48).", [["EBOV", "ORGANISM", 31, 35], ["RdRp", "ORGANISM", 36, 40], ["EBOV RdRp complex", "PROTEIN", 31, 48], ["EBOV RdRp", "SPECIES", 31, 40], ["EBOV RdRp complex", "PROBLEM", 31, 48]]], ["LASV L protein full-length (NCBI: AIT17397.1) was also expressed in insect cells through the Baculovirus expression system and purified using Strep-Tactin affinity chromatography (IBA Lifesciences, G\u00f6ttingen, Germany) of the N-terminal Strep-tag according to the manufacturer's specifications (IBA Lifesciences).", [["cells", "ANATOMY", 75, 80], ["LASV L", "GENE_OR_GENE_PRODUCT", 0, 6], ["insect cells", "CELL", 68, 80], ["Baculovirus", "ORGANISM", 93, 104], ["LASV L protein", "PROTEIN", 0, 14], ["insect cells", "CELL_TYPE", 68, 80], ["N-terminal Strep-tag", "PROTEIN", 225, 245], ["LASV", "SPECIES", 0, 4], ["Baculovirus", "SPECIES", 93, 104], ["LASV L protein", "TEST", 0, 14], ["the Baculovirus expression system", "TREATMENT", 89, 122], ["Strep", "TEST", 142, 147], ["Tactin affinity chromatography", "TEST", 148, 178], ["the N-terminal Strep-tag", "PROBLEM", 221, 245]]], ["The identities of the purified LASV, SARS-CoV, and SARS-CoV-2 proteins were confirmed by MS analysis (Dr. Jack Moore, Alberta Proteomics and Mass Spectrometry, Edmonton, Alberta, Canada).Evaluation of RNA synthesis and inhibition studies ::: Experimental proceduresRNA synthesis assays, data acquisition, and quantification were done as previously reported by us (9, 17, 48).", [["LASV", "ORGANISM", 31, 35], ["SARS-CoV", "ORGANISM", 37, 45], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["LASV", "PROTEIN", 31, 35], ["SARS-CoV, and SARS-CoV-2 proteins", "PROTEIN", 37, 70], ["LASV", "SPECIES", 31, 35], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 51, 59], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["MS analysis", "TEST", 89, 100], ["Alberta Proteomics", "TREATMENT", 118, 136], ["Mass Spectrometry", "TREATMENT", 141, 158], ["Evaluation of RNA synthesis", "TEST", 187, 214], ["inhibition studies", "TEST", 219, 237], ["Experimental proceduresRNA synthesis assays", "TEST", 242, 285], ["data acquisition", "TEST", 287, 303], ["quantification", "TEST", 309, 323], ["LASV", "OBSERVATION", 31, 35], ["RNA synthesis", "OBSERVATION", 201, 214]]], ["The following 5\u2032-monophosphorylated RNA templates were used in this study (the portion of the template that is complementary to the 4-nt primer is underlined): 3\u2032-UGCGCUAGAAAAAAp for measurements of the selectivity values of ATP analogues and determination of the patterns of inhibition with the incorporated RDV at a single position; 3\u2032-UGCGCUAGAGAGAGAGAGAGAGAGAGp for determination of the pattern of inhibition of LASV RdRp with the incorporated RDV at a single position but on a 26-nt template; 3\u2032-UGCGCUUGUAUAUUp for determination of the patterns of inhibition with the consecutively incorporated RDV; 3\u2032-UGCGGUACUUUAUUp for measurements of the selectivity values of favipiravir-TP and ribavirin-TP; 3\u2032-UGCGCGUAAAAAAAp for measurements of the selectivity values of 2\u2032-d2\u2032fluoro-CTP, and 3\u2032-UCGCGAUCUUUAUU for measurements of the selectivity values of sofosbuvir-TP.Evaluation of RNA synthesis and inhibition studies ::: Experimental proceduresBriefly, RNA synthesis assay consisted of mixing (final concentrations) Tris-HCl (pH 8, 25 mm), RNA primer (200 \u03bcm), RNA template (2 \u03bcm), [\u03b1-32P]NTP (0.1 \u03bcm), various concentrations and combinations (as indicated) of NTP and NTP analogues, and MERS-, SARS- and SARS-CoV-2 RdRp complex (\u223c0.1 \u03bcm) on ice.", [["ATP", "CHEMICAL", 225, 228], ["RDV", "CHEMICAL", 309, 312], ["RDV", "CHEMICAL", 448, 451], ["favipiravir", "CHEMICAL", 671, 682], ["TP", "CHEMICAL", 683, 685], ["ribavirin", "CHEMICAL", 690, 699], ["TP", "CHEMICAL", 700, 702], ["2\u2032-d2\u2032fluoro-CTP", "CHEMICAL", 769, 785], ["sofosbuvir-TP", "CHEMICAL", 855, 868], ["Tris-HCl", "CHEMICAL", 1019, 1027], ["\u03b1-32P", "CHEMICAL", 1086, 1091], ["NTP", "CHEMICAL", 1092, 1095], ["NTP", "CHEMICAL", 1164, 1167], ["NTP", "CHEMICAL", 1172, 1175], ["SARS", "DISEASE", 1198, 1202], ["ATP", "CHEMICAL", 225, 228], ["RDV", "CHEMICAL", 601, 604], ["favipiravir-TP", "CHEMICAL", 671, 685], ["ribavirin-TP", "CHEMICAL", 690, 702], ["3\u2032-UGCGCGUAAAAAAAp", "CHEMICAL", 704, 722], ["2\u2032-d2\u2032fluoro-CTP", "CHEMICAL", 769, 785], ["sofosbuvir-TP", "CHEMICAL", 855, 868], ["Tris-HCl", "CHEMICAL", 1019, 1027], ["[\u03b1-32P]NTP", "CHEMICAL", 1085, 1095], ["NTP", "CHEMICAL", 1164, 1167], ["NTP", "CHEMICAL", 1172, 1175], ["ATP", "SIMPLE_CHEMICAL", 225, 228], ["RDV", "SIMPLE_CHEMICAL", 309, 312], ["LASV", "ORGANISM", 416, 420], ["favipiravir-TP", "SIMPLE_CHEMICAL", 671, 685], ["ribavirin-TP", "SIMPLE_CHEMICAL", 690, 702], ["3\u2032-UGCGCGUAAAAAAAp", "SIMPLE_CHEMICAL", 704, 722], ["2\u2032-d2\u2032fluoro-CTP", "SIMPLE_CHEMICAL", 769, 785], ["sofosbuvir-TP", "GENE_OR_GENE_PRODUCT", 855, 868], ["Tris-HCl", "SIMPLE_CHEMICAL", 1019, 1027], ["[\u03b1-32P]NTP", "SIMPLE_CHEMICAL", 1085, 1095], ["NTP", "SIMPLE_CHEMICAL", 1164, 1167], ["NTP analogues", "SIMPLE_CHEMICAL", 1172, 1185], ["MERS", "SIMPLE_CHEMICAL", 1191, 1195], ["5\u2032-monophosphorylated RNA templates", "DNA", 14, 49], ["4-nt primer", "DNA", 132, 143], ["RDV", "PROTEIN", 309, 312], ["LASV RdRp", "PROTEIN", 416, 425], ["RDV", "PROTEIN", 448, 451], ["RNA primer", "RNA", 1043, 1053], ["SARS-CoV-2 RdRp complex", "PROTEIN", 1208, 1231], ["LASV RdRp", "SPECIES", 416, 425], ["The following 5\u2032-monophosphorylated RNA templates", "TREATMENT", 0, 49], ["this study", "TEST", 63, 73], ["ATP analogues", "TREATMENT", 225, 238], ["LASV RdRp", "TREATMENT", 416, 425], ["a 26-nt template", "TREATMENT", 480, 496], ["the selectivity values", "TEST", 645, 667], ["favipiravir", "TEST", 671, 682], ["TP", "TEST", 683, 685], ["ribavirin", "TREATMENT", 690, 699], ["the selectivity values", "TEST", 743, 765], ["CTP", "TEST", 782, 785], ["sofosbuvir", "TREATMENT", 855, 865], ["Evaluation of RNA synthesis", "TEST", 869, 896], ["inhibition studies", "TEST", 901, 919], ["Experimental procedures", "TREATMENT", 924, 947], ["RNA synthesis assay", "TEST", 956, 975], ["Tris", "TEST", 1019, 1023], ["HCl", "TEST", 1024, 1027], ["pH", "TEST", 1029, 1031], ["RNA primer", "TEST", 1043, 1053], ["RNA template", "TEST", 1064, 1076], ["NTP", "TEST", 1092, 1095], ["various concentrations", "PROBLEM", 1106, 1128], ["NTP", "TEST", 1164, 1167], ["NTP analogues", "TREATMENT", 1172, 1185], ["MERS", "TEST", 1191, 1195], ["SARS", "PROBLEM", 1198, 1202], ["SARS", "PROBLEM", 1208, 1212], ["CoV-2 RdRp complex", "TREATMENT", 1213, 1231], ["LASV RdRp", "OBSERVATION", 416, 425], ["sofosbuvir", "OBSERVATION", 855, 865], ["RNA synthesis", "OBSERVATION", 883, 896]]], ["Reactions with LASV L protein contained \u223c0.02 \u03bcm enzyme.", [["LASV L", "GENE_OR_GENE_PRODUCT", 15, 21], ["LASV L protein", "PROTEIN", 15, 29], ["\u223c0.02 \u03bcm enzyme", "PROTEIN", 40, 55], ["LASV", "SPECIES", 15, 19], ["LASV L protein", "TEST", 15, 29], ["\u03bcm enzyme", "TEST", 46, 55]]], ["Reaction mixtures (10 \u03bcl) were incubated for 10 min at 30 \u00b0C followed by the addition of 5 \u03bcl of MgCl2 (5 mm).", [["MgCl2", "CHEMICAL", 97, 102], ["MgCl2", "CHEMICAL", 97, 102], ["MgCl2", "SIMPLE_CHEMICAL", 97, 102], ["MgCl2", "TREATMENT", 97, 102]]], ["Reactions were stopped after 30 min by the addition of 15 \u03bcl of formamide/EDTA (50 mm) mixture and incubated at 95 \u00b0C for 10 min.", [["formamide/EDTA", "CHEMICAL", 64, 78], ["formamide", "CHEMICAL", 64, 73], ["EDTA", "CHEMICAL", 74, 78], ["formamide", "SIMPLE_CHEMICAL", 64, 73], ["EDTA", "SIMPLE_CHEMICAL", 74, 78], ["formamide/EDTA", "TREATMENT", 64, 78]]], ["Data were collected and analyzed using GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA) as reported previously (9, 17, 48).", [["GraphPad", "TEST", 39, 47], ["Prism", "TEST", 48, 53], ["GraphPad Software", "TEST", 59, 76]]], ["Our assay involves incorporation of [\u03b1-32P]GTP into the primer.", [["[\u03b1-32P", "CHEMICAL", 36, 42], ["GTP", "CHEMICAL", 43, 46], ["[\u03b1-32P]GTP", "CHEMICAL", 36, 46], ["[\u03b1-32P]GTP", "SIMPLE_CHEMICAL", 36, 46], ["Our assay", "TEST", 0, 9], ["GTP into the primer", "TREATMENT", 43, 62]]], ["With this approach, it is not possible to quantify the fraction of the extended primer; however, the reaction products are clearly defined by the correct incorporation of [\u03b1-32P]GTP.Structural model of elongating SARS-CoV-2 nsp12 ::: Experimental proceduresA model of the SARS-CoV-2 replication complex in its elongating state was constructed based on the recent cryo-EM structure of the apo-SARS-CoV nsp12/nsp7/nsp8 complex (PDB entry 6NUR) (1).", [["[\u03b1-32P", "CHEMICAL", 171, 177], ["GTP", "CHEMICAL", 178, 181], ["SARS", "DISEASE", 213, 217], ["SARS", "DISEASE", 272, 276], ["[\u03b1-32P]GTP", "CHEMICAL", 171, 181], ["[\u03b1-32P]GTP", "SIMPLE_CHEMICAL", 171, 181], ["apo-SARS-CoV", "GENE_OR_GENE_PRODUCT", 388, 400], ["nsp7", "GENE_OR_GENE_PRODUCT", 407, 411], ["nsp8", "GENE_OR_GENE_PRODUCT", 412, 416], ["SARS-CoV-2 replication complex", "PROTEIN", 272, 302], ["apo-SARS-CoV nsp12", "PROTEIN", 388, 406], ["nsp7", "PROTEIN", 407, 411], ["nsp8 complex", "PROTEIN", 412, 424], ["PDB entry 6NUR", "PROTEIN", 426, 440], ["SARS-CoV", "SPECIES", 272, 280], ["this approach", "TREATMENT", 5, 18], ["the reaction products", "PROBLEM", 97, 118], ["32P]GTP", "TREATMENT", 174, 181], ["elongating SARS", "TEST", 202, 217], ["the SARS", "PROBLEM", 268, 276], ["CoV-2 replication complex", "TREATMENT", 277, 302], ["the apo-SARS", "TEST", 384, 396], ["CoV nsp12", "TEST", 397, 406], ["not possible", "UNCERTAINTY", 26, 38], ["elongating", "OBSERVATION_MODIFIER", 202, 212], ["SARS", "OBSERVATION", 213, 217]]], ["With high sequence identity (nsp12 = 96%, nsp7 = 98%, nsp8 = 97%), a homology model was generated with Prime (49, 50).", [["nsp12", "TEST", 29, 34], ["nsp7", "TEST", 42, 46], ["nsp8", "TEST", 54, 58], ["a homology model", "TEST", 67, 83]]], ["To this, an X-ray structure of HCV RdRp in its elongating state (PDB entry 4WTD) (3) was aligned to the SARS-CoV-2 model.", [["HCV", "ORGANISM", 31, 34], ["HCV RdRp", "PROTEIN", 31, 39], ["HCV", "SPECIES", 31, 34], ["an X-ray structure", "TEST", 9, 27], ["HCV RdRp", "PROBLEM", 31, 39], ["HCV RdRp", "OBSERVATION", 31, 39]]], ["Rather than doing a whole structure alignment, key residues that interact with the RNA in the RNA binding channel were aligned.", [["RNA", "RNA", 83, 86], ["RNA binding channel", "PROTEIN", 94, 113], ["a whole structure alignment", "TREATMENT", 18, 45]]], ["These include Ala-97, Phe-193, Gly-283, and Ser-367 in NS5B and Ser-501, Gly-590, Gly-683, and Ser-814 in nsp12.", [["Ser-814", "CHEMICAL", 95, 102], ["Ala", "CHEMICAL", 14, 17], ["Phe", "CHEMICAL", 22, 25], ["Gly", "CHEMICAL", 31, 34], ["Ser", "CHEMICAL", 44, 47], ["Ser", "CHEMICAL", 64, 67], ["Gly", "CHEMICAL", 73, 76], ["Gly", "CHEMICAL", 82, 85], ["Ser", "CHEMICAL", 95, 98], ["Ala-97", "AMINO_ACID", 14, 20], ["Phe-193", "AMINO_ACID", 22, 29], ["Gly-283", "AMINO_ACID", 31, 38], ["Ser-367", "AMINO_ACID", 44, 51], ["NS5B", "GENE_OR_GENE_PRODUCT", 55, 59], ["Ser-501", "AMINO_ACID", 64, 71], ["Gly-590", "AMINO_ACID", 73, 80], ["Gly-683", "AMINO_ACID", 82, 89], ["Ser-814", "AMINO_ACID", 95, 102], ["nsp12", "GENE_OR_GENE_PRODUCT", 106, 111], ["NS5B", "PROTEIN", 55, 59], ["nsp12", "PROTEIN", 106, 111], ["Ala", "TEST", 14, 17], ["Phe", "TEST", 22, 25], ["Gly", "TEST", 31, 34], ["Ser", "TEST", 44, 47], ["NS5B", "TEST", 55, 59], ["Ser", "TEST", 64, 67], ["Gly", "TEST", 73, 76], ["Gly", "TEST", 82, 85], ["Ser", "TEST", 95, 98], ["nsp12", "TEST", 106, 111]]], ["The two Mn2+ ions and the ADP substrate from the HCV RdRp structure were changed to Mg2+ and ATP, and these, as well as the aligned RNA, were added to the SARS-CoV-2 model.", [["Mn2", "CHEMICAL", 8, 11], ["ADP", "CHEMICAL", 26, 29], ["Mg2", "CHEMICAL", 84, 87], ["ATP", "CHEMICAL", 93, 96], ["Mn2+", "CHEMICAL", 8, 12], ["ADP", "CHEMICAL", 26, 29], ["Mg2+", "CHEMICAL", 84, 88], ["ATP", "CHEMICAL", 93, 96], ["Mn2+ ions", "SIMPLE_CHEMICAL", 8, 17], ["ADP", "SIMPLE_CHEMICAL", 26, 29], ["Mg2+", "SIMPLE_CHEMICAL", 84, 88], ["ATP", "SIMPLE_CHEMICAL", 93, 96], ["Mn2", "PROTEIN", 8, 11], ["HCV RdRp structure", "PROTEIN", 49, 67], ["Mg2", "PROTEIN", 84, 87], ["HCV", "SPECIES", 49, 52], ["The two Mn2+ ions", "TREATMENT", 0, 17], ["the ADP substrate", "TREATMENT", 22, 39], ["the HCV RdRp structure", "PROBLEM", 45, 67], ["Mg2", "TEST", 84, 87], ["ATP", "TREATMENT", 93, 96], ["the SARS", "TEST", 151, 159], ["ions", "OBSERVATION", 13, 17], ["HCV RdRp", "OBSERVATION", 49, 57]]], ["Several active-site residues were manually adjusted to accommodate the incoming metals and substrate following the NS5B structure.", [["NS5B structure", "PROTEIN", 115, 129], ["Several active-site residues", "PROBLEM", 0, 28], ["the incoming metals", "TREATMENT", 67, 86], ["active", "OBSERVATION_MODIFIER", 8, 14], ["site residues", "OBSERVATION", 15, 28], ["NS5B", "OBSERVATION", 115, 119]]], ["These residues include Lys-545, Arg-555, Asp-618, Ser-682, Gly-683, Asp-760, and Asp-761.", [["Lys-545", "CHEMICAL", 23, 30], ["Gly-683, Asp-760", "CHEMICAL", 59, 75], ["Asp-761", "CHEMICAL", 81, 88], ["Lys", "CHEMICAL", 23, 26], ["Arg-555", "CHEMICAL", 32, 39], ["Asp", "CHEMICAL", 41, 44], ["Ser", "CHEMICAL", 50, 53], ["Gly", "CHEMICAL", 59, 62], ["Asp", "CHEMICAL", 68, 71], ["Asp-761", "CHEMICAL", 81, 88], ["Lys-545", "AMINO_ACID", 23, 30], ["Arg-555", "AMINO_ACID", 32, 39], ["Asp-618", "AMINO_ACID", 41, 48], ["Ser-682", "AMINO_ACID", 50, 57], ["Gly-683", "AMINO_ACID", 59, 66], ["Asp-760", "AMINO_ACID", 68, 75], ["Asp-761", "AMINO_ACID", 81, 88], ["These residues", "TEST", 0, 14], ["Lys", "TEST", 23, 26], ["Arg", "TEST", 32, 35], ["Asp", "TEST", 41, 44], ["Ser", "TEST", 50, 53], ["Gly", "TEST", 59, 62], ["Asp", "TEST", 68, 71], ["Asp", "TEST", 81, 84]]], ["This was followed by a series of constrained optimizations in both Prime and Macromodel (Schr\u00f6dinger, LLC, New York).", [["constrained optimizations", "TREATMENT", 33, 58], ["LLC", "ANATOMY", 102, 105]]], ["RDV-TP and other inhibitors were modeled into the nsp12 active site, allowing only limited protein flexibility.", [["RDV-TP", "CHEMICAL", 0, 6], ["RDV-TP", "CHEMICAL", 0, 6], ["RDV-TP", "GENE_OR_GENE_PRODUCT", 0, 6], ["nsp12", "GENE_OR_GENE_PRODUCT", 50, 55], ["nsp12 active site", "DNA", 50, 67], ["RDV", "TEST", 0, 3], ["TP", "TREATMENT", 4, 6], ["other inhibitors", "TREATMENT", 11, 27], ["TP", "ANATOMY", 4, 6], ["protein flexibility", "OBSERVATION", 91, 110]]], ["Homology models of other coronaviruses, including SARS and MERS, were generated from this model with Prime.Data availability ::: Experimental proceduresAll data are included within this article.Author contributionsC.", [["SARS", "DISEASE", 50, 54], ["coronaviruses", "ORGANISM", 25, 38], ["other coronaviruses", "PROBLEM", 19, 38], ["SARS", "PROBLEM", 50, 54], ["Experimental procedures", "TREATMENT", 129, 152], ["All data", "TEST", 152, 160], ["coronaviruses", "OBSERVATION", 25, 38]]], ["J. G., E. P. T., and M. G. data curation; C. J. G., E. P. T., J. K. P., and M. G. software; C. J. G., E. P. T., and M. G. formal analysis; C. J. G., E. P. T., and M. G. validation; C. J. G., E. P. T., E. W., J. K. P., and M. G. investigation; C. J. G., E. P.T., and M. G. visualization; C. J. G., E. P. T., E. W., J. K. P., and M. G. methodology; E. P. T. and M. G. conceptualization; E. P. T. and M. G. writing-original draft; E. P. T., J. K. P., J. Y. F., D. P. P., and M. G. writing-review and editing; M. G. resources; M. G. supervision; M. G. funding acquisition; M. G. project administration.", [["C. J. G., E. P. T.", "SPECIES", 92, 110], ["C. J. G., E. P. T.", "SPECIES", 139, 157], ["M. G. writing-original draft; E. P. T.", "SPECIES", 398, 436]]]], "PMC7144304": [["Why is a vaccine needed?While the first wave of this outbreak appears to be under control in many parts of China, there are a number of remaining concerns:When will new cases of infection stop emerging from the \u201cground zero\u201d Wuhan City?", [["infection", "DISEASE", 178, 187], ["a vaccine", "TREATMENT", 7, 16], ["this outbreak", "PROBLEM", 48, 61], ["infection", "PROBLEM", 178, 187], ["appears to be", "UNCERTAINTY", 62, 75], ["infection", "OBSERVATION", 178, 187]]], ["Since the real origin of infection is still not fully confirmed, a complete control of infection in Wuhan is essential for a sustained control in the whole country.Will there be any near-term resurging of cluster cases in other parts of China, including regions in Hubei beyond Wuhan, capital of the province?", [["infection", "DISEASE", 25, 34], ["infection", "DISEASE", 87, 96], ["infection", "PROBLEM", 25, 34], ["infection", "PROBLEM", 87, 96], ["infection", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 87, 96]]], ["But the cluster cases may pose a new threat for their potential to generate another regional outbreak.Will the world, especially those countries less prepared or with less healthcare resources, be able to handle the sudden appearance of cases at their doorstep?", [["another regional outbreak", "PROBLEM", 76, 101]]], ["The assumption of persistent transmission of SARS-2 at a global scale may no longer be so far-fetched.", [["SARS", "DISEASE", 45, 49], ["SARS-2", "GENE_OR_GENE_PRODUCT", 45, 51], ["persistent transmission of SARS", "PROBLEM", 18, 49], ["persistent", "OBSERVATION_MODIFIER", 18, 28], ["no longer", "UNCERTAINTY", 74, 83]]], ["Even if the virus does not bring a high mortality, the scenario of Community Acquired Coronavirus Infection (CACI) caused by a SARS type virus as part of our daily life will likely disrupt the world social and economic order.Why is a vaccine needed?The same calls for vaccines against SARS and Zika faded after the peak of those mysterious outbreaks, partially due to no public demand or limited commercial return to the vaccine investment.", [["Acquired Coronavirus Infection", "DISEASE", 77, 107], ["CACI", "DISEASE", 109, 113], ["SARS", "DISEASE", 127, 131], ["SARS", "DISEASE", 285, 289], ["SARS type virus", "ORGANISM", 127, 142], ["SARS type virus", "SPECIES", 127, 142], ["the virus", "PROBLEM", 8, 17], ["a high mortality", "PROBLEM", 33, 49], ["Community Acquired Coronavirus Infection", "PROBLEM", 67, 107], ["a SARS type virus", "PROBLEM", 125, 142], ["a vaccine", "TREATMENT", 232, 241], ["vaccines", "TREATMENT", 268, 276], ["SARS", "PROBLEM", 285, 289], ["Zika", "PROBLEM", 294, 298], ["public demand", "PROBLEM", 371, 384], ["the vaccine investment", "TREATMENT", 417, 439]]], ["However, a timely development of vaccines against SARS-2 is needed this time, not only for controlling the infection but also for stabilizing the global mood and bringing the economy back on track.The current efforts to quickly develop a SARS-2 vaccineThe good news now is that many entities have taken actions.", [["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 107, 116], ["SARS", "DISEASE", 238, 242], ["vaccines", "TREATMENT", 33, 41], ["SARS", "PROBLEM", 50, 54], ["the infection", "PROBLEM", 103, 116], ["the global mood", "PROBLEM", 142, 157], ["a SARS-2 vaccine", "TREATMENT", 236, 252], ["infection", "OBSERVATION", 107, 116], ["good", "OBSERVATION_MODIFIER", 256, 260]]], ["CEPI (Coalition for Epidemic Preparedness Innovations) [11] announced on January 23, 2020, the funding to three platform vaccine technologies, DNA, mRNA, and \u201cmolecular clamp\u201d, to develop vaccines against SARS-2.", [["CEPI", "CHEMICAL", 0, 4], ["SARS", "DISEASE", 205, 209], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["mRNA", "RNA", 148, 152], ["three platform vaccine technologies", "TREATMENT", 106, 141], ["\u201cmolecular clamp", "TREATMENT", 158, 174], ["SARS", "PROBLEM", 205, 209]]], ["CEPI's mission is to \u201caccelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.\u201d", [["infectious diseases", "DISEASE", 78, 97], ["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154], ["vaccines", "TREATMENT", 52, 60], ["emerging infectious diseases", "PROBLEM", 69, 97], ["these vaccines", "TREATMENT", 129, 143]]], ["The current outbreak will be the first major test to CEPI since its establishment in 2017.The current efforts to quickly develop a SARS-2 vaccineThere is a growing list of global public and private institutions joining the efforts to develop vaccines against SARS-2.", [["SARS", "DISEASE", 131, 135], ["SARS", "DISEASE", 259, 263], ["a SARS-2 vaccine", "TREATMENT", 129, 145], ["vaccines", "TREATMENT", 242, 250], ["SARS", "PROBLEM", 259, 263], ["growing", "OBSERVATION_MODIFIER", 156, 163]]], ["The US NIAID Vaccine Research Centre (VRC) is drawing on broad research experience with coronaviruses, combined with a wide network of collaborators from academia, other government agencies, and industry, on the development of various SARS-2 vaccine candidates.", [["SARS", "DISEASE", 235, 239], ["coronaviruses", "ORGANISM", 88, 101], ["The US NIAID Vaccine", "TREATMENT", 0, 20], ["coronaviruses", "PROBLEM", 88, 101], ["various SARS", "PROBLEM", 227, 239]]], ["Biotech and traditional vaccine companies in many countries announced their plans to quickly develop vaccines using their respective technologies.The current efforts to quickly develop a SARS-2 vaccineFrom very early in the onset of this outbreak, China demonstrated confidence in developing a vaccine against this viral infection.", [["SARS", "DISEASE", 187, 191], ["viral infection", "DISEASE", 315, 330], ["Biotech and traditional vaccine", "TREATMENT", 0, 31], ["vaccines", "TREATMENT", 101, 109], ["a SARS", "PROBLEM", 185, 191], ["a vaccine", "TREATMENT", 292, 301], ["this viral infection", "PROBLEM", 310, 330], ["infection", "OBSERVATION", 321, 330]]], ["More recently, the official announcement by the Chinese Health Commission indicated that at least five vaccine technologies will be explored: inactivated vaccine, subunit protein vaccine, nucleic acid vaccine, adenoviral vector vaccine, and recombinant influenza viral vector vaccine.", [["nucleic acid", "CHEMICAL", 188, 200], ["nucleic acid", "SIMPLE_CHEMICAL", 188, 200], ["adenoviral", "ORGANISM", 210, 220], ["recombinant influenza viral", "ORGANISM", 241, 268], ["subunit protein", "PROTEIN", 163, 178], ["adenoviral", "SPECIES", 210, 220], ["five vaccine technologies", "TREATMENT", 98, 123], ["inactivated vaccine", "TREATMENT", 142, 161], ["subunit protein vaccine", "TREATMENT", 163, 186], ["nucleic acid vaccine", "TREATMENT", 188, 208], ["adenoviral vector vaccine", "TREATMENT", 210, 235], ["recombinant influenza viral vector vaccine", "TREATMENT", 241, 283]]], ["With the growing size of the domestic vaccine industry in recent years, China vaccine developers are expected to announce multiple leading candidate vaccines in the near future.What are the challengesThe vaccine industry based on the empirical technology has made major contributions to human health over the last 100 years.", [["human", "ORGANISM", 287, 292], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 287, 292], ["China vaccine", "TREATMENT", 72, 85], ["multiple leading candidate vaccines", "TREATMENT", 122, 157], ["The vaccine industry", "TREATMENT", 200, 220], ["growing", "OBSERVATION_MODIFIER", 9, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["domestic", "OBSERVATION_MODIFIER", 29, 37]]], ["However, vaccine science is still young in light of the modern immunology and molecular microbiology which have contributed to the requirement of a longer time to develop a new vaccine.", [["a new vaccine", "TREATMENT", 171, 184]]], ["Enhanced safety concerns, increasingly complicated manufacturing processes, and related assay requirements are adding to the time and cost for new vaccine development.", [["increasingly complicated manufacturing processes", "PROBLEM", 26, 74], ["related assay requirements", "PROBLEM", 80, 106], ["new vaccine development", "TREATMENT", 143, 166]]], ["A new set of rules and standards will need to be adopted to balance the competing scientific, technical, regulatory, and public health considerations, if a quick response SARS-2 vaccine needs to be developed for near future clinical use.What are the challengesIn recent years, immune correlates of protection are increasingly asked for a candidate vaccine [12].", [["SARS", "DISEASE", 171, 175], ["a quick response SARS-2 vaccine", "TREATMENT", 154, 185], ["a candidate vaccine", "TREATMENT", 336, 355]]], ["At the same time, vaccine development is still far from being a perfect science.", [["vaccine", "TREATMENT", 18, 25]]], ["The discontinuation of HVTN702 reported within the last few weeks reminded us again of the big gap between science and the development of an HIV vaccine after almost four decades\u2019 effort.", [["HVTN702", "CHEMICAL", 23, 30], ["HVTN702", "CHEMICAL", 23, 30], ["HIV", "SPECIES", 141, 144], ["HVTN702", "TREATMENT", 23, 30], ["an HIV vaccine", "TREATMENT", 138, 152]]], ["Will protective antibody responses be the targeted immune responses for various vaccine programs against SARS-2?", [["SARS", "DISEASE", 105, 109], ["various vaccine programs", "TREATMENT", 72, 96], ["SARS", "PROBLEM", 105, 109]]], ["Given the potential challenge in quickly organizing efficacy studies, the animal models against challenge will be extremely valuable for selecting the candidates into humans.What are the challengesTraditional vaccine technologies need improvement and a wide variety of new technologies have emerged in the last two decades [13].", [["humans", "ORGANISM", 167, 173], ["humans", "SPECIES", 167, 173], ["humans", "SPECIES", 167, 173], ["efficacy studies", "TEST", 52, 68], ["Traditional vaccine technologies", "TREATMENT", 197, 229]]], ["Given the unique requirements of a vaccine against the rapidly spreading emerging viral infection, vaccine technologies with previous human study experience will have the advantage, especially for the consideration of safety.", [["viral infection", "DISEASE", 82, 97], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["a vaccine", "TREATMENT", 33, 42], ["viral infection", "PROBLEM", 82, 97], ["vaccine technologies", "TREATMENT", 99, 119], ["previous human study", "TEST", 125, 145], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97]]], ["Furthermore, whether the developer can quickly move its vaccine technology into a scale-up GMP production for potentially 10-million doses is another challenge.", [["GMP", "CHEMICAL", 91, 94], ["GMP", "CHEMICAL", 91, 94], ["GMP", "SIMPLE_CHEMICAL", 91, 94], ["a scale", "TEST", 80, 87]]], ["Anyone with an existing facility and the experience of such production will be in a much more favourable position.What are the challengesThe challenge to the regulatory agencies for a timely SARS-2 vaccine is similar to that of the vaccine developers.", [["SARS", "DISEASE", 191, 195], ["a timely SARS-2 vaccine", "TREATMENT", 182, 205]]], ["Safety evaluation of a candidate vaccine against SARS-2 will receive high-level attention.", [["SARS", "DISEASE", 49, 53], ["Safety evaluation", "TEST", 0, 17], ["a candidate vaccine", "TREATMENT", 21, 40], ["SARS", "PROBLEM", 49, 53], ["high-level attention", "TREATMENT", 69, 89]]], ["The immunopathogenesis plays a major role in SARS-2 infection and thus it is important to ensure that vaccines against this virus should not elicit the same type of detrimental immune responses.", [["SARS-2 infection", "DISEASE", 45, 61], ["SARS-2", "GENE_OR_GENE_PRODUCT", 45, 51], ["SARS", "PROBLEM", 45, 49], ["2 infection", "PROBLEM", 50, 61], ["vaccines", "TREATMENT", 102, 110], ["this virus", "PROBLEM", 119, 129], ["infection", "OBSERVATION", 52, 61]]], ["This will affect the type of vaccines to be selected and immunogens to be designed.", [["vaccines", "TREATMENT", 29, 37], ["immunogens", "TREATMENT", 57, 67]]], ["Will a qualified manufacturing process be sufficient for the advancement of a candidate vaccine or it has to be validated?", [["a qualified manufacturing process", "TREATMENT", 5, 38], ["a candidate vaccine", "TREATMENT", 76, 95]]], ["Can the manufacturing and regulatory experience achieved in other countries be applied to the review of a vaccine application in the current country?", [["a vaccine application", "TREATMENT", 104, 125]]], ["Can the cell banks or other intermediate products be accepted across country borders?", [["cell", "ANATOMY", 8, 12], ["cell", "CELL", 8, 12], ["cell banks", "OBSERVATION", 8, 18]]], ["Will the political or commercial considerations become the barriers to the global effort in addressing the urgent need of a SARS-2 vaccine?What are the challengesFinally, the planning should start now on how to let the world have equal access to a successful SARS-2 vaccine if the need is global.", [["SARS", "DISEASE", 124, 128], ["SARS", "DISEASE", 259, 263], ["a SARS-2 vaccine", "TREATMENT", 122, 138], ["a successful SARS-2 vaccine", "TREATMENT", 246, 273]]], ["The following issues need to be addressed: vaccine ownership, the funding for production at an unprecedented scale, the pricing and supply chain, and the coordinated administration of such a vaccine to achieve the best outcome of full control of the endemic.A vaccine beyond the current outbreakEven if the global spread of SARS-2 is finally under control before a successful vaccine is fully developed, the vaccine community and world public health leaders need to decide whether a SARS-2 vaccine still should be licensed to serve as a template for vaccines in the future to prevent the outbreaks of other SARS-like viruses.", [["SARS", "DISEASE", 324, 328], ["SARS", "DISEASE", 483, 487], ["SARS-like viruses", "DISEASE", 607, 624], ["SARS-2", "GENE_OR_GENE_PRODUCT", 324, 330], ["SARS-2", "ORGANISM", 483, 489], ["SARS-like viruses", "ORGANISM", 607, 624], ["a vaccine", "TREATMENT", 189, 198], ["A vaccine", "TREATMENT", 258, 267], ["SARS", "PROBLEM", 324, 328], ["a successful vaccine", "TREATMENT", 363, 383], ["a SARS-2 vaccine", "TREATMENT", 481, 497], ["a template for vaccines", "TREATMENT", 535, 558], ["other SARS", "PROBLEM", 601, 611], ["global", "OBSERVATION_MODIFIER", 307, 313], ["spread", "OBSERVATION_MODIFIER", 314, 320], ["viruses", "OBSERVATION", 617, 624]]], ["Within 18 years, the world has witnessed three major emerging pathogenic beta coronaviruses (SARS, MERS, and SARS-2) entering large human populations.", [["SARS", "DISEASE", 93, 97], ["SARS", "DISEASE", 109, 113], ["beta coronaviruses", "ORGANISM", 73, 91], ["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["pathogenic beta coronaviruses", "PROBLEM", 62, 91], ["large human populations", "PROBLEM", 126, 149], ["beta coronaviruses", "OBSERVATION", 73, 91]]], ["It may not be too ambitious to suggest a vaccine that can provide broad coverage against more than one of these pathogenic viruses to prevent for future outbreaks.A vaccine beyond the current outbreakIt is generally agreed that developing a new vaccine needs many years\u2019 efforts.", [["a vaccine", "TREATMENT", 39, 48], ["broad coverage", "TREATMENT", 66, 80], ["these pathogenic viruses", "PROBLEM", 106, 130], ["A vaccine", "TREATMENT", 163, 172], ["a new vaccine", "TREATMENT", 239, 252], ["viruses", "OBSERVATION", 123, 130]]], ["However, the development of vaccines in recent years against EV71, a highly pathogenic virus causing severe Hand, Foot and Mouth Disease (HFMD) in children, has provided a good example that it is possible to develop a vaccine against a modern emerging infection [14,15].", [["EV71", "DISEASE", 61, 65], ["Hand, Foot and Mouth Disease", "DISEASE", 108, 136], ["HFMD", "DISEASE", 138, 142], ["infection", "DISEASE", 252, 261], ["EV71", "ORGANISM", 61, 65], ["children", "ORGANISM", 147, 155], ["children", "SPECIES", 147, 155], ["EV71", "SPECIES", 61, 65], ["vaccines", "TREATMENT", 28, 36], ["EV71", "PROBLEM", 61, 65], ["a highly pathogenic virus", "PROBLEM", 67, 92], ["severe Hand, Foot and Mouth Disease", "PROBLEM", 101, 136], ["a vaccine", "TREATMENT", 216, 225], ["a modern emerging infection", "PROBLEM", 234, 261], ["pathogenic virus", "OBSERVATION", 76, 92], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["Foot", "ANATOMY", 114, 118], ["Mouth", "ANATOMY", 123, 128], ["Disease", "OBSERVATION", 129, 136], ["infection", "OBSERVATION", 252, 261]]], ["Hopefully, it can be even faster this time and possibly using newer vaccine technologies.", [["newer vaccine technologies", "TREATMENT", 62, 88]]]], "eab669f62aaa3d0902770bf881b084ba349dee5e": [["AbsTrACTCountries throughout the world are counting the health and socioeconomic costs of the COVID-19 pandemic, including the strategies necessary to contain it.", [["the COVID", "TREATMENT", 90, 99], ["the strategies", "TREATMENT", 123, 137]]], ["Profound consequences from social isolation are beginning to emerge, and there is an urgency about charting a path to recovery, albeit to a 'new normal' that mitigates them.", [["Profound consequences", "PROBLEM", 0, 21], ["social isolation", "TREATMENT", 27, 43], ["an urgency", "PROBLEM", 82, 92], ["social isolation", "OBSERVATION", 27, 43]]], ["Children have not suffered as much from the direct effects of COVID-19 infection as older adults.", [["COVID-19", "CHEMICAL", 62, 70], ["infection", "DISEASE", 71, 80], ["Children", "ORGANISM", 0, 8], ["COVID-19", "ORGANISM", 62, 70], ["Children", "SPECIES", 0, 8], ["COVID-19 infection", "PROBLEM", 62, 80], ["infection", "OBSERVATION", 71, 80]]], ["Closure of schools has been a critical component of social isolation but has a far broader impact than the diminution of educational opportunities, as important as these are.", [["social isolation", "TREATMENT", 52, 68], ["social isolation", "OBSERVATION", 52, 68]]], ["Children's interests are vital considerations in any recovery plan, but the question remains as to how to address them within the context of how society views children; should they be regarded as pawns, pathfinders or partners in this enterprise?sCienTifiC And eThiCAl guidAnCeAs countries emerge from lockdown, the true effects of widespread social isolation can be assessed.", [["CienTifiC", "CHEMICAL", 247, 256], ["CienTifiC", "CHEMICAL", 247, 256], ["children", "ORGANISM", 159, 167], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 159, 167], ["eThiCAl guidAnCeAs countries", "TREATMENT", 261, 289], ["widespread social isolation", "TREATMENT", 332, 359], ["widespread", "OBSERVATION_MODIFIER", 332, 342], ["social isolation", "OBSERVATION", 343, 359]]], ["1 Covid-19 infection has been comparatively benign in children, but there is mounting evidence that their health and welfare have been aversely affected by social measures to control the pandemic.", [["infection", "DISEASE", 11, 20], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["infection", "PROBLEM", 11, 20], ["the pandemic", "PROBLEM", 183, 195], ["infection", "OBSERVATION", 11, 20], ["benign", "OBSERVATION_MODIFIER", 44, 50]]], ["2 The UK response to COVID-19 has been guided by science, operating within an ethical framework developed in response to previous pandemic threats.", [["COVID-19", "CHEMICAL", 21, 29], ["COVID-19", "CHEMICAL", 21, 29], ["UK", "GENE_OR_GENE_PRODUCT", 6, 8], ["COVID-19", "DNA", 21, 29], ["COVID", "TEST", 21, 26]]], ["There have been little scientific data to guide how children might be involved in the recovery from social isolation.", [["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["social isolation", "TREATMENT", 100, 116], ["little", "OBSERVATION_MODIFIER", 16, 22]]], ["COVID-19 seems to have, at least initially, affected children less severely than adults with <2% of infected children needing critical care and mercifully few deaths.", [["deaths", "DISEASE", 159, 165], ["children", "ORGANISM", 53, 61], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 53, 61], ["children", "SPECIES", 109, 117], ["critical care", "TREATMENT", 126, 139]]], ["4 5 But the extent to which they may be asymptomatic carriers is unclear, though they do not appear to be super spreaders.", [["asymptomatic carriers", "PROBLEM", 40, 61], ["may be", "UNCERTAINTY", 33, 39], ["asymptomatic", "OBSERVATION", 40, 52]]], ["In this context, school closures may have a relatively small contribution in preventing the spread of the virus when compared with other social distancing techniques but have profound adverse socioeconomic effects.", [["school closures", "TREATMENT", 17, 32], ["the virus", "PROBLEM", 102, 111], ["profound adverse socioeconomic effects", "PROBLEM", 175, 213], ["relatively", "OBSERVATION_MODIFIER", 44, 54], ["small", "OBSERVATION_MODIFIER", 55, 60]]], ["6 Also, the relationship between past exposure and consequent immune status is currently unknown, but plainly essential information in considering children's potential part in the recovery process.", [["children", "ORGANISM", 147, 155], ["children", "SPECIES", 147, 155]]], ["The role of specific host defence factors, genetic factors, ethnicity and socioeconomic deprivation (the latter two parameters seemingly related to COVID-19 susceptibility and severity in adults) is also not known-though all are important in other childhood diseases.", [["host defence factors", "PROTEIN", 21, 41], ["genetic factors", "PROTEIN", 43, 58], ["genetic factors", "PROBLEM", 43, 58], ["socioeconomic deprivation", "PROBLEM", 74, 99], ["COVID", "TEST", 148, 153]]], ["In the sense that they operate in childhood, they create additional jeopardy to any conferred by the state of childhood per se.sCienTifiC And eThiCAl guidAnCeEthical guidance so far issued makes no specific provision or concession for children-or indeed any vulnerable group, or those with instrumental value to society, 3 but is founded on the principle of equal concern and respect.", [["CienTifiC", "CHEMICAL", 128, 137], ["CienTifiC", "CHEMICAL", 128, 137], ["children", "ORGANISM", 235, 243], ["children", "SPECIES", 235, 243], ["eThiCAl guidAnCeEthical guidance", "TREATMENT", 142, 174]]], ["Application of the underpinning principles of inclusivity, respect, solidarity, proportionality and reciprocity necessarily entail that the interests of children are given as much weight by society as those of adults.", [["children", "ORGANISM", 153, 161], ["children", "SPECIES", 153, 161]]], ["It is not clear the extent to which application of this principle to children has occurred.", [["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["clear", "OBSERVATION", 10, 15]]], ["Indeed, it may be the case that children effectively continue to be regarded as pawns, insofar as their interests can be sacrificed by others in pursuit of other goals-as they have in the past.", [["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40]]], ["7Children as pawnsTraditional moral theories grant children limited moral status, broadly proportionate to their state of moral development; others have ethical and legal authority to make appropriate decisions on their behalf.", [["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59]]], ["Granting children rights confers some moral agency; the UN Convention on the Rights of the Child provides protection, welfare and education rights, irrespective of the child's ability to claim them.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17]]], ["8 This Convention would apply to children's involvement in the recovery from lockdown, for example, return to school, even if a consequence was of significant concomitant benefit to adults such as the ability of parents to return to work, improvement of family social circumstances and mental health.", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41]]], ["It follows that children, even if they had no say in the process, should receive adequate protection, for example, by provision of appropriate public health facilities and social distancing.", [["children", "ORGANISM", 16, 24], ["children", "SPECIES", 16, 24]]], ["Adequate and appropriate PPE for staff and supporters is an essential requirement for all staged returns to school.Children as pawnsNevertheless, contemporary thinking about childhood accords children more active roles and a voice in matters that concern them.", [["Children", "ORGANISM", 115, 123], ["children", "ORGANISM", 192, 200], ["Children", "SPECIES", 115, 123], ["children", "SPECIES", 192, 200]]], ["Current controversyChildren as pathfindersA staged return to the 'new normal' might plausibly cast children in a pathfinder role.", [["Children", "ORGANISM", 19, 27], ["children", "ORGANISM", 99, 107], ["Children", "SPECIES", 19, 27], ["children", "SPECIES", 99, 107]]], ["In the case of children's return to school, this might mean that older children, whose educational prospects and crucial examinations have been compromised, might lead the process, with appropriate safeguards, and use of technology such as track and trace apps.", [["children", "ORGANISM", 15, 23], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 15, 23], ["children", "SPECIES", 71, 79], ["crucial examinations", "TEST", 113, 133]]], ["An additional reason for selecting older children might be that they are more likely to have the capacity to give valid consent for the use of technology and for minimally invasive testing, for example, swabs and blood sampling necessary to safeguard the process.", [["blood", "ANATOMY", 213, 218], ["children", "ORGANISM", 41, 49], ["blood", "ORGANISM_SUBSTANCE", 213, 218], ["children", "SPECIES", 41, 49], ["minimally invasive testing", "TEST", 162, 188], ["swabs", "TEST", 203, 208], ["blood sampling", "TEST", 213, 227]]], ["Arguably they might be more likely to comply with hand hygiene social distancing and understand the need to do so.Children as pathfindersIf predetermined endpoints could document the efficacy and safety of this approach, it could be useful in extending the return to school more widely.", [["hand", "ANATOMY", 50, 54], ["hand", "ORGANISM_SUBDIVISION", 50, 54], ["Children", "ORGANISM", 114, 122], ["Children", "SPECIES", 114, 122], ["this approach", "TREATMENT", 206, 219]]], ["It would also encourage the more active involvement of children in the process, be compatible with participation rights as granted by the United Nations Convention on the Rights of the Child (UNRC) and give participants a sense of inclusivity and partnership that would be of social utility.Children as partnersIt might seem to strain credulity to regard children as partners in the easing of lockdown; after all, they may lack the ability to define and claim the liberty rights that adults have.", [["children", "ORGANISM", 55, 63], ["Children", "ORGANISM", 291, 299], ["children", "ORGANISM", 355, 363], ["adults", "ORGANISM", 484, 490], ["children", "SPECIES", 55, 63], ["participants", "SPECIES", 207, 219], ["Children", "SPECIES", 291, 299], ["children", "SPECIES", 355, 363]]], ["9 However, they will inhabit the new normal, with all its attendant socioeconomic changes, just as inevitably as adults will.", [["new", "OBSERVATION_MODIFIER", 33, 36], ["normal", "OBSERVATION", 37, 43]]], ["In support of this concept of partnership and participation, article 12 of the UNRC requires children to be informed and consulted over matters that concern them and that their views be given due weight in accordance with their age and maturity.", [["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101]]], ["8 In recent years, children have become actively involved in healthcare, 10 11 research 12 and as activists for prevention of climate change.", [["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27]]], ["13 Some children have shown the capacity for self-directed acts of kindness and altruism, in keeping with a level of moral development that some adults may never achieve.", [["children", "ORGANISM", 8, 16], ["adults", "ORGANISM", 145, 151], ["children", "SPECIES", 8, 16]]], ["14 In short, their evolving moral agency throughout childhood is unquestionable, and for many of serious weight before adulthood.Children as partnersBecause of the attendant uncertainties attached to the easing of lockdown, such as the existence of any second wave of infection and its containment, easing can be considered an experimental procedure in which children, in common with other groups, are de facto research subjects.", [["infection", "DISEASE", 268, 277], ["Children", "ORGANISM", 129, 137], ["children", "ORGANISM", 359, 367], ["Children", "SPECIES", 129, 137], ["children", "SPECIES", 359, 367], ["infection", "PROBLEM", 268, 277], ["an experimental procedure", "TREATMENT", 324, 349], ["short", "OBSERVATION_MODIFIER", 6, 11], ["moral agency", "OBSERVATION", 28, 40], ["infection", "OBSERVATION", 268, 277]]], ["Since children are increasingly active participants in the identification of research topics and the design and implementation of trials, it seems logical to include them in this 'project', especially as they will experience the future consequences of the pandemic.", [["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["participants", "SPECIES", 39, 51], ["trials", "TREATMENT", 130, 136], ["the pandemic", "PROBLEM", 252, 264], ["active", "OBSERVATION_MODIFIER", 32, 38]]], ["Children in common with others need clear explanations of the risks and benefits of leaving lockdown in terms that they can understand.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["If future societies (including today's children) are to retain trust in governmental strategies, it is essential that governments 'show their working out'; the principles of ethical decision-making require transparency, accountability and reasonableness.ConClusionsSociety has a clear duty to protect children from the harms that the pandemic and the means to control it can cause.", [["children", "ORGANISM", 39, 47], ["children", "ORGANISM", 301, 309], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 301, 309]]], ["But, necessary as this is, children should be more than passive recipients of our concern, they are after all future citizens with a right to an open future.", [["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35]]], ["15 Post COVID-19, we need to build a new normal, that is a kinder, more inclusive and equal society, in which today's children are to be active members.", [["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["COVID", "TEST", 8, 13], ["new", "OBSERVATION_MODIFIER", 37, 40], ["normal", "OBSERVATION", 41, 47]]]], "ccfb2c36ed846669870272ce39b37b0555a80c40": [["I. INTRODUCTIONPercolation and epidemic spreading are among the most interesting processes unfolding on complex network substrates, and their investigation has attracted a huge interest in the past 20 years [1] [2] [3] [4] [5] .", [["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 207, 226], ["INTRODUCTIONPercolation", "TREATMENT", 3, 26], ["epidemic spreading", "PROBLEM", 31, 49]]], ["One of the most successful achievements of this endeavor is the realization that the properties of one of the fundamental models for epidemics without a steady state, the susceptible-infected-recovered (SIR) dynamics [6] , can be mapped onto bond percolation [7] [8] [9] .", [["epidemics", "PROBLEM", 133, 142]]], ["This connection has permitted the application to the SIR model of the powerful tools devised for percolation, leading to a full understanding of this epidemic process [8, [10] [11] [12] [13] .", [["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 171, 190], ["this epidemic process", "PROBLEM", 145, 166]]], ["For the other fundamental class of epidemic dynamics, allowing for a steady, endemic state, whose simplest representative is the susceptible-infectedsusceptible (SIS) model [6] , no direct mapping to a percolative framework is available, and theoretical progress has been slower.", [["a steady, endemic state", "PROBLEM", 67, 90], ["direct mapping", "TEST", 182, 196], ["slower", "OBSERVATION_MODIFIER", 272, 278]]], ["In the SIS model, susceptible individuals acquire the disease at rate \u03b2 through any edge connected to an infected individual, while infected individuals spontaneously heal with rate \u03bc.", [["individuals", "ORGANISM", 30, 41], ["individuals", "ORGANISM", 141, 152], ["susceptible individuals", "PROBLEM", 18, 41], ["the disease", "PROBLEM", 50, 61], ["an infected individual", "PROBLEM", 102, 124], ["infected", "OBSERVATION", 105, 113]]], ["The epidemic threshold \u03bb c defines the value of the ratio \u03bb \u00bc \u03b2=\u03bc separating a healthy (absorbing) phase from an endemic one with everlasting activity.", [["the value", "TEST", 35, 44], ["the ratio", "TEST", 48, 57]]], ["Initial work showed that degree heterogeneity leads to disruptive effects on scale-free networks [14] , namely, a vanishing threshold in networks with power-law degree distribution P\u00f0k\u00de \u223c k \u2212\u03b3 and \u03b3 \u2264 3 [15, 16] .", [["degree heterogeneity", "PROBLEM", 25, 45], ["disruptive effects", "PROBLEM", 55, 73], ["P\u00f0k\u00de", "TEST", 181, 185], ["k \u2212\u03b3", "TEST", 188, 192], ["law degree", "OBSERVATION_MODIFIER", 157, 167]]], ["Later efforts have shifted toward less heterogeneous networks, those with \u03b3 > 3 [3] .I. INTRODUCTIONThe quenched mean-field (QMF) theory [17] [18] [19] predicts a vanishing threshold \u03bb c \u2192 0 in the infinite networksize limit for any value of \u03b3 [20] , due to the existence of hubs able to sustain the epidemic for long times only by interacting with their direct neighbors [21] .", [["\u03b3", "TEST", 74, 75], ["a vanishing threshold", "TEST", 161, 182]]], ["[24] , where it is shown that a genuine non-mean-field effect, mutual reinfection among distant hubs, is the key mechanism triggering the appearance of an endemic stationary state for any \u03bb in networks with \u03b3 > 5=2.", [["\u03bb", "PROTEIN", 188, 189], ["a genuine non-mean-field effect", "PROBLEM", 30, 61]]], ["However, the decay observed is slower than the one predicted by the QMF theory [24] [25] [26] and, moreover, in contradiction with recent mathematical results derived by Huang and Durrett [27] and Mountford, Valesin, and Yao [28] .", [["slower", "OBSERVATION_MODIFIER", 31, 37]]], ["An additional puzzling question in this area is the striking disagreement between the exact mathematical prediction for the singular behavior of the prevalence (\u03c1 \u223c \u03bb 2\u03b3\u22123 , apart from logarithmic corrections) [28] and numerical simulations exhibiting a much faster growth.", [["An additional puzzling", "PROBLEM", 0, 22], ["numerical simulations", "TEST", 219, 240], ["a much faster growth", "PROBLEM", 252, 272]]], ["This lack of a precise agreement between analytics and numerics represents one standing issue in our understanding of epidemic processes on complex topologies.I. INTRODUCTIONA precise mathematical formulation of the mutual reinfection process was recently proposed by M\u00e9nard and Singh [29] .", [["numerics", "TREATMENT", 55, 63], ["the mutual reinfection process", "PROBLEM", 212, 242], ["reinfection", "OBSERVATION", 223, 234]]], ["They introduce the cumulative merging percolation (CMP) process, a long-range site percolation process [30] aimed at describing the geometry of the sets where SIS epidemics survive for a long time on a network.", [["the cumulative merging percolation (CMP) process", "TREATMENT", 15, 63], ["a long-range site percolation process", "TREATMENT", 65, 102]]], ["The presence of a CMP giant component corresponds to the existence of an endemic SIS stationary state, so that the calculation of the CMP threshold allows one to locate also the position of the SIS epidemic transition [31] .I. INTRODUCTIONIn this paper, we contribute to the current state-of-the-art in this area in two ways.", [["a CMP giant component", "PROBLEM", 16, 37], ["the CMP threshold", "TEST", 130, 147], ["CMP giant", "OBSERVATION_MODIFIER", 18, 27], ["endemic", "OBSERVATION_MODIFIER", 73, 80]]], ["First, we consider a generalized version of the CMP process proposed in Ref.", [["a generalized version of the CMP process", "TREATMENT", 19, 59], ["CMP process", "OBSERVATION", 48, 59]]], ["This theory-which provides a clear understanding of competing physical mechanisms, critical properties, crossover scales, and finite-size effects-is general and can be related with other processes.", [["size", "OBSERVATION_MODIFIER", 133, 137]]], ["[27, 28] and reassuringly recovered by our approach) can be observed only for huge system sizes, out of reach for present computer resources.", [["sizes", "OBSERVATION_MODIFIER", 90, 95]]], ["We show instead that, for network sizes that can be currently simulated, a preasymptotic regime holds, whose nontrivial properties are determined, providing a prediction for the finite-size scaling of the SIS epidemic threshold in agreement with (previously unexplained) numerical results.", [["a preasymptotic regime", "TREATMENT", 73, 95], ["size", "OBSERVATION_MODIFIER", 185, 189]]], ["Our work reconciles in a comprehensive way the different theories proposed to interpret the behavior of the SIS model, placing them in the proper context regarding the network size considered, and thus ends a long debate between the physics and mathematics communities.I. INTRODUCTIONThe paper is organized as follows: In Sec.", [["size", "OBSERVATION_MODIFIER", 176, 180]]], ["II, we define the cumulative merging percolation process which is the subject of our study.", [["the cumulative merging percolation process", "PROBLEM", 14, 56], ["our study", "TEST", 81, 90], ["percolation process", "OBSERVATION", 37, 56]]], ["Section III presents a scaling solution of this model, whose behavior in finite networks is discussed in Sec.", [["a scaling solution", "TREATMENT", 21, 39]]], ["IV.", [["IV", "TREATMENT", 0, 2]]], ["A numerical check of the scaling solution is provided in Sec.", [["the scaling solution", "TREATMENT", 21, 41]]], ["VI, we apply the results obtained to the SIS epidemic model, backing up our conclusions by comparison with existing numerical simulations.", [["VI", "GENE_OR_GENE_PRODUCT", 0, 2]]], ["VII, we summarize our main results and discuss the interesting perspectives they open.", [["VII", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Several Appendixes provide some detailed analytical calculations and additional information.II. CUMULATIVE MERGING PERCOLATION PROCESSWe consider a generalization of the cumulative merging process proposed in Ref.", [["II", "CHEMICAL", 92, 94], ["the cumulative merging process", "TREATMENT", 166, 196]]], ["[29] , defined along the following lines.", [["lines", "CELL", 35, 40]]], ["In a given network, composed by N nodes, each node i is active with probability p i .", [["node", "ANATOMY", 46, 50], ["N nodes", "MULTI-TISSUE_STRUCTURE", 32, 39], ["nodes", "OBSERVATION", 34, 39], ["node", "ANATOMY", 46, 50], ["active", "OBSERVATION_MODIFIER", 56, 62]]], ["Inactive nodes do not play any role apart from determining the topological distances between pairs of active nodes (see below).", [["nodes", "ANATOMY", 9, 14], ["nodes", "ANATOMY", 109, 114], ["nodes", "MULTI-TISSUE_STRUCTURE", 109, 114], ["Inactive nodes", "PROBLEM", 0, 14], ["active nodes", "PROBLEM", 102, 114], ["nodes", "OBSERVATION", 9, 14], ["active", "OBSERVATION_MODIFIER", 102, 108], ["nodes", "OBSERVATION", 109, 114]]], ["Each active node i defines a cluster of size 1, associated with an initial mass m \u00f00\u00de i .", [["node", "ANATOMY", 12, 16], ["active", "OBSERVATION_MODIFIER", 5, 11], ["node", "OBSERVATION", 12, 16], ["cluster", "OBSERVATION_MODIFIER", 29, 36], ["size", "OBSERVATION_MODIFIER", 40, 44], ["mass", "OBSERVATION", 75, 79]]], ["Starting with these initial clusters, an iterative process takes place whose elementary step is the merging of a pair of clusters into a single one.", [["an iterative process", "TREATMENT", 38, 58]]], ["Two clusters, \u03b1 and \u03b2, are merged in a single cluster if there are at least a node i \u03b1 in \u03b1 and a node j \u03b2 in \u03b2, such thatII.", [["node", "ANATOMY", 98, 102], ["\u03b1", "GENE_OR_GENE_PRODUCT", 14, 15], ["\u03b2", "GENE_OR_GENE_PRODUCT", 20, 21], ["\u03b1", "GENE_OR_GENE_PRODUCT", 90, 91], ["\u03b1", "DNA", 14, 15], ["\u03b2", "DNA", 20, 21], ["\u03b1", "DNA", 85, 86], ["\u03b1", "DNA", 90, 91], ["\u03b2", "CELL_LINE", 110, 111], ["node", "OBSERVATION", 78, 82], ["node", "OBSERVATION", 98, 102]]], ["CUMULATIVE MERGING PERCOLATION PROCESSwhere d i;j is the topological distance between nodes i and j and r\u00f0m\u00de \u2265 1 is an interaction range associated to a cluster of mass m.", [["mass m.", "PROBLEM", 164, 171], ["nodes", "OBSERVATION", 86, 91], ["interaction range", "OBSERVATION", 119, 136], ["mass", "OBSERVATION", 164, 168]]], ["The mass of the merged cluster is the sum of the masses of the original clusters: m \u03b1\u00fe\u03b2 \u00bc m \u03b1 \u00fe m \u03b2 .", [["\u03b1 \u00fe m \u03b2", "GENE_OR_GENE_PRODUCT", 92, 99], ["\u03b1\u00fe\u03b2", "PROTEIN", 84, 87], ["\u03b1", "PROTEIN", 92, 93], ["\u03b2", "PROTEIN", 98, 99], ["mass", "OBSERVATION", 4, 8], ["merged", "OBSERVATION_MODIFIER", 16, 22], ["cluster", "OBSERVATION_MODIFIER", 23, 30], ["sum", "OBSERVATION_MODIFIER", 38, 41], ["masses", "OBSERVATION", 49, 55], ["clusters", "OBSERVATION_MODIFIER", 72, 80]]], ["The iteration of this procedure converges to a limiting partition of the network that does not depend on the order in which the merging is performed [32] .", [["this procedure", "TREATMENT", 17, 31]]], ["Notice that if p i \u00bc p and r\u00f0m\u00de \u00bc 1, CMP coincides with random site percolation [1] .", [["CMP", "PROBLEM", 37, 40]]], ["(1) implies that two clusters merge only if each one of them is within the interaction range of the other: An asymmetric situation, with a massive cluster interacting with a far and small cluster, does not lead to merging.", [["An asymmetric situation", "PROBLEM", 107, 130], ["a massive cluster interacting", "PROBLEM", 137, 166], ["asymmetric", "OBSERVATION_MODIFIER", 110, 120], ["situation", "OBSERVATION", 121, 130], ["massive", "OBSERVATION_MODIFIER", 139, 146], ["cluster", "OBSERVATION_MODIFIER", 147, 154], ["small", "OBSERVATION_MODIFIER", 182, 187], ["cluster", "OBSERVATION", 188, 195]]], ["In Fig. 1 , we present a graphical illustration of the mechanism of the CMP process.", [["the CMP process", "PROBLEM", 68, 83], ["CMP process", "OBSERVATION", 72, 83]]], ["We stress again that a cluster is defined as a set of (only) active nodes resulting from the iteration of merging events.", [["active nodes", "PROBLEM", 61, 73], ["merging events", "PROBLEM", 106, 120], ["active", "OBSERVATION_MODIFIER", 61, 67], ["nodes", "OBSERVATION", 68, 73]]], ["1(c) and 1(d).II. CUMULATIVE MERGING PERCOLATION PROCESSThe connection between CMP and the mutual reinfection of distant hubs in the SIS epidemics is operated by taking as active nodes the hubs able to independently sustain the epidemic [29] ; see Appendix A for a detailed description.III. SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONLet us focus now on a specific yet broad class of CMP processes, where nodes are active if their degree is larger than a threshold value k a :III.", [["nodes", "ANATOMY", 411, 416], ["II", "CHEMICAL", 14, 16], ["nodes", "MULTI-TISSUE_STRUCTURE", 411, 416], ["CMP", "PROBLEM", 79, 82], ["CMP processes", "PROBLEM", 390, 403], ["Appendix", "ANATOMY", 248, 256], ["CMP processes", "OBSERVATION", 390, 403], ["nodes", "OBSERVATION", 411, 416], ["active", "OBSERVATION_MODIFIER", 421, 427], ["larger", "OBSERVATION_MODIFIER", 447, 453]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONIn an uncorrelated network with degree distribution P\u00f0k\u00de \u00bc \u00f0\u03b3 \u2212 1\u00dek \u03b3\u22121 min k \u2212\u03b3 in the continuous approximation, where k min is the minimum degree, the fraction of active nodes isIII.", [["P\u00f0k\u00de", "PROTEIN", 101, 105], ["\u00f0\u03b3", "PROTEIN", 108, 110], ["\u03b3", "PROTEIN", 117, 118], ["isIII", "PROTEIN", 227, 232], ["P\u00f0k\u00de", "TEST", 101, 105], ["the continuous approximation", "TEST", 133, 161], ["active nodes isIII", "PROBLEM", 214, 232], ["minimum degree", "OBSERVATION_MODIFIER", 182, 196], ["active", "OBSERVATION_MODIFIER", 214, 220], ["nodes isIII", "OBSERVATION", 221, 232]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONWe are interested in understanding the possible existence of a CMP giant component as a function of k a , in particular, in the limit k a \u2192 \u221e, when only a small fraction of nodes is active.III. SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONA.", [["nodes", "ANATOMY", 222, 227], ["a CMP giant component", "PROBLEM", 110, 131], ["CMP giant", "OBSERVATION_MODIFIER", 112, 121], ["small", "OBSERVATION_MODIFIER", 204, 209], ["nodes", "OBSERVATION", 222, 227], ["active", "OBSERVATION_MODIFIER", 231, 237]]], ["The case r\u00f0m\u00de = 1: Degree-ordered percolationIII.", [["Degree-ordered percolationIII", "PROBLEM", 19, 48]]], ["In this case, the CMP process defined above coincides with the degree-ordered percolation (DOP) process proposed in Ref.", [["the CMP process", "PROBLEM", 14, 29], ["ordered percolation (DOP) process", "TREATMENT", 70, 103]]], ["For a node of degree k, the probability that a given neighbor is active isIII.", [["node", "ANATOMY", 6, 10], ["isIII", "DNA", 72, 77], ["a node of degree k", "PROBLEM", 4, 22], ["node", "OBSERVATION", 6, 10], ["active", "OBSERVATION", 65, 71]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONwhere P\u00f0k 0 jk\u00de is the conditional probability that a neighbor of a node k has degree k 0 [34] .", [["node", "ANATOMY", 117, 121], ["a node k", "TEST", 115, 123], ["node", "OBSERVATION", 117, 121]]], ["For uncorrelated networks, P\u00f0k 0 jk\u00de \u00bc (k 0 P\u00f0k 0 \u00de=hki) [34] ; thus, we have P a \u00bc \u00f0k a =k min \u00de 2\u2212\u03b3 , independent of k.", [["uncorrelated networks", "TEST", 4, 25], ["P\u00f0k", "TEST", 27, 30], ["jk\u00de", "TEST", 33, 36], ["k", "TEST", 40, 41], ["P\u00f0k", "TEST", 44, 47], ["hki", "TEST", 52, 55]]], ["The mean number of active neighbors of a node of degree k is kP a ; therefore, the inverse of P a ,III.", [["node", "ANATOMY", 41, 45], ["P", "DNA", 94, 95], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["active", "OBSERVATION_MODIFIER", 19, 25], ["node", "OBSERVATION", 41, 45]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONdefines a degree scale separating nodes likely to have many active neighbors k=k c \u226b 1 from those likely to be isolated, i.e., not in direct contact with any active node.", [["node", "ANATOMY", 214, 218], ["node", "MULTI-TISSUE_STRUCTURE", 214, 218], ["a degree scale separating nodes", "PROBLEM", 57, 88], ["any active node", "PROBLEM", 203, 218], ["nodes", "OBSERVATION", 83, 88], ["active", "OBSERVATION_MODIFIER", 207, 213], ["node", "OBSERVATION", 214, 218]]], ["The average number of active neighbors for each active node isIII.", [["node", "ANATOMY", 55, 59], ["each active node isIII", "TREATMENT", 43, 65], ["active", "OBSERVATION_MODIFIER", 22, 28], ["active", "OBSERVATION_MODIFIER", 48, 54], ["node", "OBSERVATION", 55, 59]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONFor \u03b3 < 3, this quantity diverges as k a grows: Each active node has a very large number of active neighbors, so that all of them belong to a connected giant component for any k a [23, 33] , and the relative size S of the giant component is simply given by the fraction of active nodesIII.", [["node", "ANATOMY", 109, 113], ["node", "MULTI-TISSUE_STRUCTURE", 109, 113], ["nodesIII", "PROTEIN", 329, 337], ["active", "OBSERVATION_MODIFIER", 102, 108], ["node", "OBSERVATION", 109, 113], ["very", "OBSERVATION_MODIFIER", 120, 124], ["large", "OBSERVATION_MODIFIER", 125, 130], ["size", "OBSERVATION_MODIFIER", 257, 261], ["giant", "OBSERVATION", 271, 276], ["active", "OBSERVATION_MODIFIER", 322, 328], ["nodesIII", "OBSERVATION", 329, 337]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONFor \u03b3 > 3, instead, the average number of active neighbors of an active node decreases with k a and tends to zero in the limit k a \u2192 \u221e.", [["node", "ANATOMY", 121, 125], ["node", "MULTI-TISSUE_STRUCTURE", 121, 125], ["an active node", "PROBLEM", 111, 125], ["active", "OBSERVATION_MODIFIER", 91, 97], ["active", "OBSERVATION_MODIFIER", 114, 120], ["node", "OBSERVATION", 121, 125], ["decreases", "OBSERVATION_MODIFIER", 126, 135]]], ["This result indicates that a degreeordered percolation giant component (DOPGC) can exist only up to a finite threshold value, in agreement with Refs.", [["a degreeordered percolation giant component", "PROBLEM", 27, 70]]], ["For k a \u00bc k min , k c \u00bc 1.", [["k", "TEST", 4, 5], ["k c \u00bc", "TEST", 18, 23]]], ["Hence, even for \u03b3 > 3, there is an interval of k a values such that k a =k c > 1.", [["k a values", "TEST", 47, 57], ["k", "TEST", 68, 69]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONNotice that, for \u03b3 \u00bc 3.2 and k min \u00bc 3, k \u00c3 0 \u00bc 729, a quite large value, while it decays quickly for increasing \u03b3: For \u03b3 \u00bc 3.5, it is already k \u00c3 0 \u00bc 27.", [["k min", "TEST", 78, 83], ["k", "TEST", 89, 90], ["a quite large value", "PROBLEM", 102, 121], ["k \u00c3", "TEST", 192, 195]]], ["In this regime, the situation is similar to the case \u03b3 < 3, with practically all active nodes belonging to the DOPGC and S DOP \u2248 N a =N \u223c k 1\u2212\u03b3 a .", [["DOP", "CHEMICAL", 123, 126], ["DOPGC", "CHEMICAL", 111, 116], ["DOP", "CHEMICAL", 123, 126], ["practically all active nodes", "PROBLEM", 65, 93], ["the DOPGC", "TEST", 107, 116], ["S DOP", "TEST", 121, 126], ["a", "TEST", 131, 132], ["k", "TEST", 138, 139], ["a", "PROBLEM", 144, 145], ["active", "OBSERVATION_MODIFIER", 81, 87], ["nodes", "OBSERVATION", 88, 93]]], ["However, one must notice that, even if k a =k c > 1, this ratio is not very large, as its maximum value is k min , corresponding to k a \u00bc k min .", [["k a =k c", "TEST", 39, 47], ["this ratio", "TEST", 53, 63], ["not", "UNCERTAINTY", 67, 70], ["very", "OBSERVATION_MODIFIER", 71, 75], ["large", "OBSERVATION", 76, 81]]], ["(6); as soon as k a is increased, one immediately starts to see the transition to a different regime, where k a =k c < 1.", [["a different regime", "TREATMENT", 82, 100]]], ["In this second regime, a giant component still exists, but some active nodes are isolated (not directly connected to other active nodes) and others are nonisolated but form small clusters.", [["nodes", "ANATOMY", 71, 76], ["a giant component", "PROBLEM", 23, 40], ["some active nodes", "PROBLEM", 59, 76], ["giant", "OBSERVATION_MODIFIER", 25, 30], ["component", "OBSERVATION_MODIFIER", 31, 40], ["some", "OBSERVATION_MODIFIER", 59, 63], ["active", "OBSERVATION_MODIFIER", 64, 70], ["nodes", "OBSERVATION", 71, 76], ["active", "OBSERVATION_MODIFIER", 123, 129], ["nodes", "OBSERVATION", 130, 135], ["small", "OBSERVATION_MODIFIER", 173, 178], ["clusters", "OBSERVATION_MODIFIER", 179, 187]]], ["The set of all active nodes is therefore composed by three classes:III.", [["nodes", "MULTI-TISSUE_STRUCTURE", 22, 27], ["all", "OBSERVATION_MODIFIER", 11, 14], ["active", "OBSERVATION_MODIFIER", 15, 21], ["nodes", "OBSERVATION", 22, 27]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATION(1) nonisolated nodes belonging to the DOPGC;III.", [["nodes", "ANATOMY", 65, 70], ["nodes", "MULTI-TISSUE_STRUCTURE", 65, 70], ["DOPGC;III", "DNA", 88, 97], ["nonisolated nodes", "PROBLEM", 53, 70], ["nodes", "OBSERVATION", 65, 70]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATION(2) nonisolated nodes belonging to small clusters; and (3) isolated nodes, which necessarily do not belong to the DOPGC.", [["nodes", "ANATOMY", 65, 70], ["nodes", "ANATOMY", 117, 122], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 108, 122], ["DOPGC", "PROTEIN", 163, 168], ["nonisolated nodes belonging to small clusters", "PROBLEM", 53, 98], ["isolated nodes", "PROBLEM", 108, 122], ["nodes", "OBSERVATION", 65, 70], ["small clusters", "OBSERVATION_MODIFIER", 84, 98], ["nodes", "OBSERVATION", 117, 122]]], ["As k a increases, a growing fraction of active nodes passes from the first category to the other two, and the order parameter S DOP \u00bc N GC =N decreases faster than the fraction of active nodes N a =N (see Fig. 2 ).", [["nodes", "ANATOMY", 47, 52], ["N GC =N", "CHEMICAL", 134, 141], ["active nodes passes", "PROBLEM", 40, 59], ["DOP", "TEST", 128, 131], ["GC", "TEST", 136, 138], ["active nodes", "PROBLEM", 180, 192], ["active", "OBSERVATION_MODIFIER", 40, 46], ["nodes", "OBSERVATION", 47, 52], ["active", "OBSERVATION_MODIFIER", 180, 186], ["nodes", "OBSERVATION", 187, 192]]], ["At the threshold, the fraction of nonisolated nodes belonging to the DOPGC vanishes.III. SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONThe calculation of the behavior of S DOP in this regime and of the transition point is a nontrivial task.", [["nodes", "ANATOMY", 46, 51], ["DOP", "CHEMICAL", 175, 178], ["DOP", "CHEMICAL", 175, 178], ["DOPGC", "GENE_OR_GENE_PRODUCT", 69, 74], ["DOPGC", "DNA", 69, 74], ["nonisolated nodes", "PROBLEM", 34, 51], ["the DOPGC vanishes", "TREATMENT", 65, 83], ["S DOP", "TEST", 173, 178], ["this regime", "TREATMENT", 182, 193], ["nodes", "OBSERVATION", 46, 51], ["nontrivial task", "OBSERVATION", 227, 242]]], ["It is important to observe that N NI , the number of nonisolated nodes, which upper bounds the number N GC of nodes belonging to the giant component, keeps decaying with the same exponent even well above the DOP transition (see Fig. 2 ).III. SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONB.", [["nodes", "ANATOMY", 65, 70], ["DOP", "CHEMICAL", 208, 211], ["nodes", "MULTI-TISSUE_STRUCTURE", 65, 70], ["nonisolated nodes", "PROBLEM", 53, 70], ["nodes", "OBSERVATION", 65, 70], ["nodes", "OBSERVATION", 110, 115], ["giant", "OBSERVATION_MODIFIER", 133, 138]]], ["The range of interaction grows with its mass, so that, if r\u00f0m\u00de \u2265 2, clusters of nodes can merge even if not in direct contact.", [["nodes", "ANATOMY", 80, 85], ["nodes", "MULTI-TISSUE_STRUCTURE", 80, 85], ["its mass", "PROBLEM", 36, 44], ["nodes", "PROBLEM", 80, 85], ["range", "OBSERVATION_MODIFIER", 4, 9], ["mass", "OBSERVATION", 40, 44], ["nodes", "OBSERVATION", 80, 85]]], ["In this case, it is clear that, for a given value of k a , the giant component of the DOP process is a subset of the giant component of the full CMP process (CMPGC).", [["DOP", "CHEMICAL", 86, 89], ["DOP", "CHEMICAL", 86, 89], ["DOP", "SIMPLE_CHEMICAL", 86, 89], ["the DOP process", "PROBLEM", 82, 97], ["the full CMP process", "PROBLEM", 136, 156], ["giant", "OBSERVATION_MODIFIER", 63, 68], ["DOP process", "OBSERVATION", 86, 97], ["giant", "OBSERVATION_MODIFIER", 117, 122], ["component", "OBSERVATION_MODIFIER", 123, 132], ["full CMP process", "OBSERVATION", 140, 156]]], ["Thus, for \u03b3 < 3, the CMPGC is again given by the whole set of active nodes and has, therefore, a relative sizeIII.", [["nodes", "ANATOMY", 69, 74], ["CMPGC", "GENE_OR_GENE_PRODUCT", 21, 26], ["nodes", "MULTI-TISSUE_STRUCTURE", 69, 74], ["CMPGC", "PROTEIN", 21, 26], ["active nodes", "PROBLEM", 62, 74], ["active", "OBSERVATION_MODIFIER", 62, 68], ["nodes", "OBSERVATION", 69, 74]]], ["SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONIn this case, for large k a , the DOPGC vanishes asymptotically and nonisolated active nodes form DOP clusters of a small size.", [["nodes", "ANATOMY", 136, 141], ["DOP", "CHEMICAL", 147, 150], ["DOP", "CHEMICAL", 147, 150], ["nodes", "MULTI-TISSUE_STRUCTURE", 136, 141], ["DOP", "SIMPLE_CHEMICAL", 147, 150], ["the DOPGC vanishes asymptotically", "TEST", 79, 112], ["active", "OBSERVATION_MODIFIER", 129, 135], ["nodes", "OBSERVATION", 136, 141], ["DOP", "OBSERVATION_MODIFIER", 147, 150], ["clusters", "OBSERVATION_MODIFIER", 151, 159], ["small", "OBSERVATION_MODIFIER", 165, 170], ["size", "OBSERVATION_MODIFIER", 171, 175]]], ["Still, an extensive CMPGC could be induced by long-range merging of clusters or nodes which cannot be joined in a DOP process, as they are separated by distances larger than 1.", [["CMPGC", "CANCER", 20, 25], ["CMPGC", "DNA", 20, 25], ["an extensive CMPGC", "PROBLEM", 7, 25], ["nodes", "PROBLEM", 80, 85], ["extensive", "OBSERVATION_MODIFIER", 10, 19], ["CMPGC", "OBSERVATION", 20, 25], ["long-range", "OBSERVATION_MODIFIER", 46, 56], ["clusters", "OBSERVATION_MODIFIER", 68, 76], ["nodes", "OBSERVATION", 80, 85]]], ["Whether these long-range mergings take place or not depends, of course, on the particular choice of the mass m and of the form of the interaction range.", [["mass", "OBSERVATION", 104, 108]]], ["[29] , here we focus on the case of initial masses equal to node degrees m \u00f00\u00de i \u00bc k i (so that the total mass of a cluster is the sum of the degrees of the active nodes forming it) and of an interaction range of the form r\u00f0m\u00de \u00bc m=k a .", [["node", "ANATOMY", 60, 64], ["initial masses", "PROBLEM", 36, 50], ["the total mass", "PROBLEM", 96, 110], ["masses", "OBSERVATION", 44, 50], ["node", "OBSERVATION", 60, 64], ["mass", "OBSERVATION", 106, 110], ["active", "OBSERVATION_MODIFIER", 157, 163], ["nodes", "OBSERVATION", 164, 169]]], ["This case is a particular case of a generic CMP process with r\u00f0m\u00de \u00bc f\u00f0m=k a \u00de, where f\u00f0z\u00de \u00bc z \u03b1 , with \u03b1 > 0, so that active nodes with the smallest degree have a range exactly equal to 1.", [["nodes", "ANATOMY", 125, 130], ["nodes", "MULTI-TISSUE_STRUCTURE", 125, 130], ["a generic CMP process", "PROBLEM", 34, 55], ["f\u00f0z\u00de", "TEST", 85, 89], ["\u03b1", "TEST", 103, 104], ["active nodes", "PROBLEM", 118, 130], ["active", "OBSERVATION_MODIFIER", 118, 124], ["nodes", "OBSERVATION", 125, 130], ["smallest degree", "OBSERVATION_MODIFIER", 140, 155]]], ["We defer to a future work a comprehensive analysis of this model for \u03b1 \u2260 1.III. SCALING THEORY FOR CUMULATIVE MERGING PERCOLATIONIn the present setting, we identify two competing mechanisms leading to the formation of a CMP giant component.", [["\u03b1 \u2260 1", "GENE_OR_GENE_PRODUCT", 69, 74], ["\u03b1 \u2260 1", "PROTEIN", 69, 74], ["a CMP giant component", "PROBLEM", 218, 239], ["giant", "OBSERVATION_MODIFIER", 224, 229], ["component", "OBSERVATION_MODIFIER", 230, 239]]], ["The first is an extension of DOP percolation, based on the merging of DOP clusters separated by distances larger than 1.", [["DOP", "CHEMICAL", 29, 32], ["DOP", "CHEMICAL", 29, 32], ["DOP", "CHEMICAL", 70, 73], ["DOP", "SIMPLE_CHEMICAL", 29, 32], ["DOP", "SIMPLE_CHEMICAL", 70, 73], ["DOP percolation", "TREATMENT", 29, 44], ["DOP percolation", "OBSERVATION", 29, 44]]], ["The second involves the buildup of CMP clusters formed by isolated nodes interacting at a large distance.", [["nodes", "ANATOMY", 67, 72], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 58, 72], ["isolated nodes", "PROBLEM", 58, 72], ["buildup", "OBSERVATION_MODIFIER", 24, 31], ["CMP clusters", "OBSERVATION", 35, 47], ["isolated", "OBSERVATION_MODIFIER", 58, 66], ["nodes", "OBSERVATION", 67, 72], ["large", "OBSERVATION_MODIFIER", 90, 95]]], ["We now discuss the two mechanisms in detail.First mechanism: Extended DOP mechanismFor very small k a close to k min , CMP is clearly equivalent to the first regime for DOP with S \u2248 N a =N. Upon increasing k a , above the crossover scale k \u00c3 0 , DOP enters the second regime with an increasing presence of isolated nodes and nodes belonging to small DOP clusters.", [["nodes", "ANATOMY", 315, 320], ["DOP", "CHEMICAL", 70, 73], ["DOP", "CHEMICAL", 169, 172], ["DOP", "CHEMICAL", 246, 249], ["DOP", "CHEMICAL", 350, 353], ["DOP", "CHEMICAL", 70, 73], ["DOP", "CHEMICAL", 169, 172], ["DOP", "CHEMICAL", 246, 249], ["DOP", "CHEMICAL", 350, 353], ["DOP", "SIMPLE_CHEMICAL", 70, 73], ["DOP", "SIMPLE_CHEMICAL", 169, 172], ["DOP", "SIMPLE_CHEMICAL", 246, 249], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 306, 320], ["DOP", "SIMPLE_CHEMICAL", 350, 353], ["CMP", "PROBLEM", 119, 122], ["DOP", "TEST", 169, 172], ["k", "TEST", 238, 239], ["DOP", "TEST", 246, 249], ["isolated nodes", "PROBLEM", 306, 320], ["nodes belonging to small DOP clusters", "PROBLEM", 325, 362], ["isolated", "OBSERVATION_MODIFIER", 306, 314], ["nodes", "OBSERVATION", 315, 320], ["nodes", "OBSERVATION", 325, 330]]], ["CMP and DOP behaviors start to diverge at this point, because some nodes, even if they are not directly connected to the DOPGC, are at distance 2 from it and, thus, can join the CMPGC if their interaction range is at least 2.", [["nodes", "ANATOMY", 67, 72], ["DOP", "CHEMICAL", 8, 11], ["DOP", "CHEMICAL", 8, 11], ["DOP", "SIMPLE_CHEMICAL", 8, 11], ["CMPGC", "CANCER", 178, 183], ["DOPGC", "DNA", 121, 126], ["CMP", "PROBLEM", 0, 3], ["DOP behaviors", "PROBLEM", 8, 21], ["some nodes", "PROBLEM", 62, 72], ["DOP behaviors", "OBSERVATION_MODIFIER", 8, 21], ["nodes", "OBSERVATION", 67, 72]]], ["In particular, this situation occurs for all small DOP clusters: As their aggregate degree is k agg \u2265 2k a , they necessarily have a range of interaction r \u2265 2.", [["DOP", "CHEMICAL", 51, 54], ["DOP", "CHEMICAL", 51, 54], ["k agg", "TEST", 94, 99]]], ["For this reason, in this regime all N NI nonisolated nodes belong to the CMPGC.", [["nodes", "MULTI-TISSUE_STRUCTURE", 53, 58], ["CMPGC", "DNA", 73, 78], ["nodes", "OBSERVATION", 53, 58]]], ["Notice that N NI =N is finite even well beyond the DOP threshold.", [["DOP", "CHEMICAL", 51, 54], ["DOP", "SIMPLE_CHEMICAL", 51, 54]]], ["In this limit, the formation of the CMPGC is still triggered by the largest DOP cluster (that does not percolate).", [["CMPGC", "CHEMICAL", 36, 41], ["DOP", "CHEMICAL", 76, 79], ["DOP", "CHEMICAL", 76, 79], ["CMPGC", "GENE_OR_GENE_PRODUCT", 36, 41], ["DOP", "SIMPLE_CHEMICAL", 76, 79], ["CMPGC", "PROTEIN", 36, 41], ["largest", "OBSERVATION_MODIFIER", 68, 75]]], ["For any value of \u03b3, there are always nodes in the network with k > k c \u226b k a .", [["k", "TEST", 63, 64], ["nodes", "OBSERVATION", 37, 42]]], ["They form local clusters with a large interaction range that progressively incorporate other small clusters giving rise to a CMPGC, even if no DOPGC is present.", [["CMPGC", "DISEASE", 125, 130], ["CMPGC", "CANCER", 125, 130], ["DOPGC", "GENE_OR_GENE_PRODUCT", 143, 148], ["DOPGC", "PROTEIN", 143, 148], ["a CMPGC", "TEST", 123, 130], ["DOPGC", "PROBLEM", 143, 148]]], ["To calculate N NI , we consider the probability that an active node of degree k has at least one neighboring active node: The total fraction N NI =N of nonisolated active nodes in a power-law distributed network is thenFirst mechanism: Extended DOP mechanismwhere \u0393\u00f0a; z\u00de is the incomplete Gamma function [36] .First mechanism: Extended DOP mechanismIn this second regime, not only small DOP clusters, but also isolated active nodes can join the CMPGC, provided they have degree k \u2265 2k a so that their range is r \u2265 2.", [["node", "ANATOMY", 63, 67], ["node", "ANATOMY", 116, 120], ["nodes", "ANATOMY", 171, 176], ["DOP", "CHEMICAL", 337, 340], ["DOP", "CHEMICAL", 388, 391], ["DOP", "CHEMICAL", 245, 248], ["DOP", "CHEMICAL", 337, 340], ["DOP", "CHEMICAL", 388, 391], ["node", "MULTI-TISSUE_STRUCTURE", 116, 120], ["nodes", "MULTI-TISSUE_STRUCTURE", 171, 176], ["DOP", "SIMPLE_CHEMICAL", 388, 391], ["nodes", "MULTI-TISSUE_STRUCTURE", 427, 432], ["an active node of degree k", "PROBLEM", 53, 79], ["The total fraction", "TEST", 122, 140], ["nonisolated active nodes", "PROBLEM", 152, 176], ["Extended DOP mechanismwhere \u0393\u00f0a", "PROBLEM", 236, 267], ["Extended DOP mechanismIn", "TREATMENT", 328, 352], ["this second regime", "TREATMENT", 353, 371], ["small DOP clusters", "PROBLEM", 382, 400], ["isolated active nodes", "PROBLEM", 411, 432], ["active", "OBSERVATION_MODIFIER", 56, 62], ["node", "OBSERVATION", 63, 67], ["active", "OBSERVATION_MODIFIER", 109, 115], ["node", "OBSERVATION", 116, 120], ["active", "OBSERVATION_MODIFIER", 164, 170], ["nodes", "OBSERVATION", 171, 176], ["active", "OBSERVATION_MODIFIER", 420, 426], ["nodes", "OBSERVATION", 427, 432]]], ["The total fraction of isolated nodes with range r \u2265 2 isFirst mechanism: Extended DOP mechanismOverall, the CMP order parameter in this regime is, therefore,First mechanism: Extended DOP mechanismFor k a \u2192 k min , one has k a > k c , and the first contribution in Eq.", [["nodes", "ANATOMY", 31, 36], ["DOP", "CHEMICAL", 82, 85], ["DOP", "CHEMICAL", 183, 186], ["DOP", "CHEMICAL", 82, 85], ["DOP", "CHEMICAL", 183, 186], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 22, 36], ["DOP", "SIMPLE_CHEMICAL", 82, 85], ["DOP", "SIMPLE_CHEMICAL", 183, 186], ["The total fraction", "TEST", 0, 18], ["isolated nodes", "PROBLEM", 22, 36], ["Extended DOP mechanismOverall", "PROBLEM", 73, 102], ["the CMP order parameter", "TREATMENT", 104, 127], ["k", "TEST", 222, 223], ["total", "OBSERVATION_MODIFIER", 4, 9], ["fraction", "OBSERVATION_MODIFIER", 10, 18], ["isolated nodes", "OBSERVATION", 22, 36], ["DOP", "OBSERVATION_MODIFIER", 82, 85], ["mechanismOverall", "OBSERVATION", 86, 102]]], ["(13) is larger than the second, for any \u03b3.", [["larger", "OBSERVATION_MODIFIER", 8, 14]]], ["For large k a , instead, one can expand the \u0393 functions for small k a =k c , findingFirst mechanism: Extended DOP mechanismandFirst mechanism: Extended DOP mechanismThe exponent of N NI is, in absolute value, larger than the one of N r\u22652 ; hence, the first contribution dominates up to a crossover scaleFirst mechanism: Extended DOP mechanismThe conclusion of this line of reasoning is that for k a \u226a k \u00c3 1 the size of the CMPGC decays asFirst mechanism: Extended DOP mechanismfollowed by a crossover to S 1 \u2248 \u00f0N r\u22652 =N\u00de \u223c k 1\u2212\u03b3 a .", [["DOP", "CHEMICAL", 110, 113], ["DOP", "CHEMICAL", 152, 155], ["DOP", "CHEMICAL", 329, 332], ["DOP", "CHEMICAL", 464, 467], ["DOP", "CHEMICAL", 110, 113], ["DOP", "CHEMICAL", 152, 155], ["N", "CHEMICAL", 232, 233], ["DOP", "CHEMICAL", 329, 332], ["DOP", "CHEMICAL", 464, 467], ["DOP", "SIMPLE_CHEMICAL", 152, 155], ["DOP", "SIMPLE_CHEMICAL", 329, 332], ["DOP", "SIMPLE_CHEMICAL", 464, 467], ["N r\u22652", "PROTEIN", 232, 237], ["small k a =k c", "PROBLEM", 60, 74], ["a crossover scale", "TREATMENT", 286, 303], ["Extended DOP mechanism", "PROBLEM", 320, 342], ["k", "TEST", 395, 396], ["a crossover to S", "TEST", 489, 505], ["N", "TEST", 511, 512], ["N\u00de", "TEST", 518, 520], ["k", "TEST", 523, 524], ["exponent", "OBSERVATION_MODIFIER", 169, 177], ["N NI", "OBSERVATION_MODIFIER", 181, 185], ["larger", "OBSERVATION_MODIFIER", 209, 215], ["size", "OBSERVATION_MODIFIER", 411, 415]]], ["The crossover scale k \u00c3 1 decreases rapidly with \u03b3, but, since the maximum degree in a network grows as N 1=\u00f0\u03b3\u22121\u00de , the minimum network size necessary to have a sufficiently large maximum degree k max \u00bc k \u00c3 1 is always larger than N \u2248 4.2 \u00d7 10 5 (the minimum occurring for \u03b3 \u2248 5 for k min \u00bc 3).", [["The crossover scale k", "TEST", 0, 21], ["the minimum network size", "TEST", 116, 140], ["k \u00c3", "TEST", 203, 206]]], ["Hence, it should be possible to observe the crossover on large networks (although k max grows very slowly with N; hence, one needs networks of a size much larger than 10 5 nodes to have a still limited range of k a values).", [["k max", "TEST", 82, 87]]], ["As a matter of fact, we do not observe such a crossover.First mechanism: Extended DOP mechanismThis result happens because, as k a grows, the extended DOP mechanism becomes less and less effective.", [["DOP", "CHEMICAL", 82, 85], ["DOP", "CHEMICAL", 151, 154], ["DOP", "CHEMICAL", 82, 85], ["DOP", "CHEMICAL", 151, 154], ["DOP", "SIMPLE_CHEMICAL", 82, 85], ["DOP", "SIMPLE_CHEMICAL", 151, 154], ["the extended DOP mechanism", "PROBLEM", 138, 164]]], ["DOP clusters become smaller and smaller, and the distances among them (and between isolated active nodes and them) increase: It is no longer sufficient to have r \u00bc 2 to join the CMP giant component.", [["DOP", "CHEMICAL", 0, 3], ["DOP", "CHEMICAL", 0, 3], ["DOP", "SIMPLE_CHEMICAL", 0, 3], ["nodes", "MULTI-TISSUE_STRUCTURE", 99, 104], ["DOP clusters", "PROBLEM", 0, 12], ["clusters", "OBSERVATION_MODIFIER", 4, 12], ["smaller", "OBSERVATION_MODIFIER", 20, 27], ["smaller", "OBSERVATION_MODIFIER", 32, 39], ["active", "OBSERVATION_MODIFIER", 92, 98], ["nodes", "OBSERVATION", 99, 104], ["no longer", "UNCERTAINTY", 131, 140], ["CMP", "OBSERVATION", 178, 181], ["giant", "OBSERVATION_MODIFIER", 182, 187], ["component", "OBSERVATION_MODIFIER", 188, 197]]], ["(13) , but the second term is most affected, as can be seen in Fig. 3 , where we compare the ratio of the first and second terms in Eq.", [["most affected", "OBSERVATION_MODIFIER", 30, 43]]], ["(13) (which becomes 1 at the crossover scale k \u00c3 1 ) and the same ratio restricted to nodes belonging to the CMPGC.", [["nodes", "ANATOMY", 86, 91], ["CMPGC", "PROTEIN", 109, 114], ["nodes", "OBSERVATION", 86, 91]]], ["We observe that the latter is always larger than the former and does not seem to go to 1 for large k a .", [["larger", "OBSERVATION_MODIFIER", 37, 43]]], ["This result implies that, in practice, S 1 behaves as predicted by Eq.", [["S 1", "GENE_OR_GENE_PRODUCT", 39, 42]]], ["(17) even for values of k a larger than the crossover scale k \u00c3 1 estimated in Eq.", [["values", "TEST", 14, 20], ["k", "TEST", 24, 25], ["the crossover scale k", "TEST", 40, 61], ["larger", "OBSERVATION_MODIFIER", 28, 34]]], ["(16) .First mechanism: Extended DOP mechanismA more important consequence of the asymptotic ineffectiveness of the extended DOP mechanism is that it cannot work for arbitrarily large k a .", [["DOP", "CHEMICAL", 32, 35], ["DOP", "CHEMICAL", 124, 127], ["DOP", "CHEMICAL", 32, 35], ["DOP", "SIMPLE_CHEMICAL", 32, 35], ["DOP", "SIMPLE_CHEMICAL", 124, 127], ["Extended DOP mechanismA", "PROBLEM", 23, 46]]], ["A different mechanism governs the formation of the CMPGC in the limit k a \u2192 \u221e.Second mechanism: Merging of distant isolated nodesNodes with degree k a \u2264 k \u226a k c have on average a very small number of active nearest neighbors, as FIG.", [["nodes", "ANATOMY", 124, 129], ["CMPGC", "CHEMICAL", 51, 56], ["CMPGC", "SIMPLE_CHEMICAL", 51, 56], ["nodesNodes", "MULTI-TISSUE_STRUCTURE", 124, 134], ["CMPGC", "PROTEIN", 51, 56], ["FIG", "DNA", 229, 232], ["A different mechanism", "PROBLEM", 0, 21], ["distant isolated nodesNodes", "PROBLEM", 107, 134], ["distant", "OBSERVATION_MODIFIER", 107, 114], ["isolated", "OBSERVATION_MODIFIER", 115, 123], ["nodesNodes", "OBSERVATION", 124, 134], ["very", "OBSERVATION_MODIFIER", 179, 183], ["small", "OBSERVATION_MODIFIER", 184, 189]]], ["(13) evaluated on UCM networks with \u03b3 \u00bc 4, k min \u00bc 3, and size N \u00bc 10 7 , computed over all nodes, and restricted to nodes belonging to the CMPGC. kP a \u00bc k=k c \u226a 1.", [["UCM networks", "MULTI-TISSUE_STRUCTURE", 18, 30], ["CMPGC", "PROTEIN", 140, 145], ["UCM networks", "TEST", 18, 30], ["size N \u00bc", "TEST", 58, 66], ["kP", "TEST", 147, 149], ["k c \u226a", "TEST", 156, 161], ["size", "OBSERVATION_MODIFIER", 58, 62], ["nodes", "OBSERVATION", 92, 97], ["nodes", "OBSERVATION", 117, 122]]], ["However, if k is large enough, they may still have a large interaction range and may merge with other distant nodes.", [["nodes", "ANATOMY", 110, 115], ["nodes", "MULTI-TISSUE_STRUCTURE", 110, 115], ["other distant nodes", "PROBLEM", 96, 115], ["large", "OBSERVATION_MODIFIER", 17, 22], ["large", "OBSERVATION_MODIFIER", 53, 58], ["interaction", "OBSERVATION", 59, 70], ["distant", "OBSERVATION_MODIFIER", 102, 109], ["nodes", "OBSERVATION", 110, 115]]], ["To analyze this process in detail, let us denote as d\u00f0k\u00de the mean distance between a node of degree k and the closest node of degree at least k.", [["node", "ANATOMY", 85, 89], ["node", "ANATOMY", 118, 122], ["node", "OBSERVATION", 85, 89], ["node", "OBSERVATION", 118, 122]]], ["In the limit of a large network size, this distance is (see Appendix B for an analytical derivation)Second mechanism: Merging of distant isolated nodeswhere \u03ba \u00bc hk 2 i=hki \u2212 1 is the network branching factor.", [["hki \u2212 1", "GENE_OR_GENE_PRODUCT", 168, 175], ["\u03ba", "PROTEIN", 157, 158], ["network branching factor", "PROTEIN", 183, 207], ["an analytical derivation", "TREATMENT", 75, 99], ["distant isolated nodeswhere", "PROBLEM", 129, 156], ["large", "OBSERVATION_MODIFIER", 18, 23], ["size", "OBSERVATION_MODIFIER", 32, 36], ["distant", "OBSERVATION_MODIFIER", 129, 136]]], ["Since the interaction range of a node grows linearly with its degree k, it grows faster than the distance to its closest peer.", [["node", "ANATOMY", 33, 37], ["node", "MULTI-TISSUE_STRUCTURE", 33, 37], ["node", "OBSERVATION", 33, 37], ["faster", "OBSERVATION_MODIFIER", 81, 87]]], ["Hence, there exists a degree k x such thatSecond mechanism: Merging of distant isolated nodesand, for any k > k x , r\u00f0k\u00de > d\u00f0k\u00de.", [["distant isolated nodesand", "PROBLEM", 71, 96], ["any k", "TEST", 102, 107], ["r\u00f0k\u00de", "TEST", 116, 120], ["distant", "OBSERVATION_MODIFIER", 71, 78], ["isolated nodesand", "OBSERVATION", 79, 96]]], ["As a consequence, nodes with k > k x have an interaction range larger (on average) than their mutual topological distance.", [["nodes", "ANATOMY", 18, 23], ["nodes", "TEST", 18, 23], ["k", "TEST", 29, 30], ["nodes", "OBSERVATION", 18, 23], ["interaction", "OBSERVATION", 45, 56], ["range", "OBSERVATION_MODIFIER", 57, 62], ["larger", "OBSERVATION_MODIFIER", 63, 69]]], ["They can thus merge in pairs with an even larger interaction range, and the process repeats itself, leading to the formation of a CMPGC, comprising all nodes with a degree larger than k x .", [["CMPGC", "PROTEIN", 130, 135], ["a CMPGC", "PROBLEM", 128, 135], ["nodes", "OBSERVATION", 152, 157]]], ["If we write k x in the form k x \u00bc \u03c9k a , the condition (19) implies \u03c9 \u00bc d\u00f0\u03c9k a \u00de, which, inserting the explicit expression of d\u00f0k\u00de, becomesSecond mechanism: Merging of distant isolated nodesNeglecting constants and terms of the order of ln\u00bdln\u00f0k a \u00de, the size of the giant component according to this mechanism scales then asSecond mechanism: Merging of distant isolated nodesshowing, thus, a power-law decay times a logarithmic correction.Second mechanism: Merging of distant isolated nodesIn absolute value, the leading exponent in S 2 is smaller than the exponent in S 1 .", [["nodes", "ANATOMY", 185, 190], ["isolated nodes", "ANATOMY", 476, 490], ["d\u00f0k\u00de", "GENE_OR_GENE_PRODUCT", 126, 130], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 176, 190], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 476, 490], ["d\u00f0k\u00de", "PROTEIN", 126, 130], ["ln\u00bdln\u00f0k", "PROTEIN", 237, 244], ["distant isolated nodes", "PROBLEM", 168, 190], ["the giant component", "PROBLEM", 262, 281], ["distant isolated nodesshowing", "PROBLEM", 353, 382], ["a logarithmic correction", "TREATMENT", 414, 438], ["distant isolated nodes", "PROBLEM", 468, 490], ["distant", "OBSERVATION_MODIFIER", 168, 175], ["isolated", "OBSERVATION_MODIFIER", 176, 184], ["nodes", "OBSERVATION", 185, 190], ["size", "OBSERVATION_MODIFIER", 254, 258], ["giant", "OBSERVATION_MODIFIER", 266, 271], ["distant", "OBSERVATION_MODIFIER", 353, 360], ["isolated", "OBSERVATION_MODIFIER", 361, 369], ["nodesshowing", "OBSERVATION", 370, 382], ["distant", "OBSERVATION_MODIFIER", 468, 475], ["isolated nodes", "OBSERVATION", 476, 490], ["absolute value", "OBSERVATION_MODIFIER", 493, 507], ["exponent", "OBSERVATION_MODIFIER", 521, 529], ["smaller", "OBSERVATION_MODIFIER", 540, 547]]], ["Therefore, we expect this second mechanism to dominate asymptotically, but after a crossover preceded by a scaling regime where the size of the CMPGC is given by Eq.", [["CMPGC", "CHEMICAL", 144, 149], ["CMPGC", "SIMPLE_CHEMICAL", 144, 149], ["CMPGC", "PROTEIN", 144, 149], ["a scaling regime", "TREATMENT", 105, 121], ["size", "OBSERVATION_MODIFIER", 132, 136]]], ["However, in order to observe such a crossover, one must consider networks much larger than N \u00c3 2 \u00bc kSecond mechanism: Merging of distant isolated nodes.", [["nodes", "ANATOMY", 146, 151], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 137, 151], ["distant isolated nodes", "PROBLEM", 129, 151], ["distant", "OBSERVATION_MODIFIER", 129, 136], ["isolated nodes", "OBSERVATION", 137, 151]]], ["These values are huge for any \u03b3 (much larger than 10 9 nodes in the best case), leading to the conclusion that only the first regime can be observed in currently feasible simulations.Second mechanism: Merging of distant isolated nodesThe present analysis can be extended also to the case of networks with a stretched exponential degree distribution, predicting an asymptotic stretched exponential dependence of S on k a .", [["isolated nodes", "ANATOMY", 220, 234], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 220, 234], ["These values", "TEST", 0, 12], ["distant isolated nodes", "PROBLEM", 212, 234], ["a stretched exponential degree distribution", "PROBLEM", 305, 348], ["distant", "OBSERVATION_MODIFIER", 212, 219], ["isolated nodes", "OBSERVATION", 220, 234], ["asymptotic", "OBSERVATION_MODIFIER", 364, 374], ["stretched", "OBSERVATION_MODIFIER", 375, 384], ["exponential", "OBSERVATION_MODIFIER", 385, 396], ["dependence", "OBSERVATION_MODIFIER", 397, 407]]], ["See Appendix C for details.IV. FINITE-SIZE EFFECTSSo far, we consider infinitely large networks, thus assuming that all degree classes, up to infinity, exist.", [["IV", "TREATMENT", 27, 29], ["Appendix", "ANATOMY", 4, 12], ["SIZE", "OBSERVATION_MODIFIER", 38, 42]]], ["When the network size is finite, only degrees up to the maximum value k max \u00f0N\u00de, growing as N 1=\u00f0\u03b3\u22121\u00de , are present [37] .", [["the maximum value", "TEST", 52, 69], ["k max", "TEST", 70, 75], ["N\u00de", "TEST", 77, 79], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["The CMP behavior for the infinite network (i.e., there is a CMPGC for any k a ) holds as long as k max is larger than the degree scale involved in the formation of the CMPGC.IV. FINITE-SIZE EFFECTSFor \u03b3 < 3, it is sufficient to have active nodes for observing an extensive CMPGC.", [["nodes", "ANATOMY", 240, 245], ["nodes", "MULTI-TISSUE_STRUCTURE", 240, 245], ["CMPGC", "CANCER", 273, 278], ["CMPGC", "PROTEIN", 60, 65], ["CMPGC", "PROTEIN", 168, 173], ["CMPGC", "PROTEIN", 273, 278], ["k max", "TEST", 97, 102], ["IV", "TREATMENT", 174, 176], ["active nodes", "PROBLEM", 233, 245], ["an extensive CMPGC", "TEST", 260, 278], ["larger", "OBSERVATION_MODIFIER", 106, 112], ["SIZE", "OBSERVATION_MODIFIER", 185, 189], ["active", "OBSERVATION_MODIFIER", 233, 239], ["nodes", "OBSERVATION", 240, 245], ["extensive", "OBSERVATION_MODIFIER", 263, 272], ["CMPGC", "OBSERVATION", 273, 278]]], ["Hence, the only finitesize effect trivially appears for k a > k max \u00f0N\u00de: In such a case, there are no more active nodes in the system and S \u2248 0.", [["more active nodes in the system", "PROBLEM", 102, 133], ["no", "UNCERTAINTY", 99, 101], ["more", "OBSERVATION_MODIFIER", 102, 106], ["active", "OBSERVATION_MODIFIER", 107, 113], ["nodes", "OBSERVATION", 114, 119]]], ["The finite-size effective threshold is k c a \u00bc k max \u00f0N\u00de.", [["N\u00de", "PROTEIN", 54, 56], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["On the contrary, for \u03b3 > 3, finite-size effects are less trivial.", [["finite-size effects", "PROBLEM", 28, 47], ["size", "OBSERVATION_MODIFIER", 35, 39], ["less trivial", "OBSERVATION_MODIFIER", 52, 64]]], ["The presence of active nodes is not sufficient to give rise to a CMPGC.", [["nodes", "ANATOMY", 23, 28], ["CMPGC", "DISEASE", 65, 70], ["nodes", "MULTI-TISSUE_STRUCTURE", 23, 28], ["CMPGC", "CANCER", 65, 70], ["active nodes", "PROBLEM", 16, 28], ["a CMPGC", "TEST", 63, 70], ["active", "OBSERVATION_MODIFIER", 16, 22], ["nodes", "OBSERVATION", 23, 28]]], ["One needs the presence of nodes with k > k c (first mechanism) or k > k x (second mechanism).", [["nodes", "ANATOMY", 26, 31], ["nodes", "TEST", 26, 31], ["k", "TEST", 37, 38], ["k", "TEST", 66, 67], ["nodes", "OBSERVATION", 26, 31]]], ["Notice that, since k c grows as a power of k a with an exponent larger than 1, while k x grows logarithmically, asymptotically k c \u226b k x .", [["exponent", "OBSERVATION_MODIFIER", 55, 63], ["larger", "OBSERVATION_MODIFIER", 64, 70]]], ["Different scalings of the finite-size effective threshold are possible, depending on whether the maximum degree k max \u00f0N\u00de is larger or smaller than the crossover degree k \u00c3 2 .", [["the maximum degree k max \u00f0N\u00de", "TEST", 93, 121], ["size", "OBSERVATION_MODIFIER", 33, 37], ["larger", "OBSERVATION_MODIFIER", 125, 131], ["smaller", "OBSERVATION_MODIFIER", 135, 142]]], ["If k max \u00f0N\u00de > k \u00c3 2 , finite-size effects appear during the regime where the formation of the CMPGC is governed by the second mechanism.", [["CMPGC", "GENE_OR_GENE_PRODUCT", 95, 100], ["CMPGC", "PROTEIN", 95, 100], ["k max", "TEST", 3, 8], ["N\u00de", "TEST", 10, 12], ["finite-size effects", "TREATMENT", 23, 42], ["size", "OBSERVATION_MODIFIER", 30, 34]]], ["In this case, the asymptotic behavior S \u2248 S 2 ends (i.e., S \u2248 0) when the relevant degree scale k x (growing with k a ) becomes larger than k max \u00f0N\u00de.", [["N\u00de", "PROTEIN", 147, 149], ["larger", "OBSERVATION_MODIFIER", 128, 134]]], ["In such a case, there are active nodes in the system, but neither of the two mechanisms for the formation of the giant component is at work.", [["nodes", "ANATOMY", 33, 38], ["nodes", "MULTI-TISSUE_STRUCTURE", 33, 38], ["active nodes in the system", "PROBLEM", 26, 52], ["the giant component", "PROBLEM", 109, 128], ["active", "OBSERVATION_MODIFIER", 26, 32], ["nodes", "OBSERVATION", 33, 38], ["system", "ANATOMY", 46, 52], ["giant", "OBSERVATION_MODIFIER", 113, 118]]], ["The effective threshold in this case is given by the condition k x \u00bc k max \u00f0N\u00de, implying asymptoticallyIV.", [["asymptoticallyIV", "TREATMENT", 89, 105]]], ["FINITE-SIZE EFFECTSIf, instead, k max \u00f0N\u00de < k \u00c3 2 , finite-size effects start to appear already during the preasymptotic regime where the first mechanism rules.", [["k max", "TEST", 32, 37], ["N\u00de", "TEST", 39, 41], ["finite-size effects", "PROBLEM", 52, 71], ["the preasymptotic regime", "TREATMENT", 103, 127], ["SIZE", "OBSERVATION_MODIFIER", 7, 11], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["As soon as k c > k max \u00f0N\u00de, the behavior S \u2248 S 1 ends.", [["k c", "TEST", 11, 14]]], ["FINITE-SIZE EFFECTSNotice that after this effective threshold the order parameter does not go to S \u2248 0, as there is still an interval of k a values such that k x < k max \u00f0N\u00de < k c .", [["k", "TEST", 158, 159], ["k max", "TEST", 164, 169], ["N\u00de", "TEST", 171, 173], ["SIZE", "OBSERVATION_MODIFIER", 7, 11]]], ["In this regime, the first mechanism is no longer operative; still, the second is at work, but since N < N \u00c3 2 , it cannot lead to a macroscopic giant component.V. NUMERICAL TESTWe test the correctness of the scaling analysis performed in the previous sections by means of numerical simulations of the CMP process with r\u00f0m\u00de \u00bc m=k a .", [["N < N \u00c3 2", "CHEMICAL", 100, 109], ["a macroscopic giant component", "PROBLEM", 130, 159], ["NUMERICAL TESTWe test", "TEST", 163, 184], ["the scaling analysis", "TEST", 204, 224], ["the CMP process", "TEST", 297, 312], ["no longer", "UNCERTAINTY", 39, 48]]], ["5(a) and 5(b), we report, as a function of k a , the fraction S of nodes in the largest CMP cluster for \u03b3 < 3 on uncorrelated configuration model networks (UCM) [35] of various sizes.", [["the fraction S", "TEST", 49, 63], ["nodes", "OBSERVATION", 67, 72], ["largest", "OBSERVATION_MODIFIER", 80, 87], ["CMP cluster", "OBSERVATION", 88, 99], ["sizes", "OBSERVATION_MODIFIER", 177, 182]]], ["The plot shows the presence of a CMPGC, including a fraction of active nodes independent of the system size N. The scaling of S with k a is in excellent agreement with the prediction of Eq.", [["CMPGC", "SIMPLE_CHEMICAL", 33, 38], ["The plot", "TEST", 0, 8], ["a CMPGC", "PROBLEM", 31, 38], ["active nodes", "PROBLEM", 64, 76], ["active", "OBSERVATION_MODIFIER", 64, 70], ["nodes", "OBSERVATION", 71, 76], ["size", "OBSERVATION_MODIFIER", 103, 107], ["scaling", "OBSERVATION_MODIFIER", 115, 122]]], ["Finite-size effects are also apparent and perfectly agree with the prediction formulated above: The effective threshold occurs for k a \u00bc k max \u00f0N\u00de \u00bc N 1=2 .", [["k a \u00bc k max", "TEST", 131, 142], ["N\u00de", "TEST", 144, 146], ["size", "OBSERVATION_MODIFIER", 7, 11]]], ["Increasing the network size, the effective threshold diverges: Asymptotically, there is a giant component for any k a > 0.V. NUMERICAL TESTFor \u03b3 > 3, we consider a hard cutoff M \u00bc N 1=\u00f0\u03b3\u22121\u00de for the degree sequence generated in the UCM model, in order to avoid the possible appearance of outliers having a degree much larger than the average k max [38] .", [["UCM model", "CELL_LINE", 231, 240], ["NUMERICAL TESTFor \u03b3", "TEST", 125, 144], ["a hard cutoff M", "TEST", 162, 177], ["the degree sequence", "TEST", 194, 213], ["size", "OBSERVATION_MODIFIER", 23, 27], ["giant", "OBSERVATION_MODIFIER", 90, 95]]], ["Figures 5(c) and 5(d) show that also in this case the fraction of active nodes in the CMPGC is extensive, and its dependence on k a is well described by Eq.", [["nodes", "ANATOMY", 73, 78], ["nodes", "MULTI-TISSUE_STRUCTURE", 73, 78], ["CMPGC", "PROTEIN", 86, 91], ["Figures", "TEST", 0, 7], ["active nodes", "PROBLEM", 66, 78], ["active", "OBSERVATION_MODIFIER", 66, 72], ["nodes", "OBSERVATION", 73, 78], ["CMPGC", "ANATOMY", 86, 91], ["extensive", "OBSERVATION_MODIFIER", 95, 104], ["dependence", "OBSERVATION_MODIFIER", 114, 124]]], ["This result confirms the depicted scenario about the formation of an extensive CMPGC and points out that for the sizes considered only the preasymptotic scaling regime S 1 is observed, while, as expected, we do not see any trace of the asymptotic behavior (for an infinite network) S \u00bc S 2 \u2248 k 1\u2212\u03b3 a .V. NUMERICAL TESTConcerning finite-size effects, for \u03b3 > 3 as only the first scaling regime is observed, the condition setting the effective threshold is Eq.", [["an extensive CMPGC", "PROBLEM", 66, 84], ["the sizes", "PROBLEM", 109, 118], ["the preasymptotic scaling regime", "TREATMENT", 135, 167], ["the asymptotic behavior", "PROBLEM", 232, 255], ["the first scaling regime", "TREATMENT", 368, 392], ["extensive", "OBSERVATION_MODIFIER", 69, 78], ["CMPGC", "OBSERVATION", 79, 84], ["size", "OBSERVATION_MODIFIER", 336, 340]]], ["A direct numerical verification of it for CMP is very hard, as practically all nonisolated nodes are part of the CMPGC, and finite clusters (upon which methods to determine the position of the threshold are based) are extremely rare.", [["nodes", "MULTI-TISSUE_STRUCTURE", 91, 96], ["CMPGC", "DNA", 113, 118], ["A direct numerical verification", "TEST", 0, 31], ["CMP", "PROBLEM", 42, 45], ["practically all nonisolated nodes", "PROBLEM", 63, 96], ["nodes", "OBSERVATION", 91, 96], ["clusters", "OBSERVATION_MODIFIER", 131, 139]]], ["An indirect numerical verification is provided below in the application to the SIS model.", [["An indirect numerical verification", "TEST", 0, 34]]], ["The conclusion of our analysis is that, in different manners depending on whether \u03b3 < 3 or \u03b3 > 3, a CMP giant component is present in infinite networks for any value of k a .", [["our analysis", "TEST", 18, 30], ["a CMP giant component", "PROBLEM", 98, 119], ["giant", "OBSERVATION_MODIFIER", 104, 109], ["component", "OBSERVATION_MODIFIER", 110, 119]]], ["The threshold for this class of CMP processes is infinite for any value of \u03b3.VI. APPLICATION TO SIS EPIDEMIC SPREADINGThe theoretical picture presented in the previous sections can be applied to the CMP process associated to SIS dynamics, which is an instance of this class with k a \u00bc a=\u03bb 2 ln\u00f01=\u03bb\u00de, initial mass equal to the degree, and r\u00f0m\u00de \u00bc m=k a ; see Appendix A. This application has mainly the goal of investigating the properties of the SIS epidemic transition for \u03b3 > 3.", [["sections", "ANATOMY", 168, 176], ["CMP processes", "PROBLEM", 32, 45], ["k", "TEST", 279, 280], ["initial mass", "TEST", 300, 312], ["r\u00f0m\u00de", "TEST", 338, 342], ["mass", "OBSERVATION", 308, 312], ["Appendix", "ANATOMY", 357, 365]]], ["We notice that the relation between CMP and SIS depends on the parameter a relating k a with \u03bb, whose value, either a \u00bc 1 or a \u00bc 4, is not theoretically determined.", [["the relation between CMP and SIS", "PROBLEM", 15, 47]]], ["In our application of CMP to SIS, we choose to compare with both values.A. Scaling of the CMP giant componentThe scaling of S with \u03bb for \u03b3 < 3 is obtained by inserting the expression for k a as a function of \u03bb into Eq.", [["\u03bb", "PROTEIN", 208, 209], ["CMP to SIS", "TREATMENT", 22, 32], ["the CMP giant component", "PROBLEM", 86, 109], ["Scaling", "OBSERVATION_MODIFIER", 75, 82], ["CMP giant", "OBSERVATION_MODIFIER", 90, 99], ["component", "OBSERVATION_MODIFIER", 100, 109]]], ["Scaling of the CMP giant componentThus, the approach predicts the existence of a CMPGC for any value of \u03bb > 0.", [["CMPGC", "PROTEIN", 81, 86], ["the CMP giant component", "PROBLEM", 11, 34], ["a CMPGC", "TEST", 79, 86], ["CMP", "OBSERVATION_MODIFIER", 15, 18], ["giant", "OBSERVATION_MODIFIER", 19, 24], ["component", "OBSERVATION_MODIFIER", 25, 34]]], ["Notice, however, that, while it is possible to define a CMP process associated to SIS dynamics for any value of \u03b3, the SIS epidemic transition for \u03b3 < 5=2 is due to a mechanism different from the mutual reinfection of distant hubs [21] : Hence, SIS critical properties have nothing to do with those of CMP in this case.", [["CMP", "CHEMICAL", 302, 305], ["a CMP process", "PROBLEM", 54, 67], ["SIS dynamics", "TEST", 82, 94], ["a mechanism", "PROBLEM", 165, 176]]], ["Moreover, the connection between the scaling of S and the scaling of the SIS prevalence is not trivial in this case; hence, we cannot derive from CMP any prediction on the latter even for 5=2 < \u03b3 < 3.", [["the scaling of S", "PROBLEM", 33, 49], ["scaling", "OBSERVATION_MODIFIER", 37, 44], ["scaling", "OBSERVATION_MODIFIER", 58, 65], ["not", "UNCERTAINTY", 91, 94], ["trivial", "OBSERVATION", 95, 102]]], ["For \u03b3 > 3, the fraction of active nodes in the CMPGC is extensive, and its preasymptotic dependence on \u03bb is obtained by plugging the expression for k a into Eq.", [["nodes", "ANATOMY", 34, 39], ["\u03b3 > 3", "GENE_OR_GENE_PRODUCT", 4, 9], ["nodes", "MULTI-TISSUE_STRUCTURE", 34, 39], ["CMPGC", "PROTEIN", 47, 52], ["\u03bb", "PROTEIN", 103, 104], ["active nodes", "PROBLEM", 27, 39], ["its preasymptotic dependence", "PROBLEM", 71, 99], ["active", "OBSERVATION_MODIFIER", 27, 33], ["nodes", "OBSERVATION", 34, 39], ["CMPGC", "ANATOMY_MODIFIER", 47, 52], ["extensive", "OBSERVATION_MODIFIER", 56, 65]]], ["(17):A. Scaling of the CMP giant componentWe can also calculate the asymptotic scaling of the CMPGC, by plugging the expression for k a into the expression of the scaling of the CMP giant component in the second regime, Eq.", [["CMPGC", "PROTEIN", 94, 99], ["plugging", "OBSERVATION", 104, 112], ["CMP giant", "OBSERVATION_MODIFIER", 178, 187], ["component", "OBSERVATION_MODIFIER", 188, 197]]], ["Scaling of the CMP giant componentWe recall, however, that this scaling occurs only for exceedingly large values of k a (i.e., values of \u03bb exceedingly small), so that it cannot be observed in present simulations.B. Finite-size epidemic thresholdFor \u03b3 > 3, as only the first scaling regime is observed, the condition setting the effective threshold is k max \u00f0N\u00de \u00bc k c \u00f0\u03bb\u00de, i.e., a \u03bb 2 c ln 1B.", [["c ln 1B", "PROTEIN", 384, 391], ["the CMP giant component", "PROBLEM", 11, 34], ["the first scaling regime", "TREATMENT", 264, 288], ["N\u00de", "TEST", 358, 360], ["k", "TEST", 363, 364], ["CMP", "OBSERVATION_MODIFIER", 15, 18], ["giant", "OBSERVATION_MODIFIER", 19, 24], ["component", "OBSERVATION_MODIFIER", 25, 34], ["size", "OBSERVATION_MODIFIER", 222, 226]]], ["Finite-size epidemic thresholdThis result translates (apart from logarithmic corrections) intoB.", [["size", "OBSERVATION_MODIFIER", 7, 11], ["epidemic", "OBSERVATION_MODIFIER", 12, 20], ["threshold", "OBSERVATION_MODIFIER", 21, 30]]], ["Finite-size epidemic thresholdFor k \u22121=2 max < \u03bb < \u03bb c \u00f0N\u00de, there are active hubs in the system, but they do not give rise to a CMPGC.", [["CMPGC", "DISEASE", 128, 133], ["N\u00de", "PROTEIN", 56, 58], ["CMPGC", "PROTEIN", 128, 133], ["k", "TEST", 34, 35], ["active hubs in the system", "PROBLEM", 70, 95], ["size", "OBSERVATION_MODIFIER", 7, 11], ["epidemic", "OBSERVATION_MODIFIER", 12, 20], ["threshold", "OBSERVATION_MODIFIER", 21, 30], ["active", "OBSERVATION_MODIFIER", 70, 76], ["hubs", "OBSERVATION", 77, 81]]], ["Hence, \u03bb c \u00f0N\u00de can be identified with the effective size-dependent epidemic threshold.", [["\u03bb c", "PROTEIN", 7, 10], ["N\u00de", "PROTEIN", 12, 14], ["size", "OBSERVATION_MODIFIER", 52, 56], ["dependent", "OBSERVATION_MODIFIER", 57, 66], ["epidemic", "OBSERVATION_MODIFIER", 67, 75]]], ["Equation (29) is very interesting, as it shows that the effective threshold does not vanish as k \u22121=2 max , as predicted by the QMF theory, but more slowly, with an exponent that is reduced as \u03b3 is increased.", [["\u03b3", "PROTEIN", 193, 194], ["Equation", "TEST", 0, 8], ["exponent", "OBSERVATION", 165, 173], ["reduced", "OBSERVATION_MODIFIER", 182, 189], ["increased", "OBSERVATION_MODIFIER", 198, 207]]], ["[24] , displaying a good agreement and thus clarifying a long-standing open issue.", [["a long-standing open issue", "TREATMENT", 55, 81]]], ["For reference, we also report the scaling predicted by the QMF theory, which patently disagrees with numerical results.B. Finite-size epidemic thresholdNotice, however, that this result is not the final asymptotic behavior of \u03bb c \u00f0N\u00de.", [["N\u00de", "PROTEIN", 231, 233], ["size", "OBSERVATION_MODIFIER", 129, 133]]], ["(20) , leads toB.", [["toB", "PROTEIN", 13, 16], ["toB", "OBSERVATION", 13, 16]]], ["Finite-size epidemic thresholdIn this way, we recover the asymptotic scaling of the effective threshold recently derived by Huang and Durrett [27] .B. Finite-size epidemic thresholdIn Appendix D, we show that the CMP approach provides the correct effective finite-size threshold also in the case of stretched exponential degree distributions.C. SIS prevalence as a function of \u03bbAbove the size-dependent effective threshold, there is a backbone of active nodes which sustain an endemic state by reinfecting each other.", [["nodes", "ANATOMY", 454, 459], ["C", "GENE_OR_GENE_PRODUCT", 342, 343], ["the CMP approach", "TREATMENT", 209, 225], ["active nodes", "PROBLEM", 447, 459], ["size", "OBSERVATION_MODIFIER", 7, 11], ["epidemic", "OBSERVATION_MODIFIER", 12, 20], ["threshold", "OBSERVATION_MODIFIER", 21, 30], ["size", "OBSERVATION_MODIFIER", 158, 162], ["Appendix", "ANATOMY", 184, 192], ["size", "OBSERVATION_MODIFIER", 264, 268], ["stretched", "OBSERVATION_MODIFIER", 299, 308], ["exponential degree", "OBSERVATION", 309, 327], ["size", "OBSERVATION_MODIFIER", 388, 392], ["dependent", "OBSERVATION_MODIFIER", 393, 402], ["effective threshold", "OBSERVATION_MODIFIER", 403, 422], ["active", "OBSERVATION_MODIFIER", 447, 453], ["nodes", "OBSERVATION", 454, 459], ["endemic", "OBSERVATION_MODIFIER", 477, 484]]], ["In an infinite network, when the CMP giant component is formed by distant, mutually FIG.", [["FIG", "PROTEIN", 84, 87], ["the CMP giant component", "PROBLEM", 29, 52], ["giant", "OBSERVATION_MODIFIER", 37, 42], ["component", "OBSERVATION_MODIFIER", 43, 52], ["distant", "OBSERVATION_MODIFIER", 66, 73]]], ["Comparison between the theoretical finite-size threshold (for two different values of a) (hollow symbols) and direct numerical simulations (full symbols) of the SIS process in UCM networks with degree exponent \u03b3 \u00bc 3.5 (k min \u00bc 3) and \u03b3 \u00bc 4 (k min \u00bc 2) [24] .", [["a) (hollow symbols)", "TREATMENT", 86, 105], ["direct numerical simulations", "TREATMENT", 110, 138], ["the SIS process", "TREATMENT", 157, 172], ["degree exponent", "TEST", 194, 209], ["\u00bc", "TEST", 212, 213], ["\u03b3", "TEST", 234, 235]]], ["The dashed red line is proportional to the prediction 1= ffiffiffiffiffiffiffiffi ffi k max p of the QMF theory.", [["dashed red line", "CELL_LINE", 4, 19], ["The dashed red line", "TREATMENT", 0, 19], ["red line", "OBSERVATION", 11, 19]]], ["The values of k max correspond to sizes ranging from N \u00bc 10 4 to N \u00bc 10 8 for \u03b3 \u00bc 3.5 and from N \u00bc 10 4 to N \u00bc 10 7 for \u03b3 \u00bc 4.C. SIS prevalence as a function of \u03bbinteracting hubs (second regime), we can estimate the value of the prevalence (average density of infected nodes) for small \u03bb using the following argument.", [["nodes", "MULTI-TISSUE_STRUCTURE", 269, 274], ["The values", "TEST", 0, 10], ["k max", "TEST", 14, 19], ["sizes", "TEST", 34, 39], ["N \u00bc", "TEST", 53, 56], ["\u03bbinteracting hubs (second regime", "TREATMENT", 161, 193], ["infected nodes", "PROBLEM", 260, 274], ["sizes", "OBSERVATION_MODIFIER", 34, 39], ["infected nodes", "OBSERVATION", 260, 274], ["small", "OBSERVATION_MODIFIER", 280, 285]]], ["All actives nodes with a degree larger than k x \u00bc \u03c9k a participate in the CMPGC.", [["CMPGC", "DNA", 74, 79], ["actives nodes", "OBSERVATION", 4, 17]]], ["Each one of these active nodes of degree k infects a number of other nodes of order \u03bbk.", [["\u03bbk", "GENE_OR_GENE_PRODUCT", 84, 86], ["active", "OBSERVATION_MODIFIER", 18, 24], ["nodes", "OBSERVATION", 25, 30], ["degree k", "OBSERVATION_MODIFIER", 34, 42], ["infects", "OBSERVATION_MODIFIER", 43, 50], ["nodes", "OBSERVATION", 69, 74]]], ["Since hubs are distant, these clusters of infected nodes do not overlap; hence, the total prevalence in the system is expected to be [23] \u03c1C.", [["nodes", "ANATOMY", 51, 56], ["[23] \u03c1C.", "CHEMICAL", 133, 141], ["infected nodes", "PROBLEM", 42, 56], ["distant", "OBSERVATION_MODIFIER", 15, 22], ["clusters", "OBSERVATION_MODIFIER", 30, 38], ["infected", "OBSERVATION_MODIFIER", 42, 50], ["nodes", "OBSERVATION", 51, 56]]], ["(31) leads toC.", [["toC", "PROTEIN", 11, 14]]], ["As discussed above, this prediction is, however, impossible to verify numerically, because the onset of the asymptotic regime could be seen only for exceedingly large networks, which explains the mismatch between the theory of Mountford, Valesin, and Yao and numerical results.", [["Valesin", "TREATMENT", 238, 245]]], ["In doable simulations of the SIS model, the small \u03bb regime that can be observed is the preasymptotic regime S 1 for the corresponding CMP process.", [["the SIS model", "TREATMENT", 25, 38], ["the small \u03bb regime", "TREATMENT", 40, 58], ["the preasymptotic regime S", "TREATMENT", 83, 109], ["the corresponding CMP process", "PROBLEM", 116, 145], ["small", "OBSERVATION_MODIFIER", 44, 49], ["CMP process", "OBSERVATION", 134, 145]]], ["In such a regime, since hubs are not well separated, it is not possible to assume that each of them independently infects a number of neighbors of the order of \u03bbk.", [["\u03bbk", "GENE_OR_GENE_PRODUCT", 160, 162], ["\u03bbk", "PROTEIN", 160, 162], ["not possible", "UNCERTAINTY", 59, 71]]], ["The derivation of the exponent characterizing the SIS prevalence singularity in this preasymptotic (but long) regime remains an interesting open question for future research.VII. DISCUSSIONIn this paper, we consider a long-range percolation process, the cumulative merging percolation, exhibiting a rich phenomenology that we have uncovered developing an appropriate scaling theory.", [["the SIS prevalence singularity", "PROBLEM", 46, 76], ["a long-range percolation process", "TREATMENT", 216, 248], ["exponent", "OBSERVATION_MODIFIER", 22, 30]]], ["While we mainly focus on particular forms of the model inspired by the analysis of SIS process [29] , more complex scenarios can be obtained by changing the functional form of the interaction range r\u00f0m\u00de or the activation probability p i and by considering a more complicated mass merging function m \u03b1\u00fe\u03b2 \u00bc g\u00f0m \u03b1 ;m \u03b2 \u00de.", [["\u03b1\u00fe\u03b2", "PROTEIN", 299, 302], ["g\u00f0m \u03b1", "PROTEIN", 305, 310], ["\u03b2", "PROTEIN", 314, 315], ["SIS process", "PROBLEM", 83, 94], ["a more complicated mass", "PROBLEM", 256, 279], ["mass", "OBSERVATION", 275, 279]]], ["In this sense, we expect other types of percolation transitions to arise as these features are changed.", [["percolation transitions", "TREATMENT", 40, 63]]], ["For example, if r\u00f0m\u00de saturates to a finite value when m diverges, the arguments presented above imply the presence of a finite threshold for \u03b3 > 3 as for the DOP process.", [["DOP", "CHEMICAL", 158, 161], ["DOP", "SIMPLE_CHEMICAL", 158, 161], ["r\u00f0m\u00de", "PROTEIN", 16, 20], ["the DOP process", "PROBLEM", 154, 169]]], ["The investigation of the general phenomenology of the CMP process and of its connections with other models is a promising avenue for future research.VII. DISCUSSIONConcerning the application of CMP to SIS dynamics, our results clarify how the mutual reinfection mechanism among distant hubs, underlying the epidemic transition for \u03b3 > 3 [24] , takes place.", [["VII", "PROTEIN", 149, 152], ["the CMP process", "TREATMENT", 50, 65], ["CMP to SIS dynamics", "TREATMENT", 194, 213], ["CMP process", "OBSERVATION", 54, 65]]], ["This clarification closes the last gap in our understanding of the SIS dynamics and leads to a complete and consistent physical picture that we sketch here.VII. DISCUSSIONThe original heterogeneous-mean-field theory (HMF) [15, 16] , based on an annealed network approximation [2] , predicts an epidemic threshold given \u03bb HMF c \u00bc hki=hk 2 i and thus finite in the limit of infinite-size networks for \u03b3 > 3 (see Fig. 7 ).", [["VII", "GENE_OR_GENE_PRODUCT", 156, 159], ["VII", "PROTEIN", 156, 159], ["an annealed network approximation", "TREATMENT", 242, 275], ["heterogeneous", "OBSERVATION_MODIFIER", 184, 197]]], ["Below \u03bb HMF c , this theory predicts a density of infected individuals \u03c1\u00f0t\u00de decaying exponentially to zero.", [["infected individuals", "PROBLEM", 50, 70], ["infected", "OBSERVATION", 50, 58]]], ["For \u03bb > \u03bb HMF c , the HMF predicts a finite \u03c1 in the steady state.VII. DISCUSSIONThe quenched-mean-field theory (QMF or NIMFA) [17] [18] [19] predicts the same scenario, a transition separating an active steady state with finite prevalence from an absorbing phase where the prevalence decays exponentially to zero.", [["HMF", "CHEMICAL", 10, 13], ["HMF", "CHEMICAL", 22, 25], ["VII", "GENE_OR_GENE_PRODUCT", 66, 69], ["VII", "PROTEIN", 66, 69], ["active", "OBSERVATION", 197, 203], ["absorbing phase", "OBSERVATION_MODIFIER", 248, 263]]], ["The difference with respect to the HMF is in the value of the threshold, \u03bb QMF c \u00bc 1=\u039b M , where \u039b M is the largest eigenvalue of the adjacency matrix, which vanishes as N diverges, for any \u03b3.", [["HMF", "CHEMICAL", 35, 38], ["HMF", "CHEMICAL", 35, 38], ["matrix", "CELLULAR_COMPONENT", 144, 150], ["the HMF", "TEST", 31, 38], ["largest", "OBSERVATION_MODIFIER", 108, 115], ["adjacency matrix", "OBSERVATION", 134, 150]]], ["The value of the QMF threshold is the minimum value of \u03bb such that the star graph composed by the largest hub and its direct neighbors is able to independently sustain long-lasting activity [21] .", [["largest", "OBSERVATION_MODIFIER", 98, 105]]], ["Correspondingly, the principal eigenvector for \u03b3 > 5=2 is localized around the largest hub [22] .", [["largest", "OBSERVATION_MODIFIER", 79, 86]]], ["Also, the other leading eigenvalues of the adjacency matrix are associated to eigenvectors localized on each of the hubs of the network.", [["matrix", "CELLULAR_COMPONENT", 53, 59], ["the adjacency matrix", "PROBLEM", 39, 59], ["eigenvalues", "OBSERVATION_MODIFIER", 24, 35], ["adjacency matrix", "OBSERVATION", 43, 59]]], ["In the thermodynamic limit, for any given value of \u03bb, each large hub with degree k > 1=\u03bb 2 sustains longlasting activity together with its direct neighbors, yielding an overall finite density of infected individuals that can be estimated [23] as \u03c1 \u223c \u03bb 2\u03b3\u22123 .VII. DISCUSSIONHowever, as pointed out in Refs.", [["VII", "GENE_OR_GENE_PRODUCT", 258, 261], ["VII", "PROTEIN", 258, 261], ["degree k", "TEST", 74, 82], ["infected individuals", "PROBLEM", 195, 215]]], ["In the QMF theory, there are no stochastic fluctuations, and activity in a star graph composed by k \u00fe 1 nodes persists forever if \u03bb > 1= ffiffi ffi k p .", [["stochastic fluctuations", "PROBLEM", 32, 55], ["a star graph", "TEST", 73, 85], ["no", "UNCERTAINTY", 29, 31], ["stochastic fluctuations", "OBSERVATION", 32, 55], ["nodes", "OBSERVATION", 104, 109]]], ["In SIS dynamics, instead, activity survives, in a star graph made of k \u00fe 1 nodes, only for a time of the order of exp\u00f0\u03bb 2 k=a\u00de.", [["nodes", "OBSERVATION", 75, 80]]], ["Hence, if star graphs are independent, the overall activity does not survive for a time scaling exponentially with the system size N. In other words, there is some activity surviving for some time but not a truly steady active state.", [["star graphs", "TEST", 10, 21]]], ["In the interval \u03bb QMF c < \u03bb < \u03bb HMF c , one FIG.", [["HMF", "CHEMICAL", 32, 35], ["FIG", "CHEMICAL", 44, 47], ["FIG", "PROTEIN", 44, 47]]], ["[22, 23] .VII. DISCUSSIONshould expect a Griffiths-like phase, with a slow decay of \u03c1\u00f0t\u00de [23] , due to the convolution of contributions from a decreasing number of still active individual hubs.", [["VII", "GENE_OR_GENE_PRODUCT", 10, 13], ["VII", "PROTEIN", 10, 13], ["a slow decay of \u03c1\u00f0t\u00de", "PROBLEM", 68, 88], ["decreasing", "OBSERVATION_MODIFIER", 143, 153], ["active", "OBSERVATION_MODIFIER", 170, 176]]], ["Only above a finite threshold, approximately equal to \u03bb HMF c , corresponding to the inverse of the first eigenvalue associated to a delocalized eigenvector [22] , is a truly active steady state expected (see Fig. 7 ).", [["HMF", "CHEMICAL", 56, 59], ["HMF c", "GENE_OR_GENE_PRODUCT", 56, 61]]], ["This scenario is consistent, but at odds with numerical simulations [24] and exact mathematical results [39, 40] , which find an active steady state for any value of \u03bb > 0 in the thermodynamic limit.VII. DISCUSSIONOne possible way to reconcile these findings was explored by Lee, Shim, and Noh [23] .", [["VII", "GENE_OR_GENE_PRODUCT", 199, 202], ["VII", "PROTEIN", 199, 202], ["numerical simulations", "TEST", 46, 67], ["active", "OBSERVATION", 129, 135], ["thermodynamic limit", "OBSERVATION", 179, 198]]], ["If large hubs are in mutual direct contact (i.e., they form an extensive connected cluster), should activity spontaneously disappear in one of them, neighboring hubs would be able to reinfect it; these mutual reinfections would lead to a survival time exponential in N, i.e., a truly active steady state.", [["these mutual reinfections", "PROBLEM", 196, 221], ["large", "OBSERVATION_MODIFIER", 3, 8], ["hubs", "OBSERVATION", 9, 13]]], ["Unfortunately, the study of degree-ordered-percolation reveals that such an extensive cluster of large hubs always exists only for \u03b3 < 3.", [["the study", "TEST", 15, 24], ["an extensive cluster of large hubs always", "PROBLEM", 73, 114], ["extensive", "OBSERVATION_MODIFIER", 76, 85], ["cluster", "OBSERVATION_MODIFIER", 86, 93], ["large", "OBSERVATION_MODIFIER", 97, 102], ["hubs", "OBSERVATION", 103, 107]]], ["For \u03b3 > 3, the DOP threshold is finite: The largest hubs are separated and do not form an extensive cluster [23] .VII. DISCUSSIONOur results go beyond those of Lee, Shim, and Noh and clarify what is missing in previous approaches: The activity triggered by hubs extends beyond nearest neighbors, up to a scale that grows with \u03bb, so that hubs can interact even if they are not in direct contact.", [["DOP", "CHEMICAL", 15, 18], ["DOP", "SIMPLE_CHEMICAL", 15, 18], ["VII", "GENE_OR_GENE_PRODUCT", 114, 117], ["VII", "PROTEIN", 114, 117], ["largest", "OBSERVATION_MODIFIER", 44, 51], ["do not form", "UNCERTAINTY", 75, 86], ["extensive", "OBSERVATION_MODIFIER", 90, 99], ["cluster", "OBSERVATION_MODIFIER", 100, 107], ["activity", "OBSERVATION_MODIFIER", 235, 243]]], ["This long-range interaction gives rise, above a critical value \u03bb c \u00f0N\u00de, to an extensive CMP percolating cluster of active nodes able to reinfect each other at distance and, thus, giving a veritable steady state with finite prevalence \u03c1.", [["N\u00de", "PROTEIN", 68, 70], ["active nodes", "PROBLEM", 115, 127], ["extensive", "OBSERVATION_MODIFIER", 78, 87], ["CMP percolating", "OBSERVATION_MODIFIER", 88, 103], ["cluster", "OBSERVATION_MODIFIER", 104, 111], ["active", "OBSERVATION_MODIFIER", 115, 121], ["nodes", "OBSERVATION", 122, 127]]], ["The threshold \u03bb c \u00f0N\u00de is intermediate between \u03bb QMF c and \u03bb HMF c and vanishes as a function of N (at odds with \u03bb HMF c ) but more slowly than \u03bb QMF c .", [["HMF", "CHEMICAL", 60, 63], ["HMF", "CHEMICAL", 114, 117], ["N\u00de", "PROTEIN", 19, 21]]], ["Considering finite networks, while for \u03bb c \u00f0N\u00de < \u03bb < \u03bb HMF c a CMP percolating cluster exists and prevalence is finite, for \u03bb QMF c < \u03bb < \u03bb c only small nonpercolating CMP clusters are present.", [["HMF", "CHEMICAL", 55, 58], ["CMP", "CHEMICAL", 63, 66], ["\u03bb c", "PROTEIN", 39, 42], ["N\u00de", "PROTEIN", 44, 46], ["a CMP percolating cluster exists", "PROBLEM", 61, 93], ["small nonpercolating CMP clusters", "PROBLEM", 147, 180], ["CMP clusters", "OBSERVATION", 168, 180]]], ["In this case, each of them decays independently, and, thus, a Griffiths-like phase, characterized by \u03c1\u00f0t\u00de slowly decaying to zero, is expected (Fig. 7) .", [["\u03c1\u00f0t", "PROTEIN", 101, 104]]], ["A numerical validation of this prediction, which is difficult as both interval bounds vanish with the system size, remains a challenge for future numerical studies.VII. DISCUSSIONThe consideration of long-range effects is the crucial ingredient in our analysis that makes a qualitative difference with previous approaches.", [["VII", "GENE_OR_GENE_PRODUCT", 164, 167], ["VII", "PROTEIN", 164, 167], ["A numerical validation", "TEST", 0, 22], ["this prediction", "TEST", 26, 41], ["future numerical studies", "TEST", 139, 163], ["long-range effects", "TREATMENT", 200, 218], ["our analysis", "TEST", 248, 260], ["size", "OBSERVATION_MODIFIER", 109, 113], ["long-range", "OBSERVATION_MODIFIER", 200, 210]]], ["While the QMF theory neglects correlations among the dynamical state of neighbors, other theories [41] [42] [43] take some correlations into account, but, since they consider only neighbors in a short range, they cannot capture the long-range percolative nature of the SIS epidemic transition for \u03b3 > 3.VII. DISCUSSIONOur work puts in proper place the different theories presented in recent years to explain the behavior of the SIS model in heterogeneous networks, showing, in particular, the limit in which exact mathematical results are expected to be observed, putting thus an end to the long debate on this subject.", [["VII", "GENE_OR_GENE_PRODUCT", 303, 306], ["VII", "PROTEIN", 303, 306], ["heterogeneous", "OBSERVATION_MODIFIER", 441, 454]]], ["On the other hand, it opens new perspectives, as it proposes the cumulative merging of distant clusters as a very generic phenomenon which may originate nontrivial types of percolation phenomena in networks.ACKNOWLEDGMENTSWe acknowledge financial support from the Spanish Government's MINECO, under Project No.", [["a very generic phenomenon", "PROBLEM", 107, 132], ["percolation phenomena in networks", "PROBLEM", 173, 206], ["distant clusters", "OBSERVATION", 87, 103], ["very", "OBSERVATION_MODIFIER", 109, 113], ["generic phenomenon", "OBSERVATION", 114, 132], ["percolation phenomena", "OBSERVATION", 173, 194]]], ["FIS2016-76830-C2-1-P.", [["FIS2016-76830-C2-1-P.", "CHEMICAL", 0, 21]]], ["R. P.-S. acknowledges additional financial support from ICREA Academia, funded by the Generalitat de Catalunya regional authorities.APPENDIX A: CONNECTION BETWEEN CMP AND SISThe SIS model, often called the contact process in the community of applied probabilists, is defined as follows: Individuals can be in one of two states, either susceptible or infected.", [["infected", "OBSERVATION", 350, 358]]], ["Susceptible individuals become infected by contact with infected individuals, at a rate equal to the number of infected contacts times a given spreading rate \u03b2.", [["individuals", "ORGANISM", 12, 23], ["Susceptible individuals", "PROBLEM", 0, 23], ["infected individuals", "PROBLEM", 56, 76], ["infected", "OBSERVATION", 31, 39], ["infected", "OBSERVATION_MODIFIER", 56, 64], ["infected", "OBSERVATION", 111, 119]]], ["Infected individuals, on the other hand, become spontaneously healthy again at a rate \u03bc.", [["Infected individuals", "PROBLEM", 0, 20], ["individuals", "OBSERVATION", 9, 20]]], ["The ratio \u03bb \u00bc \u03b2=\u03bc is the control parameter for the model, which experiences a transition between a healthy and an endemic (infected) steady state when \u03bb crosses an epidemic threshold \u03bb c .", [["The ratio", "TEST", 0, 9]]], ["In power-law distributed networks, for \u03b3 > 5=2 the epidemic transition is triggered by nodes with a large number k of neighbors (hubs).", [["nodes", "OBSERVATION", 87, 92]]], ["Each of these hubs together with its direct neighbors (leaves) forms a star graph, which in isolation is able to sustain the survival of the epidemic for a long time, \u03c4\u00f0k\u00de \u223c exp\u00f0\u03bb 2 k=4\u00de [24] , provided \u03bb is larger than \u03bb c \u00f0k\u00de \u00bc 1= ffiffi ffi k p .", [["leaves", "ORGANISM_SUBDIVISION", 55, 61], ["a star graph", "PROBLEM", 69, 81]]], ["During this long time interval, even if the hub recovers from the infection, it is promptly reinfected by one of its neighbors and can in its turn reinfect other leaves when they recover.", [["infection", "DISEASE", 66, 75], ["the infection", "PROBLEM", 62, 75], ["infection", "OBSERVATION", 66, 75]]], ["After a typical time \u03c4, a fluctuation takes the star graph formed by a hub and its nearest neighbors to the absorbing state.APPENDIX A: CONNECTION BETWEEN CMP AND SISSince the star graph is not isolated in the network, it can propagate activity to other nodes.", [["nodes", "ANATOMY", 254, 259], ["the star graph", "TEST", 172, 186], ["nodes", "OBSERVATION", 254, 259]]], ["It is possible to estimate [24] the average time it takes for an infected node to infect for the first time a node at distance r in the limit of small \u03bb:APPENDIX A: CONNECTION BETWEEN CMP AND SIST\u00f0r\u00de \u223c e r ln\u00f01=\u03bb\u00de :APPENDIX A: CONNECTION BETWEEN CMP AND SISBy equating \u03c4 and T\u00f0r\u00de, it is possible to estimate the \"range of interaction\" of a hub of degree k, i.e., the maximum distance at which a star surrounding an active hub is able to propagate the infection before spontaneously recovering:APPENDIX A: CONNECTION BETWEEN CMP AND SISwhere we defineAPPENDIX A: CONNECTION BETWEEN CMP AND SISConsider now another hub, of degree k 0 at a distance r 0 from the first.", [["node", "ANATOMY", 74, 78], ["node", "ANATOMY", 110, 114], ["infection", "DISEASE", 451, 460], ["an infected node", "PROBLEM", 62, 78], ["CMP AND SIST\u00f0r\u00de", "TEST", 184, 199], ["the infection", "PROBLEM", 447, 460], ["infected", "OBSERVATION_MODIFIER", 65, 73], ["node", "OBSERVATION", 74, 78], ["node", "OBSERVATION", 110, 114], ["small", "OBSERVATION_MODIFIER", 145, 150], ["APPENDIX", "ANATOMY", 153, 161], ["APPENDIX", "ANATOMY", 215, 223], ["active", "OBSERVATION", 415, 421], ["infection", "OBSERVATION", 451, 460]]], ["If r 0 < r\u00f0k\u00de, the second hub is infected by the first and it is able to stay infected (together with its direct neighbors) for a time \u03c4\u00f0k 0 \u00de.", [["infected", "OBSERVATION", 33, 41]]], ["During this time interval, it spreads the infection up to a distance r\u00f0k 0 \u00de.", [["infection", "DISEASE", 42, 51], ["the infection", "PROBLEM", 38, 51], ["infection", "OBSERVATION", 42, 51]]], ["In this way, the two distant hubs form a coupled system such that if one hub recovers, the other is able to reinfect it before recovering in its turn.", [["a coupled system", "TREATMENT", 39, 55]]], ["For the infection to die out in the system of the two hubs, they must recover almost simultaneously [29] .", [["infection", "DISEASE", 8, 17], ["the infection", "PROBLEM", 4, 17], ["infection", "OBSERVATION", 8, 17]]], ["These concurrent recoveries happen after a time of the order of \u03c4\u00f0k\u00de\u03c4\u00f0k 0 \u00de\u223c exp\u00bd\u03bb 2 \u00f0k \u00fe k 0 \u00de; see Fig. 8 .APPENDIX A: CONNECTION BETWEEN CMP AND SISHence, the combined set of hubs are able to infect nodes at an increased range of interaction r\u00f0k \u00fe k 0 \u00de.", [["nodes", "ANATOMY", 202, 207], ["exp\u00bd\u03bb", "TEST", 77, 82], ["k", "TEST", 90, 91], ["infect nodes", "PROBLEM", 195, 207], ["increased", "OBSERVATION_MODIFIER", 214, 223]]], ["It is then clear that SIS dynamics can be seen as an instance of the cumulative merging process, with active nodes those with k \u2265 k a \u00bc 4=\u03bb 2 ln\u00f01=\u03bb\u00de, initial masses equal to node degrees m \u00f00\u00de i \u00bc k i , and range of interaction given by r\u00f0m\u00de \u00bc m=k a .", [["active nodes", "PROBLEM", 102, 114], ["k", "TEST", 126, 127], ["k", "TEST", 130, 131], ["\u00de", "TEST", 148, 149], ["initial masses", "PROBLEM", 151, 165], ["node degrees m", "TEST", 175, 189], ["k i", "TEST", 198, 201], ["interaction", "TEST", 217, 228], ["active", "OBSERVATION_MODIFIER", 102, 108], ["nodes", "OBSERVATION", 109, 114], ["masses", "OBSERVATION", 159, 165], ["node degrees", "OBSERVATION", 175, 187]]], ["Alternative treatments [27, 44] give that star graphs are active for k > k a \u00bc 1=\u03bb 2 ln\u00f01=\u03bb\u00de.", [["Alternative treatments", "TREATMENT", 0, 22], ["star graphs", "TEST", 42, 53], ["k", "TEST", 69, 70]]], ["In the comparison of the CMP approach to SIS with numerical simulations, we consider both expressions.", [["numerical simulations", "TEST", 50, 71]]], ["We can estimate the average distance d\u00f0k\u00de between a node of degree k and the nearest node of degree larger than or equal to k within a treelike approximation [2] .", [["node", "ANATOMY", 52, 56], ["node", "ANATOMY", 85, 89], ["node", "OBSERVATION", 52, 56], ["node", "OBSERVATION", 85, 89], ["degree", "OBSERVATION_MODIFIER", 93, 99], ["larger", "OBSERVATION_MODIFIER", 100, 106]]], ["For random uncorrelated networks, the probability that a link points to a node of degree k 0 is k 0 P\u00f0k 0 \u00de=hki.", [["node", "ANATOMY", 74, 78], ["a node of degree k", "TEST", 72, 90], ["k", "TEST", 96, 97], ["node", "OBSERVATION", 74, 78]]], ["Arriving at this node, there are k 0 \u2212 1 possible outgoing edges (excluding the one used to arrive to node k 0 ).", [["node", "ANATOMY", 17, 21], ["node", "MULTI-TISSUE_STRUCTURE", 17, 21], ["node", "OBSERVATION", 17, 21]]], ["The average number of outgoing edges (the so-called branching factor) is, thus,APPENDIX A: CONNECTION BETWEEN CMP AND SISthat is, a finite number for power-law networks with \u03b3 > 3.APPENDIX A: CONNECTION BETWEEN CMP AND SISFrom this branching ratio, we estimate the average number of nodes at distance n as N n \u00bc k\u03ba n\u22121 , assuming the tree approximation.APPENDIX A: CONNECTION BETWEEN CMP AND SISA node of degree k has k neighbors.", [["branching factor", "PROTEIN", 52, 68], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["outgoing edges", "OBSERVATION_MODIFIER", 22, 36], ["APPENDIX", "ANATOMY", 79, 87], ["nodes", "OBSERVATION", 283, 288], ["tree", "ANATOMY_MODIFIER", 334, 338], ["node", "OBSERVATION", 397, 401]]], ["It is connected at distance d \u00bc 1 to a node of degree not less than k if at least one of these neighbors has a degree larger than or equal to k.", [["node", "OBSERVATION", 39, 43], ["degree", "OBSERVATION_MODIFIER", 111, 117], ["larger", "OBSERVATION_MODIFIER", 118, 124]]], ["The probability of this event isAPPENDIX A: CONNECTION BETWEEN CMP AND SISTherefore, the probability that the distance at the nearest neighbors with a degree larger than or equal to k is equal to d \u00bc 1 isAPPENDIX A: CONNECTION BETWEEN CMP AND SISwhere P < \u00f0k\u00de \u00bc 1 \u2212 P > \u00f0k\u00de is the probability that a nearest neighbor of a node has a degree smaller than k.APPENDIX A: CONNECTION BETWEEN CMP AND SISThe nearest neighbor with a degree not less than k is at distance d \u00bc 2 if there are no such neighbors at distance d \u00bc 1, and at least one of the neighbors at distance d \u00bc 2, in number k\u03ba, has a degree not less than k, which happens with probabilityAPPENDIX A: CONNECTION BETWEEN CMP AND SISBy induction, we can see that the nearest neighbor of a degree not less that k is at distance d \u00bc n corresponds to not observing one at any distance smaller than n and having at least one at a distance equal to n, which happens with probability P\u00f0d \u00bc n\u00de \u00bc \u00bdP < \u00f0k\u00de k \u00bdP < \u00f0k\u00de k\u03ba \u00bdP < \u00f0k\u00de k\u03ba 2 \u2026\u00bdP < \u00f0k\u00de k\u03ba n\u22122 f1 \u2212 \u00bdP < \u00f0k\u00de k\u03ba n\u22121 gAPPENDIX A: CONNECTION BETWEEN CMP AND SISwhere for simplicity we set C \u00bc \u00bdP < \u00f0k\u00de k=\u00f0\u03ba\u22121\u00de .", [["node", "ANATOMY", 322, 326], ["node", "MULTI-TISSUE_STRUCTURE", 322, 326], ["P\u00f0d", "PROTEIN", 933, 936], ["k\u03ba", "PROTEIN", 991, 993], ["f1", "PROTEIN", 998, 1000], ["CMP", "TEST", 235, 238], ["a node", "PROBLEM", 320, 326], ["P", "TEST", 945, 946], ["\u00f0k\u00de", "TEST", 949, 952], ["k", "TEST", 953, 954], ["P", "TEST", 956, 957], ["\u00f0k\u00de", "TEST", 960, 963], ["k\u03ba", "TEST", 964, 966], ["\u00bd", "TEST", 967, 968], ["P", "TEST", 968, 969], ["\u00f0k\u00de", "TEST", 972, 975], ["k\u03ba", "TEST", 976, 978], ["P", "TEST", 983, 984], ["\u00f0k\u00de", "TEST", 987, 990], ["k\u03ba", "TEST", 991, 993], ["n\u22122", "TEST", 994, 997], ["f1", "TEST", 998, 1000], ["P", "TEST", 1004, 1005], ["\u00f0k\u00de", "TEST", 1008, 1011], ["k\u03ba", "TEST", 1012, 1014], ["gAPPENDIX", "TEST", 1019, 1028], ["A", "TEST", 1029, 1030], ["CONNECTION", "TEST", 1032, 1042], ["CMP", "TEST", 1051, 1054], ["SISwhere", "TEST", 1059, 1067], ["simplicity", "TEST", 1072, 1082], ["C", "TEST", 1090, 1091], ["P", "TEST", 1095, 1096], ["k=\u00f0\u03ba\u22121\u00de", "TEST", 1103, 1110], ["APPENDIX", "OBSERVATION", 32, 40], ["degree", "OBSERVATION_MODIFIER", 151, 157], ["larger", "OBSERVATION_MODIFIER", 158, 164], ["node", "OBSERVATION", 322, 326], ["degree", "OBSERVATION_MODIFIER", 333, 339], ["smaller", "OBSERVATION_MODIFIER", 340, 347]]], ["For large k, C \u00bc \u00bd1 \u2212 \u00f0k=k min \u00de 2\u2212\u03b3 k=\u00f0\u03ba\u22121\u00de tends to 1, so we can expand the incomplete Gamma function in Eq.", [["large k", "TEST", 4, 11], ["C", "TEST", 13, 14], ["\u00f0k", "TEST", 22, 24], ["k min", "TEST", 25, 30], ["\u00de", "TEST", 31, 32], ["k=\u00f0\u03ba\u2212", "TEST", 37, 42], ["Gamma function", "OBSERVATION", 89, 103]]], ["(B8) for small arguments, \u0393\u00f00; z\u00de \u223c \u2212 ln\u00f0z\u00de [36] , to obtain the asymptotic behaviorAPPENDIX A: CONNECTION BETWEEN CMP AND SISwhere we expand C for large k.", [["small arguments", "TEST", 9, 24], ["z\u00de", "TEST", 31, 33], ["ln\u00f0z\u00de", "TEST", 38, 43], ["the asymptotic behavior", "PROBLEM", 61, 84]]], ["We therefore observe the asymptotic behavior for large k in infinite networks asAPPENDIX A: CONNECTION BETWEEN CMP AND SISwhere the term 1 accounts for the minimum possible distance between nodes.", [["nodes", "ANATOMY", 190, 195], ["nodes", "MULTI-TISSUE_STRUCTURE", 190, 195], ["the asymptotic behavior", "PROBLEM", 21, 44], ["distance between nodes", "PROBLEM", 173, 195], ["nodes", "OBSERVATION", 190, 195]]], ["This calculation, performed in the tree approximation, captures nevertheless the behavior in real uncorrelated power-law networks generated with the UCM [35] .", [["This calculation", "TEST", 0, 16], ["tree", "ANATOMY_MODIFIER", 35, 39]]], ["In Fig. 9 , we present the result of numerical simulations, together with the numerical evaluation of the summation in Eq.", [["the numerical evaluation", "TEST", 74, 98]]], ["(B6), performed using a discrete power-law degree distribution P\u00f0k\u00de \u00bc k \u2212\u03b3 =\u00bd\u03b6\u00f0\u03b3; k min \u00de \u2212 \u03b6\u00f0\u03b3; k max \u00de, where \u03b6\u00f0s; a\u00de is the Hurwitz zeta function [36] .", [["Hurwitz zeta", "GENE_OR_GENE_PRODUCT", 127, 139], ["P\u00f0k\u00de", "PROTEIN", 63, 67], ["\u00bd\u03b6\u00f0\u03b3", "PROTEIN", 76, 80], ["\u00de", "PROTEIN", 88, 89], ["\u03b6\u00f0\u03b3", "PROTEIN", 92, 95], ["\u03b6\u00f0s", "PROTEIN", 112, 115], ["Hurwitz zeta", "PROTEIN", 127, 139], ["P\u00f0k\u00de", "TEST", 63, 67], ["k", "TEST", 70, 71], ["\u2212\u03b3", "TEST", 72, 74], ["\u00bd\u03b6\u00f0\u03b3", "TEST", 76, 80], ["k", "TEST", 82, 83], ["\u00de", "TEST", 88, 89], ["\u2212", "TEST", 90, 91], ["\u03b6\u00f0\u03b3", "TEST", 92, 95], ["k", "TEST", 97, 98], ["\u00de", "TEST", 103, 104], ["\u03b6\u00f0s", "TEST", 112, 115], ["a\u00de", "TEST", 117, 119], ["the Hurwitz zeta function", "TEST", 123, 148]]], ["The dashed line represents the result for an infinite network (k max \u00bc \u221e), while the dot-dashed lines mark the value for networks with maximum degree k max \u00bc N 1=\u00f0\u03b3\u22121\u00de [37] .", [["dot-dashed lines", "CELL", 85, 101], ["dot-dashed lines", "CELL_LINE", 85, 101], ["The dashed line", "TREATMENT", 0, 15], ["an infinite network", "TEST", 42, 61], ["the dot-dashed lines", "TREATMENT", 81, 101], ["maximum degree k max", "TEST", 135, 155], ["N", "TEST", 158, 159]]], ["The dotted line shows the asymptotic behavior obtained in Eq.", [["The dotted line", "TEST", 0, 15], ["asymptotic behavior", "OBSERVATION", 26, 45]]], ["(B9).APPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSLet us consider the example of a network with cumulative degree distribution [27] P c \u00f0k\u00de \u00bc e \u2212k \u03b2 \u00fek \u03b2 min ; \u00f0C1\u00deAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKScorresponding to a stretched exponential degree distributionAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSApplying the extreme value theory, for a finite network of size N we have FIG.", [["FIG", "PROTEIN", 481, 484], ["cumulative degree distribution", "TEST", 127, 157], ["\u00f0k\u00de", "TEST", 167, 170], ["\u00fek", "TEST", 180, 182]]], ["Average distance between a node of degree k and the closest node of a degree at least k in power-law networks with degree exponent \u03b3 \u00bc 3.APPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSThe other relevant quantities for CMP areAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSandAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSwhere we develop the numerator in the limit of large k a .", [["node", "ANATOMY", 27, 31], ["node", "ANATOMY", 60, 64], ["CMP", "PROBLEM", 247, 250], ["node", "OBSERVATION", 27, 31], ["degree k", "OBSERVATION_MODIFIER", 35, 43], ["node", "OBSERVATION", 60, 64], ["degree exponent", "OBSERVATION_MODIFIER", 115, 130], ["APPENDIX", "ANATOMY", 254, 262]]], ["The average number of active neighbors for each active node isAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSwhere we expand the last expression in the limit of large k a .", [["node", "ANATOMY", 55, 59], ["active", "OBSERVATION_MODIFIER", 22, 28], ["active", "OBSERVATION_MODIFIER", 48, 54], ["node", "OBSERVATION", 55, 59]]], ["Therefore, the average number of active neighbors of an active node vanishes exponentially.", [["node", "ANATOMY", 63, 67], ["node", "MULTI-TISSUE_STRUCTURE", 63, 67], ["an active node vanishes", "PROBLEM", 53, 76], ["active", "OBSERVATION_MODIFIER", 33, 39], ["active", "OBSERVATION_MODIFIER", 56, 62], ["node", "OBSERVATION", 63, 67]]], ["This result implies that the size of the DOPGC decays exponentially fast and the extended DOP mechanism is not at work: Small clusters are at a distance much larger than 2 from the DOPGC.", [["DOP", "CHEMICAL", 90, 93], ["DOP", "CHEMICAL", 90, 93], ["DOPGC", "SIMPLE_CHEMICAL", 41, 46], ["DOP", "SIMPLE_CHEMICAL", 90, 93], ["DOPGC", "CANCER", 181, 186], ["the DOPGC decays", "PROBLEM", 37, 53], ["Small clusters", "PROBLEM", 120, 134], ["size", "OBSERVATION_MODIFIER", 29, 33], ["clusters", "OBSERVATION_MODIFIER", 126, 134]]], ["The only mechanism leading to the formation of the CMPGC is the second one, based on the interaction at a distance among isolated nodes.", [["nodes", "ANATOMY", 130, 135], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 121, 135], ["CMPGC", "DNA", 51, 56], ["isolated nodes", "PROBLEM", 121, 135], ["nodes", "OBSERVATION", 130, 135]]], ["This interaction involves a scale k x \u00bc \u03c9k a , such that r\u00f0k x \u00de \u00bc d\u00f0k x \u00de, to ensure that all nodes with k > k x see each other and can merge in the same cluster.", [["k", "TEST", 106, 107], ["nodes", "OBSERVATION", 95, 100]]], ["To compute d\u00f0k\u00de, from Appendix B we must evaluate, in the limit of large k, d\u00f0k\u00de \u223c \u2212 ln \u00bd\u2212 ln\u00f0C\u00de C ln\u00f0\u03ba\u00de ; \u00f0C8\u00deAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSwith C \u00bc \u00bdP < \u00f0k\u00de k=\u00f0\u03ba\u22121\u00de and \u03ba the branching factor.", [["d\u00f0k\u00de", "PROTEIN", 11, 15], ["1\u00de", "PROTEIN", 210, 212], ["\u03ba", "PROTEIN", 217, 218], ["branching factor", "PROTEIN", 223, 239], ["large k", "TEST", 67, 74], ["d\u00f0k\u00de", "TEST", 76, 80], ["C\u00de", "TEST", 94, 96], ["\u00de", "TEST", 103, 104], ["STRETCHED", "TEST", 157, 166], ["NETWORKSwith", "TEST", 179, 191], ["C", "TEST", 192, 193], ["\u00bc", "TEST", 194, 195], ["P", "TEST", 197, 198], ["\u00f0k\u00de", "TEST", 201, 204], ["k=\u00f0\u03ba\u2212", "TEST", 205, 210], ["1\u00de", "TEST", 210, 212], ["the branching factor", "PROBLEM", 219, 239], ["Appendix", "ANATOMY", 22, 30], ["branching", "ANATOMY_MODIFIER", 223, 232]]], ["In this case,APPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSFor large k,APPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSand \u2212 ln \u00bd\u2212 ln\u00f0C\u00de \u2243 k \u03b2 \u2212 k \u03b2 min \u2212 ln k \u03ba \u2212 1 : \u00f0C11\u00de Therefore, for large k,APPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSwhere we disregard constant and logarithmic terms.", [["\u03b2", "PROTEIN", 199, 200], ["EXPONENTIAL", "TEST", 157, 168], ["NETWORKSand", "TEST", 169, 180], ["ln", "TEST", 183, 185], ["C\u00de", "TEST", 192, 194], ["k", "TEST", 197, 198], ["k", "TEST", 203, 204], ["ln", "TEST", 213, 215], ["k", "TEST", 216, 217], ["\u03ba", "TEST", 218, 219], ["\u2212", "TEST", 220, 221], ["\u00f0", "TEST", 226, 227], ["C11\u00de", "TEST", 227, 231], ["Therefore", "TEST", 232, 241], ["APPENDIX", "ANATOMY", 13, 21], ["APPENDIX", "ANATOMY", 101, 109], ["APPENDIX", "ANATOMY", 255, 263]]], ["For r\u00f0k\u00de \u00bc k=k a , from d\u00f0k x \u00de \u00bc r\u00f0k x \u00de, we obtainAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSleading toAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSSo, we haveAPPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKSAs a consequence,APPENDIX C: CUMULATIVE MERGING PERCOLATION ON STRETCHED EXPONENTIAL NETWORKS\u2248e k \u03b2 min \u2212\u00bdk a = ln\u00f0\u03ba\u00de \u03b2=\u00f01\u2212\u03b2\u00de : \u00f0C17\u00deAPPENDIX D: APPLICATION TO SIS ON STRETCHED EXPONENTIAL NETWORKSSince the asymptotic behavior of the order parameter for the CMP transition is given by S 2 , the effective finite-size threshold is given by the condition k x \u2243 k max , that is,APPENDIX D: APPLICATION TO SIS ON STRETCHED EXPONENTIAL NETWORKSUsing k a \u00bc a\u00f01=\u03bb\u00de 2 ln\u00f01=\u03bb\u00de, this equation impliesAPPENDIX D: APPLICATION TO SIS ON STRETCHED EXPONENTIAL NETWORKSDisregarding logarithmic factors, this expression can be inverted, leading, in the limit of large k max , toAPPENDIX D: APPLICATION TO SIS ON STRETCHED EXPONENTIAL NETWORKSFor a stretched exponential degree distribution, k max \u2243 \u00bdln\u00f0N\u00de 1=\u03b2 , so we finally have \u03bb c \u2243 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi a\u00f01 \u2212 \u03b2\u00de 2\u03b2 ln\u00f0\u03ba\u00de s \u00bdln\u00f0N\u00de \u00f0\u03b2\u22121\u00de=\u00f02\u03b2\u00de fln\u00bdln\u00f0N\u00deg 1=2 : \u00f0D4\u00deAPPENDIX D: APPLICATION TO SIS ON STRETCHED EXPONENTIAL NETWORKSIn this way, we recover the exact logarithmic dependence of the effective threshold on N for the stretched exponential case, recently found in Ref.", [["N\u00deg 1=2 : \u00f0D4\u00deAPPENDIX D", "CHEMICAL", 1219, 1243], ["\u00f0D4\u00deAPPENDIX D", "SIMPLE_CHEMICAL", 1229, 1243], ["a\u00f01", "PROTEIN", 1174, 1177], ["\u03b2", "PROTEIN", 1184, 1185], ["\u00bdln\u00f0", "PROTEIN", 1194, 1198], ["N\u00de", "PROTEIN", 1198, 1200], ["\u03b2", "PROTEIN", 1202, 1203], ["r\u00f0k\u00de", "TEST", 4, 8], ["k", "TEST", 13, 14], ["d\u00f0k", "TEST", 24, 27], ["EXPONENTIAL", "TEST", 374, 385], ["NETWORKS\u2248e", "TEST", 386, 396], ["k", "TEST", 397, 398], ["a", "TEST", 409, 410], ["the CMP transition", "TREATMENT", 555, 573], ["the effective finite-size threshold", "TREATMENT", 592, 627], ["k max", "TEST", 660, 665], ["STRETCHED", "TEST", 710, 719], ["EXPONENTIAL", "TEST", 720, 731], ["NETWORKSUsing", "TEST", 732, 745], ["k", "TEST", 746, 747], ["a", "TEST", 748, 749], ["a\u00f01", "TEST", 752, 755], ["ln\u00f01", "TEST", 761, 765], ["\u00de", "TEST", 767, 768], ["this equation", "TEST", 770, 783], ["a stretched exponential degree distribution", "TEST", 1031, 1074], ["k max", "TEST", 1076, 1081], ["\u2243", "TEST", 1082, 1083], ["\u00bdln\u00f0", "TEST", 1084, 1088], ["N\u00de", "TEST", 1088, 1090], ["\u03bb", "TEST", 1116, 1117], ["c", "TEST", 1118, 1119], ["ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi", "TEST", 1122, 1173], ["a\u00f01", "TEST", 1174, 1177], ["\u00de", "TEST", 1181, 1182], ["ln\u00f0\u03ba\u00de", "TEST", 1186, 1191], ["s", "TEST", 1192, 1193], ["\u00bdln\u00f0", "TEST", 1194, 1198], ["N\u00de", "TEST", 1198, 1200], ["\u00f0", "TEST", 1201, 1202], ["\u03b2", "TEST", 1202, 1203], ["\u2212", "TEST", 1203, 1204], ["1\u00de", "TEST", 1204, 1206], ["\u00f0", "TEST", 1207, 1208], ["\u03b2", "TEST", 1209, 1210], ["\u00de", "TEST", 1210, 1211], ["fln\u00bdln", "TEST", 1212, 1218], ["\u00f0", "TEST", 1218, 1219], ["N\u00deg", "TEST", 1219, 1222], ["APPENDIX", "ANATOMY", 138, 146], ["APPENDIX", "ANATOMY", 225, 233], ["APPENDIX", "ANATOMY", 318, 326], ["APPENDIX", "ANATOMY", 676, 684]]]], "fe01554a5bc8fdf8ddfb448744a528dd3b53e94d": [["INTRODUCTIONAn outbreak of novel coronavirus disease 2019 (COVID-19) spread from China worldwide since December 2019.", [["coronavirus disease", "DISEASE", 33, 52], ["COVID-19", "CHEMICAL", 59, 67], ["coronavirus disease 2019 (COVID-19", "SPECIES", 33, 67], ["novel coronavirus disease", "PROBLEM", 27, 52], ["COVID", "TEST", 59, 64], ["coronavirus disease", "OBSERVATION", 33, 52]]], ["Over 5 million people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).INTRODUCTIONApproximately 80% of patients have mild/moderate symptoms, similar to the common cold or light pneumonia, whereas the remaining 20% develop severe pneumonia necessitating supplemental oxygen or invasive cardiopulmonary support.", [["acute respiratory syndrome coronavirus", "DISEASE", 53, 91], ["pneumonia", "DISEASE", 214, 223], ["pneumonia", "DISEASE", 266, 275], ["oxygen", "CHEMICAL", 303, 309], ["oxygen", "CHEMICAL", 303, 309], ["people", "ORGANISM", 15, 21], ["SARS-CoV-2", "ORGANISM", 95, 105], ["patients", "ORGANISM", 140, 148], ["oxygen", "SIMPLE_CHEMICAL", 303, 309], ["people", "SPECIES", 15, 21], ["patients", "SPECIES", 140, 148], ["severe acute respiratory syndrome coronavirus", "SPECIES", 46, 91], ["SARS-CoV-2", "SPECIES", 95, 105], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 46, 91], ["CoV", "TEST", 100, 103], ["mild/moderate symptoms", "PROBLEM", 154, 176], ["light pneumonia", "PROBLEM", 208, 223], ["severe pneumonia", "PROBLEM", 259, 275], ["supplemental oxygen", "TREATMENT", 290, 309], ["invasive cardiopulmonary support", "TREATMENT", 313, 345], ["infected", "OBSERVATION_MODIFIER", 32, 40], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory syndrome coronavirus", "OBSERVATION", 59, 91], ["mild", "OBSERVATION_MODIFIER", 154, 158], ["moderate", "OBSERVATION_MODIFIER", 159, 167], ["symptoms", "OBSERVATION", 168, 176], ["light", "OBSERVATION_MODIFIER", 208, 213], ["pneumonia", "OBSERVATION", 214, 223], ["severe", "OBSERVATION_MODIFIER", 259, 265], ["pneumonia", "OBSERVATION", 266, 275], ["invasive", "OBSERVATION_MODIFIER", 313, 321], ["cardiopulmonary support", "OBSERVATION", 322, 345]]], ["(Guan et al., 2020; Kutsuna, 2020; Ma et al., 2020) To complicate matters, some patients with apparently mild/moderate symptoms have progressed to severe pneumonia.", [["pneumonia", "DISEASE", 154, 163], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["apparently mild/moderate symptoms", "PROBLEM", 94, 127], ["severe pneumonia", "PROBLEM", 147, 163], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["pneumonia", "OBSERVATION", 154, 163]]], ["(Cummings et al., 2020) Therefore, most COVID-19 patients require hospitalization or isolated observation, but large numbers of patients could overwhelm healthcare systems globally.INTRODUCTIONIt is important for us to avoid an increasing number of COVID-19-related deaths by early detection of the high-risk group.INTRODUCTIONPrevious studies have reported the clinical features of severe/critical patients, and they compared laboratory data between mild/moderate and severe/critical patients.", [["deaths", "DISEASE", 266, 272], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 399, 407], ["patients", "ORGANISM", 485, 493], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 399, 407], ["patients", "SPECIES", 485, 493], ["hospitalization", "TREATMENT", 66, 81], ["INTRODUCTIONPrevious studies", "TEST", 315, 343], ["severe/critical patients", "PROBLEM", 383, 407], ["laboratory data", "TEST", 427, 442], ["mild/moderate and severe/critical patients", "PROBLEM", 451, 493], ["large", "OBSERVATION_MODIFIER", 111, 116], ["moderate", "OBSERVATION_MODIFIER", 456, 464], ["severe", "OBSERVATION_MODIFIER", 469, 475]]], ["(Noroozi et al., 2020) However, these papers focused on clinical characteristics or selected biomarkers.", [["selected biomarkers", "TEST", 84, 103]]], ["(Bi et al., 2020; Chen et al., 2020b; Petrilli et al., 2020; Zhang et al., 2020a) Therefore, accurate discrimination of high-risk patients is difficult, because profiles of clinical features and commonly-used factors would resemble those of other common diseases.INTRODUCTIONIn this study, serially collected blood samples from COVID-19 patients were analyzed to identify markers that could accurately predict the development of severe/critical symptoms by a comprehensive analysis of cytokines and chemokines.", [["blood samples", "ANATOMY", 309, 322], ["patients", "ORGANISM", 130, 138], ["blood samples", "ORGANISM_SUBSTANCE", 309, 322], ["patients", "ORGANISM", 337, 345], ["cytokines", "PROTEIN", 485, 494], ["chemokines", "PROTEIN", 499, 509], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 337, 345], ["other common diseases", "PROBLEM", 241, 262], ["this study", "TEST", 278, 288], ["blood samples", "TEST", 309, 322], ["COVID", "TEST", 328, 333], ["severe/critical symptoms", "PROBLEM", 429, 453], ["a comprehensive analysis", "TEST", 457, 481], ["cytokines and chemokines", "TREATMENT", 485, 509], ["severe", "OBSERVATION_MODIFIER", 429, 435]]], ["If an effective triage marker could be found, it would be possible to properly allocate medical resources to patients requiring intensive care.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["intensive care", "TREATMENT", 128, 142]]], ["In addition, humoral factor analysis of serial blood samples was performed to show the natural course of COVID-19, which could help understand the characteristics of this infection.PatientsFor a screening cohort, a total of 28 patients who tested positive for SARS-CoV-2 RNA and were admitted to the National Center Global Health and Medicine Hospital from January to May 2020 were enrolled in this screening study.", [["blood samples", "ANATOMY", 47, 60], ["infection", "DISEASE", 171, 180], ["SARS", "DISEASE", 260, 264], ["blood samples", "ORGANISM_SUBSTANCE", 47, 60], ["Patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 227, 235], ["SARS-CoV-2", "ORGANISM", 260, 270], ["humoral factor", "PROTEIN", 13, 27], ["Patients", "SPECIES", 181, 189], ["patients", "SPECIES", 227, 235], ["SARS-CoV", "SPECIES", 260, 268], ["humoral factor analysis", "TEST", 13, 36], ["serial blood samples", "TEST", 40, 60], ["COVID", "TEST", 105, 110], ["this infection", "PROBLEM", 166, 180], ["SARS", "PROBLEM", 260, 264], ["this screening study", "TEST", 394, 414], ["infection", "OBSERVATION", 171, 180]]], ["The inclusion criteria were mild/moderate symptoms of COVID-19 when hospitalized, serum collection on the first day of hospitalization, and serial serum collection during hospitalization.", [["serum", "ANATOMY", 82, 87], ["serum", "ANATOMY", 147, 152], ["COVID", "DISEASE", 54, 59], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["The inclusion criteria", "TEST", 0, 22], ["mild/moderate symptoms", "PROBLEM", 28, 50], ["COVID", "TEST", 54, 59], ["serum collection", "TEST", 82, 98], ["serial serum collection", "TEST", 140, 163], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["moderate", "OBSERVATION_MODIFIER", 33, 41]]], ["A total of 120 serum samples were used in this study.", [["serum samples", "ANATOMY", 15, 28], ["serum samples", "ORGANISM_SUBSTANCE", 15, 28], ["serum samples", "TEST", 15, 28], ["this study", "TEST", 42, 52]]], ["Blood samples were analyzed for routine laboratory tests.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13], ["routine laboratory tests", "TEST", 32, 56]]], ["The laboratory features of patients on the first day of hospitalization are shown in Supplemental Table 1.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["For a validation cohort, 58 patients were enrolled to measure CCL17 in the early phase of hospitalization.", [["patients", "ORGANISM", 28, 36], ["CCL17", "GENE_OR_GENE_PRODUCT", 62, 67], ["CCL17", "PROTEIN", 62, 67], ["patients", "SPECIES", 28, 36], ["CCL17", "TEST", 62, 67]]], ["Serum samples from these patients were collected once between the first to third days of their hospitalization.PatientsPermission to conduct the study was given by the Ethics Committee of the National Center for Global Health and Medicine, and written, informed consent was obtained from all patients (NCGM-G-003472).PatientsDisease severity was categorized into four stages, i.e., mild, moderate, severe, and critical, according to the Guidelines on the Diagnosis and Treatment of Novel Coronavirus issued by Ministry of Health, Labour and Welfare, Japan.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["patients", "ORGANISM", 25, 33], ["Patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 292, 300], ["Patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 25, 33], ["Patients", "SPECIES", 111, 119], ["patients", "SPECIES", 292, 300], ["Patients", "SPECIES", 317, 325], ["Serum samples", "TEST", 0, 13], ["the study", "TEST", 141, 150], ["PatientsDisease severity", "PROBLEM", 317, 341], ["mild, moderate, severe", "PROBLEM", 382, 404], ["Treatment", "TREATMENT", 469, 478], ["Novel Coronavirus", "PROBLEM", 482, 499], ["Disease", "OBSERVATION", 325, 332], ["mild", "OBSERVATION_MODIFIER", 382, 386], ["moderate", "OBSERVATION_MODIFIER", 388, 396], ["severe", "OBSERVATION_MODIFIER", 398, 404], ["Coronavirus", "OBSERVATION", 488, 499]]], ["Briefly, mild disease was defined as lack of respiratory symptoms, no pulmonary radiological manifestations, and oxygen saturation levels (SpO 2 ) \u226596%.", [["respiratory", "ANATOMY", 45, 56], ["pulmonary", "ANATOMY", 70, 79], ["respiratory symptoms", "DISEASE", 45, 65], ["oxygen", "CHEMICAL", 113, 119], ["oxygen", "CHEMICAL", 113, 119], ["pulmonary", "ORGAN", 70, 79], ["oxygen", "SIMPLE_CHEMICAL", 113, 119], ["mild disease", "PROBLEM", 9, 21], ["respiratory symptoms", "PROBLEM", 45, 65], ["pulmonary radiological manifestations", "PROBLEM", 70, 107], ["oxygen saturation levels", "TEST", 113, 137], ["SpO", "TEST", 139, 142], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["disease", "OBSERVATION", 14, 21], ["no", "UNCERTAINTY", 67, 69], ["pulmonary", "ANATOMY", 70, 79]]], ["Moderate disease was defined as mild respiratory symptoms, radiological evidence of pneumonia, and 93% < SpO 2 < 96%.", [["respiratory", "ANATOMY", 37, 48], ["pneumonia", "DISEASE", 84, 93], ["Moderate disease", "PROBLEM", 0, 16], ["mild respiratory symptoms", "PROBLEM", 32, 57], ["pneumonia", "PROBLEM", 84, 93], ["SpO", "TEST", 105, 108], ["disease", "OBSERVATION", 9, 16], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["respiratory symptoms", "OBSERVATION", 37, 57], ["pneumonia", "OBSERVATION", 84, 93]]], ["Severe cases were defined as SpO 2 \u226493% requiring oxygen support.", [["oxygen", "CHEMICAL", 50, 56], ["oxygen", "CHEMICAL", 50, 56], ["oxygen", "SIMPLE_CHEMICAL", 50, 56], ["Severe cases", "PROBLEM", 0, 12], ["SpO", "TEST", 29, 32], ["oxygen support", "TREATMENT", 50, 64], ["oxygen support", "OBSERVATION", 50, 64]]], ["Critical was defined as requiring heart-lung machine or extracorporeal membrane oxygenation (ECMO) support for acute respiratory distress syndrome (ARDS).Chemokine and cytokine screeningA total of 71 humoral factors were quantified by the Bio-Plex 3D system (Bio-Rad, Hercules, CA) and the HISCL-5000 (Sugiyama et al., 2012) (Sysmex Corp., Kobe, Japan) (Supplemental Table 2 ) according to the manufacturers' instructions.Control populationPatients with common diseases were enrolled in this study.", [["heart", "ANATOMY", 34, 39], ["lung", "ANATOMY", 40, 44], ["extracorporeal membrane", "ANATOMY", 56, 79], ["respiratory", "ANATOMY", 117, 128], ["acute respiratory distress syndrome", "DISEASE", 111, 146], ["ARDS", "DISEASE", 148, 152], ["heart", "ORGAN", 34, 39], ["lung", "ORGAN", 40, 44], ["Chemokine", "GENE_OR_GENE_PRODUCT", 154, 163], ["Chemokine", "PROTEIN", 154, 163], ["cytokine", "PROTEIN", 168, 176], ["humoral factors", "PROTEIN", 200, 215], ["heart-lung machine", "TREATMENT", 34, 52], ["extracorporeal membrane oxygenation", "TREATMENT", 56, 91], ["ECMO) support", "TREATMENT", 93, 106], ["acute respiratory distress syndrome", "PROBLEM", 111, 146], ["ARDS", "PROBLEM", 148, 152], ["Chemokine", "TEST", 154, 163], ["cytokine screening", "TEST", 168, 186], ["humoral factors", "TEST", 200, 215], ["Hercules", "TEST", 268, 276], ["CA", "TEST", 278, 280], ["the HISCL", "TEST", 286, 295], ["common diseases", "PROBLEM", 454, 469], ["this study", "TEST", 487, 497], ["heart", "ANATOMY", 34, 39], ["lung", "ANATOMY", 40, 44], ["extracorporeal membrane oxygenation", "OBSERVATION", 56, 91], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory distress", "OBSERVATION", 117, 137], ["ARDS", "OBSERVATION", 148, 152], ["common", "OBSERVATION_MODIFIER", 454, 460], ["diseases", "OBSERVATION", 461, 469]]], ["The list of common diseases included: chronic hepatitis C (CHC); Child and Adolescent Psychiatry (CAP); type 2 diabetes mellitus (T2DM); chronic renal failure (CRF); chronic heart failure (CHF); interstitial pneumonia (IP); and rheumatoid arthritis (RA).", [["renal", "ANATOMY", 145, 150], ["heart", "ANATOMY", 174, 179], ["chronic hepatitis C", "DISEASE", 38, 57], ["CHC", "DISEASE", 59, 62], ["Child and Adolescent Psychiatry", "DISEASE", 65, 96], ["CAP", "DISEASE", 98, 101], ["type 2 diabetes mellitus", "DISEASE", 104, 128], ["T2DM", "DISEASE", 130, 134], ["chronic renal failure", "DISEASE", 137, 158], ["CRF", "DISEASE", 160, 163], ["chronic heart failure", "DISEASE", 166, 187], ["CHF", "DISEASE", 189, 192], ["interstitial pneumonia", "DISEASE", 195, 217], ["rheumatoid arthritis", "DISEASE", 228, 248], ["RA", "DISEASE", 250, 252], ["renal", "ORGAN", 145, 150], ["heart", "ORGAN", 174, 179], ["common diseases", "PROBLEM", 12, 27], ["chronic hepatitis C (CHC)", "PROBLEM", 38, 63], ["type 2 diabetes mellitus (T2DM)", "PROBLEM", 104, 135], ["chronic renal failure", "PROBLEM", 137, 158], ["CRF)", "PROBLEM", 160, 164], ["chronic heart failure", "PROBLEM", 166, 187], ["CHF)", "PROBLEM", 189, 193], ["interstitial pneumonia (IP)", "PROBLEM", 195, 222], ["rheumatoid arthritis", "PROBLEM", 228, 248], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["hepatitis", "OBSERVATION", 46, 55], ["chronic", "OBSERVATION_MODIFIER", 137, 144], ["renal", "ANATOMY", 145, 150], ["failure", "OBSERVATION", 151, 158], ["CRF", "OBSERVATION", 160, 163], ["chronic", "OBSERVATION_MODIFIER", 166, 173], ["heart", "ANATOMY", 174, 179], ["failure", "OBSERVATION", 180, 187], ["CHF", "OBSERVATION", 189, 192], ["interstitial", "ANATOMY_MODIFIER", 195, 207], ["pneumonia", "OBSERVATION", 208, 217], ["rheumatoid", "OBSERVATION_MODIFIER", 228, 238], ["arthritis", "OBSERVATION", 239, 248], ["RA", "ANATOMY", 250, 252]]], ["All serum samples and their related clinical information were obtained from the National Center for Global Health and Medicine BioBank.Statistical AnalysisContinuous and categorical variables are presented as means\u00b1SD or medians (interquartile range; IQR); statistical analyses were performed using the chi-squared test, the Mann-Whitney test, and Student's t-test, as appropriate.", [["serum samples", "ANATOMY", 4, 17], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["All serum samples", "TEST", 0, 17], ["Statistical AnalysisContinuous and categorical variables", "PROBLEM", 135, 191], ["statistical analyses", "TEST", 257, 277], ["the chi-squared test", "TEST", 299, 319], ["Student's t-test", "TEST", 348, 364]]], ["Multivariate logistic regression analysis was performed based on the univariate analyses.", [["Multivariate logistic regression analysis", "TEST", 0, 41], ["the univariate analyses", "TEST", 65, 88]]], ["Cut-off values were evaluated by receiver operator characteristic (ROC) curve analysis.", [["curve analysis", "TEST", 72, 86]]], ["The outcomes of oxygen support were compared by Kaplan-Meier analysis as event-free survival curves.Statistical AnalysisGraphPad Prism software v8 and SPSS v24 were used for all statistical analyses.PatientsFor a screening experiment, a total of 28 patients with COVID-19 who were eligible based on the study's criteria participated.", [["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["Patients", "ORGANISM", 199, 207], ["patients", "ORGANISM", 249, 257], ["Patients", "SPECIES", 199, 207], ["patients", "SPECIES", 249, 257], ["oxygen support", "TREATMENT", 16, 30], ["Meier analysis", "TEST", 55, 69], ["SPSS v24", "TEST", 151, 159], ["all statistical analyses", "TEST", 174, 198], ["a screening experiment", "TEST", 211, 233], ["the study", "TEST", 299, 308]]], ["All patients had mild/moderate symptoms at baseline.PatientsThe baseline characteristics of the patients were analyzed on the first day of hospitalization (Supplemental Table 1 ).", [["patients", "ORGANISM", 4, 12], ["Patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 4, 12], ["Patients", "SPECIES", 52, 60], ["patients", "SPECIES", 96, 104], ["mild/moderate symptoms", "PROBLEM", 17, 39], ["mild", "OBSERVATION_MODIFIER", 17, 21], ["moderate", "OBSERVATION_MODIFIER", 22, 30], ["symptoms", "OBSERVATION", 31, 39]]], ["The severe/critical group, who developed severe or critical symptoms after several days of hospitalization, showed significant differences in albumin (ALB), lactate dehydrogenase (LDH), C-reactive protein (CRP), and neutrophil counts compared with the mild/moderate group.", [["neutrophil", "ANATOMY", 216, 226], ["lactate", "CHEMICAL", 157, 164], ["lactate", "CHEMICAL", 157, 164], ["albumin", "GENE_OR_GENE_PRODUCT", 142, 149], ["ALB", "GENE_OR_GENE_PRODUCT", 151, 154], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 157, 178], ["LDH", "GENE_OR_GENE_PRODUCT", 180, 183], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 186, 204], ["CRP", "GENE_OR_GENE_PRODUCT", 206, 209], ["neutrophil", "CELL", 216, 226], ["albumin", "PROTEIN", 142, 149], ["ALB", "PROTEIN", 151, 154], ["lactate dehydrogenase", "PROTEIN", 157, 178], ["LDH", "PROTEIN", 180, 183], ["C-reactive protein", "PROTEIN", 186, 204], ["CRP", "PROTEIN", 206, 209], ["neutrophil", "CELL_TYPE", 216, 226], ["severe or critical symptoms", "PROBLEM", 41, 68], ["significant differences in albumin", "PROBLEM", 115, 149], ["ALB", "TEST", 151, 154], ["lactate dehydrogenase", "TEST", 157, 178], ["LDH", "TEST", 180, 183], ["C-reactive protein", "TEST", 186, 204], ["CRP", "TEST", 206, 209], ["neutrophil counts", "TEST", 216, 233], ["the mild/moderate group", "PROBLEM", 248, 271], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["neutrophil counts", "OBSERVATION", 216, 233], ["mild", "OBSERVATION_MODIFIER", 252, 256], ["moderate", "OBSERVATION_MODIFIER", 257, 265]]], ["There was no difference in the baseline SpO 2 .", [["SpO 2", "CHEMICAL", 40, 45], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Patients who developed severe/critical symptoms were significantly more likely to have hypertension than the mild/moderate group.Chemokine/cytokine screeningA total of 71 humoral factors were screened to detect predictive markers associated with the development of severe/critical disease and to show the dynamics of humoral factors using serial serum samples.", [["serum samples", "ANATOMY", 346, 359], ["hypertension", "DISEASE", 87, 99], ["Patients", "ORGANISM", 0, 8], ["Chemokine", "GENE_OR_GENE_PRODUCT", 129, 138], ["serum samples", "ORGANISM_SUBSTANCE", 346, 359], ["Chemokine", "PROTEIN", 129, 138], ["cytokine", "PROTEIN", 139, 147], ["humoral factors", "PROTEIN", 171, 186], ["humoral factors", "PROTEIN", 317, 332], ["Patients", "SPECIES", 0, 8], ["severe/critical symptoms", "PROBLEM", 23, 47], ["hypertension", "PROBLEM", 87, 99], ["the mild/moderate group", "PROBLEM", 105, 128], ["Chemokine/cytokine screening", "TEST", 129, 157], ["predictive markers", "TEST", 211, 229], ["severe/critical disease", "PROBLEM", 265, 288], ["serial serum samples", "TEST", 339, 359], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["hypertension", "OBSERVATION", 87, 99], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["moderate", "OBSERVATION_MODIFIER", 114, 122], ["severe", "OBSERVATION_MODIFIER", 265, 271], ["critical disease", "OBSERVATION", 272, 288]]], ["Five factors, CCL17, IFN-\u03bb3, IL-6, IP-10, and, CXCL9 were identified ( Figure 1 ).", [["CCL17", "GENE_OR_GENE_PRODUCT", 14, 19], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 21, 27], ["IL-6", "GENE_OR_GENE_PRODUCT", 29, 33], ["IP-10", "GENE_OR_GENE_PRODUCT", 35, 40], ["CXCL9", "GENE_OR_GENE_PRODUCT", 47, 52], ["CCL17", "PROTEIN", 14, 19], ["IFN", "PROTEIN", 21, 24], ["IL-6", "PROTEIN", 29, 33], ["IP", "PROTEIN", 35, 37], ["CXCL9", "PROTEIN", 47, 52], ["Five factors", "TEST", 0, 12], ["CCL17", "TEST", 14, 19], ["IFN", "TEST", 21, 24], ["IL", "TEST", 29, 31], ["IP", "TEST", 35, 37], ["CXCL9", "TEST", 47, 52], ["CXCL9", "ANATOMY", 47, 52]]], ["The other factors were not predictive of severe/critical disease (data not shown).", [["severe/critical disease", "PROBLEM", 41, 64], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["critical", "OBSERVATION_MODIFIER", 48, 56], ["disease", "OBSERVATION", 57, 64]]], ["Category A (Cat-A) contained CCL17, which showed higher values in the mild/moderate group than in the severe/critical group at an early phase of infection.", [["infection", "DISEASE", 145, 154], ["Cat-A", "GENE_OR_GENE_PRODUCT", 12, 17], ["CCL17", "GENE_OR_GENE_PRODUCT", 29, 34], ["CCL17", "PROTEIN", 29, 34], ["CCL17", "TEST", 29, 34], ["higher values", "PROBLEM", 49, 62], ["the mild/moderate group", "PROBLEM", 66, 89], ["infection", "PROBLEM", 145, 154], ["higher values", "OBSERVATION", 49, 62], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["moderate", "OBSERVATION_MODIFIER", 75, 83], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["early phase", "OBSERVATION_MODIFIER", 130, 141], ["infection", "OBSERVATION", 145, 154]]], ["Cat-B contained IFN-\u03bb3, IL-6, IP-10, and CXCL9, the values of each of which surged and then dropped suddenly before the development of severe deterioration requiring oxygen support.", [["oxygen", "CHEMICAL", 166, 172], ["oxygen", "CHEMICAL", 166, 172], ["Cat-B", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 16, 22], ["IL-6", "GENE_OR_GENE_PRODUCT", 24, 28], ["IP-10", "GENE_OR_GENE_PRODUCT", 30, 35], ["CXCL9", "GENE_OR_GENE_PRODUCT", 41, 46], ["oxygen", "SIMPLE_CHEMICAL", 166, 172], ["IFN", "PROTEIN", 16, 19], ["IL-6", "PROTEIN", 24, 28], ["IP", "PROTEIN", 30, 32], ["CXCL9", "PROTEIN", 41, 46], ["Cat", "TEST", 0, 3], ["IFN", "TEST", 16, 19], ["IL", "TEST", 24, 26], ["IP", "TEST", 30, 32], ["CXCL9", "TEST", 41, 46], ["severe deterioration", "PROBLEM", 135, 155], ["oxygen support", "TREATMENT", 166, 180], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["deterioration", "OBSERVATION", 142, 155], ["oxygen support", "OBSERVATION", 166, 180]]], ["CCL17 in Cat-A was analyzed using the first value on hospitalization (Table 1) , and it was found that the average CCL17 value was significantly lower in the severe/critical group than in the mild/moderate group.", [["CCL17", "GENE_OR_GENE_PRODUCT", 0, 5], ["Cat-A", "CANCER", 9, 14], ["CCL17", "GENE_OR_GENE_PRODUCT", 115, 120], ["CCL17", "PROTEIN", 0, 5], ["Cat-A", "CELL_LINE", 9, 14], ["CCL17", "PROTEIN", 115, 120], ["CCL17", "TEST", 0, 5], ["the average CCL17 value", "TEST", 103, 126], ["the mild/moderate group", "PROBLEM", 188, 211], ["lower", "OBSERVATION_MODIFIER", 145, 150], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["mild", "OBSERVATION_MODIFIER", 192, 196], ["moderate", "OBSERVATION_MODIFIER", 197, 205]]], ["The peak values of Cat-B, which were observed before the onset of severe symptoms, were compared between the mild/moderate and severe/critical groups ( Table 1 ).", [["Cat-B", "GENE_OR_GENE_PRODUCT", 19, 24], ["Cat-B", "PROTEIN", 19, 24], ["The peak values", "TEST", 0, 15], ["severe symptoms", "PROBLEM", 66, 81], ["the mild/moderate and severe/critical groups", "PROBLEM", 105, 149], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["symptoms", "OBSERVATION", 73, 81], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["moderate", "OBSERVATION_MODIFIER", 114, 122], ["severe", "OBSERVATION_MODIFIER", 127, 133]]], ["The peak values of Cat-B factors were significantly higher in the severe/critical group than in the mild/moderate group.Cut-off values of predictive markersCut-off values were determined by ROC curve analysis using the data in Table 1 Figure 1) .", [["Cat-B factors", "GENE_OR_GENE_PRODUCT", 19, 32], ["Cat-B factors", "PROTEIN", 19, 32], ["The peak values", "TEST", 0, 15], ["Cat-B factors", "TEST", 19, 32], ["the mild/moderate group", "PROBLEM", 96, 119], ["Cut", "TEST", 120, 123], ["predictive markers", "TEST", 138, 156], ["ROC curve analysis", "TEST", 190, 208], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["higher", "OBSERVATION_MODIFIER", 52, 58], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["mild", "OBSERVATION_MODIFIER", 100, 104], ["moderate", "OBSERVATION_MODIFIER", 105, 113]]], ["The start of oxygen support was defined as the event for this analysis.", [["oxygen", "CHEMICAL", 13, 19], ["oxygen", "CHEMICAL", 13, 19], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["oxygen support", "TREATMENT", 13, 27], ["this analysis", "TEST", 57, 70]]], ["Patients with critical symptoms were treated by a heart-lung machine or ECMO following oxygen support.", [["heart-lung", "ANATOMY", 50, 60], ["oxygen", "CHEMICAL", 87, 93], ["oxygen", "CHEMICAL", 87, 93], ["Patients", "ORGANISM", 0, 8], ["heart", "ORGAN", 50, 55], ["lung", "ORGAN", 56, 60], ["oxygen", "SIMPLE_CHEMICAL", 87, 93], ["Patients", "SPECIES", 0, 8], ["critical symptoms", "PROBLEM", 14, 31], ["a heart-lung machine", "TREATMENT", 48, 68], ["ECMO", "TREATMENT", 72, 76], ["oxygen support", "TREATMENT", 87, 101], ["heart", "ANATOMY", 50, 55], ["lung", "ANATOMY", 56, 60], ["oxygen support", "OBSERVATION", 87, 101]]], ["All patients were divided into two groups based on each cut-off value (Supplemental Figure 1 ).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["The five factors clearly distinguished between the mild/moderate and the severe/critical groups.", [["the mild/moderate and the severe/critical groups", "PROBLEM", 47, 95], ["mild", "OBSERVATION_MODIFIER", 51, 55], ["moderate", "OBSERVATION_MODIFIER", 56, 64], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["critical groups", "OBSERVATION", 80, 95]]], ["The EFS curve of CCL17 showed complete separation.Comparisons of expression levels of predictive markers between COVID-19 and other diseasesTo confirm the discrimination ability of the predictive markers between the COVID-19 severe population and other diseases, 114 patients with several common diseases, who were negative for SARS-CoV-2 RNA (Supplemental Information and Supplemental Table 3 ), were enrolled.", [["CCL17", "GENE_OR_GENE_PRODUCT", 17, 22], ["patients", "ORGANISM", 267, 275], ["CCL17", "PROTEIN", 17, 22], ["patients", "SPECIES", 267, 275], ["The EFS curve", "TEST", 0, 13], ["CCL17", "TEST", 17, 22], ["expression levels", "TEST", 65, 82], ["predictive markers", "TEST", 86, 104], ["COVID", "TEST", 113, 118], ["other diseases", "PROBLEM", 126, 140], ["the predictive markers", "TEST", 181, 203], ["the COVID", "TEST", 212, 221], ["severe population", "PROBLEM", 225, 242], ["other diseases", "PROBLEM", 247, 261], ["several common diseases", "PROBLEM", 281, 304], ["SARS", "PROBLEM", 328, 332], ["CoV", "TEST", 333, 336], ["separation", "OBSERVATION_MODIFIER", 39, 49], ["diseases", "OBSERVATION", 132, 140], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["population", "OBSERVATION", 232, 242]]], ["These samples were selected from a representative sample of common chronic diseases with a high number of patients.", [["samples", "ANATOMY", 6, 13], ["chronic diseases", "DISEASE", 67, 83], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["These samples", "TEST", 0, 13], ["common chronic diseases", "PROBLEM", 60, 83], ["common", "OBSERVATION_MODIFIER", 60, 66], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["diseases", "OBSERVATION", 75, 83], ["high number", "OBSERVATION_MODIFIER", 91, 102]]], ["Childhood diseases were added to the sample to account for the age range.", [["Childhood diseases", "PROBLEM", 0, 18]]], ["Figure 3 compares the data for the five predictive markers.", [["the data", "TEST", 18, 26]]], ["For Cat-B analyses, the peak value observed before the onset of severe symptoms was used to compare among common diseases.", [["Cat-B", "GENE_OR_GENE_PRODUCT", 4, 9], ["Cat-B", "PROTEIN", 4, 9], ["Cat-B analyses", "TEST", 4, 18], ["the peak value", "TEST", 20, 34], ["severe symptoms", "PROBLEM", 64, 79], ["common diseases", "PROBLEM", 106, 121]]], ["The IFN-\u03bb3 level had a broad range in chronic hepatitis C (CHC) patients, though the adjusted p value for the comparison between the severe/critical group and the others was significant for all comparison pairs.", [["chronic hepatitis C", "DISEASE", 38, 57], ["CHC", "DISEASE", 59, 62], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 4, 10], ["patients", "ORGANISM", 64, 72], ["IFN", "PROTEIN", 4, 7], ["\u03bb3", "PROTEIN", 8, 10], ["patients", "SPECIES", 64, 72], ["The IFN", "TEST", 0, 7], ["chronic hepatitis C", "PROBLEM", 38, 57], ["broad range", "OBSERVATION_MODIFIER", 23, 34], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["hepatitis", "OBSERVATION", 46, 55]]], ["IL-6 expression was high and had a broad range in rheumatoid arthritis (RA).", [["rheumatoid arthritis", "DISEASE", 50, 70], ["RA", "DISEASE", 72, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-6", "PROTEIN", 0, 4], ["rheumatoid arthritis", "PROBLEM", 50, 70], ["broad range", "OBSERVATION_MODIFIER", 35, 46], ["rheumatoid arthritis", "OBSERVATION", 50, 70], ["RA", "ANATOMY", 72, 74]]], ["However, IP-10, CXCL9, and CCL17 levels were specifically associated with the COVID-19 severe/critical group.", [["IP-10", "GENE_OR_GENE_PRODUCT", 9, 14], ["CXCL9", "GENE_OR_GENE_PRODUCT", 16, 21], ["CCL17", "GENE_OR_GENE_PRODUCT", 27, 32], ["CXCL9", "PROTEIN", 16, 21], ["CCL17", "PROTEIN", 27, 32], ["IP", "TEST", 9, 11], ["CXCL9", "TEST", 16, 21], ["CCL17 levels", "TEST", 27, 39], ["the COVID", "TEST", 74, 83]]], ["These data suggest that some predictive markers could cross-react with other diseases.", [["These data", "TEST", 0, 10], ["some predictive markers", "PROBLEM", 24, 47], ["other diseases", "PROBLEM", 71, 85]]], ["There was no effect of age or sex on the expression levels of the five predictive markers.Comparisons of expression levels of predictive markers between COVID-19 and other diseasesLaboratory data showing significant associations with the development of severe/critical symptoms (Supplemental Table 1 ) were compared between COVID-19 and common diseases (Supplemental Figure 2) .", [["predictive markers", "TEST", 126, 144], ["COVID", "TEST", 153, 158], ["other diseasesLaboratory data", "TEST", 166, 195], ["severe/critical symptoms", "PROBLEM", 253, 277], ["COVID", "TEST", 324, 329], ["common diseases", "PROBLEM", 337, 352], ["no", "UNCERTAINTY", 10, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["severe", "OBSERVATION_MODIFIER", 253, 259]]], ["The ranges of all laboratory data except for CRP overlapped between COVID-19 and common diseases.", [["CRP", "GENE_OR_GENE_PRODUCT", 45, 48], ["CRP", "PROTEIN", 45, 48], ["all laboratory data", "TEST", 14, 33], ["CRP", "TEST", 45, 48], ["COVID", "TEST", 68, 73], ["common diseases", "PROBLEM", 81, 96], ["common", "OBSERVATION_MODIFIER", 81, 87], ["diseases", "OBSERVATION", 88, 96]]], ["The range of CRP values also overlapped between the mild/moderate and severe/critical groups.", [["CRP", "GENE_OR_GENE_PRODUCT", 13, 16], ["CRP", "PROTEIN", 13, 16], ["CRP values", "TEST", 13, 23], ["the mild/moderate and severe/critical groups", "PROBLEM", 48, 92], ["range", "OBSERVATION_MODIFIER", 4, 9], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["moderate", "OBSERVATION_MODIFIER", 57, 65], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["critical groups", "OBSERVATION", 77, 92]]], ["Significant differences were observed in all comparisons between the severe/critical group and the others, except for ALB levels between severe/critical and CHC patients.Validation of CCL17Based on the above analyses, the value of CCL17 at an early phase of infection could be useful to distinguish between mild/moderate and severe/critical disease on the first day of hospitalization.", [["CHC", "DISEASE", 157, 160], ["infection", "DISEASE", 258, 267], ["ALB", "GENE_OR_GENE_PRODUCT", 118, 121], ["patients", "ORGANISM", 161, 169], ["CCL17Based", "GENE_OR_GENE_PRODUCT", 184, 194], ["CCL17", "GENE_OR_GENE_PRODUCT", 231, 236], ["ALB", "PROTEIN", 118, 121], ["CCL17Based", "PROTEIN", 184, 194], ["CCL17", "PROTEIN", 231, 236], ["patients", "SPECIES", 161, 169], ["Significant differences", "PROBLEM", 0, 23], ["ALB levels", "TEST", 118, 128], ["the above analyses", "TEST", 198, 216], ["CCL17", "TEST", 231, 236], ["infection", "PROBLEM", 258, 267], ["mild/moderate and severe/critical disease", "PROBLEM", 307, 348], ["infection", "OBSERVATION", 258, 267], ["mild", "OBSERVATION_MODIFIER", 307, 311], ["moderate", "OBSERVATION_MODIFIER", 312, 320], ["severe", "OBSERVATION_MODIFIER", 325, 331], ["critical", "OBSERVATION_MODIFIER", 332, 340], ["disease", "OBSERVATION", 341, 348]]], ["To validate the predictive power of CCL17, independent samples from COVID-19 patients were added, and CCL17 levels at an early phase of hospitalization were determined.", [["samples", "ANATOMY", 55, 62], ["CCL17", "GENE_OR_GENE_PRODUCT", 36, 41], ["patients", "ORGANISM", 77, 85], ["CCL17", "GENE_OR_GENE_PRODUCT", 102, 107], ["CCL17", "PROTEIN", 36, 41], ["CCL17", "PROTEIN", 102, 107], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 68, 73], ["CCL17 levels", "TEST", 102, 114]]], ["The cut-off value, 87.5 pg/mL, was determined from (Figure 4) .", [["The cut-off value", "TEST", 0, 17]]], ["On multivariate analysis using the validation samples, CCL17 was significant (p<0.009) (Supplemental Table 4 ).Validation of CCL17Finally, screening and validation samples were combined to analyze the predictive power of CCL17.", [["samples", "ANATOMY", 46, 53], ["samples", "ANATOMY", 164, 171], ["CCL17", "GENE_OR_GENE_PRODUCT", 55, 60], ["CCL17", "GENE_OR_GENE_PRODUCT", 221, 226], ["CCL17", "PROTEIN", 55, 60], ["CCL17Finally", "PROTEIN", 125, 137], ["CCL17", "PROTEIN", 221, 226], ["multivariate analysis", "TEST", 3, 24], ["the validation samples", "TEST", 31, 53], ["CCL17", "TEST", 55, 60], ["screening", "TEST", 139, 148], ["validation samples", "TEST", 153, 171]]], ["The cut-off value of the combined data was 95.0 pg/mL on ROC curve analysis.Validation of CCL17The combined data using 95.0 pg/mL as the cut-off value showed sensitivity of 91.9%DISCUSSIONApproximately 80% of COVID-19 patients have mild or moderate disease and recover within a few weeks, but as previously reported, the remaining COVID-19 patients develop severe or critical symptoms.", [["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 340, 348], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 340, 348], ["The cut", "TEST", 0, 7], ["the combined data", "TEST", 21, 38], ["ROC curve analysis", "TEST", 57, 75], ["sensitivity", "TEST", 158, 169], ["COVID", "TEST", 209, 214], ["mild or moderate disease", "PROBLEM", 232, 256], ["the remaining COVID", "TEST", 317, 336], ["severe or critical symptoms", "PROBLEM", 357, 384], ["mild", "OBSERVATION_MODIFIER", 232, 236], ["moderate", "OBSERVATION_MODIFIER", 240, 248], ["disease", "OBSERVATION", 249, 256], ["severe", "OBSERVATION_MODIFIER", 357, 363]]], ["(Guan et al., 2020; Wu and McGoogan, 2020) Predictive markers for the onset of severe/critical symptoms are necessary for triage to avoid overwhelming medical facilities.", [["Predictive markers", "TEST", 43, 61], ["severe/critical symptoms", "PROBLEM", 79, 103], ["severe", "OBSERVATION_MODIFIER", 79, 85]]], ["Several papers have analyzed their clinical and laboratory data to predict the development of severe and critical disease.", [["laboratory data", "TEST", 48, 63], ["severe and critical disease", "PROBLEM", 94, 121], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["critical", "OBSERVATION_MODIFIER", 105, 113], ["disease", "OBSERVATION", 114, 121]]], ["ALB, LDH, CRP, and neutrophil counts were associated with the development of severe pneumonia, (Gong et al., 2020; Mo et al., 2020; Zhang et al., 2020a) and COVID-19 patients with hypertension were also significantly more likely to develop severe disease.", [["neutrophil", "ANATOMY", 19, 29], ["pneumonia", "DISEASE", 84, 93], ["hypertension", "DISEASE", 180, 192], ["ALB", "GENE_OR_GENE_PRODUCT", 0, 3], ["LDH", "GENE_OR_GENE_PRODUCT", 5, 8], ["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["neutrophil", "CELL", 19, 29], ["patients", "ORGANISM", 166, 174], ["ALB", "PROTEIN", 0, 3], ["LDH", "PROTEIN", 5, 8], ["CRP", "PROTEIN", 10, 13], ["patients", "SPECIES", 166, 174], ["ALB", "TEST", 0, 3], ["LDH", "TEST", 5, 8], ["CRP", "TEST", 10, 13], ["neutrophil counts", "TEST", 19, 36], ["severe pneumonia", "PROBLEM", 77, 93], ["hypertension", "PROBLEM", 180, 192], ["severe disease", "PROBLEM", 240, 254], ["LDH", "ANATOMY", 5, 8], ["CRP", "ANATOMY", 10, 13], ["neutrophil counts", "OBSERVATION", 19, 36], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["pneumonia", "OBSERVATION", 84, 93], ["hypertension", "OBSERVATION", 180, 192], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["disease", "OBSERVATION", 247, 254]]], ["Although these clinical data provided important information to understand COVID-19 outcomes, these clinical features identified as predictive markers could have low accuracy and precision for outcome prediction, because overlapping values are observed between mild/moderate and severe/critical cases in COVID-19.DISCUSSIONIn the present study, serial blood samples from all enrolled patients were collected from the first day of hospitalization.", [["blood samples", "ANATOMY", 351, 364], ["blood samples", "ORGANISM_SUBSTANCE", 351, 364], ["patients", "ORGANISM", 383, 391], ["patients", "SPECIES", 383, 391], ["predictive markers", "TEST", 131, 149], ["outcome prediction", "TEST", 192, 210], ["overlapping values", "TEST", 220, 238], ["mild/moderate and severe/critical cases", "PROBLEM", 260, 299], ["COVID", "TEST", 303, 308], ["the present study", "TEST", 325, 342], ["serial blood samples", "TEST", 344, 364], ["mild", "OBSERVATION_MODIFIER", 260, 264], ["moderate", "OBSERVATION_MODIFIER", 265, 273], ["severe", "OBSERVATION_MODIFIER", 278, 284]]], ["These samples were screened for a large number of humoral factors to identify predictive markers for the development of severe COVID-19 pneumonia.", [["samples", "ANATOMY", 6, 13], ["COVID", "DISEASE", 127, 132], ["pneumonia", "DISEASE", 136, 145], ["humoral factors", "PROTEIN", 50, 65], ["These samples", "TEST", 0, 13], ["humoral factors", "PROBLEM", 50, 65], ["predictive markers", "TEST", 78, 96], ["severe COVID-19 pneumonia", "PROBLEM", 120, 145], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["pneumonia", "OBSERVATION", 136, 145]]], ["Five factors that could be classified into two groups, which we called Cat-A and Cat-B, were identified.", [["Cat-A", "GENE_OR_GENE_PRODUCT", 71, 76], ["Cat-B", "GENE_OR_GENE_PRODUCT", 81, 86], ["Cat", "PROTEIN", 71, 74], ["Cat", "PROTEIN", 81, 84]]], ["CCL17 was in Cat-A; it was expressed in low levels in severe/critical patients at an early phase of infection.", [["infection", "DISEASE", 100, 109], ["CCL17", "GENE_OR_GENE_PRODUCT", 0, 5], ["Cat-A", "GENE_OR_GENE_PRODUCT", 13, 18], ["patients", "ORGANISM", 70, 78], ["CCL17", "PROTEIN", 0, 5], ["Cat-A", "PROTEIN", 13, 18], ["patients", "SPECIES", 70, 78], ["CCL17", "TEST", 0, 5], ["infection", "PROBLEM", 100, 109], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["early phase", "OBSERVATION_MODIFIER", 85, 96], ["infection", "OBSERVATION", 100, 109]]], ["IFN-\u03bb3, IL-6, IP-10, and CXCL9 belonged to Cat-B, in which the values of each factor surged and then dropped suddenly before the development of severe disease requiring oxygen support.", [["oxygen", "CHEMICAL", 169, 175], ["oxygen", "CHEMICAL", 169, 175], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-6", "GENE_OR_GENE_PRODUCT", 8, 12], ["IP-10", "GENE_OR_GENE_PRODUCT", 14, 19], ["CXCL9", "GENE_OR_GENE_PRODUCT", 25, 30], ["Cat-B", "GENE_OR_GENE_PRODUCT", 43, 48], ["oxygen", "SIMPLE_CHEMICAL", 169, 175], ["IFN", "PROTEIN", 0, 3], ["\u03bb3", "PROTEIN", 4, 6], ["IL-6", "PROTEIN", 8, 12], ["IP", "PROTEIN", 14, 16], ["CXCL9", "PROTEIN", 25, 30], ["Cat-B", "PROTEIN", 43, 48], ["IFN", "TEST", 0, 3], ["IL", "TEST", 8, 10], ["IP", "TEST", 14, 16], ["CXCL9", "TEST", 25, 30], ["severe disease", "PROBLEM", 144, 158], ["oxygen support", "TREATMENT", 169, 183], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["disease", "OBSERVATION", 151, 158], ["oxygen support", "OBSERVATION", 169, 183]]], ["Based on these data, CCL17 may be useful as a first triage marker, and then Cat-B markers can help anticipate the onset of severe disease in the high-risk group with low or borderline CCL17 levels.DISCUSSIONThe present data showed the natural history of the cytokine and chemokine profiles and their relationships to prognosis in COVID-19 at an early phase of SARS-CoV-2 infection.DISCUSSIONInterestingly, a flare-up of Cat-B factors might be a trigger for cytokine storm with severe pneumonia; it could be considered an alarm marker for the development of severe pneumonia when the Cat-B values have passed their peak.DISCUSSIONCCL17 is a thymus and activation-regulated chemokine and induces T cell development in the thymus and its activation at inflammatory regions, (Imai et al., 1996) and it is known as a reliable biomarker of atopic dermatitis (AD) progression (Kataoka, 2014) and asthma.", [["thymus", "ANATOMY", 640, 646], ["T cell", "ANATOMY", 694, 700], ["thymus", "ANATOMY", 720, 726], ["SARS-CoV-2 infection", "DISEASE", 360, 380], ["pneumonia", "DISEASE", 484, 493], ["pneumonia", "DISEASE", 564, 573], ["atopic dermatitis", "DISEASE", 834, 851], ["AD", "DISEASE", 853, 855], ["asthma", "DISEASE", 889, 895], ["CCL17", "GENE_OR_GENE_PRODUCT", 21, 26], ["Cat-B", "GENE_OR_GENE_PRODUCT", 76, 81], ["CCL17", "GENE_OR_GENE_PRODUCT", 184, 189], ["COVID-19", "CELL", 330, 338], ["SARS-CoV-2", "ORGANISM", 360, 370], ["Cat-B", "GENE_OR_GENE_PRODUCT", 420, 425], ["Cat-B", "GENE_OR_GENE_PRODUCT", 583, 588], ["thymus", "ORGAN", 640, 646], ["T cell", "CELL", 694, 700], ["thymus", "ORGAN", 720, 726], ["CCL17", "PROTEIN", 21, 26], ["Cat-B markers", "PROTEIN", 76, 89], ["CCL17", "PROTEIN", 184, 189], ["cytokine", "PROTEIN", 258, 266], ["chemokine", "PROTEIN", 271, 280], ["Cat-B factors", "PROTEIN", 420, 433], ["cytokine", "PROTEIN", 457, 465], ["DISCUSSIONCCL17", "PROTEIN", 619, 634], ["thymus and activation-regulated chemokine", "PROTEIN", 640, 681], ["SARS-CoV-2", "SPECIES", 360, 370], ["these data", "TEST", 9, 19], ["CCL17", "TEST", 21, 26], ["a first triage marker", "TEST", 44, 65], ["severe disease", "PROBLEM", 123, 137], ["low or borderline CCL17 levels", "PROBLEM", 166, 196], ["the cytokine and chemokine profiles", "PROBLEM", 254, 289], ["COVID", "TEST", 330, 335], ["SARS", "PROBLEM", 360, 364], ["CoV-2 infection", "PROBLEM", 365, 380], ["a flare", "PROBLEM", 406, 413], ["cytokine storm", "PROBLEM", 457, 471], ["severe pneumonia", "PROBLEM", 477, 493], ["an alarm marker", "TEST", 518, 533], ["severe pneumonia", "PROBLEM", 557, 573], ["the Cat-B values", "TEST", 579, 595], ["activation-regulated chemokine", "TREATMENT", 651, 681], ["T cell development in the thymus", "PROBLEM", 694, 726], ["atopic dermatitis", "PROBLEM", 834, 851], ["asthma", "PROBLEM", 889, 895], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["disease", "OBSERVATION", 130, 137], ["CCL17 levels", "OBSERVATION", 184, 196], ["infection", "OBSERVATION", 371, 380], ["severe", "OBSERVATION_MODIFIER", 477, 483], ["pneumonia", "OBSERVATION", 484, 493], ["severe", "OBSERVATION_MODIFIER", 557, 563], ["pneumonia", "OBSERVATION", 564, 573], ["thymus", "ANATOMY", 640, 646], ["thymus", "ANATOMY", 720, 726], ["inflammatory", "OBSERVATION_MODIFIER", 749, 761], ["atopic dermatitis", "OBSERVATION", 834, 851], ["asthma", "OBSERVATION", 889, 895]]], ["(Silkoff et al., 2017) Patients with severe AD and asthma have high serum CCL17 levels.", [["serum", "ANATOMY", 68, 73], ["AD", "DISEASE", 44, 46], ["asthma", "DISEASE", 51, 57], ["Patients", "ORGANISM", 23, 31], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["CCL17", "GENE_OR_GENE_PRODUCT", 74, 79], ["CCL17", "PROTEIN", 74, 79], ["Patients", "SPECIES", 23, 31], ["severe AD", "PROBLEM", 37, 46], ["asthma", "PROBLEM", 51, 57], ["high serum CCL17 levels", "PROBLEM", 63, 86], ["asthma", "OBSERVATION", 51, 57]]], ["The present finding of low CCL17 expression in a disease state would be the first such report.", [["CCL17", "GENE_OR_GENE_PRODUCT", 27, 32], ["CCL17", "PROTEIN", 27, 32], ["low CCL17 expression", "PROBLEM", 23, 43], ["a disease state", "PROBLEM", 47, 62], ["low CCL17", "OBSERVATION_MODIFIER", 23, 32]]], ["The previous paper reporting an association between CCL17 and disease progression showed overexpression of CCL17.", [["CCL17", "GENE_OR_GENE_PRODUCT", 52, 57], ["CCL17", "GENE_OR_GENE_PRODUCT", 107, 112], ["CCL17", "PROTEIN", 52, 57], ["CCL17", "PROTEIN", 107, 112], ["CCL17", "TEST", 52, 57], ["disease progression", "PROBLEM", 62, 81], ["overexpression of CCL17", "PROBLEM", 89, 112]]], ["In COVID-19, the CCL17 expression range was very narrow in the severe/critical group.", [["COVID-19", "CELL", 3, 11], ["CCL17", "GENE_OR_GENE_PRODUCT", 17, 22], ["CCL17", "PROTEIN", 17, 22], ["COVID", "TEST", 3, 8], ["the CCL17 expression range", "TEST", 13, 39], ["narrow", "OBSERVATION_MODIFIER", 49, 55], ["severe", "OBSERVATION_MODIFIER", 63, 69]]], ["These characteristics could be useful as a predictive marker to discriminate between the pre-severe/critical population and the others.", [["a predictive marker", "TEST", 41, 60]]], ["Interestingly, baseline CCL17 levels are higher in children than in adults.", [["CCL17", "GENE_OR_GENE_PRODUCT", 24, 29], ["children", "ORGANISM", 51, 59], ["CCL17", "PROTEIN", 24, 29], ["children", "SPECIES", 51, 59], ["baseline CCL17 levels", "TEST", 15, 36], ["CCL17 levels", "OBSERVATION", 24, 36], ["higher", "OBSERVATION_MODIFIER", 41, 47]]], ["(Kataoka, 2014) This feature might explain why many more children with COVID-19 have mild symptoms than adult patients.", [["children", "ORGANISM", 57, 65], ["patients", "ORGANISM", 110, 118], ["children", "SPECIES", 57, 65], ["patients", "SPECIES", 110, 118], ["COVID", "TEST", 71, 76], ["mild symptoms", "PROBLEM", 85, 98]]], ["The specific immune response would occur at an early phase of infection in severe/critical patients.", [["infection", "DISEASE", 62, 71], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["infection", "PROBLEM", 62, 71], ["infection", "OBSERVATION", 62, 71]]], ["A previous report showed that CCL17 induced regulatory T cells via the CCR4 receptor and that CCR4-deficient mice developed pulmonary inflammation.", [["regulatory T cells", "ANATOMY", 44, 62], ["pulmonary", "ANATOMY", 124, 133], ["pulmonary inflammation", "DISEASE", 124, 146], ["CCL17", "GENE_OR_GENE_PRODUCT", 30, 35], ["T cells", "CELL", 55, 62], ["CCR4 receptor", "GENE_OR_GENE_PRODUCT", 71, 84], ["CCR4", "GENE_OR_GENE_PRODUCT", 94, 98], ["mice", "ORGANISM", 109, 113], ["pulmonary", "ORGAN", 124, 133], ["CCL17", "PROTEIN", 30, 35], ["regulatory T cells", "CELL_TYPE", 44, 62], ["CCR4 receptor", "PROTEIN", 71, 84], ["CCR4", "PROTEIN", 94, 98], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["CCL17 induced regulatory T cells", "PROBLEM", 30, 62], ["the CCR4 receptor", "TEST", 67, 84], ["CCR4", "TEST", 94, 98], ["pulmonary inflammation", "PROBLEM", 124, 146], ["pulmonary", "ANATOMY", 124, 133], ["inflammation", "OBSERVATION", 134, 146]]], ["(Sather et al., 2007; Yoshie and Matsushima, 2015) Dysfunction of Treg cells in the lung could induce severe/critical pneumonia in COVID-19 patients.", [["Treg cells", "ANATOMY", 66, 76], ["lung", "ANATOMY", 84, 88], ["pneumonia", "DISEASE", 118, 127], ["Treg cells", "CELL", 66, 76], ["lung", "ORGAN", 84, 88], ["patients", "ORGANISM", 140, 148], ["Treg cells", "CELL_TYPE", 66, 76], ["patients", "SPECIES", 140, 148], ["Dysfunction of Treg cells in the lung", "PROBLEM", 51, 88], ["severe/critical pneumonia", "PROBLEM", 102, 127], ["Treg cells", "OBSERVATION", 66, 76], ["lung", "ANATOMY", 84, 88], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["critical", "OBSERVATION_MODIFIER", 109, 117], ["pneumonia", "OBSERVATION", 118, 127]]], ["The mechanism of CCL17 suppression in COVID-19 is unknown.DISCUSSIONSupplemental CCL17 treatment might prevent the development of severe/critical symptoms.DISCUSSIONHigh expression of IP-10 was associated with severe disease in COVID-19.", [["COVID-19", "CHEMICAL", 38, 46], ["CCL17", "GENE_OR_GENE_PRODUCT", 17, 22], ["COVID-19", "GENE_OR_GENE_PRODUCT", 38, 46], ["CCL17", "GENE_OR_GENE_PRODUCT", 81, 86], ["IP-10", "GENE_OR_GENE_PRODUCT", 184, 189], ["CCL17", "PROTEIN", 17, 22], ["CCL17", "PROTEIN", 81, 86], ["IP", "PROTEIN", 184, 186], ["CCL17 suppression", "TEST", 17, 34], ["COVID", "TEST", 38, 43], ["DISCUSSIONSupplemental CCL17 treatment", "TREATMENT", 58, 96], ["severe/critical symptoms", "PROBLEM", 130, 154], ["IP", "TEST", 184, 186], ["severe disease in COVID", "PROBLEM", 210, 233], ["CCL17 suppression", "OBSERVATION", 17, 34], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["disease", "OBSERVATION", 217, 224]]], ["Runfeng et al., 2020; Xiong et al., 2020; Yang et al., 2020) IP-10 was found to be induced by IFN-\u03bb3-treated plasmacytoid dendritic cells, (Finotti et al., 2016; Finotti et al., 2017) which suggested that IP-10 belongs to an interferon-stimulated gene of IFN-\u03bb3.DISCUSSIONIFN-\u03bb3 is an initial molecule released from immune cells against a pathogen.", [["plasmacytoid dendritic cells", "ANATOMY", 109, 137], ["immune cells", "ANATOMY", 316, 328], ["IFN-\u03bb3", "CHEMICAL", 94, 100], ["IP-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 94, 100], ["plasmacytoid dendritic cells", "CELL", 109, 137], ["IP-10", "GENE_OR_GENE_PRODUCT", 205, 210], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 255, 261], ["DISCUSSIONIFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 262, 278], ["immune cells", "CELL", 316, 328], ["IFN", "PROTEIN", 94, 97], ["\u03bb3", "PROTEIN", 98, 100], ["plasmacytoid dendritic cells", "CELL_TYPE", 109, 137], ["interferon-stimulated gene", "DNA", 225, 251], ["IFN", "PROTEIN", 255, 258], ["\u03bb3", "PROTEIN", 259, 261], ["\u03bb3", "PROTEIN", 276, 278], ["immune cells", "CELL_TYPE", 316, 328], ["IP", "TEST", 61, 63], ["IFN", "TEST", 94, 97], ["plasmacytoid dendritic cells", "PROBLEM", 109, 137], ["IP", "TEST", 205, 207], ["an interferon-stimulated gene of IFN", "TREATMENT", 222, 258], ["an initial molecule", "PROBLEM", 282, 301], ["immune cells", "TREATMENT", 316, 328], ["a pathogen", "PROBLEM", 337, 347], ["plasmacytoid dendritic cells", "OBSERVATION", 109, 137]]], ["(Kotenko et al., 2003; Sheppard et al., 2003) IFN-\u03bb3 might be a key molecule for the development of severe/critical symptoms.", [["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 46, 52], ["IFN", "PROTEIN", 46, 49], ["\u03bb3", "PROTEIN", 50, 52], ["severe/critical symptoms", "PROBLEM", 100, 124], ["severe", "OBSERVATION_MODIFIER", 100, 106]]], ["IFN-\u03bb3 inhibition, such as by a specific antibody, might be a promising therapeutic strategy for severe/critical patients.DISCUSSIONThe associations of IFN-\u03bb3 and IP-10 with SARS-CoV-2 infection were similar to the profile of chronic hepatitis C (CHC), in which the related virus, the hepatitis C virus, is an RNA virus.", [["SARS-CoV-2 infection", "DISEASE", 174, 194], ["chronic hepatitis C", "DISEASE", 226, 245], ["CHC", "DISEASE", 247, 250], ["hepatitis C", "DISEASE", 285, 296], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 0, 6], ["patients", "ORGANISM", 113, 121], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 152, 158], ["IP-10", "GENE_OR_GENE_PRODUCT", 163, 168], ["SARS-CoV-2", "ORGANISM", 174, 184], ["chronic hepatitis C", "ORGANISM", 226, 245], ["CHC", "CANCER", 247, 250], ["hepatitis C virus", "ORGANISM", 285, 302], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 152, 155], ["patients", "SPECIES", 113, 121], ["CoV-2", "SPECIES", 179, 184], ["hepatitis C virus", "SPECIES", 285, 302], ["SARS-CoV-2", "SPECIES", 174, 184], ["hepatitis C virus", "SPECIES", 285, 302], ["IFN", "TEST", 152, 155], ["IP", "TEST", 163, 165], ["SARS", "PROBLEM", 174, 178], ["CoV", "PROBLEM", 179, 182], ["2 infection", "PROBLEM", 183, 194], ["chronic hepatitis C (CHC)", "PROBLEM", 226, 251], ["the related virus", "PROBLEM", 262, 279], ["the hepatitis C virus", "PROBLEM", 281, 302], ["an RNA virus", "PROBLEM", 307, 319], ["infection", "OBSERVATION", 185, 194], ["chronic", "OBSERVATION_MODIFIER", 226, 233], ["hepatitis", "OBSERVATION", 234, 243], ["virus", "OBSERVATION", 274, 279], ["hepatitis", "OBSERVATION", 285, 294], ["RNA virus", "OBSERVATION", 310, 319]]], ["(Marukian et al., 2011) Interestingly, there were no associations for both IFN-\u03bb1 and 2 in COVID-19, and IFN-\u03bb1 or 2 genes were not associated with response to interferon-\u03b1 (IFN-\u03b1) treatment for CHC.", [["interferon-\u03b1", "CHEMICAL", 160, 172], ["IFN-\u03b1", "CHEMICAL", 174, 179], ["CHC", "DISEASE", 195, 198], ["IFN-\u03bb1", "GENE_OR_GENE_PRODUCT", 75, 81], ["2", "GENE_OR_GENE_PRODUCT", 86, 87], ["COVID-19", "GENE_OR_GENE_PRODUCT", 91, 99], ["IFN-\u03bb1", "GENE_OR_GENE_PRODUCT", 105, 111], ["2", "GENE_OR_GENE_PRODUCT", 115, 116], ["interferon-\u03b1", "SIMPLE_CHEMICAL", 160, 172], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 174, 179], ["IFN", "PROTEIN", 75, 78], ["IFN-\u03bb1 or 2 genes", "DNA", 105, 122], ["interferon", "PROTEIN", 160, 170], ["IFN", "PROTEIN", 174, 177], ["IFN", "TEST", 75, 78], ["COVID", "TEST", 91, 96], ["IFN", "TEST", 105, 108], ["interferon", "TREATMENT", 160, 170], ["treatment", "TREATMENT", 181, 190], ["CHC", "PROBLEM", 195, 198]]], ["(Ge et al., 2009 ) Single nucleotide polymorphisms (SNPs) around IFN-\u03bb3 are associated with response to IFN-\u03b1 treatment in CHC.", [["IFN-\u03b1", "CHEMICAL", 104, 109], ["CHC", "DISEASE", 123, 126], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 65, 71], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 104, 109], ["CHC", "CANCER", 123, 126], ["IFN-\u03bb3", "DNA", 65, 71], ["IFN", "PROTEIN", 104, 107], ["Single nucleotide polymorphisms (SNPs)", "TREATMENT", 19, 57], ["IFN", "TREATMENT", 65, 68], ["IFN", "TREATMENT", 104, 107], ["treatment", "TREATMENT", 110, 119]]], ["(Ge et al., 2009; Tanaka et al., 2009 ) Therefore, clinical trials of IFN-\u03b1 treatment for COVID-19 that classified patients by SNP type showed that it could provide good results.", [["IFN-\u03b1", "CHEMICAL", 70, 75], ["SNP", "CHEMICAL", 127, 130], ["SNP", "CHEMICAL", 127, 130], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 70, 75], ["patients", "ORGANISM", 115, 123], ["IFN", "PROTEIN", 70, 73], ["patients", "SPECIES", 115, 123], ["IFN", "TREATMENT", 70, 73], ["treatment", "TREATMENT", 76, 85], ["COVID", "TEST", 90, 95]]], ["(Li and De Clercq, 2020; Wang et al., 2020b ) Based on the above relationships, whether patients have a background of CHC should be considered when IFN-\u03bb3 data are used for prediction of severe/critical disease.", [["Li", "CHEMICAL", 1, 3], ["CHC", "DISEASE", 118, 121], ["patients", "ORGANISM", 88, 96], ["IFN", "PROTEIN", 148, 151], ["patients", "SPECIES", 88, 96], ["CHC", "PROBLEM", 118, 121], ["IFN", "TEST", 148, 151], ["severe/critical disease", "PROBLEM", 187, 210], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["critical", "OBSERVATION_MODIFIER", 194, 202], ["disease", "OBSERVATION", 203, 210]]], ["SARS-CoV-2.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV", "SPECIES", 0, 8]]], ["The present data showed for the first time that IFN-\uf06c3 itself is a key molecule for the development of severe pneumonia, and the natural course of IFN-\uf06c3 in COVID-19 patients was shown using serial serum samples.DISCUSSIONThe association of IL-6 with COVID-19 has been previously reported.", [["serum samples", "ANATOMY", 198, 211], ["pneumonia", "DISEASE", 110, 119], ["IFN-\uf06c3", "CHEMICAL", 147, 153], ["IFN-\uf06c3", "GENE_OR_GENE_PRODUCT", 48, 54], ["IFN-\uf06c3", "GENE_OR_GENE_PRODUCT", 147, 153], ["COVID-19", "ORGANISM", 157, 165], ["patients", "ORGANISM", 166, 174], ["serum samples", "ORGANISM_SUBSTANCE", 198, 211], ["IL-6", "GENE_OR_GENE_PRODUCT", 241, 245], ["COVID-19", "GENE_OR_GENE_PRODUCT", 251, 259], ["IFN", "PROTEIN", 48, 51], ["IFN", "PROTEIN", 147, 150], ["IL-6", "PROTEIN", 241, 245], ["COVID-19", "DNA", 251, 259], ["patients", "SPECIES", 166, 174], ["IFN", "TEST", 48, 51], ["severe pneumonia", "PROBLEM", 103, 119], ["IFN", "TEST", 147, 150], ["serial serum samples", "TEST", 191, 211], ["IL", "TEST", 241, 243], ["COVID", "TREATMENT", 251, 256], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["pneumonia", "OBSERVATION", 110, 119]]], ["(Chen et al., 2020a; Gao et al., 2020; Zhang et al., 2020c) The present data confirmed the association and its usefulness as a predictive marker for severe/critical disease.", [["a predictive marker", "TEST", 125, 144], ["severe/critical disease", "PROBLEM", 149, 172], ["critical", "OBSERVATION_MODIFIER", 156, 164], ["disease", "OBSERVATION", 165, 172]]], ["As previously reported, IL-6 upregulation was observed in RA and other immune diseases.", [["IL-6", "GENE_OR_GENE_PRODUCT", 24, 28], ["RA", "CANCER", 58, 60], ["IL-6", "PROTEIN", 24, 28], ["IL-6 upregulation", "TREATMENT", 24, 41], ["other immune diseases", "PROBLEM", 65, 86], ["RA", "ANATOMY", 58, 60], ["immune diseases", "OBSERVATION", 71, 86]]], ["(Houssiau et al., 1988) The present data suggest that COVID-19 patients with RA have high levels of IL-6 without severe/critical symptoms.", [["RA", "DISEASE", 77, 79], ["patients", "ORGANISM", 63, 71], ["IL-6", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL-6", "PROTEIN", 100, 104], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 54, 59], ["IL", "TEST", 100, 102], ["severe/critical symptoms", "PROBLEM", 113, 137]]], ["Molecular targeted therapy against IL-6 might interfere with the development of severe symptoms.", [["IL-6", "GENE_OR_GENE_PRODUCT", 35, 39], ["IL-6", "PROTEIN", 35, 39], ["Molecular targeted therapy", "TREATMENT", 0, 26], ["IL-6", "TREATMENT", 35, 39], ["severe symptoms", "PROBLEM", 80, 95], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["symptoms", "OBSERVATION", 87, 95]]], ["(Houssiau et al., 1988; Zhang et al., 2020b) SNPs around IL-6 or CRP have had an effect on their high expression in serum.", [["serum", "ANATOMY", 116, 121], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["CRP", "GENE_OR_GENE_PRODUCT", 65, 68], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["IL-6", "PROTEIN", 57, 61], ["CRP", "PROTEIN", 65, 68], ["SNPs around IL", "TEST", 45, 59], ["CRP", "TEST", 65, 68]]], ["In addition, IL-6 and the related SNPs have been shown to regulate CRP expression levels in the general population.", [["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["CRP", "GENE_OR_GENE_PRODUCT", 67, 70], ["IL-6", "PROTEIN", 13, 17], ["CRP", "PROTEIN", 67, 70], ["IL", "TREATMENT", 13, 15], ["the related SNPs", "TREATMENT", 22, 38], ["CRP expression levels", "TEST", 67, 88]]], ["(Dehghan et al., 2011; Okada et al., 2011) These data suggest that the SNP type of individuals should be considered to understand the profiles of predictive markers, in addition to COVID-19 outcomes.DISCUSSIONCXCL9, which has been reported to be produced mainly by monocytes, (Liao et al., 1995) was also upregulated at an early phase of SARS-CoV-2 infection in the present study.DISCUSSIONHowever, Yang et al. reported that CXCL9 levels were elevated during disease progression of COVID-19, but they were not useful as predictive markers.", [["monocytes", "ANATOMY", 265, 274], ["SNP", "CHEMICAL", 71, 74], ["SARS-CoV-2 infection", "DISEASE", 338, 358], ["monocytes", "CELL", 265, 274], ["SARS-CoV-2", "ORGANISM", 338, 348], ["CXCL9", "GENE_OR_GENE_PRODUCT", 425, 430], ["DISCUSSIONCXCL9", "PROTEIN", 199, 214], ["monocytes", "CELL_TYPE", 265, 274], ["CXCL9", "PROTEIN", 425, 430], ["SARS-CoV-2", "SPECIES", 338, 348], ["the SNP type of individuals", "PROBLEM", 67, 94], ["predictive markers", "TEST", 146, 164], ["COVID", "TEST", 181, 186], ["SARS", "PROBLEM", 338, 342], ["CoV-2 infection", "PROBLEM", 343, 358], ["the present study", "TEST", 362, 379], ["CXCL9 levels", "TEST", 425, 437], ["elevated", "PROBLEM", 443, 451], ["COVID", "TEST", 482, 487], ["predictive markers", "TEST", 520, 538], ["SARS", "OBSERVATION", 338, 342], ["infection", "OBSERVATION", 349, 358]]], ["Their data using serial samples were limited to showing CXCL9 dynamics at an early phase of infection, though these dynamics were observed in the present study because of the mandatory requirement for blood collection on the first day of hospitalization, followed by serial collection.DISCUSSIONThe present study involved a small sample in a single hospital.", [["samples", "ANATOMY", 24, 31], ["blood", "ANATOMY", 201, 206], ["infection", "DISEASE", 92, 101], ["CXCL9", "GENE_OR_GENE_PRODUCT", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["CXCL9", "PROTEIN", 56, 61], ["serial samples", "TEST", 17, 31], ["CXCL9 dynamics", "PROBLEM", 56, 70], ["infection", "PROBLEM", 92, 101], ["the present study", "TEST", 142, 159], ["blood collection", "PROBLEM", 201, 217], ["serial collection", "TEST", 267, 284], ["The present study", "TEST", 295, 312], ["early phase", "OBSERVATION_MODIFIER", 77, 88], ["infection", "OBSERVATION", 92, 101], ["small", "OBSERVATION_MODIFIER", 324, 329]]], ["There could be a possibility of overfitting in the analyses.", [["overfitting in the analyses", "PROBLEM", 32, 59], ["could be a possibility of", "UNCERTAINTY", 6, 31], ["overfitting", "OBSERVATION", 32, 43]]], ["To confirm these predictive markers, we are conducting a multicenter, prospective study.", [["prospective study", "TEST", 70, 87]]], ["Although these predictive markers should be confirmed in COVID-19 patients with some complications, not enough data were obtained in the present study.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["these predictive markers", "TEST", 9, 33], ["some complications", "PROBLEM", 80, 98], ["the present study", "TEST", 133, 150]]], ["To identify predictive markers for the development of severe pneumonia, a comprehensive analysis of serum chemokines and cytokines was conducted using serial serum samples from COVID-19 patients.", [["serum", "ANATOMY", 100, 105], ["serum samples", "ANATOMY", 158, 171], ["pneumonia", "DISEASE", 61, 70], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["serum samples", "ORGANISM_SUBSTANCE", 158, 171], ["patients", "ORGANISM", 186, 194], ["serum chemokines", "PROTEIN", 100, 116], ["cytokines", "PROTEIN", 121, 130], ["patients", "SPECIES", 186, 194], ["predictive markers", "TEST", 12, 30], ["severe pneumonia", "PROBLEM", 54, 70], ["a comprehensive analysis", "TEST", 72, 96], ["serum chemokines", "TEST", 100, 116], ["cytokines", "TEST", 121, 130], ["serial serum samples", "TEST", 151, 171], ["COVID", "TEST", 177, 182], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["pneumonia", "OBSERVATION", 61, 70]]], ["Serum samples of common diseases were enrolled from a BioBank to confirm the usefulness of predictive markers.DISCUSSIONFive factors, IFN-\u03bb3, IL-6, IP-10, CXCL9, and CCL17, were identified as predicting the onset of severe/critical symptoms.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 134, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 142, 146], ["IP-10", "GENE_OR_GENE_PRODUCT", 148, 153], ["CXCL9", "GENE_OR_GENE_PRODUCT", 155, 160], ["CCL17", "GENE_OR_GENE_PRODUCT", 166, 171], ["DISCUSSIONFive factors", "PROTEIN", 110, 132], ["IFN", "PROTEIN", 134, 137], ["\u03bb3", "PROTEIN", 138, 140], ["IL-6", "PROTEIN", 142, 146], ["IP", "PROTEIN", 148, 150], ["CXCL9", "PROTEIN", 155, 160], ["CCL17", "PROTEIN", 166, 171], ["Serum samples", "TEST", 0, 13], ["common diseases", "PROBLEM", 17, 32], ["predictive markers", "TEST", 91, 109], ["IFN", "TEST", 134, 137], ["IL", "TEST", 142, 144], ["IP", "TEST", 148, 150], ["CXCL9", "TEST", 155, 160], ["CCL17", "TEST", 166, 171], ["severe/critical symptoms", "PROBLEM", 216, 240], ["common diseases", "OBSERVATION", 17, 32], ["severe", "OBSERVATION_MODIFIER", 216, 222]]], ["The factors were classified into two categories.DISCUSSIONCategory A included IFN-\u03bb3, IL-6, IP-10, and CXCL9, and their values surged and decreased rapidly before the onset of severe pneumonia.", [["pneumonia", "DISEASE", 183, 192], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 78, 84], ["IL-6", "GENE_OR_GENE_PRODUCT", 86, 90], ["IP-10", "GENE_OR_GENE_PRODUCT", 92, 97], ["CXCL9", "GENE_OR_GENE_PRODUCT", 103, 108], ["IFN", "PROTEIN", 78, 81], ["IL-6", "PROTEIN", 86, 90], ["CXCL9", "PROTEIN", 103, 108], ["IFN", "TEST", 78, 81], ["IL", "TEST", 86, 88], ["IP", "TEST", 92, 94], ["CXCL9", "TEST", 103, 108], ["severe pneumonia", "PROBLEM", 176, 192], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["pneumonia", "OBSERVATION", 183, 192]]], ["Category B included CCL17, which provided complete separation between the mild/moderate and the severe/critical groups at an early phase of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 140, 160], ["CCL17", "GENE_OR_GENE_PRODUCT", 20, 25], ["SARS-CoV-2", "ORGANISM", 140, 150], ["CCL17", "PROTEIN", 20, 25], ["SARS-CoV-2", "SPECIES", 140, 150], ["CCL17", "TEST", 20, 25], ["the mild/moderate and the severe/critical groups", "PROBLEM", 70, 118], ["SARS", "PROBLEM", 140, 144], ["CoV-2 infection", "PROBLEM", 145, 160], ["mild", "OBSERVATION_MODIFIER", 74, 78], ["moderate", "OBSERVATION_MODIFIER", 79, 87], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["infection", "OBSERVATION", 151, 160]]], ["The five markers provided a high predictive value (area under the receiver operating characteristic curve (AUROC): 0.9-1.0, p < 0.001).", [["a high predictive value", "PROBLEM", 26, 49], ["AUROC", "TEST", 107, 112]]], ["Low expression of CCL17 was specifically observed in pre-severe COVID-19 patients compared with other common diseases, and the predictive ability of CCL17 was confirmed in validation samples of COVID-19.DISCUSSIONThe factors identified could be promising prognostic markers to distinguish between mild/moderate and severe/critical patients, enabling triage at an early phase of infection, thus avoiding overwhelming medical facilities.", [["samples", "ANATOMY", 183, 190], ["infection", "DISEASE", 378, 387], ["CCL17", "GENE_OR_GENE_PRODUCT", 18, 23], ["patients", "ORGANISM", 73, 81], ["CCL17", "GENE_OR_GENE_PRODUCT", 149, 154], ["patients", "ORGANISM", 331, 339], ["CCL17", "PROTEIN", 18, 23], ["CCL17", "PROTEIN", 149, 154], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 331, 339], ["Low expression of CCL17", "PROBLEM", 0, 23], ["other common diseases", "PROBLEM", 96, 117], ["CCL17", "TEST", 149, 154], ["COVID", "TEST", 194, 199], ["prognostic markers", "TEST", 255, 273], ["mild/moderate and severe/critical patients", "PROBLEM", 297, 339], ["infection", "PROBLEM", 378, 387], ["CCL17", "OBSERVATION", 18, 23], ["diseases", "OBSERVATION", 109, 117], ["mild", "OBSERVATION_MODIFIER", 297, 301], ["moderate", "OBSERVATION_MODIFIER", 302, 310], ["severe", "OBSERVATION_MODIFIER", 315, 321], ["infection", "OBSERVATION", 378, 387]]]], "7afc9af635949f4d23c249dbd01080deda49ec2b": [["AbstractTraditional Chinese Medicine (TCM) represents thousands of years in treatment protocols for health, healing, and longevity and has evolved into a complex healthcare system.", [["treatment protocols", "TREATMENT", 76, 95], ["healing", "PROBLEM", 108, 115]]], ["The following chapter is designed to give a basic concise overview of TCM principles and practices, in relation to clinical pharmacology, and focuses on mutually relevant areas of interest.", [["TCM principles", "TREATMENT", 70, 84]]], ["Much as society learned to harness electrical currents to empower machinery, TCM theories of energetic patterns help to empower the functionality of the human body.", [["body", "ANATOMY", 159, 163], ["human", "ORGANISM", 153, 158], ["body", "ORGANISM_SUBDIVISION", 159, 163], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["human body", "ANATOMY", 153, 163]]], ["The major theories include the vital life force, known as Qi, Yin and Yang, Five Elements, herbal medicine, multivariate diagnostics, syndrome differentiation, and acupuncture, among others.", [["syndrome differentiation", "DISEASE", 134, 158], ["herbal medicine", "TREATMENT", 91, 106], ["multivariate diagnostics", "TEST", 108, 132], ["syndrome differentiation", "PROBLEM", 134, 158], ["acupuncture", "TREATMENT", 164, 175]]], ["In TCM, there is a direct relationship to the energy of nature and the energetic patterns within the human body and the human consciousness.", [["body", "ANATOMY", 107, 111], ["human", "ORGANISM", 101, 106], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["human", "ORGANISM", 120, 125], ["TCM", "CELL_TYPE", 3, 6], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 120, 125], ["energetic patterns", "OBSERVATION", 71, 89], ["human", "ANATOMY", 101, 106], ["body", "ANATOMY_MODIFIER", 107, 111]]], ["This comprehensive approach is gaining momentum in clinical and network pharmacology, as new technologies emerge regarding TCM collaborative compounds versus singular chemical constituents in treatment modalities.", [["TCM collaborative compounds", "PROBLEM", 123, 150], ["treatment modalities", "TREATMENT", 192, 212]]], ["Of major importance to clinical pharmacology are recent TCM evidenced-based empirical studies, correlations, and interactions between herbs and pharmaceuticals, updated data on toxicity, adverse reactions, quality assurance, and herbal medicine standardization.", [["toxicity", "DISEASE", 177, 185], ["empirical studies", "TEST", 76, 93], ["herbs and pharmaceuticals", "TREATMENT", 134, 159], ["toxicity", "PROBLEM", 177, 185], ["adverse reactions", "TREATMENT", 187, 204], ["quality assurance", "TREATMENT", 206, 223], ["herbal medicine standardization", "TREATMENT", 229, 260]]], ["Global concerns over antimicrobial resistance to drugs have put a spotlight on TCM herbal medicines as alternatives with greatly reduced resistance factors.", [["Global concerns", "PROBLEM", 0, 15], ["drugs", "TREATMENT", 49, 54], ["TCM herbal medicines", "TREATMENT", 79, 99], ["greatly reduced resistance factors", "PROBLEM", 121, 155], ["antimicrobial resistance", "OBSERVATION", 21, 45]]], ["From ancient archives to the Introduction Traditional Chinese Medicine (TCM) is renowned and respected among the world's time-honored systems of wellness and healing.", [["healing", "PROBLEM", 158, 165], ["healing", "OBSERVATION_MODIFIER", 158, 165]]], ["Although legend and mythology allude to TCM origins as far back as 5000 years BCE, it was during China's Shang dynasty (1766-1122 BCE) TCM was systematized among the highly esteemed traditional herbalists and healing practitioners of the imperial courts.", [["healing", "OBSERVATION_MODIFIER", 209, 216]]], ["Together with the concept of Qi (\u6c23), vital life force, also translated as Chi (pronounced as \"chee\"), they provide the basic foundation for TCM's comprehensive mind, body, and spirit ideology and practice.AbstractOn May 25, 2019, TCM was officially adopted into the 11th version of the International Statistical Classification of Diseases and Related Health Problems (ICD).", [["body", "ANATOMY", 166, 170], ["body", "ORGANISM_SUBDIVISION", 166, 170], ["Diseases", "PROBLEM", 330, 338], ["Diseases", "OBSERVATION", 330, 338]]], ["This document represents the formal global classification of diseases by the World Health Assembly, the governing body of the World Health Organization (WHO).", [["body", "ORGANISM_SUBDIVISION", 114, 118], ["diseases", "PROBLEM", 61, 69], ["diseases", "OBSERVATION", 61, 69]]], ["Excerpted from the WHO website regarding the ICD-11: \"ICD is the foundation for the identification of health trends and statistics globally, and the international standard for reporting diseases and health conditions.", [["the ICD", "TREATMENT", 41, 48], ["ICD", "TREATMENT", 54, 57], ["reporting diseases and health conditions", "PROBLEM", 176, 216]]], ["ICD-11 was submitted to the Seventy-second World Health Assembly in May, 2019 and, following endorsement, Member States will start reporting using ICD-11on1 January 2022. \"", [["ICD", "TREATMENT", 0, 3], ["ICD", "TREATMENT", 147, 150]]], ["This chapter has been carefully written to inform and inspire readers to evaluate better the benefits of TCM in relation to conventional medicine and clinical pharmacology.", [["conventional medicine", "TREATMENT", 124, 145]]], ["TCM has a rich lineage of traditional knowledge bases and skill sets and has survived millennia of medical and scientific evolution to be acknowledged as a major contributor to twenty-first-century global healthcare.", [["TCM", "CHEMICAL", 0, 3], ["TCM", "CELL_TYPE", 0, 3], ["rich", "OBSERVATION_MODIFIER", 10, 14], ["lineage", "OBSERVATION_MODIFIER", 15, 22]]], ["The compelling wisdom that TCM offers modern medicine is the primary position of prevention above treatment and discovering each individual's unique blueprint of wellness.Principles and Practices of Traditional Chinese Medicine (TCM)One of the most important theoretical concepts of TCM is Yin (\u9634) and Yang (\u9633) that were recorded in the \"Book of Change\" (Yi Jing \u6613\u7d93) , dating from 700 BCE.", [["modern medicine", "TREATMENT", 38, 53], ["prevention above treatment", "TREATMENT", 81, 107], ["Traditional Chinese Medicine", "TREATMENT", 199, 227]]], ["The iconic Yin/Yang symbol represents opposite properties and functions but has complementary qualities (see Table 1 ).", [["iconic Yin/Yang symbol", "DNA", 4, 26], ["iconic Yin", "OBSERVATION", 4, 14], ["Yang symbol", "OBSERVATION", 15, 26], ["opposite properties", "OBSERVATION_MODIFIER", 38, 57]]], ["There is Yin (small dark circle) within Yang (large white area above) and Yang (small white circle) within Yin (large dark area below), as illustrated in the Yin/Yang symbol.Principles and Practices of Traditional Chinese Medicine (TCM)All treatment goals are centralized around balancing the Yin and Yang through harmonizing the body, mind, and spirit.", [["body", "ANATOMY", 330, 334], ["body", "ORGANISM_SUBDIVISION", 330, 334], ["Yin (small dark circle)", "PROBLEM", 9, 32], ["Yang (large white area", "PROBLEM", 40, 62], ["Yang (small white circle)", "PROBLEM", 74, 99], ["Traditional Chinese Medicine", "TREATMENT", 202, 230], ["All treatment goals", "TREATMENT", 236, 255], ["Yin", "OBSERVATION", 9, 12], ["small", "OBSERVATION_MODIFIER", 14, 19], ["dark circle", "OBSERVATION_MODIFIER", 20, 31], ["Yang", "ANATOMY", 40, 44], ["large", "OBSERVATION_MODIFIER", 46, 51], ["white", "OBSERVATION_MODIFIER", 52, 57], ["Yang", "ANATOMY", 74, 78], ["small", "OBSERVATION_MODIFIER", 80, 85], ["large", "OBSERVATION_MODIFIER", 112, 117], ["dark", "OBSERVATION_MODIFIER", 118, 122], ["Yang", "ANATOMY", 162, 166], ["body", "ANATOMY", 330, 334]]], ["Internally, this is accomplished through a combination of the healing properties of food, herbs, acupuncture, moxibustion, Tui Na massage, cupping, meditation, and Taichi and Qigong exercises.", [["Na", "CHEMICAL", 127, 129], ["cupping", "DISEASE", 139, 146], ["Na", "CHEMICAL", 127, 129], ["herbs", "TREATMENT", 90, 95], ["acupuncture", "TREATMENT", 97, 108], ["moxibustion", "TREATMENT", 110, 121], ["Tui Na massage", "TREATMENT", 123, 137], ["cupping", "TREATMENT", 139, 146], ["meditation", "TREATMENT", 148, 158], ["Taichi", "TREATMENT", 164, 170], ["Qigong exercises", "TREATMENT", 175, 191], ["healing", "OBSERVATION_MODIFIER", 62, 69]]], ["In addition, there is correcting of harmful external environmental factors: expelling toxins, avoiding extreme temperatures, and eliminating physiological and emotional stressors.", [["harmful external environmental factors", "PROBLEM", 36, 74], ["expelling toxins", "PROBLEM", 76, 92], ["extreme temperatures", "PROBLEM", 103, 123]]], ["In TCM, a state of wellness and well-being can only be achieved when there is a state of equilibrium.", [["TCM", "CELL_TYPE", 3, 6]]], ["What may be viewed in metaphysics as the harmonic convergence is expressed in conventional medicine as homeostasis and in TCM as ultimate balance.Principles and Practices of Traditional Chinese Medicine (TCM)TCM has been a champion of energetic medicine for millennia, because its underlying principles and practices stem from a foundational philosophy of the pervasive energetic force that permeates all of nature.", [["Traditional Chinese Medicine", "TREATMENT", 174, 202], ["energetic medicine", "TREATMENT", 235, 253], ["millennia", "PROBLEM", 258, 267], ["energetic force", "OBSERVATION", 370, 385]]], ["In TCM, Qi is the key which opens the meridian channels or energy pathways and provides movement throughout the interconnected domains of health and healing.", [["TCM", "CELL_TYPE", 3, 6], ["healing", "OBSERVATION_MODIFIER", 149, 156]]], ["In the Yellow Emperor's Inner Classic (Huang Di Nei Jing, \u9ec4\u5e1d\u5185\u7ecf), the most revered ancient text of TCM, there is a description of the principles of Yin and Yang, the blood vessels, and meridians, also known as channels (Jing Mai \u7ecf\u8108).", [["blood vessels", "ANATOMY", 165, 178], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 165, 178], ["blood vessels", "ANATOMY", 165, 178]]], ["Qi flows within the body, as well as the five Zang organs (\u4e94\u810f), the small intestine, gall bladder, large intestine, stomach, and urinary bladder; six Fu organs (\u516d\u8151), the heart, liver, lungs, spleen, kidneys, and pericardium; and associated acupuncture points (Xue Wei \u7a74\u4f4d).Principles and Practices of Traditional Chinese Medicine (TCM)In addition to the concept of Yin/Yang in TCM, this text also introduces the Five Elements Theory (\u4e94\u884c).", [["body", "ANATOMY", 20, 24], ["Zang organs", "ANATOMY", 46, 57], ["small intestine", "ANATOMY", 68, 83], ["gall bladder", "ANATOMY", 85, 97], ["intestine", "ANATOMY", 105, 114], ["stomach", "ANATOMY", 116, 123], ["urinary bladder", "ANATOMY", 129, 144], ["organs", "ANATOMY", 153, 159], ["heart", "ANATOMY", 170, 175], ["liver", "ANATOMY", 177, 182], ["lungs", "ANATOMY", 184, 189], ["spleen", "ANATOMY", 191, 197], ["kidneys", "ANATOMY", 199, 206], ["pericardium", "ANATOMY", 212, 223], ["body", "ORGANISM_SUBDIVISION", 20, 24], ["Zang organs", "TISSUE", 46, 57], ["small intestine", "ORGAN", 68, 83], ["gall bladder", "MULTI-TISSUE_STRUCTURE", 85, 97], ["intestine", "ORGAN", 105, 114], ["stomach", "ORGAN", 116, 123], ["urinary bladder", "ORGAN", 129, 144], ["Fu organs", "TISSUE", 150, 159], ["heart", "ORGAN", 170, 175], ["liver", "ORGAN", 177, 182], ["lungs", "ORGAN", 184, 189], ["spleen", "ORGAN", 191, 197], ["kidneys", "ORGAN", 199, 206], ["pericardium", "ORGAN", 212, 223], ["the small intestine, gall bladder, large intestine, stomach, and urinary bladder", "PROBLEM", 64, 144], ["Traditional Chinese Medicine", "TREATMENT", 300, 328], ["flows", "OBSERVATION_MODIFIER", 3, 8], ["body", "ANATOMY", 20, 24], ["small intestine", "ANATOMY", 68, 83], ["gall bladder", "ANATOMY", 85, 97], ["large intestine", "ANATOMY", 99, 114], ["stomach", "ANATOMY", 116, 123], ["urinary bladder", "ANATOMY", 129, 144], ["heart", "ANATOMY", 170, 175], ["liver", "ANATOMY", 177, 182], ["lungs", "ANATOMY", 184, 189], ["spleen", "ANATOMY", 191, 197], ["kidneys", "ANATOMY", 199, 206], ["pericardium", "ANATOMY", 212, 223], ["acupuncture", "OBSERVATION", 240, 251]]], ["This theory encompasses all natural phenomena, as they symbolically relate to human nature.", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["all", "OBSERVATION_MODIFIER", 24, 27], ["natural phenomena", "OBSERVATION", 28, 45]]], ["As expressed in the Yellow Emperor's Inner Classic, the Five Element activities of Wood (liver, gallbladder), Fire (heart, small intestine), Earth (spleen, stomach), Metal (lung, large intestine), and Water (kidney, urinary bladder) are arranged in relationship sequences in which each element interacts with one another by generating, controlling, overacting, and insulting.", [["liver", "ANATOMY", 89, 94], ["gallbladder", "ANATOMY", 96, 107], ["heart", "ANATOMY", 116, 121], ["small intestine", "ANATOMY", 123, 138], ["spleen", "ANATOMY", 148, 154], ["stomach", "ANATOMY", 156, 163], ["lung", "ANATOMY", 173, 177], ["intestine", "ANATOMY", 185, 194], ["kidney", "ANATOMY", 208, 214], ["urinary bladder", "ANATOMY", 216, 231], ["liver", "ORGAN", 89, 94], ["gallbladder", "ORGAN", 96, 107], ["heart", "ORGAN", 116, 121], ["small intestine", "MULTI-TISSUE_STRUCTURE", 123, 138], ["spleen", "ORGAN", 148, 154], ["stomach", "ORGAN", 156, 163], ["lung", "ORGAN", 173, 177], ["intestine", "ORGAN", 185, 194], ["kidney", "ORGAN", 208, 214], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 216, 231], ["Metal (lung, large intestine)", "TREATMENT", 166, 195], ["Water (kidney, urinary bladder", "TREATMENT", 201, 231], ["liver", "ANATOMY", 89, 94], ["gallbladder", "ANATOMY", 96, 107], ["heart", "ANATOMY", 116, 121], ["small intestine", "ANATOMY", 123, 138], ["spleen", "ANATOMY", 148, 154], ["stomach", "ANATOMY", 156, 163], ["Metal", "ANATOMY_MODIFIER", 166, 171], ["lung", "ANATOMY", 173, 177], ["large intestine", "ANATOMY", 179, 194], ["kidney", "ANATOMY", 208, 214], ["urinary bladder", "ANATOMY", 216, 231]]], ["When the element becomes excessive, it will insult and weaken the corresponding element and, over time, it will result in imbalances and pathological symptoms (Fig. 1 ).Applications of Five Elements TheoryThe applications of the Five Elements Theory in TCM are numerous, and the systems of correspondences are linked to many explicit phenomena and qualities in nature and the human body.", [["body", "ANATOMY", 382, 386], ["human", "ORGANISM", 376, 381], ["body", "ORGANISM_SUBDIVISION", 382, 386], ["TCM", "CELL_TYPE", 253, 256], ["human", "SPECIES", 376, 381], ["human", "SPECIES", 376, 381], ["imbalances and pathological symptoms", "PROBLEM", 122, 158], ["excessive", "OBSERVATION", 25, 34], ["numerous", "OBSERVATION_MODIFIER", 261, 269], ["many", "OBSERVATION_MODIFIER", 320, 324], ["explicit phenomena", "OBSERVATION", 325, 343], ["human", "ANATOMY", 376, 381], ["body", "ANATOMY_MODIFIER", 382, 386]]], ["These correspondences are inclusive of organs, tissues, tastes, directions, climates, colors, seasons, etc. TCM also recognizes the healing power of musical tones, which correspond to each of the five elements.", [["organs", "ANATOMY", 39, 45], ["tissues", "ANATOMY", 47, 54], ["organs", "ORGAN", 39, 45], ["tissues", "TISSUE", 47, 54], ["TCM", "CELL_TYPE", 108, 111], ["healing", "OBSERVATION_MODIFIER", 132, 139], ["power", "OBSERVATION_MODIFIER", 140, 145], ["musical tones", "OBSERVATION", 149, 162], ["five elements", "ANATOMY_MODIFIER", 196, 209]]], ["Just as music is composed of harmonic and resonant layers, these unique tones are intrinsic to the interrelated vibratory balance of the human body, mind, and spirit, which TCM understands are needed to be in harmony with each other to achieve a sense of balance and health.", [["body", "ANATOMY", 143, 147], ["human", "ORGANISM", 137, 142], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["harmonic and resonant layers", "PROBLEM", 29, 57], ["human body", "ANATOMY", 137, 147]]], ["Considering the importance of these tonal qualities, TCM recognizes music therapy as a vital healing modality.", [["music therapy", "TREATMENT", 68, 81], ["a vital healing modality", "TREATMENT", 85, 109]]], ["Each food and herb in TCM has a certain taste which is related to one of the elements.", [["TCM", "CHEMICAL", 22, 25], ["TCM", "CELL_TYPE", 22, 25]]], ["The five tastes are sour for Wood, bitter for Fire, sweet for Earth, pungent for Metal, and salty for Water.", [["Metal", "CHEMICAL", 81, 86], ["sweet", "ORGANISM_SUBDIVISION", 52, 57]]], ["Each of the tastes has a unique effect on the body.", [["body", "ANATOMY", 46, 50], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["unique", "OBSERVATION_MODIFIER", 25, 31], ["effect", "OBSERVATION_MODIFIER", 32, 38], ["body", "ANATOMY", 46, 50]]], ["For example, the sour taste generates fluids and Yin; it has an astringent quality and, therefore, can control perspiration and diarrhea.", [["diarrhea", "DISEASE", 128, 136], ["perspiration", "PROBLEM", 111, 123], ["diarrhea", "PROBLEM", 128, 136], ["astringent quality", "OBSERVATION_MODIFIER", 64, 82]]], ["As another example, bitter taste clears heat, sedates, and hardens.", [["sedates", "TREATMENT", 46, 53]]], ["Table 2 outlines these integrated corresponding aspects.TCM Diagnostic MethodsDuring the Song dynasty (960-1279 CE), TCM was fully systematized to include comprehensive diagnosis, disease symptom profile analysis, and multivariate treatment protocols.", [["disease symptom profile analysis", "TEST", 180, 212], ["multivariate treatment protocols", "TREATMENT", 218, 250]]], ["Together with the theory of Yin and Yang, the Five Elements Theory forms the essential philosophy and methodology of TCM.", [["TCM", "CELL_TYPE", 117, 120], ["essential", "OBSERVATION_MODIFIER", 77, 86], ["philosophy", "OBSERVATION", 87, 97]]], ["As mentioned previously, TCM practitioners use a combination of the theories of Yin/Yang and the Five Elements to identify the cause of each disease, excess, deficiency, or debility and develop a customized treatment protocol.", [["TCM practitioners", "TREATMENT", 25, 42], ["Yin/Yang", "TREATMENT", 80, 88], ["each disease", "PROBLEM", 136, 148], ["excess, deficiency", "PROBLEM", 150, 168], ["debility", "PROBLEM", 173, 181], ["a customized treatment protocol", "TREATMENT", 194, 225]]], ["In the course of this cohesive cycle of diagnosis from root causes to customized remedies, appropriate treatments are prescribed.TCM Diagnostic MethodsTCM uses the body's microsystems to treat the whole person effectively, mirroring a holographic perspective of each part reflecting the whole.", [["root", "ANATOMY", 55, 59], ["body", "ANATOMY", 164, 168], ["root", "ORGAN", 55, 59], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["person", "SPECIES", 203, 209], ["customized remedies", "TREATMENT", 70, 89], ["appropriate treatments", "TREATMENT", 91, 113], ["the body's microsystems", "TREATMENT", 160, 183]]], ["This Charts and Graphs, 1994) can be seen in various parts of the body reflected in multiple areas within the face, eyes, ears, hands, and feet.", [["body", "ANATOMY", 66, 70], ["face", "ANATOMY", 110, 114], ["eyes", "ANATOMY", 116, 120], ["ears", "ANATOMY", 122, 126], ["feet", "ANATOMY", 139, 143], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["eyes", "ORGAN", 116, 120], ["ears", "ORGAN", 122, 126], ["hands", "ORGANISM_SUBDIVISION", 128, 133], ["feet", "ORGANISM_SUBDIVISION", 139, 143], ["eyes, ears, hands, and feet", "PROBLEM", 116, 143], ["body", "ANATOMY_MODIFIER", 66, 70], ["multiple", "OBSERVATION_MODIFIER", 84, 92], ["areas", "OBSERVATION", 93, 98], ["face", "ANATOMY_MODIFIER", 110, 114], ["eyes", "ANATOMY", 116, 120], ["ears", "ANATOMY", 122, 126], ["hands", "ANATOMY", 128, 133], ["feet", "ANATOMY", 139, 143]]], ["On a therapeutic level, TCM addresses these through acupuncture point manipulation.", [["TCM", "TREATMENT", 24, 27], ["acupuncture point manipulation", "TREATMENT", 52, 82]]], ["As an example: auricular acupuncture, hand and foot reflexology, etc.TCM Diagnostic MethodsWhile western medicine utilizes a stethoscope for detecting auscultations, TCM takes note of various sounds and pitches of the voice, coughing, breathing, wheezing, hiccupping, groaning, etc. In general, a loud sound reflects a full/excess pattern, while a weak sound is indicative of an empty/deficient pattern.", [["auricular", "ANATOMY", 15, 24], ["hand", "ANATOMY", 38, 42], ["foot", "ANATOMY", 47, 51], ["coughing", "DISEASE", 225, 233], ["wheezing", "DISEASE", 246, 254], ["hiccupping", "DISEASE", 256, 266], ["hand", "ORGANISM_SUBDIVISION", 38, 42], ["foot", "ORGANISM_SUBDIVISION", 47, 51], ["auricular acupuncture", "TREATMENT", 15, 36], ["hand and foot reflexology", "TEST", 38, 63], ["a stethoscope", "TREATMENT", 123, 136], ["various sounds", "PROBLEM", 184, 198], ["pitches of the voice", "PROBLEM", 203, 223], ["coughing", "PROBLEM", 225, 233], ["breathing", "PROBLEM", 235, 244], ["wheezing", "PROBLEM", 246, 254], ["hiccupping", "PROBLEM", 256, 266], ["groaning", "PROBLEM", 268, 276], ["a loud sound", "TEST", 295, 307], ["a full/excess pattern", "PROBLEM", 317, 338], ["a weak sound", "PROBLEM", 346, 358], ["an empty/deficient pattern", "PROBLEM", 376, 402], ["auricular", "ANATOMY", 15, 24], ["acupuncture", "OBSERVATION", 25, 36], ["hand", "ANATOMY", 38, 42], ["foot", "ANATOMY", 47, 51], ["indicative of", "UNCERTAINTY", 362, 375], ["empty", "OBSERVATION", 379, 384], ["deficient pattern", "OBSERVATION", 385, 402]]], ["TCM also takes into account the various odors emanating from the body.", [["body", "ANATOMY", 65, 69], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["TCM", "CELL_TYPE", 0, 3], ["the various odors", "PROBLEM", 28, 45], ["various", "OBSERVATION_MODIFIER", 32, 39], ["odors", "OBSERVATION", 40, 45], ["body", "ANATOMY", 65, 69]]], ["These odors can be related to different organ imbalances within the five elements system of correspondences, for example, rancid for the liver, scorched for the heart, sweet for the spleen, rotten for the lungs, and putrid for the kidneys.", [["organ", "ANATOMY", 40, 45], ["liver", "ANATOMY", 137, 142], ["heart", "ANATOMY", 161, 166], ["spleen", "ANATOMY", 182, 188], ["lungs", "ANATOMY", 205, 210], ["kidneys", "ANATOMY", 231, 238], ["organ", "ORGAN", 40, 45], ["liver", "ORGAN", 137, 142], ["heart", "ORGAN", 161, 166], ["sweet", "ORGANISM_SUBDIVISION", 168, 173], ["spleen", "ORGAN", 182, 188], ["lungs", "ORGAN", 205, 210], ["kidneys", "ORGAN", 231, 238], ["different organ imbalances", "PROBLEM", 30, 56], ["imbalances", "OBSERVATION", 46, 56], ["liver", "ANATOMY", 137, 142], ["heart", "ANATOMY", 161, 166], ["spleen", "ANATOMY", 182, 188], ["lungs", "ANATOMY", 205, 210], ["kidneys", "ANATOMY", 231, 238]]], ["Halitosis indicates heat in the stomach and so on.TCM Diagnostic MethodsExamination and consultation in TCM are similar to taking a western medical history and complete physical.", [["stomach", "ANATOMY", 32, 39], ["Halitosis", "DISEASE", 0, 9], ["stomach", "ORGAN", 32, 39], ["Halitosis", "PROBLEM", 0, 9], ["heat in the stomach", "PROBLEM", 20, 39], ["heat", "OBSERVATION_MODIFIER", 20, 24], ["stomach", "ANATOMY", 32, 39]]], ["This process is extensive and can help to find the causative factors of the illness by determining the timing, environment, situations with living conditions, emotional and social issues, environmental exposures, etc. The most commonly asked questions are regarding symptom profiles, such as fever, chills, sweating, painful areas, urination and bowel movement, food and taste, thirst and drink, sleep patterns, and condition of eyes, ears, throat, and other body parts.", [["bowel", "ANATOMY", 346, 351], ["eyes", "ANATOMY", 429, 433], ["ears", "ANATOMY", 435, 439], ["throat", "ANATOMY", 441, 447], ["body parts", "ANATOMY", 459, 469], ["illness", "DISEASE", 76, 83], ["fever", "DISEASE", 292, 297], ["chills", "DISEASE", 299, 305], ["bowel", "ORGAN", 346, 351], ["eyes", "ORGAN", 429, 433], ["ears", "ORGAN", 435, 439], ["throat", "ORGANISM_SUBDIVISION", 441, 447], ["body", "ORGANISM_SUBDIVISION", 459, 463], ["the illness", "PROBLEM", 72, 83], ["symptom profiles", "PROBLEM", 266, 282], ["fever", "PROBLEM", 292, 297], ["chills", "PROBLEM", 299, 305], ["sweating", "PROBLEM", 307, 315], ["painful areas", "PROBLEM", 317, 330], ["urination", "PROBLEM", 332, 341], ["bowel movement", "PROBLEM", 346, 360], ["sleep patterns", "PROBLEM", 396, 410], ["condition of eyes, ears, throat, and other body parts", "PROBLEM", 416, 469], ["bowel", "ANATOMY", 346, 351], ["eyes", "ANATOMY", 429, 433], ["ears", "ANATOMY", 435, 439], ["throat", "ANATOMY", 441, 447]]], ["There are specific questions for women regarding menstruation, discharges, pregnancy, and childbirth, as well as, for men, regarding virility and impotence, loss of strength, hair loss, hearing loss, and other targeted male issues.TCM Diagnostic MethodsPulses: Of particular importance to TCM, which distinguishes it from allopathy, is the attention to various pulses, unique to major organs and meridians.", [["hair", "ANATOMY", 175, 179], ["organs", "ANATOMY", 385, 391], ["virility", "DISEASE", 133, 141], ["impotence", "DISEASE", 146, 155], ["loss of strength", "DISEASE", 157, 173], ["hair loss", "DISEASE", 175, 184], ["hearing loss", "DISEASE", 186, 198], ["allopathy", "DISEASE", 322, 331], ["women", "ORGANISM", 33, 38], ["men", "ORGANISM", 118, 121], ["hair", "MULTI-TISSUE_STRUCTURE", 175, 179], ["organs", "ORGAN", 385, 391], ["TCM", "CELL_TYPE", 289, 292], ["women", "SPECIES", 33, 38], ["men", "SPECIES", 118, 121], ["impotence", "PROBLEM", 146, 155], ["loss of strength", "PROBLEM", 157, 173], ["hair loss", "PROBLEM", 175, 184], ["hearing loss", "PROBLEM", 186, 198], ["other targeted male issues", "PROBLEM", 204, 230], ["various pulses", "TEST", 353, 367], ["hearing loss", "OBSERVATION", 186, 198]]], ["Chinese pulse diagnosis is an effective tool to extract detailed information on the state of the internal organs and the corresponding meridians by palpating the radial artery on both wrists, dividing them into three areas and accessing them at three different levels: superficial, middle, and deep.TCM Diagnostic MethodsAs important as the rate of pulses are the qualities of pulses, which can be described as fast, slow, strong, weak, thin, wiry, tight, choppy, slippery, floating, deep, etc. These pulse indicators give the TCM practitioner a clear view of underlying conditions.", [["internal organs", "ANATOMY", 97, 112], ["radial artery", "ANATOMY", 162, 175], ["wrists", "ANATOMY", 184, 190], ["organs", "ORGAN", 106, 112], ["radial artery", "MULTI-TISSUE_STRUCTURE", 162, 175], ["wrists", "ORGANISM_SUBDIVISION", 184, 190], ["Chinese pulse diagnosis", "TEST", 0, 23], ["weak, thin, wiry, tight, choppy, slippery, floating, deep, etc", "PROBLEM", 431, 493], ["These pulse", "TEST", 495, 506], ["underlying conditions", "PROBLEM", 560, 581], ["internal organs", "ANATOMY", 97, 112], ["radial artery", "ANATOMY", 162, 175], ["wrists", "ANATOMY", 184, 190], ["superficial", "OBSERVATION_MODIFIER", 269, 280], ["middle", "ANATOMY_MODIFIER", 282, 288], ["deep", "ANATOMY_MODIFIER", 294, 298], ["weak", "OBSERVATION_MODIFIER", 431, 435], ["tight", "OBSERVATION_MODIFIER", 449, 454], ["deep", "ANATOMY_MODIFIER", 484, 488]]], ["For example, a strong wiry pulse may indicate liver Qi stagnation and excess of stress; a slippery pulse indicates dampness within the meridians, and a floating pulse indicates allergy condition or cold symptoms.TCM Diagnostic MethodsTongue: Another specialized TCM diagnostic area is the microsystem of the tongue.", [["liver", "ANATOMY", 46, 51], ["microsystem", "ANATOMY", 289, 300], ["tongue", "ANATOMY", 308, 314], ["allergy", "DISEASE", 177, 184], ["liver", "ORGAN", 46, 51], ["tongue", "ORGAN", 308, 314], ["a strong wiry pulse", "TEST", 13, 32], ["liver Qi stagnation", "PROBLEM", 46, 65], ["stress", "PROBLEM", 80, 86], ["a slippery pulse", "TEST", 88, 104], ["dampness", "PROBLEM", 115, 123], ["a floating pulse", "PROBLEM", 150, 166], ["allergy condition", "PROBLEM", 177, 194], ["cold symptoms", "PROBLEM", 198, 211], ["liver", "ANATOMY", 46, 51], ["Qi stagnation", "OBSERVATION", 52, 65], ["dampness", "OBSERVATION", 115, 123], ["microsystem", "ANATOMY_MODIFIER", 289, 300], ["tongue", "ANATOMY", 308, 314]]], ["The practitioner takes careful note of the different shapes, colors, patterns, and coatings of the tongue, each giving specific details regarding the patient's condition.", [["tongue", "ANATOMY", 99, 105], ["tongue", "ORGAN", 99, 105], ["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 150, 157], ["coatings of the tongue", "PROBLEM", 83, 105], ["tongue", "ANATOMY", 99, 105]]], ["As treatments progress, multiple changes in the appearance of the tongue take place, indicating the efficacy of the chosen protocol.TCM Diagnostic MethodsA central principle of TCM diagnostic protocol is known as syndrome differentiation.", [["tongue", "ANATOMY", 66, 72], ["tongue", "ORGAN", 66, 72], ["the chosen protocol", "TREATMENT", 112, 131], ["TCM diagnostic protocol", "TREATMENT", 177, 200], ["syndrome differentiation", "PROBLEM", 213, 237], ["multiple", "OBSERVATION_MODIFIER", 24, 32], ["tongue", "ANATOMY", 66, 72]]], ["This concept summarizes the interconnections of sensory diagnostic methods of observation, auditory, olfactory, consultative, pulse-taking, and palpation, in conjunction with pathological signs of the body, including the unique stages of disease development.", [["olfactory", "ANATOMY", 101, 110], ["body", "ANATOMY", 201, 205], ["body", "ORGANISM_SUBDIVISION", 201, 205], ["pulse", "TEST", 126, 131], ["palpation", "TEST", 144, 153], ["pathological signs", "TEST", 175, 193], ["disease development", "PROBLEM", 238, 257], ["body", "ANATOMY", 201, 205], ["disease", "OBSERVATION", 238, 245]]], ["Combined, these diagnostic methods are useful in identifying disease etiology, location, nature, and the relationship between the disease factors and a functional, balanced Qi.", [["disease factors", "PROTEIN", 130, 145], ["the disease factors", "PROBLEM", 126, 145], ["disease", "OBSERVATION", 130, 137]]], ["After evaluating these properties through diagnostic methods, the combined information leads to a syndrome differentiation analysis that aids in determining the most effective therapeutic protocol to eliminate pathogenic profiles.TCM TreatmentsTCM is a holistic and complex treatment system containing several treatment modalities that are utilized to promote healing and wellness.", [["diagnostic methods", "TEST", 42, 60], ["a syndrome differentiation analysis", "PROBLEM", 96, 131], ["therapeutic protocol", "TREATMENT", 176, 196], ["pathogenic profiles", "PROBLEM", 210, 229], ["TCM TreatmentsTCM", "TREATMENT", 230, 247], ["complex treatment system", "TREATMENT", 266, 290], ["several treatment modalities", "TREATMENT", 302, 330], ["healing", "OBSERVATION_MODIFIER", 360, 367]]], ["These modalities are acupuncture, herbal medicine, moxibustion, acupressure, Tui Na massage, cupping, nutrition and lifestyle consultation, meditation, and Taichi and Qigong exercises to strengthen the body and promote Qi and blood circulation (Fig. 2) .TCM TreatmentsMoxibustion involves the heating of acupuncture points with smoldering mugwort herb (known as moxa).", [["body", "ANATOMY", 202, 206], ["blood", "ANATOMY", 226, 231], ["Na", "CHEMICAL", 81, 83], ["Moxibustion", "CHEMICAL", 268, 279], ["Na", "CHEMICAL", 81, 83], ["body", "ORGANISM_SUBDIVISION", 202, 206], ["blood", "ORGANISM_SUBSTANCE", 226, 231], ["acupuncture", "TREATMENT", 21, 32], ["herbal medicine", "TREATMENT", 34, 49], ["moxibustion", "TREATMENT", 51, 62], ["acupressure", "TREATMENT", 64, 75], ["Tui Na massage", "TREATMENT", 77, 91], ["cupping", "TREATMENT", 93, 100], ["nutrition", "TREATMENT", 102, 111], ["lifestyle consultation", "TREATMENT", 116, 138], ["meditation", "TREATMENT", 140, 150], ["Taichi", "TREATMENT", 156, 162], ["Qigong exercises", "TREATMENT", 167, 183], ["TCM Treatments", "TREATMENT", 254, 268], ["Moxibustion", "TREATMENT", 268, 279], ["the heating of acupuncture", "TREATMENT", 289, 315], ["smoldering mugwort herb", "TREATMENT", 328, 351], ["body", "ANATOMY", 202, 206]]], ["Moxibustion stimulates circulation, counteracts cold and dampness in the body, and promotes the smooth flow of blood and Qi.", [["body", "ANATOMY", 73, 77], ["blood", "ANATOMY", 111, 116], ["Moxibustion", "CHEMICAL", 0, 11], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["Moxibustion stimulates circulation", "TREATMENT", 0, 34], ["cold", "PROBLEM", 48, 52], ["dampness in the body", "PROBLEM", 57, 77], ["dampness", "OBSERVATION", 57, 65], ["body", "ANATOMY", 73, 77]]], ["This safe, noninvasive technique may be used alone, but it is generally used in conjunction with acupuncture treatment.TCM TreatmentsAcupressure uses the same acupuncture points with gentle but firm pressure of the fingers and hands on the surface of the skin to increase the Qi and blood circulation, stimulating the body's natural curative abilities.", [["fingers", "ANATOMY", 215, 222], ["surface", "ANATOMY", 240, 247], ["skin", "ANATOMY", 255, 259], ["blood", "ANATOMY", 283, 288], ["body", "ANATOMY", 318, 322], ["Acupressure", "CHEMICAL", 133, 144], ["fingers", "ORGANISM_SUBDIVISION", 215, 222], ["hands", "ORGANISM_SUBDIVISION", 227, 232], ["skin", "ORGAN", 255, 259], ["blood", "ORGANISM_SUBSTANCE", 283, 288], ["body", "ORGANISM_SUBDIVISION", 318, 322], ["noninvasive technique", "TREATMENT", 11, 32], ["acupuncture treatment", "TREATMENT", 97, 118], ["TCM Treatments", "TREATMENT", 119, 133], ["Acupressure", "TREATMENT", 133, 144], ["the same acupuncture", "TREATMENT", 150, 170], ["blood circulation", "TEST", 283, 300], ["firm", "OBSERVATION_MODIFIER", 194, 198], ["pressure", "OBSERVATION", 199, 207], ["fingers", "ANATOMY", 215, 222], ["hands", "ANATOMY", 227, 232], ["skin", "ANATOMY", 255, 259]]], ["Acupressure is the most effective method for treatment of tension-related ailments by using the power and sensitivity of the human hand, relaxing the muscles and relieving tension.TCM TreatmentsTui Na massage means \"pushing grasping\" and is a powerful form of Chinese medical bodywork.", [["hand", "ANATOMY", 131, 135], ["muscles", "ANATOMY", 150, 157], ["Acupressure", "DISEASE", 0, 11], ["Tui Na", "CHEMICAL", 194, 200], ["Na", "CHEMICAL", 198, 200], ["human", "ORGANISM", 125, 130], ["hand", "ORGANISM_SUBDIVISION", 131, 135], ["muscles", "ORGANISM_SUBDIVISION", 150, 157], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["Acupressure", "TREATMENT", 0, 11], ["tension-related ailments", "PROBLEM", 58, 82], ["the human hand", "TREATMENT", 121, 135], ["tension", "PROBLEM", 172, 179], ["TCM Treatments", "TREATMENT", 180, 194], ["Chinese medical bodywork", "TREATMENT", 260, 284], ["most effective", "OBSERVATION_MODIFIER", 19, 33], ["human hand", "ANATOMY", 125, 135], ["muscles", "ANATOMY", 150, 157], ["tension", "OBSERVATION", 172, 179]]], ["Based on the same Oriental medical principles as acupuncture, Tui Na seeks to improve the flow of Qi through the meridian channels and is particularly effective for conditions involving muscles, tendons, and joints, such as structural misalignment, orthopedic problems, and sports injuries.", [["muscles", "ANATOMY", 186, 193], ["tendons", "ANATOMY", 195, 202], ["joints", "ANATOMY", 208, 214], ["Tui Na", "CHEMICAL", 62, 68], ["sports injuries", "DISEASE", 274, 289], ["Na", "CHEMICAL", 66, 68], ["muscles", "ORGANISM_SUBDIVISION", 186, 193], ["tendons", "MULTI-TISSUE_STRUCTURE", 195, 202], ["joints", "MULTI-TISSUE_STRUCTURE", 208, 214], ["acupuncture", "TREATMENT", 49, 60], ["muscles, tendons, and joints", "PROBLEM", 186, 214], ["structural misalignment, orthopedic problems", "PROBLEM", 224, 268], ["sports injuries", "PROBLEM", 274, 289], ["muscles", "ANATOMY", 186, 193], ["tendons", "ANATOMY", 195, 202], ["joints", "ANATOMY", 208, 214]]], ["It can also be used to treat internal diseases.TCM TreatmentsCupping is an ancient technique, in which a special cup is applied to the skin and held in place by vacuum-like suction.", [["skin", "ANATOMY", 135, 139], ["skin", "ORGAN", 135, 139], ["internal diseases", "PROBLEM", 29, 46], ["TCM Treatments", "TREATMENT", 47, 61], ["Cupping", "TREATMENT", 61, 68], ["an ancient technique", "TREATMENT", 72, 92], ["a special cup", "TREATMENT", 103, 116], ["skin", "ANATOMY", 135, 139], ["vacuum", "OBSERVATION", 161, 167]]], ["The suction draws superficial tissue into the cup, which may be left in place or moved along the body.", [["superficial tissue", "ANATOMY", 18, 36], ["cup", "ANATOMY", 46, 49], ["body", "ANATOMY", 97, 101], ["superficial tissue", "TISSUE", 18, 36], ["cup", "TISSUE", 46, 49], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["The suction draws superficial tissue", "TREATMENT", 0, 36], ["suction", "OBSERVATION", 4, 11], ["superficial tissue", "OBSERVATION_MODIFIER", 18, 36], ["may be", "UNCERTAINTY", 57, 63], ["left", "ANATOMY_MODIFIER", 64, 68], ["body", "ANATOMY", 97, 101]]], ["Cupping brings fresh blood to the area and helps improve circulation.", [["blood", "ANATOMY", 21, 26], ["area", "ANATOMY", 34, 38], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["Cupping", "PROBLEM", 0, 7], ["fresh blood to the area", "PROBLEM", 15, 38]]], ["Traditional cupping, sometimes referred to as fire cupping, uses heat to create a suction inside of glass cups.", [["cupping", "DISEASE", 12, 19], ["cupping", "DISEASE", 51, 58], ["Traditional cupping", "TREATMENT", 0, 19], ["heat", "TREATMENT", 65, 69], ["a suction inside of glass cups", "TREATMENT", 80, 110], ["cupping", "OBSERVATION", 12, 19], ["glass cups", "OBSERVATION", 100, 110]]], ["In modern times, plastic cups are used with a small vacuum pump to create suction, and small rubber cups that can be hand manipulated, without heat, have been introduced for convenience and safety.TCM TreatmentsDietary therapy and nutritional consultation refers to selection of foods to help enhance patient's overall health, based on their patterns of disharmony.", [["hand", "ANATOMY", 117, 121], ["TCM", "CHEMICAL", 197, 200], ["patient", "ORGANISM", 301, 308], ["patient", "SPECIES", 301, 308], ["plastic cups", "TREATMENT", 17, 29], ["a small vacuum pump", "TREATMENT", 44, 63], ["suction", "TREATMENT", 74, 81], ["small rubber cups", "TREATMENT", 87, 104], ["TCM Treatments", "TREATMENT", 197, 211], ["Dietary therapy", "TREATMENT", 211, 226], ["nutritional consultation", "TREATMENT", 231, 255], ["selection of foods", "TREATMENT", 266, 284], ["disharmony", "PROBLEM", 354, 364], ["small", "OBSERVATION_MODIFIER", 46, 51], ["vacuum pump", "OBSERVATION", 52, 63], ["suction", "OBSERVATION", 74, 81], ["small", "OBSERVATION_MODIFIER", 87, 92], ["rubber cups", "OBSERVATION", 93, 104]]], ["According to TCM, everyone has a different body constitution, temperament, and health conditions, which change at different ages.", [["body", "ANATOMY", 43, 47], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["TCM", "CELL_TYPE", 13, 16]]], ["Diet and nutrition can lead the body back to balance by avoiding foods that aggravate imbalances.", [["body", "ANATOMY", 32, 36], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["nutrition", "TREATMENT", 9, 18], ["aggravate imbalances", "PROBLEM", 76, 96]]], ["This concept correlates well in today's modern medicine where a large percentage of cancers and other degenerative diseases are known to be caused by improper diet and nutritional deficiencies.TCM TreatmentsImplicit in any diet is consideration of the agronomic factors in growing and cultivating plants with toxic pesticides, herbicides, and fungicides, as well as commercial farming of fish, poultry, and cattle with GMO feed, added hormones, and antibiotics, adding to toxic overload of the environment.", [["cancers", "ANATOMY", 84, 91], ["cancers", "DISEASE", 84, 91], ["degenerative diseases", "DISEASE", 102, 123], ["nutritional deficiencies", "DISEASE", 168, 192], ["TCM", "CHEMICAL", 193, 196], ["cancers", "CANCER", 84, 91], ["fish", "ORGANISM_SUBDIVISION", 388, 392], ["cattle", "SPECIES", 407, 413], ["cattle", "SPECIES", 407, 413], ["a large percentage of cancers", "PROBLEM", 62, 91], ["other degenerative diseases", "PROBLEM", 96, 123], ["nutritional deficiencies", "PROBLEM", 168, 192], ["TCM Treatments", "TREATMENT", 193, 207], ["the agronomic factors", "PROBLEM", 248, 269], ["toxic pesticides", "TREATMENT", 309, 325], ["herbicides", "TREATMENT", 327, 337], ["fungicides", "TREATMENT", 343, 353], ["GMO feed", "TREATMENT", 419, 427], ["hormones", "TREATMENT", 435, 443], ["antibiotics", "TREATMENT", 449, 460], ["toxic overload", "PROBLEM", 472, 486], ["large", "OBSERVATION_MODIFIER", 64, 69], ["percentage", "OBSERVATION_MODIFIER", 70, 80], ["cancers", "OBSERVATION", 84, 91], ["degenerative", "OBSERVATION_MODIFIER", 102, 114], ["diseases", "OBSERVATION", 115, 123], ["nutritional deficiencies", "OBSERVATION", 168, 192]]], ["These were nonexistent thousands of years ago when TCM was first developed but, in a modern polluted global environment, represent a very real challenge to contemporary human, animal, and environmental health.TCM TreatmentsA definitive landmark study, published in The Lancet in April 2019, involved a compilation of statistics (1990-2017) on morbidity and mortality related to dietary factors on a global scale.", [["TCM", "CHEMICAL", 51, 54], ["human", "ORGANISM", 169, 174], ["dietary factors", "PROTEIN", 378, 393], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["TCM Treatments", "TREATMENT", 209, 223], ["A definitive landmark study", "TEST", 223, 250], ["morbidity", "TREATMENT", 343, 352], ["dietary factors", "PROBLEM", 378, 393], ["a global scale", "TREATMENT", 397, 411]]], ["The findings indicate that 11 million deaths in 2017 were attributable to dietary risk factors showing suboptimal diet is responsible for more deaths than any other risks globally, including tobacco smoking.", [["deaths", "DISEASE", 38, 44], ["deaths", "DISEASE", 143, 149], ["tobacco", "ORGANISM", 191, 198], ["tobacco", "SPECIES", 191, 198], ["11 million deaths", "PROBLEM", 27, 44], ["dietary risk factors", "PROBLEM", 74, 94]]], ["TCM acknowledged the vital importance of diet and nutrition thousands of years ago and continues to rank food therapy as the first line of treatment (Afshin et al. 2019) .TCM TreatmentsQigong means \"life force energy cultivation\" by practicing deep breathing techniques along with certain forms of movement, some of which mimic animals in nature.", [["TCM", "CHEMICAL", 0, 3], ["the first line of treatment", "TREATMENT", 121, 148], ["TCM Treatments", "TREATMENT", 171, 185], ["Qigong means", "TREATMENT", 185, 197], ["deep breathing techniques", "TREATMENT", 244, 269]]], ["Medical Qigong is used as a treatment modality to promote, preserve, and restore health.", [["Medical Qigong", "TREATMENT", 0, 14], ["a treatment modality", "TREATMENT", 26, 46]]], ["The full benefits of Qigong exercises can be achieved when using correct posture and diaphragmatic breathing with conscious mental direction in a daily regimen.", [["diaphragmatic", "ANATOMY", 85, 98], ["diaphragmatic", "ORGAN", 85, 98], ["Qigong exercises", "TREATMENT", 21, 37], ["diaphragmatic breathing", "PROBLEM", 85, 108], ["conscious mental direction", "TREATMENT", 114, 140], ["a daily regimen", "TREATMENT", 144, 159], ["diaphragmatic", "ANATOMY", 85, 98]]], ["Qigong is often used to help reduce blood pressure, stress, and anxiety and promote restful sleep and wellbeing, in addition to eliminating common aging degeneration and promoting longevity.TCM TreatmentsTaichi, a form of Qigong, is a slow movement system of set forms of exercise based on Qigong principles of breathing, meditation, strength, and balance.", [["blood", "ANATOMY", 36, 41], ["anxiety", "DISEASE", 64, 71], ["Taichi", "CHEMICAL", 204, 210], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["Qigong", "TREATMENT", 0, 6], ["blood pressure", "TEST", 36, 50], ["stress", "PROBLEM", 52, 58], ["anxiety", "PROBLEM", 64, 71], ["common aging degeneration", "PROBLEM", 140, 165], ["TCM Treatments", "TREATMENT", 190, 204], ["Qigong", "TREATMENT", 222, 228], ["a slow movement system", "PROBLEM", 233, 255], ["Qigong principles of breathing", "TREATMENT", 290, 320], ["degeneration", "OBSERVATION", 153, 165], ["longevity", "OBSERVATION_MODIFIER", 180, 189]]], ["Hua Tuo (\u534e\u4f57) is a reputed physician during 140-208 CE, who gained fame for his profound abilities in acupuncture, moxibustion, and medical Da Yian (\u5927\u96c1) exercises.", [["acupuncture", "TREATMENT", 101, 112], ["moxibustion", "TREATMENT", 114, 125]]], ["It was his keen observation of the animal kingdom that lead him to develop the Wuqinxi (Exercise of the Five Animals, \u4e94\u79bd\u6232) from studying movements of the tiger, deer, bear, monkey, and crane.AcupunctureIn TCM, there are 12 major meridians with more than 700 acupuncture points distributed bilaterally throughout the entire body and 2 central Acupuncture is a treatment modality performed by inserting very fine sterile needles, not much thicker than a human hair, in specific locations on the skin, known as acupuncture points.", [["body", "ANATOMY", 323, 327], ["hair", "ANATOMY", 458, 462], ["skin", "ANATOMY", 493, 497], ["tiger", "ORGANISM", 154, 159], ["deer", "ORGANISM_SUBDIVISION", 161, 165], ["bear", "ORGANISM_SUBDIVISION", 167, 171], ["monkey", "ORGANISM", 173, 179], ["body", "ORGANISM_SUBDIVISION", 323, 327], ["human", "ORGANISM", 452, 457], ["hair", "ORGAN", 458, 462], ["skin", "ORGAN", 493, 497], ["deer", "SPECIES", 161, 165], ["monkey", "SPECIES", 173, 179], ["human", "SPECIES", 452, 457], ["human", "SPECIES", 452, 457], ["a treatment modality", "TREATMENT", 357, 377], ["very fine sterile needles", "TREATMENT", 401, 426], ["bilaterally", "ANATOMY_MODIFIER", 289, 300], ["entire", "OBSERVATION_MODIFIER", 316, 322], ["body", "OBSERVATION_MODIFIER", 323, 327], ["central Acupuncture", "OBSERVATION", 334, 353], ["much thicker", "OBSERVATION_MODIFIER", 432, 444], ["human hair", "OBSERVATION_MODIFIER", 452, 462], ["skin", "ANATOMY", 493, 497]]], ["The depth of needle insertion depends on the disease being treated and the location of the acupuncture point.", [["The depth of needle insertion", "TREATMENT", 0, 29], ["the disease", "PROBLEM", 41, 52], ["depth", "OBSERVATION_MODIFIER", 4, 9], ["needle insertion", "OBSERVATION", 13, 29], ["disease", "OBSERVATION", 45, 52], ["acupuncture", "OBSERVATION", 91, 102]]], ["For example, a shallow insertion is generally used for treating disease at the superficial level, i.e., initial stage of common colds and skin and muscle conditions.", [["skin", "ANATOMY", 138, 142], ["muscle", "ANATOMY", 147, 153], ["colds", "DISEASE", 128, 133], ["skin", "ORGAN", 138, 142], ["muscle", "ORGAN", 147, 153], ["a shallow insertion", "TREATMENT", 13, 32], ["treating disease at the superficial level", "PROBLEM", 55, 96], ["common colds and skin and muscle conditions", "PROBLEM", 121, 164], ["shallow insertion", "OBSERVATION", 15, 32], ["superficial", "ANATOMY_MODIFIER", 79, 90], ["common", "OBSERVATION_MODIFIER", 121, 127], ["colds", "OBSERVATION", 128, 133], ["skin", "ANATOMY", 138, 142], ["muscle", "ANATOMY", 147, 153]]], ["By contrast, deeper needle insertion is generally required for treating internal disease, e.g., organs and bones.AcupunctureAcupuncture stimulation regulates the flow of Qi within the energy pathways, which is referred to as meridian or channel that interconnects throughout the entire body.", [["organs", "ANATOMY", 96, 102], ["bones", "ANATOMY", 107, 112], ["body", "ANATOMY", 286, 290], ["organs", "ORGAN", 96, 102], ["bones", "ORGAN", 107, 112], ["body", "ORGANISM_SUBDIVISION", 286, 290], ["Qi", "PROTEIN", 170, 172], ["deeper needle insertion", "TREATMENT", 13, 36], ["treating internal disease, e.g., organs and bones", "PROBLEM", 63, 112], ["AcupunctureAcupuncture stimulation", "TREATMENT", 113, 147], ["organs", "ANATOMY", 96, 102], ["bones", "ANATOMY", 107, 112], ["entire body", "ANATOMY_MODIFIER", 279, 290]]], ["The practice of acupuncture affects the endocrine and central nervous system, including responses from both the sympathetic nervous system (Yang) and the parasympathetic nervous system (Yin) to achieve equilibrium and promote the body's innate healing ability (Fig. 3 ).AcupunctureAccording to ancient Chinese texts, each organ has a two-hour ultimate activity period per day.", [["endocrine", "ANATOMY", 40, 49], ["central nervous system", "ANATOMY", 54, 76], ["sympathetic nervous system", "ANATOMY", 112, 138], ["parasympathetic nervous system", "ANATOMY", 154, 184], ["body", "ANATOMY", 230, 234], ["organ", "ANATOMY", 322, 327], ["endocrine", "ANATOMICAL_SYSTEM", 40, 49], ["central nervous system", "ANATOMICAL_SYSTEM", 54, 76], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 112, 138], ["parasympathetic nervous system", "ANATOMICAL_SYSTEM", 154, 184], ["body", "ORGANISM_SUBDIVISION", 230, 234], ["organ", "ORGAN", 322, 327], ["acupuncture", "TREATMENT", 16, 27], ["the parasympathetic nervous system", "PROBLEM", 150, 184], ["acupuncture", "OBSERVATION", 16, 27], ["central", "ANATOMY_MODIFIER", 54, 61], ["nervous system", "ANATOMY", 62, 76], ["sympathetic nervous", "ANATOMY", 112, 131], ["parasympathetic nervous", "ANATOMY", 154, 177]]], ["When the energy of a meridian is not flowing well, it will exert certain symptoms, and the symptoms become exacerbated.", [["certain symptoms", "PROBLEM", 65, 81], ["the symptoms", "PROBLEM", 87, 99]]], ["By paying attention to the timing of the symptoms, a TCM practitioner can detect the underlying root cause of the problem.AcupunctureFor example, patients with asthmatic conditions often awaken coughing with an asthma attack between 3 and 5 AM (Lung meridian period) during the pre-dawn time.", [["root", "ANATOMY", 96, 100], ["Lung", "ANATOMY", 245, 249], ["coughing", "DISEASE", 194, 202], ["asthma", "DISEASE", 211, 217], ["root", "ORGAN", 96, 100], ["patients", "ORGANISM", 146, 154], ["Lung", "ORGAN", 245, 249], ["patients", "SPECIES", 146, 154], ["the symptoms", "PROBLEM", 37, 49], ["a TCM practitioner", "TREATMENT", 51, 69], ["the problem", "PROBLEM", 110, 121], ["Acupuncture", "TREATMENT", 122, 133], ["asthmatic conditions", "PROBLEM", 160, 180], ["coughing", "PROBLEM", 194, 202], ["an asthma attack", "PROBLEM", 208, 224], ["Lung", "ANATOMY", 245, 249]]], ["The TCM doctor can utilize the time of the meridian to design the treatment protocol.", [["the treatment protocol", "TREATMENT", 62, 84]]], ["For example, the best time to tonify the Kidney meridian deficiency is 5-7 PM.", [["Kidney", "ANATOMY", 41, 47], ["the Kidney meridian deficiency", "PROBLEM", 37, 67], ["Kidney", "ANATOMY", 41, 47], ["meridian deficiency", "OBSERVATION", 48, 67]]], ["If the Liver meridian (1-3 AM) is excessive, one can use the Small Intestine meridian period (1) (2) (3) to sedate the Liver meridian ( Fig. 4) (Table 3) .AcupunctureAccording to the World Health Organization publication reporting the effectiveness of acupuncture as evidenced in reviews and analysis of clinical trials (WHO 2002) and the 2017 Acupuncture Evidence Project from Australia, acupuncture has been recognized with significant clinical results for: allergic rhinitis, chemotherapy-induced nausea and vomiting (with anti-emetics), chronic low back pain, headache (tension and chronic), knee osteoarthritis, migraine prevention, postoperative nausea and vomiting and postoperative pain.", [["Liver", "ANATOMY", 7, 12], ["Liver", "ANATOMY", 119, 124], ["knee", "ANATOMY", 596, 600], ["allergic rhinitis", "DISEASE", 460, 477], ["nausea and vomiting", "DISEASE", 500, 519], ["low back pain", "DISEASE", 549, 562], ["headache", "DISEASE", 564, 572], ["osteoarthritis", "DISEASE", 601, 615], ["migraine", "DISEASE", 617, 625], ["postoperative nausea and vomiting", "DISEASE", 638, 671], ["postoperative pain", "DISEASE", 676, 694], ["Liver", "ORGAN", 119, 124], ["knee", "ORGANISM_SUBDIVISION", 596, 600], ["the Small Intestine meridian period", "TREATMENT", 57, 92], ["acupuncture", "TREATMENT", 252, 263], ["acupuncture", "TREATMENT", 389, 400], ["allergic rhinitis", "PROBLEM", 460, 477], ["chemotherapy", "TREATMENT", 479, 491], ["nausea", "PROBLEM", 500, 506], ["vomiting", "PROBLEM", 511, 519], ["anti-emetics", "TREATMENT", 526, 538], ["chronic low back pain", "PROBLEM", 541, 562], ["headache (tension and chronic)", "PROBLEM", 564, 594], ["knee osteoarthritis", "PROBLEM", 596, 615], ["migraine prevention", "PROBLEM", 617, 636], ["postoperative nausea", "PROBLEM", 638, 658], ["vomiting", "PROBLEM", 663, 671], ["postoperative pain", "PROBLEM", 676, 694], ["Liver", "ANATOMY", 7, 12], ["Small", "OBSERVATION_MODIFIER", 61, 66], ["Intestine", "ANATOMY", 67, 76], ["Liver", "ANATOMY", 119, 124], ["allergic rhinitis", "OBSERVATION", 460, 477], ["chronic", "OBSERVATION_MODIFIER", 541, 548], ["low", "OBSERVATION_MODIFIER", 549, 552], ["back", "ANATOMY", 553, 557], ["pain", "OBSERVATION", 558, 562], ["chronic", "OBSERVATION_MODIFIER", 586, 593], ["knee", "ANATOMY", 596, 600], ["osteoarthritis", "OBSERVATION", 601, 615]]], ["These conditions show the strongest evidence for acupuncture effectiveness, while there are hundreds of more conditions that show a positive response (McDonald and Janz 2017).", [["acupuncture effectiveness", "PROBLEM", 49, 74], ["positive response", "OBSERVATION", 132, 149]]], ["In addition, acupuncture has been acknowledged in the Journal of Integrative Medicine in 2017, involving thirteen professional institutes and clinical venues in the US, as having been proven to be a nonpharmacological option as a solution to the opioid crisis in America (Fan et al. 2017 ).Chinese Herbal MedicineNature is the most prolific and elaborate laboratory on earth, and Chinese herbal formulations have held historical influence for nearly 5000 years.", [["acupuncture", "TREATMENT", 13, 24], ["a nonpharmacological option", "TREATMENT", 197, 224], ["Chinese herbal formulations", "TREATMENT", 380, 407]]], ["China has developed into the largest population in human history, over 1.4 billion as of 2019, noted by the United Nations.", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["largest", "OBSERVATION_MODIFIER", 29, 36], ["population", "OBSERVATION_MODIFIER", 37, 47]]], ["This grand vision on the ultimate human experience gives TCM the perfect empirical model for human trials that has proven highly effective over several millennia and now is center stage in the global arena of pharmaceutical research and development.Chinese Herbal MedicineCentral to TCM is herbology and the cultivation, combination, and application of herbal remedies.", [["human", "ORGANISM", 34, 39], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 93, 98], ["human trials", "TREATMENT", 93, 105], ["the cultivation", "TREATMENT", 304, 319], ["herbal remedies", "TREATMENT", 353, 368]]], ["TCM makes use of herbs and herbal decoctions to strengthen organ function and rebalance the metabolism.", [["organ", "ANATOMY", 59, 64], ["TCM", "CHEMICAL", 0, 3], ["organ", "ORGAN", 59, 64], ["herbs", "TREATMENT", 17, 22], ["herbal decoctions", "TREATMENT", 27, 44], ["strengthen organ function", "TEST", 48, 73]]], ["A deep base of knowledge and a keen sensitivity to the essence of various herbal components give the TCM practitioner a precise method of generating a healing effect that reaches beyond the chemical composition and physical properties of the herbs.Chinese Herbal MedicineThe practitioner chooses the herbal formula that best complements the individual's unique symptom profile and the body's energetic vibration, as determined through various diagnostic processes.Chinese Herbal MedicineAccording to the World Health Organization (WHO), herbal medicines provide the basis of Charts and Graphs, 1994) primary healthcare for more than four billion people on a global level, comprising over half of the world's population.Chinese Herbal MedicineIt is estimated that nearly 85% of traditional medicine modalities involve plant extracts that have been the foundation of modern pharmacology for centuries.", [["body", "ANATOMY", 385, 389], ["extracts", "ANATOMY", 823, 831], ["body", "ORGANISM_SUBDIVISION", 385, 389], ["people", "ORGANISM", 646, 652], ["extracts", "ORGANISM_SUBSTANCE", 823, 831], ["people", "SPECIES", 646, 652], ["A deep base of knowledge", "PROBLEM", 0, 24], ["various herbal components", "TREATMENT", 66, 91], ["a healing effect", "PROBLEM", 149, 165], ["Chinese Herbal Medicine", "TREATMENT", 248, 271], ["the body's energetic vibration", "TEST", 381, 411], ["herbal medicines", "TREATMENT", 537, 553], ["traditional medicine modalities", "TREATMENT", 777, 808], ["deep", "ANATOMY_MODIFIER", 2, 6], ["herbs", "ANATOMY", 242, 247]]], ["There is a bounty of intrinsic and extrinsic properties that TCM recognizes as complementary to the innate healing capacity of the human metabolism.", [["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["extrinsic properties", "OBSERVATION", 35, 55], ["healing", "OBSERVATION_MODIFIER", 107, 114], ["capacity", "OBSERVATION_MODIFIER", 115, 123], ["human metabolism", "OBSERVATION", 131, 147]]], ["Herbs have biochemical compositions of active and buffering agents that synergistically balance each other.", [["Herbs", "TREATMENT", 0, 5], ["buffering agents", "TREATMENT", 50, 66], ["active", "OBSERVATION_MODIFIER", 39, 45]]], ["Some herbs are well known as food sources, while others are purely medicinal.Chinese Herbal MedicineIn contrast to the targeted medications of conventional allopathy that are largely developed and prescribed to ameliorate specific metabolic dysfunctions or specific symptoms, TCM herbal formulations work in collaboration with one another to achieve a systemic rebalancing.", [["metabolic dysfunctions", "DISEASE", 231, 253], ["Chinese Herbal MedicineIn contrast", "TREATMENT", 77, 111], ["conventional allopathy", "TREATMENT", 143, 165], ["specific metabolic dysfunctions", "PROBLEM", 222, 253], ["specific symptoms", "PROBLEM", 257, 274], ["TCM herbal formulations", "TREATMENT", 276, 299], ["a systemic rebalancing", "TREATMENT", 350, 372], ["herbs", "OBSERVATION", 5, 10]]], ["Each herb plays a unique role in the ultimate goal of achieving equilibrium, which is specific to each person.", [["person", "SPECIES", 103, 109]]], ["By combining the expertise of multiple herbal formulations, TCM can precisely address an individual patient's particular set of issues and develop a custom-designed healing protocol.Chinese Herbal MedicineVolumes of herbal formulas, medical applications, and variables on TCM practices for individualized protocols can be found in numerous historical texts from various pivotal TCM authors and practitioners, and many still are circulated and researched today.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["multiple herbal formulations", "TREATMENT", 30, 58], ["a custom-designed healing protocol", "TREATMENT", 147, 181], ["herbal formulas", "TREATMENT", 216, 231], ["medical applications", "TREATMENT", 233, 253], ["TCM practices", "TREATMENT", 272, 285], ["individualized protocols", "TREATMENT", 290, 314]]], ["All TCM practitioners are grateful to pass on this heritage and offer their personal contributions for the next generation.", [["this heritage", "TREATMENT", 46, 59]]], ["This manuscript elucidated the complex subjects of combination, reaction, taste, temperature, toxicity, function, primary clinical application, processing, and preparation.", [["toxicity", "DISEASE", 94, 102], ["reaction", "PROBLEM", 64, 72]]], ["Precise differentiation of the pattern of symptoms is correlated to the distinguished properties of each herb in herbal medicine.", [["symptoms", "PROBLEM", 42, 50], ["herbal medicine", "TREATMENT", 113, 128]]], ["These characteristics reference specific value sets that are uniquely descriptive and, therefore, aid the practitioner in determining the herbal choices which correlate best to a series of symptoms and individual patient constitution.", [["patient", "ORGANISM", 213, 220], ["patient", "SPECIES", 213, 220], ["symptoms", "PROBLEM", 189, 197]]], ["The characteristics of Chinese Herbal medicine are divided according to taste, thermal property, direction, and channel affiliations.", [["Chinese Herbal medicine", "TREATMENT", 23, 46]]], ["While different characteristics have separate evaluative criteria, each of them must be taken into account while formulating the herbal medicine.", [["the herbal medicine", "TREATMENT", 125, 144]]], ["In exploring these options, for instance, choosing the correct taste, but the wrong thermal property or an inappropriate meridian, could result in an ineffective treatment.", [["an ineffective treatment", "TREATMENT", 147, 171]]], ["If the patient has a heat condition, they should not be given herbs with hot or warm thermal property.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["a heat condition", "PROBLEM", 19, 35], ["warm thermal property", "TREATMENT", 80, 101]]], ["By doing so, it would not only be ineffective but may also worsen the heat condition.", [["the heat condition", "PROBLEM", 66, 84]]], ["The directional affinity is used to guide the herb's function toward the treatment area.", [["the treatment area", "TREATMENT", 69, 87]]], ["For example, Huang Qin (Radix Scutellariae) clears heat in the upper jiao (chest) area and, therefore, can be used to treat lung or liver diseases.", [["chest) area", "ANATOMY", 75, 86], ["lung", "ANATOMY", 124, 128], ["liver", "ANATOMY", 132, 137], ["lung or liver diseases", "DISEASE", 124, 146], ["Radix Scutellariae", "ORGANISM", 24, 42], ["upper jiao", "ORGANISM_SUBDIVISION", 63, 73], ["chest", "ORGANISM_SUBDIVISION", 75, 80], ["lung", "ORGAN", 124, 128], ["liver", "ORGAN", 132, 137], ["Huang Qin (Radix Scutellariae", "TREATMENT", 13, 42], ["lung or liver diseases", "PROBLEM", 124, 146], ["upper", "ANATOMY_MODIFIER", 63, 68], ["jiao", "ANATOMY", 69, 73], ["chest", "ANATOMY", 75, 80], ["lung", "ANATOMY", 124, 128], ["liver", "ANATOMY", 132, 137], ["diseases", "OBSERVATION", 138, 146]]], ["Du Huo (Radix Angelicae Pubescentis) moves in a downward direction, useful for both treating and guiding other herbs in treatment for musculoskeletal disorders of the lower body (Fig. 5 ).Contemporary Applications of TCM Herbs in Clinical PharmacologyHistorically, herbal medicine was the single most effective medicinal option available to humans.", [["musculoskeletal", "ANATOMY", 134, 149], ["lower body", "ANATOMY", 167, 177], ["Du Huo", "CHEMICAL", 0, 6], ["musculoskeletal disorders of the lower body", "DISEASE", 134, 177], ["lower body", "ORGANISM_SUBDIVISION", 167, 177], ["humans", "ORGANISM", 341, 347], ["humans", "SPECIES", 341, 347], ["humans", "SPECIES", 341, 347], ["Du Huo (Radix Angelicae Pubescentis", "TREATMENT", 0, 35], ["other herbs", "TREATMENT", 105, 116], ["treatment", "TREATMENT", 120, 129], ["musculoskeletal disorders of the lower body", "PROBLEM", 134, 177], ["TCM Herbs", "TREATMENT", 217, 226], ["herbal medicine", "TREATMENT", 265, 280], ["Huo", "OBSERVATION_MODIFIER", 3, 6], ["Radix Angelicae", "OBSERVATION_MODIFIER", 8, 23], ["musculoskeletal", "ANATOMY", 134, 149], ["disorders", "OBSERVATION", 150, 159], ["lower body", "ANATOMY", 167, 177]]], ["Food and plant derivatives were the centerpiece of treatment protocols before the advent of industrialization, synthesis of chemicals, and pharmaceutical development.", [["plant derivatives", "TREATMENT", 9, 26], ["treatment protocols", "TREATMENT", 51, 70], ["synthesis of chemicals", "TREATMENT", 111, 133]]], ["Today, there is resurgence of interest toward potent phytochemicals and other compounds from plants to discover more effective and less toxic therapeutic modalities for infectious and degenerative diseases, as well as cancer treatments.Contemporary Applications of TCM Herbs in Clinical PharmacologyTCM is currently at the forefront of global medical research and is evolving exhaustive databases of the complexity of chemical compounds found within classic TCM herbal decoctions that are being currently investigated in pharmaceutical studies.", [["cancer", "ANATOMY", 218, 224], ["infectious and degenerative diseases", "DISEASE", 169, 205], ["cancer", "DISEASE", 218, 224], ["cancer", "CANCER", 218, 224], ["infectious and degenerative diseases", "PROBLEM", 169, 205], ["cancer treatments", "TREATMENT", 218, 235], ["TCM Herbs", "TREATMENT", 265, 274], ["chemical compounds", "PROBLEM", 418, 436], ["classic TCM herbal decoctions", "PROBLEM", 450, 479], ["infectious", "OBSERVATION_MODIFIER", 169, 179], ["degenerative", "OBSERVATION_MODIFIER", 184, 196], ["diseases", "OBSERVATION", 197, 205], ["cancer", "OBSERVATION", 218, 224], ["chemical compounds", "OBSERVATION", 418, 436], ["herbal decoctions", "OBSERVATION", 462, 479]]], ["Over 71,000 entries, between 1945 and 2019 (abstracts not available until the 1980s), are noted for TCM in Pubmed.gov from the US National Library of Medicine and the National Institutes of Health.Contemporary Applications of TCM Herbs in Clinical PharmacologyAdditionally, there are over 3000 studies, specific to certain herbal compounds that are used in infectious and degenerative diseases, many of which have developed states of resistance, despite standard antibiotics and pharmaceuticals.Contemporary Applications of TCM Herbs in Clinical PharmacologyJust as herbal medicine is a cornerstone of TCM, pharmaceuticals have become the mainstay of conventional medicine.", [["infectious and degenerative diseases", "DISEASE", 357, 393], ["infectious and degenerative diseases", "PROBLEM", 357, 393], ["standard antibiotics", "TREATMENT", 454, 474], ["pharmaceuticals", "TREATMENT", 479, 494], ["herbal medicine", "TREATMENT", 566, 581], ["pharmaceuticals", "TREATMENT", 607, 622], ["conventional medicine", "TREATMENT", 651, 672], ["infectious", "OBSERVATION_MODIFIER", 357, 367], ["degenerative", "OBSERVATION_MODIFIER", 372, 384], ["diseases", "OBSERVATION", 385, 393]]], ["Major pharmaceutical companies in the USA, Europe, and Asia are premiere research and development sources for these drugs.", [["these drugs", "TREATMENT", 110, 121], ["pharmaceutical companies", "OBSERVATION", 6, 30]]], ["Much of the history of pharmaceuticals has its origin with herbal traditions, such as TCM.", [["pharmaceuticals", "TREATMENT", 23, 38], ["herbal traditions", "TREATMENT", 59, 76]]], ["An examination of this history and how herbs and drugs have become synonymous for medicine in different eras can be quite enlightening.", [["An examination", "TEST", 0, 14], ["drugs", "TREATMENT", 49, 54], ["medicine", "TREATMENT", 82, 90]]], ["Current statistics indicate an estimated wealth of 300,000-500,000 plant species on the planet, of which only 10% has been cultivated and developed for medicinal purposes.", [["medicinal purposes", "TEST", 152, 170]]], ["Biodiversity efforts are being proposed to help protect these plants from extinction and to sustain their natural global habitats (Rates 2001).Contemporary Applications of TCM Herbs in Clinical PharmacologyHerbal compounds have a well-documented history for treating diseases.", [["Biodiversity efforts", "TREATMENT", 0, 20], ["treating diseases", "PROBLEM", 258, 275]]], ["Between 35,000 and 70,000 plant species have been screened for medicinal compounds, and over 200 modern drugs owe their origins to the plant kingdom (Veeresham 2012) .", [["medicinal compounds", "TREATMENT", 63, 82]]], ["It was reported by Fabricant and Farnsworth (2001) that 80% of 122 plant-derived drugs were related to their original ethnopharmacological purposes.Contemporary Applications of TCM Herbs in Clinical PharmacologyMany of the commonly known herbal compounds used today, such as curcumin from Jiang Huang (Rhizoma Curcumae Longae, turmeric), Sheng Jiang (ginger), and Guan Ye Lian Qiao (Hypericum perforatum, aka, St. John's wort), are utilized for their anti-inflammatory, antidepressant, and antiemetic properties.", [["curcumin", "CHEMICAL", 275, 283], ["antidepressant", "CHEMICAL", 470, 484], ["curcumin", "CHEMICAL", 275, 283], ["curcumin", "SIMPLE_CHEMICAL", 275, 283], ["Jiang Huang", "ORGANISM", 289, 300], ["Rhizoma Curcumae Longae", "ORGANISM", 302, 325], ["turmeric", "ORGANISM_SUBDIVISION", 327, 335], ["Sheng Jiang", "ORGANISM", 338, 349], ["ginger", "ORGANISM_SUBDIVISION", 351, 357], ["Hypericum perforatum", "ORGANISM", 383, 403], ["aka", "ORGANISM", 405, 408], ["St. John's wort", "ORGANISM", 410, 425], ["turmeric", "SPECIES", 327, 335], ["ginger", "SPECIES", 351, 357], ["Hypericum perforatum", "SPECIES", 383, 403], ["Guan Ye Lian Qiao", "SPECIES", 364, 381], ["Hypericum perforatum", "SPECIES", 383, 403], ["drugs", "TREATMENT", 81, 86], ["the commonly known herbal compounds", "PROBLEM", 219, 254], ["their anti-inflammatory", "TREATMENT", 445, 468], ["antidepressant", "TREATMENT", 470, 484], ["antiemetic properties", "TREATMENT", 490, 511], ["herbal compounds", "OBSERVATION", 238, 254]]], ["Curcumin has become a major component in cancer research in the decades between 1999 and 2019 with over 21,000 studies cited in the PMC -National Library of Medicine and National Institutes of Health databases.", [["cancer", "ANATOMY", 41, 47], ["Curcumin", "CHEMICAL", 0, 8], ["cancer", "DISEASE", 41, 47], ["Curcumin", "CHEMICAL", 0, 8], ["Curcumin", "SIMPLE_CHEMICAL", 0, 8], ["cancer", "CANCER", 41, 47], ["major", "OBSERVATION_MODIFIER", 22, 27], ["component", "OBSERVATION_MODIFIER", 28, 37], ["cancer", "OBSERVATION", 41, 47]]], ["Many of these are landmark studies indicating curcumin's significance in cancer prevention, cancer stem cell elimination, and advanced cancer therapies.Contemporary Applications of TCM Herbs in Clinical PharmacologyIt is postulated that 60% of antitumor and anti-infectious drugs, already on the market or under clinical trials, are of plant origin (Cragg 1997) .", [["cancer", "ANATOMY", 73, 79], ["cancer stem cell", "ANATOMY", 92, 108], ["cancer", "ANATOMY", 135, 141], ["antitumor", "ANATOMY", 244, 253], ["curcumin", "CHEMICAL", 46, 54], ["cancer", "DISEASE", 73, 79], ["cancer", "DISEASE", 92, 98], ["cancer", "DISEASE", 135, 141], ["curcumin", "CHEMICAL", 46, 54], ["curcumin", "SIMPLE_CHEMICAL", 46, 54], ["cancer", "CANCER", 73, 79], ["cancer stem cell", "CELL", 92, 108], ["cancer", "CANCER", 135, 141], ["antitumor", "CANCER", 244, 253], ["landmark studies", "TEST", 18, 34], ["curcumin's significance", "PROBLEM", 46, 69], ["cancer prevention", "TREATMENT", 73, 90], ["cancer stem cell elimination", "PROBLEM", 92, 120], ["advanced cancer therapies", "TREATMENT", 126, 151], ["antitumor", "TREATMENT", 244, 253], ["anti-infectious drugs", "TREATMENT", 258, 279], ["curcumin", "OBSERVATION_MODIFIER", 46, 54], ["cancer", "OBSERVATION", 73, 79], ["cancer stem cell elimination", "OBSERVATION", 92, 120], ["advanced", "OBSERVATION_MODIFIER", 126, 134], ["cancer", "OBSERVATION", 135, 141], ["anti-infectious drugs", "OBSERVATION", 258, 279]]], ["Other plant compounds including cannabinoids, muscarine, physostigmine, yohimbine, forskolin, and colchicine have been clinically used in numerous pharmacological and biomedical studies (Williamson et al. 1996) .", [["cannabinoids", "CHEMICAL", 32, 44], ["muscarine", "CHEMICAL", 46, 55], ["physostigmine", "CHEMICAL", 57, 70], ["yohimbine", "CHEMICAL", 72, 81], ["forskolin", "CHEMICAL", 83, 92], ["colchicine", "CHEMICAL", 98, 108], ["cannabinoids", "CHEMICAL", 32, 44], ["muscarine", "CHEMICAL", 46, 55], ["physostigmine", "CHEMICAL", 57, 70], ["yohimbine", "CHEMICAL", 72, 81], ["forskolin", "CHEMICAL", 83, 92], ["colchicine", "CHEMICAL", 98, 108], ["cannabinoids", "SIMPLE_CHEMICAL", 32, 44], ["muscarine", "SIMPLE_CHEMICAL", 46, 55], ["physostigmine", "SIMPLE_CHEMICAL", 57, 70], ["yohimbine", "SIMPLE_CHEMICAL", 72, 81], ["forskolin", "SIMPLE_CHEMICAL", 83, 92], ["colchicine", "SIMPLE_CHEMICAL", 98, 108], ["cannabinoids", "TREATMENT", 32, 44], ["muscarine", "TREATMENT", 46, 55], ["physostigmine", "TREATMENT", 57, 70], ["yohimbine", "TREATMENT", 72, 81], ["forskolin", "TREATMENT", 83, 92], ["colchicine", "TREATMENT", 98, 108], ["biomedical studies", "TEST", 167, 185]]], ["Studies have shown a TCM herbal formula may be applied for several western classifications of pathologies.Contemporary Applications of TCM Herbs in Clinical PharmacologyFor example, Liu Wei Di Huang Wan is a classic TCM formula used for the TCM pattern \"Yin deficiency and tonify Kidney meridian.\"", [["Kidney", "ANATOMY", 280, 286], ["Studies", "TEST", 0, 7], ["a TCM herbal formula", "TREATMENT", 19, 39], ["pathologies", "PROBLEM", 94, 105], ["a classic TCM formula", "TREATMENT", 206, 227], ["Yin deficiency", "PROBLEM", 254, 268], ["pathologies", "OBSERVATION", 94, 105], ["Yin deficiency", "OBSERVATION", 254, 268]]], ["Recent studies have proven that this formula is effective for multiple diseases, including metabolic syndrome, diabetes, and cardiovascular disease, based on clinical experiences and pharmacological studies (Jiang 2005) .Contemporary Applications of TCM Herbs in Clinical PharmacologyClinical pharmacology now involves a multidisciplinary cohort of sciences including botany, chemistry, toxicology, anthropology, agronomy, and biotechnology, all of which have advanced pharmacology and improved the standards of drug development.", [["cardiovascular", "ANATOMY", 125, 139], ["metabolic syndrome", "DISEASE", 91, 109], ["diabetes", "DISEASE", 111, 119], ["cardiovascular disease", "DISEASE", 125, 147], ["Recent studies", "TEST", 0, 14], ["this formula", "TREATMENT", 32, 44], ["multiple diseases", "PROBLEM", 62, 79], ["metabolic syndrome", "PROBLEM", 91, 109], ["diabetes", "PROBLEM", 111, 119], ["cardiovascular disease", "PROBLEM", 125, 147], ["pharmacological studies", "TEST", 183, 206], ["diseases", "OBSERVATION", 71, 79], ["metabolic syndrome", "OBSERVATION", 91, 109], ["diabetes", "OBSERVATION", 111, 119], ["cardiovascular disease", "OBSERVATION", 125, 147]]], ["Principles in TCM that adhere to a philosophy of interrelated networks in nature and the human physiology and psychology are now being seriously investigated in network pharmacology and systems biology.Contemporary Applications of TCM Herbs in Clinical PharmacologyA modern pharmacological approach, bioactivity-guided fractionation, is essential in the isolation of active substances.", [["human", "ORGANISM", 89, 94], ["TCM", "CELL_TYPE", 14, 17], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["TCM Herbs", "TREATMENT", 231, 240], ["A modern pharmacological approach", "TREATMENT", 265, 298], ["guided fractionation", "TREATMENT", 312, 332], ["active", "OBSERVATION_MODIFIER", 367, 373], ["substances", "OBSERVATION", 374, 384]]], ["Because TCM often prescribes a multivariate decoction of several herbs, designed to assist a core biological response, research in standardization may not always rely on a singular compound or focus of action, but on a synergistic result, which has both pharmacodynamic and pharmacokinetic properties.Contemporary Applications of TCM Herbs in Clinical PharmacologyFor instance, Radix Ginseng, well reputed in TCM circles, is a prime example in which the whole plant or its saponin fractions are more active than the isolated compounds (Hamburger and Hostettman 1989) .", [["Radix Ginseng", "CHEMICAL", 378, 391], ["saponin", "CHEMICAL", 473, 480], ["saponin", "SIMPLE_CHEMICAL", 473, 480], ["Radix Ginseng", "TREATMENT", 378, 391], ["its saponin fractions", "TEST", 469, 490], ["pharmacokinetic properties", "OBSERVATION", 274, 300], ["Radix Ginseng", "OBSERVATION_MODIFIER", 378, 391]]], ["As TCM and network pharmacology continue to join efforts toward cataloguing herbal compounds and designing an international platform of standardization, herbal medicines will be more acceptable to empirical review parameters of clinical study.Herbal Medicine FormulationChinese herbal medicine recognizes an optimal therapeutic effect is achieved through identifying and analyzing the intricate nuances of the specific disorder in relationship to the person's unique character and constitution.", [["person", "SPECIES", 451, 457], ["cataloguing herbal compounds", "TREATMENT", 64, 92], ["herbal medicines", "TREATMENT", 153, 169], ["clinical study", "TEST", 228, 242], ["Herbal Medicine Formulation", "TREATMENT", 243, 270], ["Chinese herbal medicine", "TREATMENT", 270, 293], ["the specific disorder", "PROBLEM", 406, 427]]], ["Single herbs may be prescribed in the event of a clear diagnosis without additional complexities.", [["Single herbs", "TREATMENT", 0, 12]]], ["However, as most pathological conditions are aggregations of imbalances, a system of complementary herbal remedies, custom-designed for the individual and the pattern of symptoms, has evolved from ancient days.Herbal Medicine FormulationIn Huang Di Nei Jing (The Yellow Emperor's Inner Classic), the basic principle of formulating an herbal medicine is described as the system of Jun Chen Zuo Shi (Chief, Deputy, Assistant, Envoy).", [["complementary herbal remedies", "TREATMENT", 85, 114], ["symptoms", "PROBLEM", 170, 178], ["Herbal Medicine", "TREATMENT", 210, 225], ["an herbal medicine", "TREATMENT", 331, 349]]], ["Each herb performs an important and essential function within the formula.Herbal Medicine FormulationThis general concept has been expanded from the original, but the basic principle is still being followed in modern times.Herbal Medicine FormulationJun Yao (Chief Herb) is the most important component in each formula.", [["FormulationJun Yao", "CHEMICAL", 239, 257], ["Herbal Medicine Formulation", "TREATMENT", 74, 101], ["Herbal Medicine", "TREATMENT", 223, 238], ["expanded", "OBSERVATION_MODIFIER", 131, 139]]], ["It is used to treat the key disease or symptom, which is used at a large dose to maximize the effect.", [["the key disease", "PROBLEM", 20, 35], ["symptom", "PROBLEM", 39, 46]]], ["Chen Yao (Deputy Herb) reinforces the effects of the chief herb and also treats the associated disease or symptoms.", [["the chief herb", "TREATMENT", 49, 63], ["the associated disease", "PROBLEM", 80, 102], ["symptoms", "PROBLEM", 106, 114]]], ["Zuo Yao (Assistant Herb) reinforces the chief or deputy herb to treat the disease or directly treat the secondary symptoms.", [["Zuo Yao", "CHEMICAL", 0, 7], ["the disease", "PROBLEM", 70, 81], ["the secondary symptoms", "PROBLEM", 100, 122]]], ["It is used to counteract the toxicity or to minimize the undesirable strong effects of the chief and deputy herb.", [["toxicity", "DISEASE", 29, 37], ["the toxicity", "PROBLEM", 25, 37]]], ["Shi Yao (Envoy Herb) acts as a channel-guiding herb to direct the formula to the affected area of the body and also to harmonize all of the herbs within the formula, which is usually used in small doses.Interactions Between HerbsAlthough TCM herbal medicine has thousands of years of history attesting to its efficacy and safety, there are defined situations of toxicity that TCM practitioners are trained to understand and address.", [["body", "ANATOMY", 102, 106], ["Shi Yao", "CHEMICAL", 0, 7], ["toxicity", "DISEASE", 362, 370], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["a channel-guiding herb", "TREATMENT", 29, 51], ["toxicity", "PROBLEM", 362, 370], ["body", "ANATOMY", 102, 106]]], ["These guidelines contain six herb/herb interaction categories: In conjunction with these categories of interactions, there are two levels of cautions and contraindications that are important: safety and effectiveness factors.", [["contraindications", "TREATMENT", 154, 171]]], ["These include interaction of the specific herbal natures with the specific symptoms of the condition and interaction of herbs directly with other herbs.", [["the specific symptoms", "PROBLEM", 62, 83], ["the condition", "PROBLEM", 87, 100]]], ["While most herbs have been proven safe individually or in combination, certain herbal combinations have created adverse side effects and reactions.Interactions Between Herbs and DrugsAs people are increasingly taking medications and herbal supplements, especially in the geriatric population, the potential of herb and drug interactions is becoming a growing concern for healthcare professionals, as well as the general public.", [["DrugsAs people", "ORGANISM", 178, 192], ["people", "SPECIES", 186, 192], ["certain herbal combinations", "TREATMENT", 71, 98], ["created adverse side effects and reactions", "PROBLEM", 104, 146], ["Herbs", "TREATMENT", 168, 173], ["medications", "TREATMENT", 217, 228], ["herbal supplements", "TREATMENT", 233, 251]]], ["Pharmacokinetic interactions refer to the fluctuations in bioavailability of herb and drug molecules in the body, as a result of changes in absorption, distribution, metabolism, and elimination.", [["body", "ANATOMY", 108, 112], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["Pharmacokinetic interactions", "PROBLEM", 0, 28], ["herb", "TREATMENT", 77, 81], ["drug molecules in the body", "PROBLEM", 86, 112], ["changes in absorption", "PROBLEM", 129, 150], ["body", "ANATOMY", 108, 112]]], ["Pharmacodynamic interactions refer to the fluctuations in bioavailability of ingested substances, as a result of synergistic or antagonistic interaction between herb and drug molecules.Interactions Between Herbs and DrugsHerbs also are known to exhibit numerous interactions with drugs.", [["herb", "SIMPLE_CHEMICAL", 161, 165], ["DrugsHerbs", "SIMPLE_CHEMICAL", 216, 226], ["Pharmacodynamic interactions", "PROBLEM", 0, 28]]], ["Duplicating similar reactions of herbs and drugs could cause overdose or ineffectiveness of drugs in the patient's metabolism.", [["overdose", "DISEASE", 61, 69], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["herbs", "TREATMENT", 33, 38], ["drugs", "TREATMENT", 43, 48], ["overdose", "PROBLEM", 61, 69], ["drugs", "TREATMENT", 92, 97], ["similar", "OBSERVATION_MODIFIER", 12, 19], ["reactions", "OBSERVATION", 20, 29], ["herbs", "OBSERVATION", 33, 38]]], ["Following are descriptions of herbal functions which may interfere with or exacerbate biochemical reactions of specific classifications of drugs.Interactions Between Herbs and DrugsGuan Ye Lian Qiao (Hypericum perforatum), aka St. John's wort, is commonly used as an OTC supplement for depression and it is a liver enzyme inducer, which will lower the blood level of other medications if given together, leading to decreased therapeutic effect.", [["liver", "ANATOMY", 309, 314], ["blood", "ANATOMY", 352, 357], ["Hypericum perforatum", "CHEMICAL", 200, 220], ["depression", "DISEASE", 286, 296], ["Hypericum perforatum", "ORGANISM", 200, 220], ["aka", "ORGANISM", 223, 226], ["St. John", "ORGANISM", 227, 235], ["'s wort", "ORGANISM", 235, 242], ["OTC", "SIMPLE_CHEMICAL", 267, 270], ["liver", "ORGAN", 309, 314], ["blood", "ORGANISM_SUBSTANCE", 352, 357], ["Hypericum perforatum", "SPECIES", 200, 220], ["Hypericum perforatum", "SPECIES", 200, 220], ["herbal functions", "PROBLEM", 30, 46], ["biochemical reactions", "PROBLEM", 86, 107], ["drugs", "TREATMENT", 139, 144], ["Herbs", "TREATMENT", 166, 171], ["DrugsGuan", "TREATMENT", 176, 185], ["an OTC supplement", "TREATMENT", 264, 281], ["depression", "PROBLEM", 286, 296], ["a liver enzyme inducer", "PROBLEM", 307, 329], ["other medications", "TREATMENT", 367, 384], ["decreased therapeutic effect", "PROBLEM", 415, 443], ["liver", "ANATOMY", 309, 314]]], ["It may also cause serotonin syndrome, if given concurrently with Selective Serotonin Reuptake Inhibitor (SSRI) drugs.", [["serotonin", "CHEMICAL", 18, 27], ["SSRI", "CHEMICAL", 105, 109], ["serotonin", "CHEMICAL", 18, 27], ["Serotonin", "CHEMICAL", 75, 84], ["serotonin", "SIMPLE_CHEMICAL", 18, 27], ["Selective Serotonin Reuptake Inhibitor", "GENE_OR_GENE_PRODUCT", 65, 103], ["serotonin syndrome", "PROBLEM", 18, 36], ["Selective Serotonin Reuptake Inhibitor (SSRI) drugs", "TREATMENT", 65, 116], ["may also cause", "UNCERTAINTY", 3, 17], ["serotonin syndrome", "OBSERVATION", 18, 36]]], ["Another herb, Chai Hu (Radix Bupleuri), should be used with caution with the drug interferon, as this herb has shown increased risk of acute pneumonitis.", [["pneumonitis", "DISEASE", 141, 152], ["Chai Hu", "ORGANISM", 14, 21], ["Radix Bupleuri", "ORGANISM", 23, 37], ["interferon", "PROTEIN", 82, 92], ["Chai Hu (Radix Bupleuri", "SPECIES", 14, 37], ["Chai Hu (Radix Bupleuri)", "TREATMENT", 14, 38], ["the drug interferon", "TREATMENT", 73, 92], ["this herb", "TREATMENT", 97, 106], ["acute pneumonitis", "PROBLEM", 135, 152], ["Chai Hu", "OBSERVATION_MODIFIER", 14, 21], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["pneumonitis", "OBSERVATION", 141, 152]]], ["The herb may over stimulate neutrophils to release granulocytes elastase and oxygen radicals which may cause damage to lung tissues.Interactions Between Herbs and DrugsPhysicians and clinical pharmacologists may be interested in exploring possibilities of TCM herbal medicines that offer similar bioactive properties as pharmaceutical drugs, yet with fewer to no adverse reactions.Interactions Between Herbs and DrugsUnderstanding both the chemical compatibility and incompatibility between herb and drug functions can develop options in research and treatment protocols that may provide safer and more effective modalities.", [["neutrophils", "ANATOMY", 28, 39], ["granulocytes", "ANATOMY", 51, 63], ["lung tissues", "ANATOMY", 119, 131], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 77, 83], ["neutrophils", "CELL", 28, 39], ["granulocytes", "CELL", 51, 63], ["elastase", "GENE_OR_GENE_PRODUCT", 64, 72], ["oxygen radicals", "SIMPLE_CHEMICAL", 77, 92], ["lung tissues", "TISSUE", 119, 131], ["neutrophils", "CELL_TYPE", 28, 39], ["granulocytes", "CELL_TYPE", 51, 63], ["The herb", "TREATMENT", 0, 8], ["granulocytes elastase", "TEST", 51, 72], ["oxygen radicals", "TREATMENT", 77, 92], ["damage to lung tissues", "PROBLEM", 109, 131], ["TCM herbal medicines", "TREATMENT", 256, 276], ["similar bioactive properties", "TREATMENT", 288, 316], ["pharmaceutical drugs", "TREATMENT", 320, 340], ["adverse reactions", "PROBLEM", 363, 380], ["Herbs", "TREATMENT", 402, 407], ["herb", "TREATMENT", 491, 495], ["treatment protocols", "TREATMENT", 551, 570], ["oxygen radicals", "OBSERVATION", 77, 92], ["lung", "ANATOMY", 119, 123]]], ["Especially in major cardiovascular areas, where multiple drugs are often prescribed to achieve one effect, such as modulating hypertension or anticoagulation, TCM herbs may be more targeted to achieve the same results with a single herbal compound.", [["cardiovascular", "ANATOMY", 20, 34], ["hypertension", "DISEASE", 126, 138], ["multiple drugs", "TREATMENT", 48, 62], ["modulating hypertension", "PROBLEM", 115, 138], ["anticoagulation", "TREATMENT", 142, 157], ["TCM herbs", "TREATMENT", 159, 168], ["major", "OBSERVATION_MODIFIER", 14, 19], ["cardiovascular areas", "ANATOMY", 20, 40], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["drugs", "OBSERVATION", 57, 62], ["hypertension", "OBSERVATION", 126, 138]]], ["Also, in areas of diabetes, depression, and anxiety, TCM herbal medicines have proven to be effective alternatives to more toxic multiple drug regimens.", [["diabetes", "DISEASE", 18, 26], ["depression", "DISEASE", 28, 38], ["anxiety", "DISEASE", 44, 51], ["diabetes", "PROBLEM", 18, 26], ["depression", "PROBLEM", 28, 38], ["anxiety", "PROBLEM", 44, 51], ["TCM herbal medicines", "TREATMENT", 53, 73], ["toxic multiple drug regimens", "TREATMENT", 123, 151], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["diabetes", "OBSERVATION", 18, 26], ["depression", "OBSERVATION", 28, 38]]], ["As with all active substances that can alter metabolic functions, caution should be used when prescribing any herb or drug that could be contraindicated.", [["all active substances", "TREATMENT", 8, 29], ["drug", "TREATMENT", 118, 122]]], ["Table 4 displays certain interactions of herbs and drugs that should be considered in any combined treatment protocol.Herbal Processing, Quality Assurance, and StandardizationThe herbal extracts can be derived from the raw herbs through a solvent, such as grain alcohol, or an alcohol-free solvent, such as vegetable glycerin.", [["extracts", "ANATOMY", 186, 194], ["alcohol", "CHEMICAL", 262, 269], ["alcohol", "CHEMICAL", 277, 284], ["glycerin", "CHEMICAL", 317, 325], ["alcohol", "CHEMICAL", 262, 269], ["alcohol", "CHEMICAL", 277, 284], ["glycerin", "CHEMICAL", 317, 325], ["extracts", "ORGANISM_SUBSTANCE", 186, 194], ["grain alcohol", "SIMPLE_CHEMICAL", 256, 269], ["alcohol", "SIMPLE_CHEMICAL", 277, 284], ["vegetable", "ORGANISM_SUBDIVISION", 307, 316], ["glycerin", "SIMPLE_CHEMICAL", 317, 325], ["herbs", "TREATMENT", 41, 46], ["drugs", "TREATMENT", 51, 56], ["any combined treatment protocol", "TREATMENT", 86, 117], ["Herbal Processing", "TREATMENT", 118, 135], ["The herbal extracts", "TREATMENT", 175, 194], ["a solvent", "TREATMENT", 237, 246], ["vegetable glycerin", "TREATMENT", 307, 325]]], ["However, the herbal decoction is the most common dosage form for herbs in China.", [["the herbal decoction", "TREATMENT", 9, 29]]], ["The herbs are presoaked in enough water to cover them for a period of time, depending on the nature of the herbs and purpose.", [["herbs", "OBSERVATION", 4, 9]]], ["The herbs are then cooked until the water boils and then let simmer for a period of time, between 30 and 60 min, depending upon the particular blend of herbs, before the decoction (tea) is ready for consumption.", [["tea", "ORGANISM_SUBDIVISION", 181, 184], ["the water boils", "TREATMENT", 32, 47]]], ["The remainder of the herbs can be boiled the second time or discarded.", [["remainder", "OBSERVATION_MODIFIER", 4, 13], ["herbs", "OBSERVATION", 21, 26]]], ["In addition, a variation on the herbal decoction can be freeze-dried and condensed into granules.", [["granules", "ANATOMY", 88, 96], ["granules", "ORGANISM_SUBSTANCE", 88, 96], ["the herbal decoction", "TREATMENT", 28, 48], ["variation", "OBSERVATION_MODIFIER", 15, 24]]], ["Herbal extracts and granules, similar to contemporary medications, are more convenient for patients to take than the customary traditional raw herbs.Herbal Processing, Quality Assurance, and StandardizationThe process of preparing the raw herbs can be complex in timing.", [["extracts", "ANATOMY", 7, 15], ["granules", "ANATOMY", 20, 28], ["extracts", "ORGANISM_SUBSTANCE", 7, 15], ["granules", "ORGANISM_SUBSTANCE", 20, 28], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Herbal extracts", "TREATMENT", 0, 15], ["granules", "PROBLEM", 20, 28], ["contemporary medications", "TREATMENT", 41, 65], ["Herbal Processing", "TREATMENT", 149, 166], ["preparing the raw herbs", "TREATMENT", 221, 244], ["granules", "OBSERVATION", 20, 28]]], ["Leaves and flowers take less time to decoct than barks and roots; therefore, they should be added to the decoction process last.", [["Leaves", "ANATOMY", 0, 6], ["flowers", "ANATOMY", 11, 18], ["barks", "ANATOMY", 49, 54], ["roots", "ANATOMY", 59, 64], ["Leaves", "ORGANISM_SUBSTANCE", 0, 6], ["flowers", "ORGANISM_SUBDIVISION", 11, 18], ["barks", "ORGANISM_SUBDIVISION", 49, 54], ["roots", "ORGAN", 59, 64], ["roots", "ANATOMY", 59, 64]]], ["He Shou Wu (Radix Polygoni Multiflori) should be decocted with black beans at least for 30 min to decrease the side effects of loose stools, diarrhea, and liver toxicity.", [["liver", "ANATOMY", 155, 160], ["loose stools", "DISEASE", 127, 139], ["diarrhea", "DISEASE", 141, 149], ["liver toxicity", "DISEASE", 155, 169], ["beans", "ORGANISM_SUBDIVISION", 69, 74], ["liver", "ORGAN", 155, 160], ["black beans", "SPECIES", 63, 74], ["Radix Polygoni Multiflori)", "TREATMENT", 12, 38], ["loose stools", "PROBLEM", 127, 139], ["diarrhea", "PROBLEM", 141, 149], ["liver toxicity", "PROBLEM", 155, 169], ["loose stools", "OBSERVATION", 127, 139], ["diarrhea", "OBSERVATION", 141, 149], ["liver", "ANATOMY", 155, 160], ["toxicity", "OBSERVATION", 161, 169]]], ["Long-term consumption of He Shou Wu has been associated with liver toxicity.", [["liver", "ANATOMY", 61, 66], ["liver toxicity", "DISEASE", 61, 75], ["liver", "ORGAN", 61, 66], ["liver toxicity", "PROBLEM", 61, 75], ["liver", "ANATOMY", 61, 66], ["toxicity", "OBSERVATION", 67, 75]]], ["If discontinued, adverse reactions are reversible.", [["adverse reactions", "PROBLEM", 17, 34]]], ["However, if it is overdosed through unmonitored consistent consumption, cirrhosis or death may occur (Lei et al. 2015) .Herbal Processing, Quality Assurance, and StandardizationMany factors must be considered in the cultivation, concentration, toxicity/adverse reactions, and standardization of herbal medicines.", [["cirrhosis", "DISEASE", 72, 81], ["death", "DISEASE", 85, 90], ["toxicity", "DISEASE", 244, 252], ["cirrhosis", "PROBLEM", 72, 81], ["death", "PROBLEM", 85, 90], ["Herbal Processing", "TREATMENT", 120, 137], ["toxicity", "PROBLEM", 244, 252], ["adverse reactions", "PROBLEM", 253, 270], ["herbal medicines", "TREATMENT", 295, 311], ["cirrhosis", "OBSERVATION", 72, 81]]], ["These include geographical origin, varying processing and manufacturing techniques, as well as contraindications and compatibility with other herbs and pharmaceuticals (Zhang et al. 2017) .Herbal Processing, Quality Assurance, and StandardizationAs language can be a challenging issue in identifying a Chinese herb, in the interests of international standardization, use of both the Chinese term and the binomial, including the Latin botanical name and/or pharmaceutical name and any specific genus, would help to establish a global consensus regarding the exact herb in question.", [["manufacturing techniques", "TREATMENT", 58, 82], ["pharmaceuticals", "TREATMENT", 152, 167], ["Herbal Processing", "TREATMENT", 189, 206], ["geographical origin", "OBSERVATION", 14, 33], ["varying", "OBSERVATION_MODIFIER", 35, 42]]], ["Effective monitoring of herbal medicine safety will result from the collaboration of botanists, phytochemists, pharmacologists, and other major contributors to the cultivation, processing, and distribution of herbal medicines (Ekor 2014).Herbal Processing, Quality Assurance, and StandardizationThe accurate processing of herbal decoctions can reduce the toxicity of a few specific herbs.", [["toxicity", "DISEASE", 355, 363], ["herbal medicine", "TREATMENT", 24, 39], ["the cultivation", "TREATMENT", 160, 175], ["herbal medicines", "TREATMENT", 209, 225], ["Herbal Processing", "TREATMENT", 238, 255], ["herbal decoctions", "TREATMENT", 322, 339], ["the toxicity", "PROBLEM", 351, 363]]], ["For example, improper preparation or overdose of Fu Zi (Radix Aconiti Lateralis Praeparata) is the main cause of possible adverse reactions.", [["overdose", "DISEASE", 37, 45], ["Fu Zi (Radix Aconiti Lateralis Praeparata", "CHEMICAL", 49, 90], ["Fu Zi", "SIMPLE_CHEMICAL", 49, 54], ["improper preparation", "PROBLEM", 13, 33], ["Fu Zi (Radix Aconiti Lateralis Praeparata", "TREATMENT", 49, 90], ["adverse reactions", "PROBLEM", 122, 139]]], ["A person with a weak constitution may also have toxic reactions to Fu Zi, even when taken in low doses.", [["Fu Zi", "CHEMICAL", 67, 72], ["Fu Zi", "SIMPLE_CHEMICAL", 67, 72], ["person", "SPECIES", 2, 8], ["toxic reactions", "PROBLEM", 48, 63], ["Fu Zi", "TREATMENT", 67, 72]]], ["Patients who have a past history of cardiovascular disease, or are taking anti-arrhythmic medications, should take Fu Zi with extreme caution due to its strong cardiovascular effects.", [["cardiovascular", "ANATOMY", 36, 50], ["cardiovascular", "ANATOMY", 160, 174], ["cardiovascular disease", "DISEASE", 36, 58], ["Fu Zi", "CHEMICAL", 115, 120], ["Patients", "ORGANISM", 0, 8], ["cardiovascular", "ANATOMICAL_SYSTEM", 36, 50], ["Patients", "SPECIES", 0, 8], ["cardiovascular disease", "PROBLEM", 36, 58], ["anti-arrhythmic medications", "TREATMENT", 74, 101], ["Fu Zi", "TREATMENT", 115, 120], ["extreme caution", "TREATMENT", 126, 141], ["its strong cardiovascular effects", "PROBLEM", 149, 182], ["cardiovascular", "ANATOMY", 36, 50], ["disease", "OBSERVATION", 51, 58]]], ["Fu Zi should be decocted for more than an hour until the roots are very soft to decrease strong undesirable side effects and toxicity.", [["roots", "ANATOMY", 57, 62], ["Fu", "CHEMICAL", 0, 2], ["toxicity", "DISEASE", 125, 133], ["Fu", "CHEMICAL", 0, 2], ["roots", "ORGAN", 57, 62], ["Fu", "SPECIES", 0, 2], ["Zi", "TREATMENT", 3, 5], ["very soft", "PROBLEM", 67, 76], ["toxicity", "PROBLEM", 125, 133], ["roots", "ANATOMY", 57, 62]]], ["Gross overdose can be fatal.Herbal Processing, Quality Assurance, and StandardizationProper processing, concentration, and dosages are as relevant in clinical pharmacology.", [["Gross", "ANATOMY", 0, 5], ["overdose", "DISEASE", 6, 14], ["Gross overdose", "PROBLEM", 0, 14], ["Herbal Processing", "TREATMENT", 28, 45], ["StandardizationProper processing", "TREATMENT", 70, 102], ["overdose", "OBSERVATION", 6, 14], ["fatal", "OBSERVATION_MODIFIER", 22, 27]]], ["Quality assurance and manufacturing integrity are related to effectiveness and toxicity, as well as less regulated sources, such as the generic drug industry.", [["toxicity", "DISEASE", 79, 87], ["Quality assurance", "TREATMENT", 0, 17], ["manufacturing integrity", "TREATMENT", 22, 45], ["toxicity", "PROBLEM", 79, 87]]], ["Quality assurance is now a major issue regarding the safety standards and potency of drug manufacturing for both herbal medicines and pharmaceuticals.Herbal Processing, Quality Assurance, and StandardizationPrime examples of this are the industry recalls in 2018-2019 of losartan and valsartan, the widely prescribed angiotensin II receptor blockers for treating hypertension.", [["losartan", "CHEMICAL", 271, 279], ["valsartan", "CHEMICAL", 284, 293], ["angiotensin II", "CHEMICAL", 317, 331], ["hypertension", "DISEASE", 363, 375], ["losartan", "CHEMICAL", 271, 279], ["valsartan", "CHEMICAL", 284, 293], ["losartan", "SIMPLE_CHEMICAL", 271, 279], ["valsartan", "SIMPLE_CHEMICAL", 284, 293], ["angiotensin II receptor blockers", "GENE_OR_GENE_PRODUCT", 317, 349], ["drug manufacturing", "TREATMENT", 85, 103], ["both herbal medicines", "TREATMENT", 108, 129], ["pharmaceuticals", "TREATMENT", 134, 149], ["losartan", "TREATMENT", 271, 279], ["valsartan", "TREATMENT", 284, 293], ["angiotensin II receptor blockers", "TREATMENT", 317, 349], ["hypertension", "PROBLEM", 363, 375], ["hypertension", "OBSERVATION", 363, 375]]], ["In addition, the popular OTC medication for heartburn, Ranitidine (Zantac), was recalled in October 2019.", [["heartburn", "DISEASE", 44, 53], ["Ranitidine", "CHEMICAL", 55, 65], ["Zantac", "CHEMICAL", 67, 73], ["Ranitidine", "CHEMICAL", 55, 65], ["OTC", "SIMPLE_CHEMICAL", 25, 28], ["Ranitidine", "SIMPLE_CHEMICAL", 55, 65], ["the popular OTC medication", "TREATMENT", 13, 39], ["heartburn", "PROBLEM", 44, 53], ["Ranitidine (Zantac", "TREATMENT", 55, 73]]], ["Generic manufacturers are under the FDA microscope since it was discovered that these drugs were contaminated with ingredients containing trace amounts of N-nitroso-N-methyl-4-amino butyric acid (NMBA) and other carcinogens.", [["N-nitroso-N-methyl-4-amino butyric acid", "CHEMICAL", 155, 194], ["NMBA", "CHEMICAL", 196, 200], ["N-nitroso-N-methyl-4-amino butyric acid", "CHEMICAL", 155, 194], ["NMBA", "CHEMICAL", 196, 200], ["N-nitroso-N-methyl-4-amino butyric acid", "SIMPLE_CHEMICAL", 155, 194], ["NMBA", "SIMPLE_CHEMICAL", 196, 200], ["these drugs", "TREATMENT", 80, 91], ["N-nitroso", "TREATMENT", 155, 164], ["methyl", "TREATMENT", 167, 173], ["amino butyric acid (NMBA", "TREATMENT", 176, 200]]], ["The genotoxic impurities may be caused by changes made in the active pharmaceutical ingredient (API) manufacturing process but could also came from the reuse of materials, such as solvents.", [["genotoxic impurities", "OBSERVATION", 4, 24], ["may be caused", "UNCERTAINTY", 25, 38], ["active", "OBSERVATION_MODIFIER", 62, 68]]], ["The growing concern over adulterated products and contamination of the API in China and India has grown into a regulatory challenge as to how to improve quality while maintaining costeffectiveness.Herbal Processing, Quality Assurance, and StandardizationUp to 70% of drug manufacturing plants in China and India are being rated as substandard: falsifying records, tainting products, and allowing unsanitary conditions (Bottle of Lies: The Inside Story of the Generic Drug Boom, book by Katherine Eban 2019).", [["StandardizationUp", "TREATMENT", 239, 256], ["growing", "OBSERVATION_MODIFIER", 4, 11]]], ["It appears that the pharmaceutical industry in the USA and Europe, which obtains 80% of its raw materials from subcontracted global sources, is finding itself in a challenging situation.", [["pharmaceutical", "OBSERVATION_MODIFIER", 20, 34], ["industry", "OBSERVATION", 35, 43]]], ["Inspection of the raw materials and these offshore manufacturing facilities and processes is integral to the future of safer and more effective pharmaceuticals, as well as herbal medicines and nutraceuticals (Identifying the Root Causes of Drug Shortages and Finding Enduring SolutionsHerbal Medicine and Pharmaceuticals: Toxicity, Adverse Reactions, and MortalityTCM herbal medicine is often scrutinized and criticized by the scientific community for nonregulated issues of safety and efficacy, as well as lack of evidence-based, peer-reviewed studies.", [["Toxicity", "DISEASE", 322, 330], ["herbal medicines", "TREATMENT", 172, 188], ["nutraceuticals", "TREATMENT", 193, 207], ["Herbal Medicine", "TREATMENT", 285, 300], ["Adverse Reactions", "TREATMENT", 332, 349], ["MortalityTCM herbal medicine", "TREATMENT", 355, 383]]], ["The interesting aspect of empiricism is that it is based on observation, induction, deduction, experimentation, and evaluation.", [["experimentation", "TEST", 95, 110], ["evaluation", "TEST", 116, 126], ["empiricism", "OBSERVATION", 26, 36]]], ["TCM has a documented history of such empirical values in the development of its multivariate diagnostics, combinative herbal therapies, and intrinsic relationship with the philosophical and physiological factors of human nature within the entirety of nature.", [["TCM", "CHEMICAL", 0, 3], ["human", "ORGANISM", 215, 220], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["such empirical values", "PROBLEM", 32, 53], ["combinative herbal therapies", "TREATMENT", 106, 134], ["herbal therapies", "OBSERVATION", 118, 134]]], ["The isolation of critical active ingredients may often be misleading in verifying how nature navigates both in the environment and within living inhabitants.Herbal Medicine and Pharmaceuticals: Toxicity, Adverse Reactions, and MortalityAs regards toxicity and adverse reactions to TCM herbal formulations, there are several encyclopedias and collected documents, some of which are being translated into English.", [["Toxicity", "DISEASE", 194, 202], ["toxicity", "DISEASE", 247, 255], ["Herbal Medicine", "TREATMENT", 157, 172], ["Adverse Reactions", "PROBLEM", 204, 221], ["toxicity", "PROBLEM", 247, 255], ["adverse reactions", "PROBLEM", 260, 277], ["TCM herbal formulations", "TREATMENT", 281, 304], ["critical", "OBSERVATION_MODIFIER", 17, 25], ["active", "OBSERVATION_MODIFIER", 26, 32]]], ["These China's State Administration of Traditional Chinese Medicine requires all TCM practitioners to obtain the education and Chinese medicine degree to be officially registered and practice legally.", [["Traditional Chinese Medicine", "TREATMENT", 38, 66], ["all TCM practitioners", "TREATMENT", 76, 97], ["Chinese medicine degree", "TREATMENT", 126, 149]]], ["In the Traditional Medicine Strategy 2014-2023 report, the WHO addressed concerns regarding toxicity and adverse reactions to TCM herbal medicines to strengthen safety protocols of TCM herbal products by global practitioners.", [["toxicity", "DISEASE", 92, 100], ["toxicity", "PROBLEM", 92, 100], ["adverse reactions", "PROBLEM", 105, 122], ["TCM herbal medicines", "TREATMENT", 126, 146], ["TCM herbal products", "TREATMENT", 181, 200]]], ["The International Organization for Standardization (ISO) is in the process of developing quality standardization options for Chinese herbal medications, inclusive of raw materials, processing, and finished product quality assurance.", [["Standardization (ISO)", "TREATMENT", 35, 56], ["Chinese herbal medications", "TREATMENT", 125, 151]]], ["These efforts will be beneficial in the regulation and standardization of the globalized marketing of TCM herbal medications (Zhou et al. 2019) .Herbal Medicine and Pharmaceuticals: Toxicity, Adverse Reactions, and MortalityThe concepts of toxicity and adverse reactions are no strangers to TCM, historically.", [["Toxicity", "DISEASE", 182, 190], ["toxicity", "DISEASE", 240, 248], ["TCM herbal medications", "TREATMENT", 102, 124], ["Herbal Medicine", "TREATMENT", 145, 160], ["Adverse Reactions", "PROBLEM", 192, 209], ["toxicity", "PROBLEM", 240, 248], ["adverse reactions", "PROBLEM", 253, 270], ["toxicity", "OBSERVATION", 240, 248]]], ["In the Qing dynasty (1644 ( -1911 , Herbal Lihai authored by Ling Huan identified a variety of species of medicinal plants in the order of three aspects: harm, benefit, and therapy.", [["medicinal plants", "TREATMENT", 106, 122], ["therapy", "TREATMENT", 173, 180]]], ["The harmful side effects and contraindications were listed in the beginning, indicating that TCM practitioners recognized possible adverse effects of herbal remedies, long before the age of clinical pharmacology (Zeng and Jiang 2010) .Herbal Medicine and Pharmaceuticals: Toxicity, Adverse Reactions, and MortalityAccording to a 2014 report by Donald Light, PhD, from the Edmond J. Safra Center for Ethics at Harvard University, the following information depicts the adverse reactions and deaths from prescribed drugs in the USA and European Union as gleaned from systemic hospital reviews: serious adverse reactions result in over 1.9 million hospitalizations a year, with 840,000 hospitalized patients being given drugs that cause serious adverse reactions for a total of 2.74 million serious adverse drug reactions annually.", [["Toxicity", "DISEASE", 272, 280], ["deaths", "DISEASE", 489, 495], ["adverse drug reactions", "DISEASE", 795, 817], ["patients", "ORGANISM", 695, 703], ["patients", "SPECIES", 695, 703], ["The harmful side effects", "PROBLEM", 0, 24], ["contraindications", "TREATMENT", 29, 46], ["herbal remedies", "TREATMENT", 150, 165], ["Herbal Medicine", "TREATMENT", 235, 250], ["the adverse reactions", "PROBLEM", 463, 484], ["drugs", "TREATMENT", 512, 517], ["serious adverse reactions", "PROBLEM", 591, 616], ["drugs", "TREATMENT", 716, 721], ["serious adverse reactions", "PROBLEM", 733, 758], ["serious adverse drug reactions", "PROBLEM", 787, 817]]], ["In addition, prescribed drugs result in an estimated 128,000 deaths annually in the USA alone, accounting the use of prescription drugs being the 4thleading cause of death, along with stroke.", [["deaths", "DISEASE", 61, 67], ["death", "DISEASE", 166, 171], ["stroke", "DISEASE", 184, 190], ["drugs", "TREATMENT", 24, 29], ["prescription drugs", "TREATMENT", 117, 135], ["death", "PROBLEM", 166, 171], ["stroke", "PROBLEM", 184, 190]]], ["The European Commission estimates that adverse reactions from prescription drugs cause 200,000 annual deaths (Light 2014) .Herbal Medicine and Pharmaceuticals: Toxicity, Adverse Reactions, and MortalityThe International Regulatory Cooperation for Herbal Medicines (IRCH) and the WHO Collaborating Centre for International Drug Monitoring are focusing on the regulation, education, and standardization of traditional herbal medicine throughout the 129 member states.", [["deaths", "DISEASE", 102, 108], ["Toxicity", "DISEASE", 160, 168], ["adverse reactions", "PROBLEM", 39, 56], ["prescription drugs", "TREATMENT", 62, 80], ["Herbal Medicine", "TREATMENT", 123, 138], ["Adverse Reactions", "PROBLEM", 170, 187], ["Herbal Medicines", "TREATMENT", 247, 263], ["International Drug Monitoring", "TREATMENT", 308, 337], ["traditional herbal medicine", "TREATMENT", 404, 431]]], ["Once data is collected and analyzed, adverse reactions and morbidity and mortality rates for traditional herbal medicines may be discerned by equitable comparison of pharmaceuticals and TCM herbal medicines.Antimicrobial Resistance and Herbal MedicineAntimicrobial resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress, said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General.", [["adverse reactions", "PROBLEM", 37, 54], ["morbidity", "PROBLEM", 59, 68], ["mortality rates", "TEST", 73, 88], ["traditional herbal medicines", "TREATMENT", 93, 121], ["pharmaceuticals", "TREATMENT", 166, 181], ["TCM herbal medicines", "TREATMENT", 186, 206], ["Antimicrobial Resistance", "TREATMENT", 207, 231], ["Herbal MedicineAntimicrobial resistance", "TREATMENT", 236, 275], ["Herbal MedicineAntimicrobial resistance", "OBSERVATION", 236, 275]]], ["Drug-resistant bacteria and viruses have adapted over several decades due to rampant use of antibiotics.", [["Drug-resistant bacteria", "PROBLEM", 0, 23], ["viruses", "PROBLEM", 28, 35], ["antibiotics", "TREATMENT", 92, 103], ["bacteria", "OBSERVATION", 15, 23], ["viruses", "OBSERVATION", 28, 35]]], ["There has been a monumental rise of refractory infections causing thousands of deaths annually worldwide.Antimicrobial Resistance and Herbal MedicineThe standard anti-pathogenic strategies of clinical pharmacology through modern medicine have reached a pivotal turning point in effectiveness, and a different approach needs to be investigated to reduce the current epidemic levels of antimicrobial resistance to drug therapies.", [["infections", "DISEASE", 47, 57], ["deaths", "DISEASE", 79, 85], ["refractory infections", "PROBLEM", 36, 57], ["Antimicrobial Resistance", "TREATMENT", 105, 129], ["Herbal Medicine", "TREATMENT", 134, 149], ["The standard anti-pathogenic strategies", "TREATMENT", 149, 188], ["modern medicine", "TREATMENT", 222, 237], ["a different approach", "TREATMENT", 297, 317], ["antimicrobial resistance", "TREATMENT", 384, 408], ["drug therapies", "TREATMENT", 412, 426], ["monumental", "OBSERVATION_MODIFIER", 17, 27], ["rise", "OBSERVATION_MODIFIER", 28, 32], ["refractory", "OBSERVATION_MODIFIER", 36, 46], ["infections", "OBSERVATION", 47, 57], ["antimicrobial resistance", "OBSERVATION", 384, 408]]], ["There are a number of herbs that exhibit antibacterial and antiviral properties that may provide ways to decrease the development of antimicrobial resistance.Antimicrobial Resistance and Herbal MedicineThe WHO has enacted a new program to address resolution of this antimicrobial resistance dilemma entitled AWaRe (Access, Watch and Reserve).", [["herbs", "TREATMENT", 22, 27], ["antibacterial and antiviral properties", "TREATMENT", 41, 79], ["antimicrobial resistance", "PROBLEM", 133, 157], ["Antimicrobial Resistance", "TREATMENT", 158, 182], ["Herbal Medicine", "TREATMENT", 187, 202], ["this antimicrobial resistance dilemma", "PROBLEM", 261, 298], ["antibacterial", "OBSERVATION", 41, 54], ["antiviral properties", "OBSERVATION", 59, 79], ["antimicrobial resistance", "OBSERVATION", 133, 157]]], ["Released in October 2019, the program outlined a tool was developed by the WHO Essential Medicines List to contain the rising resistance and make antibiotic use safer and more effective.", [["the rising resistance", "PROBLEM", 115, 136], ["antibiotic use", "TREATMENT", 146, 160]]], ["It classifies antibiotics into three groups: Access, Watch and Reserve to help emphasize their optimal uses and potential for antimicrobial resistance.", [["Reserve", "TREATMENT", 63, 70], ["antimicrobial resistance", "TREATMENT", 126, 150], ["antimicrobial resistance", "OBSERVATION", 126, 150]]], ["(1) Access group: Have activity against common infections while have lower potential to develop resistance.", [["infections", "DISEASE", 47, 57], ["common infections", "PROBLEM", 40, 57], ["resistance", "PROBLEM", 96, 106]]], ["(3) Reserve group: Should be used sparingly and reserved for treatment of infections caused by multi-drug resistant organisms.", [["infections", "DISEASE", 74, 84], ["treatment", "TREATMENT", 61, 70], ["infections", "PROBLEM", 74, 84], ["multi-drug resistant organisms", "PROBLEM", 95, 125], ["infections", "OBSERVATION", 74, 84]]], ["It should be used only as a last resort.Antimicrobial Resistance and Herbal MedicineThe AWaRe campaign promoted by the WHO has mandated several actions areas including increasing the consumption of antibiotics in the Access group to at least 60% and reducing the use of the antibiotics in most at risk of resistance from the Watch and Reserve groups.", [["a last resort", "TREATMENT", 26, 39], ["Antimicrobial Resistance", "TREATMENT", 40, 64], ["Herbal Medicine", "TREATMENT", 69, 84], ["antibiotics", "TREATMENT", 198, 209], ["the antibiotics", "TREATMENT", 270, 285], ["resistance", "PROBLEM", 305, 315], ["Reserve groups", "TREATMENT", 335, 349]]], ["Using Access antibiotics lowers the risk of resistance because they are \"narrow-spectrum\" antibiotics (that target a specific microorganism rather than several).", [["Access antibiotics", "TREATMENT", 6, 24], ["resistance", "PROBLEM", 44, 54], ["narrow-spectrum\" antibiotics", "TREATMENT", 73, 101], ["a specific microorganism", "PROBLEM", 115, 139]]], ["They can be made available in generic forms and represent a less costly treatment option.TCM and Infectious DiseaseConventional western medicine addresses infectious disease by a linear approach in suppressing and eliminating suspected viruses and bacteria that are presumed to be the primary causative factors.", [["TCM", "CHEMICAL", 89, 92], ["infectious disease", "DISEASE", 155, 173], ["a less costly treatment option", "TREATMENT", 58, 88], ["infectious disease", "PROBLEM", 155, 173], ["a linear approach", "TREATMENT", 177, 194], ["suspected viruses", "PROBLEM", 226, 243], ["bacteria", "PROBLEM", 248, 256], ["Infectious", "OBSERVATION_MODIFIER", 97, 107], ["viruses", "OBSERVATION", 236, 243], ["presumed to be", "UNCERTAINTY", 266, 280]]], ["TCM and herbal medicine tend to offer a more comprehensive approach to infectious disease by applying the syndrome differentiation principle, a core feature of the TCM approach to individualized treatment.", [["TCM", "CHEMICAL", 0, 3], ["infectious disease", "DISEASE", 71, 89], ["herbal medicine", "TREATMENT", 8, 23], ["infectious disease", "PROBLEM", 71, 89], ["the syndrome differentiation principle", "PROBLEM", 102, 140], ["the TCM approach", "TREATMENT", 160, 176], ["individualized treatment", "TREATMENT", 180, 204]]], ["It has a vantage point in going beyond the viral and bacterial etiology concept to address the environment of the patient constitution in which the pathogens exist and the numerous influences affecting the patient's natural immunity.", [["patient", "ORGANISM", 114, 121], ["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 114, 121], ["patient", "SPECIES", 206, 213], ["the pathogens", "PROBLEM", 144, 157], ["viral", "OBSERVATION", 43, 48], ["bacterial", "OBSERVATION_MODIFIER", 53, 62]]], ["TCM protocols not only consider inhibition of pathogens but also, simultaneously, establish balance in the body and maintain organ recovery during severe and drug-resistant infection.TCM and Infectious DiseaseTCM acknowledges two syndromes, deficiency and excess, which occur commonly in severe infectious disease situations.", [["body", "ANATOMY", 107, 111], ["organ", "ANATOMY", 125, 130], ["infection", "DISEASE", 173, 182], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["organ", "ORGAN", 125, 130], ["TCM protocols", "TREATMENT", 0, 13], ["pathogens", "PROBLEM", 46, 55], ["severe and drug-resistant infection", "PROBLEM", 147, 182], ["TCM", "PROBLEM", 183, 186], ["two syndromes", "PROBLEM", 226, 239], ["deficiency and excess", "PROBLEM", 241, 262], ["severe infectious disease situations", "PROBLEM", 288, 324], ["pathogens", "OBSERVATION", 46, 55], ["resistant", "OBSERVATION_MODIFIER", 163, 172], ["infection", "OBSERVATION", 173, 182], ["Infectious", "OBSERVATION_MODIFIER", 191, 201], ["severe", "OBSERVATION_MODIFIER", 288, 294], ["infectious", "OBSERVATION", 295, 305]]], ["In these cases, distinct treatments are used to dispel the pathogens by choosing either a deficiency or excess protocol which may include detoxification, clearing heat, cooling blood, removing blood stagnation, tonifying Qi, and nourishing Yin.TCM and Infectious DiseaseBy carefully appropriating the treatments to the syndrome differentiation, these methods can reduce inflammation, ameliorate circulation disorders, and aid in tissue fibrinolysis.TCM and Infectious DiseaseAccording to a comprehensive report on SARS (Severe Acute Respiratory Syndrome) from the WHO (2004), TCM has been shown to be an valuable adjunct therapy with western medicine for treatment of the epidemic outbreak of SARS in 2003.", [["blood", "ANATOMY", 177, 182], ["blood", "ANATOMY", 193, 198], ["tissue", "ANATOMY", 429, 435], ["inflammation", "DISEASE", 370, 382], ["circulation disorders", "DISEASE", 395, 416], ["Infectious DiseaseAccording", "DISEASE", 457, 484], ["SARS", "DISEASE", 514, 518], ["Acute Respiratory Syndrome", "DISEASE", 527, 553], ["TCM", "CHEMICAL", 576, 579], ["SARS", "DISEASE", 693, 697], ["blood", "ORGANISM_SUBSTANCE", 177, 182], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["tissue", "TISSUE", 429, 435], ["Yin.", "SPECIES", 240, 244], ["distinct treatments", "TREATMENT", 16, 35], ["the pathogens", "PROBLEM", 55, 68], ["a deficiency", "PROBLEM", 88, 100], ["excess protocol", "TREATMENT", 104, 119], ["cooling blood", "TREATMENT", 169, 182], ["blood stagnation", "TREATMENT", 193, 209], ["the treatments", "TREATMENT", 297, 311], ["the syndrome differentiation", "PROBLEM", 315, 343], ["these methods", "TREATMENT", 345, 358], ["inflammation", "PROBLEM", 370, 382], ["ameliorate circulation disorders", "PROBLEM", 384, 416], ["tissue fibrinolysis", "PROBLEM", 429, 448], ["SARS", "PROBLEM", 514, 518], ["Severe Acute Respiratory Syndrome", "PROBLEM", 520, 553], ["an valuable adjunct therapy", "TREATMENT", 601, 628], ["western medicine", "TREATMENT", 634, 650], ["treatment", "TREATMENT", 655, 664], ["SARS", "PROBLEM", 693, 697], ["Infectious", "OBSERVATION_MODIFIER", 252, 262], ["tissue fibrinolysis", "OBSERVATION", 429, 448], ["Infectious", "OBSERVATION", 457, 467], ["Severe", "OBSERVATION_MODIFIER", 520, 526], ["Acute", "OBSERVATION_MODIFIER", 527, 532], ["Respiratory Syndrome", "OBSERVATION", 533, 553]]], ["It should be applied at the beginning stage of the infection while considering a patient's individual differences and underlying conditions.", [["infection", "DISEASE", 51, 60], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["the infection", "PROBLEM", 47, 60], ["a patient's individual differences", "PROBLEM", 79, 113], ["underlying conditions", "PROBLEM", 118, 139], ["infection", "OBSERVATION", 51, 60]]], ["The outbreak of Coronavirus Disease (COVID-19), originated from Wuhan, China in December 2019, spread rapidly in China and around the world, was declared pandemic by the WHO on March 11, 2020.", [["Coronavirus Disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 37, 45], ["Coronavirus Disease (COVID-19", "SPECIES", 16, 45], ["Coronavirus Disease", "PROBLEM", 16, 35], ["COVID", "TEST", 37, 42], ["Coronavirus Disease", "OBSERVATION", 16, 35]]], ["There were 1,853,155 confirmed cases with 114,247 death reported by April 12, 2020.", [["death", "DISEASE", 50, 55]]], ["In February 2020, there were a few reports from China indicating that TCM and integrated therapies had shown advantages over western medicine alone in treating hospitalized patient with severe acute respiratory syndrome.TCM and Infectious DiseaseA report from Chen, JK.", [["TCM", "CHEMICAL", 70, 73], ["acute respiratory syndrome", "DISEASE", 193, 219], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["integrated therapies", "TREATMENT", 78, 98], ["severe acute respiratory syndrome", "PROBLEM", 186, 219], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["respiratory syndrome", "OBSERVATION", 199, 219], ["Infectious", "OBSERVATION", 228, 238]]], ["It listed 4 different stages of treatment for COVID-19 in China.", [["treatment", "TREATMENT", 32, 41], ["COVID", "TEST", 46, 51], ["4 different stages", "OBSERVATION_MODIFIER", 10, 28]]], ["(1) Prevention phase (2) Influenza phase (3) Pneumonia phase (4) Recovery phase.", [["Influenza", "DISEASE", 25, 34], ["Pneumonia", "DISEASE", 45, 54], ["Prevention phase (2) Influenza phase", "TEST", 4, 40], ["Pneumonia phase", "TEST", 45, 60]]], ["Each phase presented a different clinical condition; therefore, it required different herbal formulas to treat the underlining conditions.", [["different herbal formulas", "TREATMENT", 76, 101], ["the underlining conditions", "PROBLEM", 111, 137]]], ["The advantages of TCM treatments are primarily due to its effectiveness in relieving symptoms, decreasing lung inflammation, improving the degree of blood oxygen saturation, modulating immunological responses, reducing the required dosage of glucocorticoid and other Western medicines, decreasing the morbidity and mortality rate, and lowering the cost of treatment by shortening the duration of infectious stage.", [["lung", "ANATOMY", 106, 110], ["blood", "ANATOMY", 149, 154], ["lung inflammation", "DISEASE", 106, 123], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 155, 161], ["lung", "ORGAN", 106, 110], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["glucocorticoid", "SIMPLE_CHEMICAL", 242, 256], ["TCM treatments", "TREATMENT", 18, 32], ["relieving symptoms", "PROBLEM", 75, 93], ["decreasing lung inflammation", "PROBLEM", 95, 123], ["blood oxygen saturation", "TEST", 149, 172], ["glucocorticoid", "TREATMENT", 242, 256], ["other Western medicines", "TREATMENT", 261, 284], ["mortality rate", "TEST", 315, 329], ["treatment", "TREATMENT", 356, 365], ["infectious stage", "PROBLEM", 396, 412], ["decreasing", "OBSERVATION_MODIFIER", 95, 105], ["lung", "ANATOMY", 106, 110], ["inflammation", "OBSERVATION", 111, 123], ["oxygen saturation", "OBSERVATION", 155, 172], ["infectious", "OBSERVATION", 396, 406]]], ["Since there is currently no effective treatment and no vaccine for COVID-19, the national authorities, health care workers and researchers should be inspired to explore the potential of a TCM integrative treatment approach.TCM and Infectious DiseaseThe following categories of TCM herbs show antiviral, antibacterial, antifungal, and antiparasitic properties by their primary biochemical compounds and exhibit bioactivities in relation to the unique disease etiology: elimination of parasites; may contain alkaloids and phenols (Ma et al. 2019) Advancements in Cancer Research with TCM Cancer research has gained unparalleled momentum as the world population topped 7.7 billion in 2019 with over 14 million new cases of cancer being diagnosed annually and over 9.6 million cancer-related deaths reported worldwide.", [["Cancer", "ANATOMY", 561, 567], ["cancer", "ANATOMY", 720, 726], ["cancer", "ANATOMY", 773, 779], ["TCM", "DISEASE", 223, 226], ["Infectious Disease", "DISEASE", 231, 249], ["phenols", "CHEMICAL", 520, 527], ["Cancer", "DISEASE", 561, 567], ["Cancer", "DISEASE", 586, 592], ["cancer", "DISEASE", 720, 726], ["cancer", "DISEASE", 773, 779], ["deaths", "DISEASE", 788, 794], ["phenols", "CHEMICAL", 520, 527], ["alkaloids", "SIMPLE_CHEMICAL", 506, 515], ["phenols", "SIMPLE_CHEMICAL", 520, 527], ["Cancer", "CANCER", 561, 567], ["TCM Cancer", "CANCER", 582, 592], ["cancer", "CANCER", 720, 726], ["cancer", "CANCER", 773, 779], ["effective treatment", "TREATMENT", 28, 47], ["vaccine", "TREATMENT", 55, 62], ["COVID", "TEST", 67, 72], ["a TCM integrative treatment approach", "TREATMENT", 186, 222], ["TCM herbs", "TREATMENT", 277, 286], ["antiviral", "TREATMENT", 292, 301], ["antibacterial", "TREATMENT", 303, 316], ["antifungal", "TREATMENT", 318, 328], ["antiparasitic properties", "TREATMENT", 334, 358], ["parasites", "PROBLEM", 483, 492], ["alkaloids", "TREATMENT", 506, 515], ["TCM Cancer", "PROBLEM", 582, 592], ["cancer", "PROBLEM", 720, 726], ["no", "UNCERTAINTY", 25, 27], ["effective", "OBSERVATION_MODIFIER", 28, 37], ["Infectious", "OBSERVATION", 231, 241], ["cancer", "OBSERVATION", 720, 726]]], ["New cancer cases are expected to rise, inexorably, to 23.6 million by 2030.", [["cancer", "ANATOMY", 4, 10], ["cancer", "DISEASE", 4, 10], ["cancer", "CANCER", 4, 10], ["New cancer cases", "PROBLEM", 0, 16], ["cancer", "OBSERVATION", 4, 10]]], ["Cancer now has become the second leading cause of death globally (WHO 2018) .", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["death", "DISEASE", 50, 55], ["Cancer", "CANCER", 0, 6], ["Cancer", "PROBLEM", 0, 6], ["death", "PROBLEM", 50, 55]]], ["These staggering statistics point to the imperative for all nations to focus on more effective protocols for cancer prevention and treatment.TCM and Infectious DiseaseMeta-analyses of randomized controlled studies involving TCM as adjunctive supportive cancer therapy show improved survival rates and performance status of chemotherapy and radiation treatments.", [["cancer", "ANATOMY", 109, 115], ["cancer", "ANATOMY", 253, 259], ["cancer", "DISEASE", 109, 115], ["TCM", "CHEMICAL", 224, 227], ["cancer", "DISEASE", 253, 259], ["cancer", "CANCER", 109, 115], ["cancer", "CANCER", 253, 259], ["more effective protocols", "TREATMENT", 80, 104], ["cancer prevention", "TREATMENT", 109, 126], ["treatment", "TREATMENT", 131, 140], ["randomized controlled studies", "TEST", 184, 213], ["TCM", "TREATMENT", 224, 227], ["adjunctive supportive cancer therapy", "TREATMENT", 231, 267], ["improved survival rates", "PROBLEM", 273, 296], ["chemotherapy", "TREATMENT", 323, 335], ["radiation treatments", "TREATMENT", 340, 360], ["cancer", "OBSERVATION", 109, 115], ["Infectious", "OBSERVATION_MODIFIER", 149, 159], ["cancer", "OBSERVATION", 253, 259]]], ["TCM in partnership with clinical pharmacology offers promise for such research and development, both as adjuvant and primary cancer treatments.", [["primary cancer", "ANATOMY", 117, 131], ["TCM", "CHEMICAL", 0, 3], ["cancer", "DISEASE", 125, 131], ["cancer", "CANCER", 125, 131], ["primary cancer treatments", "TREATMENT", 117, 142], ["cancer", "OBSERVATION", 125, 131]]], ["The following information has been excerpted from the chapter \"Principles of Supportive and Palliative Care/Chinese Herbal Medicine as Adjunct Therapy in Patients with Lung Cancer\" published in the textbook Modern Thoracic Oncology, Vol.", [["Lung Cancer", "ANATOMY", 168, 179], ["Lung Cancer", "DISEASE", 168, 179], ["Patients", "ORGANISM", 154, 162], ["Lung Cancer", "CANCER", 168, 179], ["Patients", "SPECIES", 154, 162], ["Palliative Care", "TREATMENT", 92, 107], ["Chinese Herbal Medicine", "TREATMENT", 108, 131], ["Adjunct Therapy", "TREATMENT", 135, 150], ["Lung Cancer", "PROBLEM", 168, 179], ["Lung", "ANATOMY", 168, 172], ["Cancer", "OBSERVATION", 173, 179], ["Thoracic", "ANATOMY", 214, 222]]], ["Extensive evaluations have been conducted evaluating the specific mechanisms by which adjunctive Chinese herbs address the needs of cancer patients.", [["cancer", "ANATOMY", 132, 138], ["cancer", "DISEASE", 132, 138], ["cancer", "CANCER", 132, 138], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Extensive evaluations", "TEST", 0, 21], ["adjunctive Chinese herbs", "TREATMENT", 86, 110]]], ["Table 5 shows the bioactivities of herbs exhibiting therapeutic and palliative action (McCulloch et al. 2018) .TCM and Infectious DiseaseOne remarkable adjuvant herbal medicine development getting examined since 1999 is known as PHY906.", [["TCM", "DISEASE", 111, 114], ["Infectious Disease", "DISEASE", 119, 137], ["PHY906", "CHEMICAL", 229, 235], ["PHY906", "CHEMICAL", 229, 235], ["PHY906", "SIMPLE_CHEMICAL", 229, 235], ["herbs", "TREATMENT", 35, 40], ["palliative action", "TREATMENT", 68, 85], ["adjuvant herbal medicine", "TREATMENT", 152, 176], ["Infectious", "OBSERVATION", 119, 129], ["remarkable", "OBSERVATION_MODIFIER", 141, 151], ["adjuvant", "OBSERVATION", 152, 160]]], ["The original herbal formula in TCM is referred to as Huang Qin Tang and is comprised of four herbs: Huang Qin (Radix Scutellaria), Bai Shao (Radix Paeoniae Alba), Gan Cao (Radix Glycyrrhizae), and Da Zao (Fructus Jujubae).", [["Huang Qin", "CHEMICAL", 100, 109], ["Radix Scutellaria", "CHEMICAL", 111, 128], ["Gan Cao", "CHEMICAL", 163, 170], ["Radix Scutellaria", "ORGANISM", 111, 128], ["Scutellaria", "SPECIES", 117, 128], ["The original herbal formula", "TREATMENT", 0, 27], ["Huang Qin (Radix Scutellaria", "TREATMENT", 100, 128], ["Bai Shao (Radix Paeoniae Alba)", "TREATMENT", 131, 161], ["Gan Cao (Radix Glycyrrhizae)", "TREATMENT", 163, 191], ["Da Zao (Fructus Jujubae", "TREATMENT", 197, 220], ["herbal formula", "OBSERVATION", 13, 27]]], ["Huang Qin Tang has been used for centuries in Asia to treat gastrointestinal disorders, nausea, and diarrhea.TCM and Infectious DiseasePHY906 has now been formulated as a powder containing a spray-dried aqueous extract derived from the four principal herbs.", [["gastrointestinal", "ANATOMY", 60, 76], ["extract", "ANATOMY", 211, 218], ["gastrointestinal disorders", "DISEASE", 60, 86], ["nausea", "DISEASE", 88, 94], ["diarrhea", "DISEASE", 100, 108], ["TCM", "CHEMICAL", 109, 112], ["DiseasePHY906", "CHEMICAL", 128, 141], ["gastrointestinal", "ORGAN", 60, 76], ["gastrointestinal disorders", "PROBLEM", 60, 86], ["nausea", "PROBLEM", 88, 94], ["diarrhea", "PROBLEM", 100, 108], ["Infectious DiseasePHY906", "TREATMENT", 117, 141], ["a powder", "TREATMENT", 169, 177], ["a spray", "TREATMENT", 189, 196], ["dried aqueous extract", "TREATMENT", 197, 218], ["gastrointestinal", "ANATOMY", 60, 76], ["disorders", "OBSERVATION", 77, 86], ["nausea", "OBSERVATION", 88, 94], ["diarrhea", "OBSERVATION", 100, 108], ["Infectious", "OBSERVATION", 117, 127], ["principal herbs", "OBSERVATION", 241, 256]]], ["The research was undertaken by Professor Ying Chi Cheng, who co-founded with Yale University's Office of Cooperative Research, PhytoCeutica, a biopharmaceutical company dedicated to developing cancer drugs from TCM herbs.", [["cancer", "ANATOMY", 193, 199], ["PhytoCeutica", "CHEMICAL", 127, 139], ["cancer", "DISEASE", 193, 199], ["cancer", "CANCER", 193, 199], ["cancer drugs", "TREATMENT", 193, 205], ["TCM herbs", "TREATMENT", 211, 220], ["cancer", "OBSERVATION", 193, 199]]], ["According to the National Cancer Institute's drug trial information site: \". . .PHY906 possesses a wide range of pharmacological activities such as the enhancement of oral uptake of pharmacologically active agents, inhibition of CYP3A4, modulation of certain cytokines, macrophages and lymphocytes, and inhibition of expression of MMP, NF-kB, betaglucuronidase, the NK-1 receptor, and the deltaopioid receptor\" (Dillon 2007 ).TCM and Infectious DiseaseTCM has now been shown to be a clinical competitor of pharmaceutical drugs in efficacy with recent studies proving the bio-chemotherapeutic effects of synergistic herbal compounds in oncological applications.", [["oral", "ANATOMY", 167, 171], ["macrophages", "ANATOMY", 270, 281], ["lymphocytes", "ANATOMY", 286, 297], ["Cancer", "DISEASE", 26, 32], ["PHY906", "CHEMICAL", 80, 86], ["TCM", "CHEMICAL", 426, 429], ["DiseaseTCM", "CHEMICAL", 445, 455], ["PHY906", "CHEMICAL", 80, 86], ["PHY906", "SIMPLE_CHEMICAL", 80, 86], ["oral", "ORGANISM_SUBDIVISION", 167, 171], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 229, 235], ["macrophages", "CELL", 270, 281], ["lymphocytes", "CELL", 286, 297], ["MMP", "GENE_OR_GENE_PRODUCT", 331, 334], ["NF-kB", "GENE_OR_GENE_PRODUCT", 336, 341], ["betaglucuronidase", "GENE_OR_GENE_PRODUCT", 343, 360], ["NK-1 receptor", "GENE_OR_GENE_PRODUCT", 366, 379], ["deltaopioid receptor", "GENE_OR_GENE_PRODUCT", 389, 409], ["CYP3A4", "PROTEIN", 229, 235], ["cytokines", "PROTEIN", 259, 268], ["macrophages", "CELL_TYPE", 270, 281], ["lymphocytes", "CELL_TYPE", 286, 297], ["MMP", "PROTEIN", 331, 334], ["NF-kB", "PROTEIN", 336, 341], ["betaglucuronidase", "PROTEIN", 343, 360], ["NK-1 receptor", "PROTEIN", 366, 379], ["deltaopioid receptor", "PROTEIN", 389, 409], ["pharmacological activities", "TREATMENT", 113, 139], ["pharmacologically active agents", "TREATMENT", 182, 213], ["inhibition of CYP3A4", "TREATMENT", 215, 235], ["certain cytokines", "PROBLEM", 251, 268], ["macrophages", "PROBLEM", 270, 281], ["lymphocytes", "PROBLEM", 286, 297], ["MMP", "PROBLEM", 331, 334], ["betaglucuronidase", "TREATMENT", 343, 360], ["the deltaopioid receptor\"", "TREATMENT", 385, 410], ["pharmaceutical drugs", "TREATMENT", 506, 526], ["recent studies", "TEST", 544, 558], ["synergistic herbal compounds", "TREATMENT", 603, 631], ["oncological applications", "TREATMENT", 635, 659], ["wide range", "OBSERVATION_MODIFIER", 99, 109], ["lymphocytes", "ANATOMY", 286, 297], ["Infectious", "OBSERVATION", 434, 444]]], ["These same herbs are also proving superior ratings over standard of care in decreased adverse effects and toxicity levels.TCM and Infectious DiseaseThe result of a German study on pancreatic cancer elimination with dietary and herbal compounds was published in 2014 in the International Journal of Oncology (Li et al. 2014) .TCM and Infectious DiseaseThe unique aspects of this study are the bioactivities of a collection of multiple agents found as superior to a singular agent in increasing apoptosis and remission and decreasing tumorigenicity and metastasis and the targeting of cancer stem cells as primary in elimination of advanced pancreatic ductal adenocarcinoma.", [["pancreatic cancer", "ANATOMY", 180, 197], ["cancer stem cells", "ANATOMY", 583, 600], ["pancreatic ductal adenocarcinoma", "ANATOMY", 639, 671], ["toxicity", "DISEASE", 106, 114], ["TCM", "DISEASE", 122, 125], ["Infectious Disease", "DISEASE", 130, 148], ["pancreatic cancer", "DISEASE", 180, 197], ["Infectious Disease", "DISEASE", 333, 351], ["cancer", "DISEASE", 583, 589], ["pancreatic ductal adenocarcinoma", "DISEASE", 639, 671], ["pancreatic cancer", "CANCER", 180, 197], ["cancer stem cells", "CELL", 583, 600], ["pancreatic ductal adenocarcinoma", "CANCER", 639, 671], ["cancer stem cells", "CELL_TYPE", 583, 600], ["decreased adverse effects", "PROBLEM", 76, 101], ["toxicity levels", "PROBLEM", 106, 121], ["a German study", "TEST", 162, 176], ["pancreatic cancer", "PROBLEM", 180, 197], ["dietary and herbal compounds", "TREATMENT", 215, 243], ["this study", "TEST", 373, 383], ["multiple agents", "TREATMENT", 425, 440], ["increasing apoptosis", "PROBLEM", 482, 502], ["decreasing tumorigenicity", "PROBLEM", 521, 546], ["metastasis", "PROBLEM", 551, 561], ["cancer stem cells", "PROBLEM", 583, 600], ["advanced pancreatic ductal adenocarcinoma", "PROBLEM", 630, 671], ["Infectious", "OBSERVATION", 130, 140], ["pancreatic", "ANATOMY", 180, 190], ["cancer", "OBSERVATION", 191, 197], ["Infectious", "OBSERVATION", 333, 343], ["increasing", "OBSERVATION_MODIFIER", 482, 492], ["apoptosis", "OBSERVATION", 493, 502], ["decreasing", "OBSERVATION_MODIFIER", 521, 531], ["tumorigenicity", "OBSERVATION_MODIFIER", 532, 546], ["metastasis", "OBSERVATION", 551, 561], ["cancer stem cells", "OBSERVATION", 583, 600], ["advanced", "OBSERVATION_MODIFIER", 630, 638], ["pancreatic ductal", "ANATOMY", 639, 656], ["adenocarcinoma", "OBSERVATION", 657, 671]]], ["PDA is a highly aggressive malignancy with poor prognosis given the current therapeutic options, which do not target cancer stem cells (CSCs), considered to be the central cause for the aggressiveness.TCM and Infectious DiseasePolyphenols from dietary agents, sulforaphane and quercetin, along with the green tea catechin EGCG, resveratrol, genistein, and curcumin, hold promise as anti-CSC agents in PDA.", [["malignancy", "ANATOMY", 27, 37], ["cancer stem cells", "ANATOMY", 117, 134], ["CSCs", "ANATOMY", 136, 140], ["malignancy", "DISEASE", 27, 37], ["cancer", "DISEASE", 117, 123], ["aggressiveness", "DISEASE", 186, 200], ["TCM", "CHEMICAL", 201, 204], ["Infectious DiseasePolyphenols", "DISEASE", 209, 238], ["sulforaphane", "CHEMICAL", 260, 272], ["quercetin", "CHEMICAL", 277, 286], ["green tea catechin", "CHEMICAL", 303, 321], ["EGCG", "CHEMICAL", 322, 326], ["resveratrol", "CHEMICAL", 328, 339], ["genistein", "CHEMICAL", 341, 350], ["curcumin", "CHEMICAL", 356, 364], ["sulforaphane", "CHEMICAL", 260, 272], ["quercetin", "CHEMICAL", 277, 286], ["catechin", "CHEMICAL", 313, 321], ["EGCG", "CHEMICAL", 322, 326], ["resveratrol", "CHEMICAL", 328, 339], ["genistein", "CHEMICAL", 341, 350], ["curcumin", "CHEMICAL", 356, 364], ["malignancy", "CANCER", 27, 37], ["cancer stem cells", "CELL", 117, 134], ["CSCs", "CELL", 136, 140], ["sulforaphane", "SIMPLE_CHEMICAL", 260, 272], ["quercetin", "SIMPLE_CHEMICAL", 277, 286], ["tea catechin", "SIMPLE_CHEMICAL", 309, 321], ["EGCG", "SIMPLE_CHEMICAL", 322, 326], ["resveratrol", "SIMPLE_CHEMICAL", 328, 339], ["genistein", "SIMPLE_CHEMICAL", 341, 350], ["curcumin", "SIMPLE_CHEMICAL", 356, 364], ["anti-CSC agents", "SIMPLE_CHEMICAL", 382, 397], ["cancer stem cells", "CELL_TYPE", 117, 134], ["CSCs", "CELL_TYPE", 136, 140], ["a highly aggressive malignancy", "PROBLEM", 7, 37], ["the aggressiveness", "PROBLEM", 182, 200], ["TCM", "PROBLEM", 201, 204], ["Infectious DiseasePolyphenols", "TREATMENT", 209, 238], ["dietary agents", "TREATMENT", 244, 258], ["sulforaphane", "TREATMENT", 260, 272], ["quercetin", "TREATMENT", 277, 286], ["the green tea catechin EGCG", "TREATMENT", 299, 326], ["resveratrol", "TREATMENT", 328, 339], ["genistein", "TREATMENT", 341, 350], ["curcumin", "TREATMENT", 356, 364], ["anti-CSC agents", "TREATMENT", 382, 397], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["aggressive", "OBSERVATION_MODIFIER", 16, 26], ["malignancy", "OBSERVATION", 27, 37], ["Infectious", "OBSERVATION_MODIFIER", 209, 219]]], ["In vitro data and mouse experiments suggest that sulforaphane eliminates pancreatic CSCs by inhibition of bioactive agents for cancer stem cells targeting NF-\u03baB activity and self-renewal potential and sensitizes the cells to apoptosis induction.", [["pancreatic CSCs", "ANATOMY", 73, 88], ["cancer stem cells", "ANATOMY", 127, 144], ["cells", "ANATOMY", 216, 221], ["sulforaphane", "CHEMICAL", 49, 61], ["cancer", "DISEASE", 127, 133], ["sulforaphane", "CHEMICAL", 49, 61], ["mouse", "ORGANISM", 18, 23], ["sulforaphane", "SIMPLE_CHEMICAL", 49, 61], ["pancreatic CSCs", "CELL", 73, 88], ["cancer stem cells", "CELL", 127, 144], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["cells", "CELL", 216, 221], ["pancreatic CSCs", "CELL_TYPE", 73, 88], ["cancer stem cells", "CELL_TYPE", 127, 144], ["NF-\u03baB", "PROTEIN", 155, 160], ["mouse", "SPECIES", 18, 23], ["mouse", "SPECIES", 18, 23], ["sulforaphane", "TREATMENT", 49, 61], ["pancreatic CSCs", "PROBLEM", 73, 88], ["bioactive agents", "TREATMENT", 106, 122], ["cancer stem cells", "PROBLEM", 127, 144], ["NF", "TEST", 155, 157], ["the cells", "PROBLEM", 212, 221], ["apoptosis induction", "TREATMENT", 225, 244], ["pancreatic", "ANATOMY", 73, 83]]], ["The combination of dietary agents was found to be superior in reducing the self-renewal potential, viability, and migratory potential, along with increased induction of apoptosis.TCM and Infectious DiseaseIn addition, the diterpenoid triepoxide triptolide was noted to be a promising combination partner.", [["TCM", "CHEMICAL", 179, 182], ["triepoxide", "CHEMICAL", 234, 244], ["triptolide", "CHEMICAL", 245, 255], ["diterpenoid", "CHEMICAL", 222, 233], ["triptolide", "CHEMICAL", 245, 255], ["diterpenoid triepoxide triptolide", "SIMPLE_CHEMICAL", 222, 255], ["dietary agents", "TREATMENT", 19, 33], ["apoptosis", "PROBLEM", 169, 178], ["the diterpenoid triepoxide triptolide", "TREATMENT", 218, 255], ["apoptosis", "OBSERVATION", 169, 178], ["Infectious", "OBSERVATION_MODIFIER", 187, 197]]], ["Triptolide has a long history in Traditional Chinese Medicine for the treatment of rheumatoid arthritis and cancer.", [["cancer", "ANATOMY", 108, 114], ["Triptolide", "CHEMICAL", 0, 10], ["rheumatoid arthritis", "DISEASE", 83, 103], ["cancer", "DISEASE", 108, 114], ["Triptolide", "CHEMICAL", 0, 10], ["Triptolide", "SIMPLE_CHEMICAL", 0, 10], ["cancer", "CANCER", 108, 114], ["Triptolide", "TREATMENT", 0, 10], ["Traditional Chinese Medicine", "TREATMENT", 33, 61], ["rheumatoid arthritis", "PROBLEM", 83, 103], ["cancer", "PROBLEM", 108, 114], ["rheumatoid", "OBSERVATION_MODIFIER", 83, 93], ["arthritis", "OBSERVATION", 94, 103], ["cancer", "OBSERVATION", 108, 114]]], ["It is an active compound of Lei Gong Teng (Tripterygium wilfordii), demonstrated in a prior study to effectively inhibit NF-\u03baB activity, epithelial-mesenchymal transition, and stemlike features in PDA cells (Li et al. 2014) .", [["epithelial", "ANATOMY", 137, 147], ["mesenchymal", "ANATOMY", 148, 159], ["PDA cells", "ANATOMY", 197, 206], ["Lei Gong Teng", "ORGANISM", 28, 41], ["Tripterygium wilfordii", "ORGANISM", 43, 65], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 121, 126], ["epithelial", "CELL", 137, 147], ["mesenchymal", "CELL", 148, 159], ["PDA cells", "CELL", 197, 206], ["NF-\u03baB", "PROTEIN", 121, 126], ["PDA cells", "CELL_LINE", 197, 206], ["Tripterygium wilfordii", "SPECIES", 43, 65], ["Tripterygium wilfordii", "SPECIES", 43, 65], ["Lei Gong Teng (Tripterygium wilfordii", "TREATMENT", 28, 65], ["a prior study", "TEST", 84, 97], ["NF", "TEST", 121, 123], ["epithelial-mesenchymal transition", "PROBLEM", 137, 170], ["stemlike features in PDA cells", "PROBLEM", 176, 206], ["active", "OBSERVATION_MODIFIER", 9, 15], ["compound", "OBSERVATION_MODIFIER", 16, 24], ["epithelial", "ANATOMY_MODIFIER", 137, 147], ["mesenchymal transition", "OBSERVATION", 148, 170], ["PDA cells", "OBSERVATION", 197, 206]]], ["Previous studies have shown chemopreventive nutritional polyphenols, and isothiocyanates may neutralize genetic defects by epigenetic regulation, the potential reason why these substances attenuate the processes of tumorigenesis, progression and metastasis, and sensitization for drug treatment.", [["metastasis", "DISEASE", 246, 256], ["polyphenols", "CHEMICAL", 56, 67], ["isothiocyanates", "CHEMICAL", 73, 88], ["polyphenols", "SIMPLE_CHEMICAL", 56, 67], ["isothiocyanates", "SIMPLE_CHEMICAL", 73, 88], ["Previous studies", "TEST", 0, 16], ["chemopreventive nutritional polyphenols", "TREATMENT", 28, 67], ["isothiocyanates", "TREATMENT", 73, 88], ["genetic defects", "PROBLEM", 104, 119], ["tumorigenesis", "PROBLEM", 215, 228], ["progression", "PROBLEM", 230, 241], ["metastasis", "PROBLEM", 246, 256], ["drug treatment", "TREATMENT", 280, 294], ["chemopreventive", "OBSERVATION_MODIFIER", 28, 43], ["nutritional polyphenols", "OBSERVATION", 44, 67], ["tumorigenesis", "OBSERVATION", 215, 228], ["progression", "OBSERVATION_MODIFIER", 230, 241], ["metastasis", "OBSERVATION", 246, 256]]], ["Future studies will need to address an \"epigenetic diet\" created for the presence of selected bioactive agents for prevention and treatment of cancer (Appari et al. 2014) .TCM and Infectious DiseaseThe previous illustrarion (Fig. 6 ) details many of the study's findings regarding the links with genetics, epigenetics, and tumorigenicity and how cancer stem cells are biologically affected by the compounds found in TCM herbal medicines and dietary considerations.TCM and Infectious DiseaseThe emerging sciences of nutrigenetics and nutrigenomics are embracing these concepts and developing strategies to educate healthcare professionals and patients as to the imperative of nutritional therapy in healthcare.", [["cancer", "ANATOMY", 143, 149], ["cancer stem cells", "ANATOMY", 346, 363], ["cancer", "DISEASE", 143, 149], ["Infectious Disease", "DISEASE", 180, 198], ["cancer", "DISEASE", 346, 352], ["TCM", "DISEASE", 464, 467], ["Infectious Disease", "DISEASE", 472, 490], ["cancer", "CANCER", 143, 149], ["cancer stem cells", "CELL", 346, 363], ["patients", "ORGANISM", 642, 650], ["cancer stem cells", "CELL_TYPE", 346, 363], ["patients", "SPECIES", 642, 650], ["Future studies", "TEST", 0, 14], ["an \"epigenetic diet", "TREATMENT", 36, 55], ["selected bioactive agents", "TREATMENT", 85, 110], ["cancer", "PROBLEM", 143, 149], ["the study", "TEST", 250, 259], ["tumorigenicity", "PROBLEM", 323, 337], ["how cancer stem cells", "PROBLEM", 342, 363], ["TCM herbal medicines", "TREATMENT", 416, 436], ["nutrigenetics", "TREATMENT", 515, 528], ["nutrigenomics", "TREATMENT", 533, 546], ["nutritional therapy", "TREATMENT", 675, 694], ["bioactive agents", "OBSERVATION", 94, 110], ["cancer", "OBSERVATION", 143, 149], ["Infectious", "OBSERVATION_MODIFIER", 180, 190], ["cancer stem cells", "OBSERVATION", 346, 363], ["Infectious", "OBSERVATION", 472, 482]]], ["The evidence contained in the study relating to the elimination of cancer stem cells by phytochemical influences should motivate advanced investigation for future cancer research and treatment protocols.Network Pharmacology and Systems Biology: The Next Generation of Herbal MedicineAligned with the meridian concepts of TCM, network pharmacology includes regulation of the signaling pathway with multiple channels, upgraded drug efficacy, and higher success rates for clinical trials, as well as reduced adverse reactions and decreased budgetary considerations of pharmaceutical research and development.", [["cancer stem cells", "ANATOMY", 67, 84], ["cancer", "ANATOMY", 163, 169], ["cancer", "DISEASE", 67, 73], ["cancer", "DISEASE", 163, 169], ["cancer stem cells", "CELL", 67, 84], ["cancer", "CANCER", 163, 169], ["cancer stem cells", "CELL_TYPE", 67, 84], ["the study", "TEST", 26, 35], ["cancer stem cells", "PROBLEM", 67, 84], ["advanced investigation", "TEST", 129, 151], ["future cancer research", "TREATMENT", 156, 178], ["treatment protocols", "TREATMENT", 183, 202], ["reduced adverse reactions", "PROBLEM", 497, 522], ["pharmaceutical research", "TREATMENT", 565, 588], ["cancer stem cells", "OBSERVATION", 67, 84]]], ["Network pharmacology also explores the parameters of how and where a singular target can inhibit or activate disease phenotypes.Network Pharmacology and Systems Biology: The Next Generation of Herbal MedicineThis vital information can assist in developing therapies that are less vulnerable to drug resistance.", [["activate disease phenotypes", "PROBLEM", 100, 127], ["Herbal Medicine", "TREATMENT", 193, 208]]], ["These mechanisms can be accomplished by a synergistic effect, much like the TCM principles and practices that embrace a multivariate, collaborative approach.", [["the TCM principles", "TREATMENT", 72, 90]]], ["Network pharmacology also offers molecular interaction validation technology as a viable tool which reveals drug activity mechanisms and verifies the predictability of a drug network.Network Pharmacology and Systems Biology: The Next Generation of Herbal MedicineOwing to its origins to bioscience research, systems biology is a recent trend, providing a more holistic view on the complexity of biological systems interactions.", [["drug activity mechanisms", "PROBLEM", 108, 132], ["Herbal", "TREATMENT", 248, 254]]], ["This is a more encompassing perspective than isolating and altering a singular molecular component.", [["a singular molecular component", "PROBLEM", 68, 98], ["singular", "OBSERVATION_MODIFIER", 70, 78], ["molecular", "OBSERVATION_MODIFIER", 79, 88], ["component", "OBSERVATION_MODIFIER", 89, 98]]], ["Network pharmacology, as a systems biology-based methodology, replaces the standard accepted drug design of a solo pharmaceutical by investigating multiple activities that drugs may exert collectively on biological networks.", [["a solo pharmaceutical", "TREATMENT", 108, 129]]], ["There is a search for combining therapeutic drug protocols that are emerging in network pharmacology.Network Pharmacology and Systems Biology: The Next Generation of Herbal MedicineIn allegiance with systems biology, network pharmacology is challenging the single-target drug research and development model in favor of a more comprehensive and collaborative approach.", [["network", "MULTI-TISSUE_STRUCTURE", 80, 87], ["combining therapeutic drug protocols", "TREATMENT", 22, 58]]], ["Over three decades of pharmaceutical development has produced hundreds of popularized and largely successful drugs.", [["hundreds", "OBSERVATION_MODIFIER", 62, 70]]], ["However, \"the single-symptom, single-disease, single-drug concept\" has not been as influential on certain degenerative diseases, including hypertension, depression, diabetes, inflammation, and cancer.", [["cancer", "ANATOMY", 193, 199], ["degenerative diseases", "DISEASE", 106, 127], ["hypertension", "DISEASE", 139, 151], ["depression", "DISEASE", 153, 163], ["diabetes", "DISEASE", 165, 173], ["inflammation", "DISEASE", 175, 187], ["cancer", "DISEASE", 193, 199], ["cancer", "CANCER", 193, 199], ["the single-symptom", "PROBLEM", 10, 28], ["single-disease", "PROBLEM", 30, 44], ["certain degenerative diseases", "PROBLEM", 98, 127], ["hypertension", "PROBLEM", 139, 151], ["depression", "PROBLEM", 153, 163], ["diabetes", "PROBLEM", 165, 173], ["inflammation", "PROBLEM", 175, 187], ["cancer", "PROBLEM", 193, 199], ["degenerative", "OBSERVATION_MODIFIER", 106, 118], ["diseases", "OBSERVATION", 119, 127], ["hypertension", "OBSERVATION", 139, 151], ["diabetes", "OBSERVATION", 165, 173], ["inflammation", "OBSERVATION", 175, 187], ["cancer", "OBSERVATION", 193, 199]]], ["While they may have marginal success in management, all too often, singular drug therapies are inadequate, and multiple drugs or increased dosages are recommended, causing an increase in adverse reactions and heightened toxicity, without achieving the needed metabolic therapeutic result (Kola and Landis 2004) .", [["toxicity", "DISEASE", 220, 228], ["singular drug therapies", "TREATMENT", 67, 90], ["multiple drugs", "TREATMENT", 111, 125], ["increased dosages", "TREATMENT", 129, 146], ["adverse reactions", "PROBLEM", 187, 204], ["heightened toxicity", "PROBLEM", 209, 228], ["marginal", "OBSERVATION_MODIFIER", 20, 28], ["success", "OBSERVATION", 29, 36], ["increase", "OBSERVATION_MODIFIER", 175, 183]]], ["Subsequent to these pharmaceutical pitfalls, the shift is toward a \"network-target, multiple-component-therapeutics\" mode (Li et al. , 2014 .Network Pharmacology and Systems Biology: The Next Generation of Herbal MedicineTCM exemplifies the natural order when approaching treatment protocols.", [["Herbal MedicineTCM", "TREATMENT", 206, 224], ["approaching treatment protocols", "TREATMENT", 260, 291]]], ["Restoring balance is paramount, and reflecting the body's natural ability to heal is considered most valuable when choosing combinative herbal prescriptions.", [["body", "ANATOMY", 51, 55], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["combinative herbal prescriptions", "TREATMENT", 124, 156]]], ["Network pharmacology is adopting some of these ancient concepts by utilizing TCM's wider lens on multiple action and reaction formulations and integrating the information of disease phenotypes, genetic influences, and biological molecules in a more integrated research model ).TCM and Clinical Pharmacology In SilicoOne of the frontline advantages of network pharmacology and systems biology is the intimate partnership with bioscience informatics and multiple exhaustive global databases being constructed.", [["TCM's wider lens", "TREATMENT", 77, 93], ["multiple action", "TREATMENT", 97, 112], ["reaction formulations", "TREATMENT", 117, 138], ["disease phenotypes", "PROBLEM", 174, 192]]], ["A number of databases have emerged over the past decade, which bring TCM herbal medicine and network pharmacology to the same dialogue through informatics, algorithms, data mining, and extensively designed digital platforms.", [["TCM herbal medicine", "TREATMENT", 69, 88]]], ["As an example, TCM-Mesh highlights TCM network pharmacology through cataloguing diseases, herbs, compounds, genes, proteins, and drugs into a comprehensive and cross-referenced biological digital data vault (Zhang et al. 2019 This provides 527 anticancer herb prescriptions, 937 components, and 9366 smallmolecule structures for the clinical treatment of different types of cancer, combined with a reference database and a molecular target aided database.", [["anticancer", "ANATOMY", 244, 254], ["cancer", "ANATOMY", 374, 380], ["cancer", "DISEASE", 374, 380], ["TCM network", "MULTI-TISSUE_STRUCTURE", 35, 46], ["anticancer", "CANCER", 244, 254], ["cancer", "CANCER", 374, 380], ["Mesh", "TREATMENT", 19, 23], ["cataloguing diseases", "PROBLEM", 68, 88], ["herbs", "TREATMENT", 90, 95], ["drugs", "TREATMENT", 129, 134], ["cancer", "PROBLEM", 374, 380], ["Mesh", "OBSERVATION", 19, 23], ["cancer", "OBSERVATION", 374, 380]]], ["CNPD (Chinese Natural Products Database), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China.", [["CNPD", "CHEMICAL", 0, 4]]], ["The CNPD database currently collects more than 57,000 natural products from 37 categories, of which 70% of the molecules are drug-like molecules.", [["drug-like molecules", "PROTEIN", 125, 144], ["The CNPD database", "TEST", 0, 17], ["drug-like molecules", "PROBLEM", 125, 144]]], ["The relevant data include the CAS number, name, molecular formula, molecular weight, melting point, and other physical and chemical properties of natural products.", [["natural products", "OBSERVATION", 146, 162]]], ["MAS3.0, CapitalBio, China.", [["China", "ANATOMY", 20, 25]]], ["MAS (molecule annotation system) is a whole data mining and function annotation solution to extract and analyze biological molecule relationships from public knowledge base of biological molecules and signification.", [["MAS (molecule annotation system", "PROBLEM", 0, 31], ["function annotation solution", "TREATMENT", 60, 88], ["biological molecules", "OBSERVATION", 176, 196]]], ["MAS analysis platform is a web client program for interactive navigation.", [["MAS analysis", "TEST", 0, 12], ["interactive navigation", "TREATMENT", 50, 72]]], ["MAS uses relational databases of biological networks created from millions of individually modeled relationships between genes, proteins, diseases, and tissues.", [["tissues", "ANATOMY", 152, 159], ["tissues", "TISSUE", 152, 159], ["diseases, and tissues", "PROBLEM", 138, 159], ["diseases", "OBSERVATION", 138, 146], ["tissues", "ANATOMY", 152, 159]]], ["PharmMapper Server is a freely accessed web server designed to identify potential target candidates for the given probe small molecules, drugs, natural products, or other newly discovered compounds with binding targets unidentified using pharmacophore mapping approach (Liu XF et al. 2010 ).Nobel Prize Honors TCMQinghao (Herba Artemisiae Annuae), a TCM herb, provided the basis for an anti-malaria formula, since the protozoan had become resistant to quinine, an older medication used for treating the pathogen.", [["quinine", "CHEMICAL", 452, 459], ["quinine", "CHEMICAL", 452, 459], ["quinine", "SIMPLE_CHEMICAL", 452, 459], ["probe small molecules", "TREATMENT", 114, 135], ["drugs", "TREATMENT", 137, 142], ["natural products", "TREATMENT", 144, 160], ["pharmacophore mapping approach", "TREATMENT", 238, 268], ["a TCM herb", "TREATMENT", 348, 358], ["an anti-malaria formula", "TREATMENT", 383, 406], ["the protozoan", "PROBLEM", 414, 427], ["quinine", "TREATMENT", 452, 459], ["an older medication", "TREATMENT", 461, 480], ["the pathogen", "PROBLEM", 499, 511]]], ["In 1972, after screening over 2000 different Chinese herbs, phytochemist and researcher Youyou Tu and a cohort of scientists uncovered the exact formulation of artemisinin (qinghaosu \u9752\u84bf\u7d20) and dihydroartemisinin from Qinghao.Nobel Prize Honors TCMA graduate of the Department of Pharmaceutics at Beijing Medical College, Tu was chosen to join the China Academy of Chinese Medical Sciences and currently holds the highest ranking post of Chief Scientist in the Academy.", [["artemisinin", "CHEMICAL", 160, 171], ["qinghaosu \u9752\u84bf\u7d20", "CHEMICAL", 173, 186], ["dihydroartemisinin", "CHEMICAL", 192, 210], ["artemisinin", "CHEMICAL", 160, 171], ["dihydroartemisinin", "CHEMICAL", 192, 210], ["artemisinin", "SIMPLE_CHEMICAL", 160, 171], ["qinghaosu \u9752\u84bf\u7d20", "SIMPLE_CHEMICAL", 173, 186], ["dihydroartemisinin", "SIMPLE_CHEMICAL", 192, 210], ["artemisinin (qinghaosu \u9752\u84bf\u7d20", "TREATMENT", 160, 186], ["dihydroartemisinin", "TREATMENT", 192, 210]]], ["According to Professor Tu, malaria was one of the epidemic diseases with the most comprehensive records in TCM literature.", [["malaria", "DISEASE", 27, 34], ["malaria", "PROBLEM", 27, 34], ["the epidemic diseases", "PROBLEM", 46, 67], ["malaria", "OBSERVATION", 27, 34]]], ["She found a landmark quote for alleviating malaria fevers that motivated the research: \"A handful of Qinghao immersed in two liters of water, wring out the juice and drink it all\" (\u9752\u84bf \u4e00\u63e1, \u4ee5\u6c34\u4e8c\u5347\u6e0d, \u7ede\u53d6\u6c41, \u5c3d\u670d\u4e4b).", [["juice", "ANATOMY", 156, 161], ["malaria fevers", "DISEASE", 43, 57], ["Qinghao", "CHEMICAL", 101, 108], ["juice", "ORGANISM_SUBSTANCE", 156, 161], ["alleviating malaria fevers", "PROBLEM", 31, 57]]], ["Tu experimented with lower heat during extraction using water, ethanol, and ether ester to arrive at dihydroartemisinin, which proved to be a clinically effective compound in curing malaria.Nobel Prize Honors TCMDue to the relentless efforts of Tu and her research team over several decades, more than 200 million malaria patients have received artemisinin or artemisinin combination therapies.Nobel Prize Honors TCMIn 2015, Youyou Tu was awarded the Nobel Prize in Medicine with William C. Campbell and Satoshi \u014cmura; this was the first time a Chinese scientist had won the coveted award.Nobel Prize Honors TCMPerspective TCM originated at a time when there were no sophisticated instruments as there are today in medicine and science.", [["ethanol, and ether ester", "CHEMICAL", 63, 87], ["dihydroartemisinin", "CHEMICAL", 101, 119], ["malaria", "DISEASE", 182, 189], ["malaria", "DISEASE", 314, 321], ["artemisinin", "CHEMICAL", 345, 356], ["artemisinin", "CHEMICAL", 360, 371], ["ethanol", "CHEMICAL", 63, 70], ["ether ester", "CHEMICAL", 76, 87], ["dihydroartemisinin", "CHEMICAL", 101, 119], ["artemisinin", "CHEMICAL", 345, 356], ["artemisinin", "CHEMICAL", 360, 371], ["water", "SIMPLE_CHEMICAL", 56, 61], ["ethanol", "SIMPLE_CHEMICAL", 63, 70], ["ether ester", "SIMPLE_CHEMICAL", 76, 87], ["dihydroartemisinin", "SIMPLE_CHEMICAL", 101, 119], ["patients", "ORGANISM", 322, 330], ["artemisinin", "SIMPLE_CHEMICAL", 345, 356], ["artemisinin", "SIMPLE_CHEMICAL", 360, 371], ["patients", "SPECIES", 322, 330], ["lower heat during extraction", "TREATMENT", 21, 49], ["dihydroartemisinin", "TREATMENT", 101, 119], ["malaria", "PROBLEM", 182, 189], ["artemisinin", "TREATMENT", 345, 356], ["artemisinin combination therapies", "TREATMENT", 360, 393], ["lower heat", "OBSERVATION_MODIFIER", 21, 31]]], ["Regardless, TCM evolved as a highly advanced system able to identify energetic patterns within the human body aligned with the energetic properties of nature.Nobel Prize Honors TCMA striking relationship between TCM and clinical pharmacology has been established through numerous international databases linking a myriad of herbal, phytochemical, molecular, cellular, genetic, and chemical components into a warehouse of possibilities for advanced pharmaceutical and nutraceutical development.", [["body", "ANATOMY", 105, 109], ["cellular", "ANATOMY", 358, 366], ["human", "ORGANISM", 99, 104], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["cellular", "CELL", 358, 366], ["TCM", "CELL_TYPE", 12, 15], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["advanced pharmaceutical", "TREATMENT", 439, 462], ["human body", "ANATOMY_MODIFIER", 99, 109], ["energetic properties", "OBSERVATION", 127, 147]]], ["A clear distinction remains, however, in the cultural identity of patents and intellectual property ownership of western pharmaceutical enterprises and the eastern mentality of a shared natural resource.", [["clear", "OBSERVATION", 2, 7]]], ["TCM has never claimed nature as its private domain and is eager to share the stage with its global counterparts for the betterment of healthcare for humanity.Nobel Prize Honors TCMA global spotlight has been placed on TCM with the 2019 adoption of the ICD-11 and the endorsement of TCM as a global healthcare option.", [["TCM", "CHEMICAL", 0, 3], ["the ICD", "TREATMENT", 248, 255], ["a global healthcare option", "TREATMENT", 289, 315], ["ICD", "OBSERVATION", 252, 255]]], ["TCM practitioners, like western medical practitioners are concerned about evidence-based knowledge and quality standardization of herbal medicines.", [["herbal medicines", "TREATMENT", 130, 146]]], ["TCM is the focus of increasing research at prestigious medical and scientific institutes, and the results are statistically remarkable.Nobel Prize Honors TCMFrom reviewing the PubMed Central (PMC) (National Library of Medicine and the National Institutes of Health), as of March 2020, 20,600+ studies were noted on TCM, 32,000+ on acupuncture, and 30,900+ on Chinese herbal medicine published in peer-reviewed journals throughout the world.Nobel Prize Honors TCMThis chapter has presented TCM with evidence-based research in relation to clinical pharmacology, including addressing viable treatment options for epidemic levels of cancer and infectious disease such as SARS and COVID-19.", [["cancer", "ANATOMY", 629, 635], ["cancer", "DISEASE", 629, 635], ["infectious disease", "DISEASE", 640, 658], ["SARS", "DISEASE", 667, 671], ["cancer", "CANCER", 629, 635], ["TCM", "TEST", 315, 318], ["acupuncture", "TEST", 331, 342], ["Chinese herbal medicine", "TREATMENT", 359, 382], ["viable treatment options", "TREATMENT", 581, 605], ["epidemic levels of cancer", "PROBLEM", 610, 635], ["infectious disease", "PROBLEM", 640, 658], ["SARS", "PROBLEM", 667, 671], ["COVID", "TEST", 676, 681], ["focus", "OBSERVATION_MODIFIER", 11, 16], ["increasing", "OBSERVATION_MODIFIER", 20, 30], ["cancer", "OBSERVATION", 629, 635]]], ["Equally important is TCM's unique ability to offer new ways of combating the rapidly progressing culture of drug-resistant bacteria and viruses, which is a result of rampant abuse of antibiotics over recent decades.", [["drug-resistant bacteria", "PROBLEM", 108, 131], ["viruses", "PROBLEM", 136, 143], ["antibiotics", "TREATMENT", 183, 194], ["viruses", "OBSERVATION", 136, 143]]], ["It also provides ways to strengthen the body and increase innate immunity with TCM diet and nutrition, acupuncture, acupressure, Chinese herbal medicine, lifestyle changes and Qigong/Taichi exercises, which is ultimately the best prophylactic medicine to prevent diseases and infections.Nobel Prize Honors TCMBoth TCM and clinical pharmacology are now at a vital crossroad with international medical and scientific proposals on herbal production and standardization, as well as advances in network pharmacology, phytopharmacology, systems biology, data mining, and informatics, among others.", [["body", "ANATOMY", 40, 44], ["infections", "DISEASE", 276, 286], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["TCM diet", "TREATMENT", 79, 87], ["nutrition", "TREATMENT", 92, 101], ["acupuncture", "TREATMENT", 103, 114], ["acupressure", "TREATMENT", 116, 127], ["Chinese herbal medicine", "TREATMENT", 129, 152], ["lifestyle changes", "TREATMENT", 154, 171], ["Qigong/Taichi exercises", "TREATMENT", 176, 199], ["the best prophylactic medicine", "TREATMENT", 221, 251], ["diseases", "PROBLEM", 263, 271], ["infections", "PROBLEM", 276, 286], ["herbal production", "TREATMENT", 428, 445], ["infections", "OBSERVATION", 276, 286]]], ["By joining forces, TCM and clinical pharmacology can accomplish together more than either can do on their own, providing preventive and holistic approaches with the goal of giving the best health care possible to people around the world.", [["people", "ORGANISM", 213, 219], ["people", "SPECIES", 213, 219]]]], "PMC6034247": [["BackgroundAcute respiratory infections (ARIs) remain one of the most common major public health threats [1].", [["respiratory", "ANATOMY", 16, 27], ["BackgroundAcute respiratory infections", "DISEASE", 0, 38], ["ARIs", "DISEASE", 40, 44], ["BackgroundAcute respiratory infections (ARIs)", "PROBLEM", 0, 45], ["respiratory", "ANATOMY", 16, 27], ["infections", "OBSERVATION", 28, 38]]], ["There were approximate 11.9 million episodes of severe acute lower respiratory infections (ALRI) resulted in hospital admissions in young children worldwide [2], and ARIs-related pneumonia was one of the leading cause of death that due to infectious disease in China (> 30,000 deaths annually) as well as globally (935,000 in 2013) [3, 4].", [["respiratory", "ANATOMY", 67, 78], ["acute lower respiratory infections", "DISEASE", 55, 89], ["ALRI", "DISEASE", 91, 95], ["ARIs", "DISEASE", 166, 170], ["pneumonia", "DISEASE", 179, 188], ["death", "DISEASE", 221, 226], ["infectious disease", "DISEASE", 239, 257], ["deaths", "DISEASE", 277, 283], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146], ["severe acute lower respiratory infections", "PROBLEM", 48, 89], ["ARIs", "PROBLEM", 166, 170], ["pneumonia", "PROBLEM", 179, 188], ["death", "PROBLEM", 221, 226], ["infectious disease in China", "PROBLEM", 239, 266], ["11.9 million", "OBSERVATION_MODIFIER", 23, 35], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["lower", "ANATOMY_MODIFIER", 61, 66], ["respiratory", "ANATOMY", 67, 78], ["infections", "OBSERVATION", 79, 89], ["pneumonia", "OBSERVATION", 179, 188], ["infectious", "OBSERVATION", 239, 249]]], ["There were, as have been suggested, associations of several viral agents with ARIs, such as: respiratory syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus (HMPV), influenza virus (IFV), parainfluenza virus (PIV), adenovirus (ADV) and human bocavirus (BoV), accounting for about 35\u201387% of children with ARI [5].", [["ARIs", "DISEASE", 78, 82], ["respiratory syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus (HMPV), influenza virus (IFV), parainfluenza virus (PIV), adenovirus (ADV) and human bocavirus", "DISEASE", 93, 268], ["ARI", "DISEASE", 321, 324], ["respiratory syncytial virus", "ORGANISM", 93, 120], ["RSV", "ORGANISM", 122, 125], ["human rhinovirus", "ORGANISM", 128, 144], ["human metapneumovirus", "ORGANISM", 152, 173], ["HMPV", "ORGANISM", 175, 179], ["influenza virus", "ORGANISM", 182, 197], ["IFV", "GENE_OR_GENE_PRODUCT", 199, 202], ["parainfluenza virus", "ORGANISM", 205, 224], ["adenovirus", "ORGANISM", 232, 242], ["ADV", "ORGANISM", 244, 247], ["human", "ORGANISM", 253, 258], ["bocavirus", "ORGANISM", 259, 268], ["BoV", "CANCER", 270, 273], ["children", "ORGANISM", 307, 315], ["respiratory syncytial virus", "SPECIES", 93, 120], ["human", "SPECIES", 128, 133], ["rhinovirus", "SPECIES", 134, 144], ["human", "SPECIES", 152, 157], ["metapneumovirus", "SPECIES", 158, 173], ["influenza virus", "SPECIES", 182, 197], ["parainfluenza virus", "SPECIES", 205, 224], ["human", "SPECIES", 253, 258], ["children", "SPECIES", 307, 315], ["respiratory syncytial virus", "SPECIES", 93, 120], ["RSV", "SPECIES", 122, 125], ["human rhinovirus", "SPECIES", 128, 144], ["HRV", "SPECIES", 146, 149], ["human metapneumovirus", "SPECIES", 152, 173], ["HMPV", "SPECIES", 175, 179], ["IFV", "SPECIES", 199, 202], ["parainfluenza virus", "SPECIES", 205, 224], ["PIV", "SPECIES", 226, 229], ["adenovirus", "SPECIES", 232, 242], ["ADV", "SPECIES", 244, 247], ["human", "SPECIES", 253, 258], ["BoV", "SPECIES", 270, 273], ["several viral agents", "TREATMENT", 52, 72], ["ARIs", "PROBLEM", 78, 82], ["respiratory syncytial virus", "PROBLEM", 93, 120], ["human rhinovirus (HRV)", "PROBLEM", 128, 150], ["human metapneumovirus (HMPV)", "PROBLEM", 152, 180], ["influenza virus (IFV)", "PROBLEM", 182, 203], ["parainfluenza virus (PIV)", "TREATMENT", 205, 230], ["adenovirus (ADV)", "TREATMENT", 232, 248], ["ARI", "PROBLEM", 321, 324], ["respiratory syncytial", "ANATOMY", 93, 114], ["metapneumovirus", "ANATOMY", 158, 173], ["parainfluenza virus", "OBSERVATION", 205, 224]]], ["Viral co-infections occurred in 4\u201333% of children hospitalized with ARIs, and may indicate an increasing risk for clinical outcome [6, 7].", [["Viral co-infections", "DISEASE", 0, 19], ["ARIs", "DISEASE", 68, 72], ["Viral", "ORGANISM", 0, 5], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["Viral co-infections", "PROBLEM", 0, 19], ["ARIs", "PROBLEM", 68, 72], ["co-infections", "OBSERVATION", 6, 19]]], ["Further, bacterial infections such as: Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae, et al., were commonly observed in the later stage of diseases due to immune-compromised viral infections [8].BackgroundSimilarities among ARI symptoms hampers the diagnostic and therapeutic efficacy among infected children, and inappropriate medication options may lead to the potential of viral escape mutants or bacterial resistance [8].", [["bacterial infections", "DISEASE", 9, 29], ["Streptococcus pneumoniae", "DISEASE", 39, 63], ["Haemophilus influenzae", "DISEASE", 65, 87], ["Staphylococcus aureus", "DISEASE", 89, 110], ["Klebsiella pneumoniae", "DISEASE", 139, 160], ["viral infections", "DISEASE", 250, 266], ["ARI", "DISEASE", 300, 303], ["Streptococcus pneumoniae", "ORGANISM", 39, 63], ["Haemophilus influenzae", "ORGANISM", 65, 87], ["Staphylococcus aureus", "ORGANISM", 89, 110], ["Pseudomonas aeruginosa", "ORGANISM", 112, 134], ["Klebsiella pneumoniae", "ORGANISM", 139, 160], ["children", "ORGANISM", 376, 384], ["Streptococcus pneumoniae", "SPECIES", 39, 63], ["Haemophilus influenzae", "SPECIES", 65, 87], ["Staphylococcus aureus", "SPECIES", 89, 110], ["Pseudomonas aeruginosa", "SPECIES", 112, 134], ["Klebsiella pneumoniae", "SPECIES", 139, 160], ["children", "SPECIES", 376, 384], ["Streptococcus pneumoniae", "SPECIES", 39, 63], ["Haemophilus influenzae", "SPECIES", 65, 87], ["Staphylococcus aureus", "SPECIES", 89, 110], ["Pseudomonas aeruginosa", "SPECIES", 112, 134], ["Klebsiella pneumoniae", "SPECIES", 139, 160], ["bacterial infections", "PROBLEM", 9, 29], ["Streptococcus pneumoniae", "PROBLEM", 39, 63], ["Haemophilus influenzae", "PROBLEM", 65, 87], ["Staphylococcus aureus", "PROBLEM", 89, 110], ["Pseudomonas aeruginosa", "PROBLEM", 112, 134], ["Klebsiella pneumoniae", "PROBLEM", 139, 160], ["diseases", "PROBLEM", 215, 223], ["immune-compromised viral infections", "PROBLEM", 231, 266], ["ARI symptoms", "PROBLEM", 300, 312], ["inappropriate medication options", "TREATMENT", 390, 422], ["viral escape mutants", "PROBLEM", 452, 472], ["bacterial resistance", "PROBLEM", 476, 496], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["Streptococcus pneumoniae", "OBSERVATION", 39, 63], ["Klebsiella pneumoniae", "OBSERVATION", 139, 160], ["diseases", "OBSERVATION", 215, 223], ["viral infections", "OBSERVATION", 250, 266], ["bacterial resistance", "OBSERVATION", 476, 496]]], ["The composition of ARIs is geographically diverse and is largely associated with the epidemic status of each ARIs and climate conditions [9, 10].", [["ARIs", "GENE_OR_GENE_PRODUCT", 19, 23], ["ARIs", "PROBLEM", 19, 23], ["each ARIs", "PROBLEM", 104, 113], ["ARIs", "OBSERVATION_MODIFIER", 19, 23], ["geographically", "OBSERVATION_MODIFIER", 27, 41], ["diverse", "OBSERVATION_MODIFIER", 42, 49]]], ["The prevalence of ARIs varies from 14.6 to 94.3% among hospitalized children with respiratory infections in some metropolitan cities such as Beijing, Shanghai and Shenzhen in China [11\u201314].", [["respiratory", "ANATOMY", 82, 93], ["ARIs", "DISEASE", 18, 22], ["respiratory infections", "DISEASE", 82, 104], ["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["ARIs", "PROBLEM", 18, 22], ["respiratory infections", "PROBLEM", 82, 104], ["respiratory", "ANATOMY", 82, 93], ["infections", "OBSERVATION", 94, 104]]], ["However, in the underdeveloped interior areas of China, epidemiology profiles of ARIs are seldom reported.", [["ARIs", "DISEASE", 81, 85], ["ARIs", "PROBLEM", 81, 85], ["underdeveloped", "OBSERVATION_MODIFIER", 16, 30], ["interior", "OBSERVATION_MODIFIER", 31, 39], ["areas", "OBSERVATION_MODIFIER", 40, 45], ["China", "ANATOMY", 49, 54]]], ["Chengdu is a mega-city in the southwest of China and has a population of more than 15 million people.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["Flu vaccination rates were pretty low in this area, which were 2.18, 1.69, 1.82 and 1.63% respectively from 2010 to 2013 [15].", [["Flu", "CHEMICAL", 0, 3], ["Flu vaccination rates", "TEST", 0, 21]]], ["The purpose of the current study is to investigate the profiles of respiratory pathogens and epidemiology characteristics of ARIs in hospitalized children in Chengdu.", [["respiratory", "ANATOMY", 67, 78], ["respiratory pathogens", "DISEASE", 67, 88], ["ARIs", "DISEASE", 125, 129], ["children", "ORGANISM", 146, 154], ["children", "SPECIES", 146, 154], ["the current study", "TEST", 15, 32], ["respiratory pathogens", "PROBLEM", 67, 88], ["respiratory pathogens", "OBSERVATION", 67, 88]]], ["The results were expected to help improve diagnosis and optimization of therapeutic regimens of ARIs in this area.Study design and patient population ::: MethodsThe cross-sectional study was conducted monthly at a sentinel tertiary women\u2019s and children\u2019s hospitals in Chengdu, West China, from September 2009 to February 2014.", [["ARIs", "DISEASE", 96, 100], ["patient", "ORGANISM", 131, 138], ["women", "ORGANISM", 232, 237], ["children", "ORGANISM", 244, 252], ["patient", "SPECIES", 131, 138], ["women", "SPECIES", 232, 237], ["children", "SPECIES", 244, 252], ["therapeutic regimens", "TREATMENT", 72, 92], ["ARIs in this area", "PROBLEM", 96, 113], ["Methods", "TREATMENT", 154, 161], ["The cross-sectional study", "TEST", 161, 186]]], ["A total of 1992 hospitalized children younger than 6 years old that presented symptoms of ARIs were recruited.", [["ARIs", "DISEASE", 90, 94], ["children", "ORGANISM", 29, 37], ["children", "SPECIES", 29, 37], ["ARIs", "PROBLEM", 90, 94]]], ["Inclusion criteria for cases were (i) acute infection, for example fever, WBC anomaly, shivering; (ii) respiratory symptoms such as cough, rhinorrhea, pharyngalgia, expectoration, nose/throat congestion, shortness of breath, abnormal breathing sounds or dyspnea.", [["respiratory", "ANATOMY", 103, 114], ["nose", "ANATOMY", 180, 184], ["throat", "ANATOMY", 185, 191], ["infection", "DISEASE", 44, 53], ["fever", "DISEASE", 67, 72], ["WBC anomaly", "DISEASE", 74, 85], ["shivering", "DISEASE", 87, 96], ["cough", "DISEASE", 132, 137], ["rhinorrhea", "DISEASE", 139, 149], ["pharyngalgia", "DISEASE", 151, 163], ["expectoration", "DISEASE", 165, 178], ["congestion", "DISEASE", 192, 202], ["shortness of breath", "DISEASE", 204, 223], ["abnormal breathing sounds", "DISEASE", 225, 250], ["dyspnea", "DISEASE", 254, 261], ["nose", "ORGANISM_SUBDIVISION", 180, 184], ["throat", "ORGANISM_SUBDIVISION", 185, 191], ["acute infection", "PROBLEM", 38, 53], ["fever", "PROBLEM", 67, 72], ["WBC anomaly", "PROBLEM", 74, 85], ["shivering", "PROBLEM", 87, 96], ["ii) respiratory symptoms", "PROBLEM", 99, 123], ["cough", "PROBLEM", 132, 137], ["rhinorrhea", "PROBLEM", 139, 149], ["pharyngalgia", "PROBLEM", 151, 163], ["expectoration", "PROBLEM", 165, 178], ["nose/throat congestion", "PROBLEM", 180, 202], ["shortness of breath", "PROBLEM", 204, 223], ["abnormal breathing sounds", "PROBLEM", 225, 250], ["dyspnea", "PROBLEM", 254, 261], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53], ["nose", "ANATOMY", 180, 184], ["throat", "ANATOMY", 185, 191], ["congestion", "OBSERVATION", 192, 202]]], ["The study protocol was approved by the Medical Ethics Committee of Sichuan University and written informed consents were obtained from the parents or the caregiver before collecting samples.Study design and patient population ::: MethodsSamples including nasopharyngeal aspirates, sputum, throat swabs, blood and bronchoalevlar lavage fluid were collected by qualified medical personnel.", [["samples", "ANATOMY", 182, 189], ["nasopharyngeal aspirates", "ANATOMY", 255, 279], ["sputum", "ANATOMY", 281, 287], ["throat swabs", "ANATOMY", 289, 301], ["blood", "ANATOMY", 303, 308], ["bronchoalevlar lavage fluid", "ANATOMY", 313, 340], ["patient", "ORGANISM", 207, 214], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 255, 279], ["sputum", "ORGANISM_SUBSTANCE", 281, 287], ["throat swabs", "ORGANISM_SUBSTANCE", 289, 301], ["blood", "ORGANISM_SUBSTANCE", 303, 308], ["bronchoalevlar lavage fluid", "ORGANISM_SUBSTANCE", 313, 340], ["patient", "SPECIES", 207, 214], ["The study protocol", "TEST", 0, 18], ["collecting samples", "TEST", 171, 189], ["MethodsSamples", "TEST", 230, 244], ["nasopharyngeal aspirates", "TEST", 255, 279], ["sputum", "TEST", 281, 287], ["throat swabs", "TEST", 289, 301], ["blood and bronchoalevlar lavage fluid", "TEST", 303, 340], ["nasopharyngeal", "ANATOMY", 255, 269], ["aspirates", "OBSERVATION", 270, 279], ["throat", "ANATOMY", 289, 295]]], ["The demographic information and medical records of the participated patients were also collected.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["All samples were delivered to the Microbiology Laboratory of Department of Public Health Laboratory Sciences, Sichuan University immediately after collection samples via cold chain transportation and stored at \u2212 80 \u00b0C.Pathogen analysis ::: MethodsNasopharyngeal aspirates, sputum, throat swabs and bronchoalevlar lavage fluid were used for respiratory virus analyses.", [["samples", "ANATOMY", 4, 11], ["Nasopharyngeal aspirates", "ANATOMY", 247, 271], ["sputum", "ANATOMY", 273, 279], ["throat swabs", "ANATOMY", 281, 293], ["bronchoalevlar lavage fluid", "ANATOMY", 298, 325], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 247, 271], ["sputum", "ORGANISM_SUBSTANCE", 273, 279], ["throat swabs", "ORGANISM_SUBSTANCE", 281, 293], ["bronchoalevlar lavage fluid", "ORGANISM_SUBSTANCE", 298, 325], ["collection samples", "TEST", 147, 165], ["cold chain transportation", "TEST", 170, 195], ["MethodsNasopharyngeal aspirates", "TEST", 240, 271], ["sputum, throat swabs", "TEST", 273, 293], ["bronchoalevlar lavage fluid", "TREATMENT", 298, 325], ["respiratory virus analyses", "TEST", 340, 366], ["Nasopharyngeal", "ANATOMY", 247, 261], ["aspirates", "OBSERVATION", 262, 271], ["throat", "ANATOMY", 281, 287]]], ["Viral RNA and DNA were extracted by Viral Nucleic Acid Extraction Kit (Geneaid, Taiwan District) according to the manufacturer\u2019s instructions. cDNA were synthesized with reverse transcription kit (BIO-RAD, California, US).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["Viral RNA", "RNA", 0, 9], ["cDNA", "DNA", 143, 147], ["Viral RNA and DNA", "PROBLEM", 0, 17], ["Viral Nucleic Acid Extraction", "TREATMENT", 36, 65]]], ["Primers and multiplex PCR conditions for IFV [16], RSV [16], PIV [17], ADV [18], HMPV [13], human coronavirus (HCoV) [19], HBoV [20] and HRV [17] have been described previously.", [["RSV", "ORGANISM", 51, 54], ["PIV [17", "ORGANISM", 61, 68], ["ADV [18", "ORGANISM", 71, 78], ["HMPV [13", "ORGANISM", 81, 89], ["human coronavirus", "ORGANISM", 92, 109], ["HCoV", "ORGANISM", 111, 115], ["HBoV", "ORGANISM", 123, 127], ["human", "SPECIES", 92, 97], ["coronavirus", "SPECIES", 98, 109], ["IFV", "SPECIES", 41, 44], ["RSV", "SPECIES", 51, 54], ["ADV", "SPECIES", 71, 74], ["HMPV", "SPECIES", 81, 85], ["human coronavirus", "SPECIES", 92, 109], ["HCoV", "SPECIES", 111, 115], ["Primers", "TEST", 0, 7], ["multiplex PCR conditions", "TEST", 12, 36], ["IFV", "TEST", 41, 44], ["RSV", "TEST", 51, 54], ["PIV", "TEST", 61, 64], ["ADV", "TEST", 71, 74], ["HMPV", "TEST", 81, 85], ["human coronavirus (HCoV", "TEST", 92, 115], ["HBoV", "TEST", 123, 127], ["HRV", "TEST", 137, 140]]], ["Primers were synthesized by Life Technology Corp. (Shanghai, China) and PCRs were performed using PCR Mastermix (Tiangen Company, China) and the S1000\u2122 Thermal Cycler (BIO-RAD, California, US).", [["S1000", "DNA", 145, 150], ["PCRs", "TEST", 72, 76], ["Thermal Cycler", "TEST", 152, 166]]], ["Respiratory viruses were initially identified by the size of PCR products following agarose gel electrophoresis, with confirmation by DNA sequencing (Life Technology Corp., Shanghai, China).Pathogen analysis ::: MethodsNasopharyngeal aspirates, sputum, blood and bronchoalevlar lavage fluid were used for bacterial analyses.", [["Nasopharyngeal aspirates", "ANATOMY", 219, 243], ["sputum", "ANATOMY", 245, 251], ["blood", "ANATOMY", 253, 258], ["bronchoalevlar lavage fluid", "ANATOMY", 263, 290], ["agarose", "SIMPLE_CHEMICAL", 84, 91], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 219, 243], ["sputum", "ORGANISM_SUBSTANCE", 245, 251], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["bronchoalevlar lavage fluid", "ORGANISM_SUBSTANCE", 263, 290], ["Respiratory viruses", "PROBLEM", 0, 19], ["PCR products", "TREATMENT", 61, 73], ["agarose gel electrophoresis", "TEST", 84, 111], ["MethodsNasopharyngeal aspirates", "TEST", 212, 243], ["sputum", "TEST", 245, 251], ["blood and bronchoalevlar lavage fluid", "TEST", 253, 290], ["bacterial analyses", "TEST", 305, 323], ["viruses", "OBSERVATION", 12, 19], ["size", "OBSERVATION_MODIFIER", 53, 57], ["Nasopharyngeal", "ANATOMY", 219, 233], ["aspirates", "OBSERVATION", 234, 243]]], ["For isolation of bacteria, specimens were cultured on sheep blood agar, chocolate agar and MacConkey\u2019s agar plates.", [["specimens", "ANATOMY", 27, 36], ["blood", "ANATOMY", 60, 65], ["specimens", "CELL", 27, 36], ["sheep", "ORGANISM", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["sheep", "SPECIES", 54, 59], ["sheep", "SPECIES", 54, 59], ["bacteria", "PROBLEM", 17, 25], ["specimens", "TEST", 27, 36], ["blood agar", "TEST", 60, 70], ["chocolate agar", "TEST", 72, 86], ["bacteria", "OBSERVATION", 17, 25]]], ["Isolated bacteria were primarily evaluated by colonial morphology, Gram staining, and were finally identified by biochemical reactions and API system.", [["Isolated bacteria", "PROBLEM", 0, 17], ["Gram staining", "TEST", 67, 80], ["bacteria", "OBSERVATION", 9, 17]]], ["S. pneumoniae were differentiated by Optochin sensitivity and Group A streptococcus were identified by bacitracin sensitivity.", [["bacitracin", "CHEMICAL", 103, 113], ["bacitracin", "CHEMICAL", 103, 113], ["S. pneumoniae", "ORGANISM", 0, 13], ["Optochin", "GENE_OR_GENE_PRODUCT", 37, 45], ["Group A streptococcus", "ORGANISM", 62, 83], ["bacitracin", "SIMPLE_CHEMICAL", 103, 113], ["S. pneumoniae", "SPECIES", 0, 13], ["S. pneumoniae", "SPECIES", 0, 13], ["S. pneumoniae", "PROBLEM", 0, 13], ["Optochin sensitivity", "TEST", 37, 57], ["Group A streptococcus", "PROBLEM", 62, 83], ["bacitracin sensitivity", "TEST", 103, 125], ["pneumoniae", "OBSERVATION", 3, 13]]], ["P. aeruginosa and K. pneumoniae were identified by API 20E.", [["API 20E", "CHEMICAL", 51, 58], ["P. aeruginosa", "ORGANISM", 0, 13], ["K. pneumoniae", "ORGANISM", 18, 31], ["P. aeruginosa", "SPECIES", 0, 13], ["K. pneumoniae", "SPECIES", 18, 31], ["P. aeruginosa", "SPECIES", 0, 13], ["K. pneumoniae", "SPECIES", 18, 31], ["P. aeruginosa", "PROBLEM", 0, 13], ["K. pneumoniae", "PROBLEM", 18, 31], ["pneumoniae", "OBSERVATION", 21, 31]]], ["H. influenzae, S. aureus were differentiated by API HN, API Staph respectively.Statistical analysis ::: MethodsThe collected data were analyzed through SPSS version 19.0.", [["H. influenzae", "ORGANISM", 0, 13], ["S. aureus", "ORGANISM", 15, 24], ["H. influenzae", "SPECIES", 0, 13], ["S. aureus", "SPECIES", 15, 24], ["H. influenzae", "SPECIES", 0, 13], ["S. aureus", "SPECIES", 15, 24], ["H. influenzae", "PROBLEM", 0, 13], ["S. aureus", "PROBLEM", 15, 24], ["API Staph", "TEST", 56, 65], ["Methods", "TREATMENT", 104, 111], ["The collected data", "TEST", 111, 129], ["SPSS version", "TEST", 152, 164], ["aureus", "OBSERVATION", 18, 24]]], ["Descriptive statistics were done in the form of means, frequencies and ranges of the variables.", [["Descriptive statistics", "TEST", 0, 22]]], ["Categorical variables such as age groups and their associations with proportions of certain pathogens were analyzed using the chi-square test or the Fisher\u2019s exact test.", [["Categorical variables", "PROBLEM", 0, 21], ["certain pathogens", "PROBLEM", 84, 101], ["the chi-square test", "TEST", 122, 141]]], ["Significant differences, associations and interrelationships of the variables were assessed at a level of P < 0.05.Profile of enrolled patients ::: ResultsThe median age of the patients was 9 months (ranged from 1 days to 6 years old), with 54% of patients under 1 year of age.", [["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 177, 185], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 177, 185], ["patients", "SPECIES", 248, 256], ["Significant differences", "PROBLEM", 0, 23]]], ["Of 1992 enrolled children, 1185 were boys and 807 were girls (gender ratio of 1.47: 1).", [["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["boys", "SPECIES", 37, 41], ["girls", "SPECIES", 55, 60]]], ["Cough was found in 1354 (68.0%) of the children, followed by fever (51.9%, 1033) and expectoration (29.0%, 578).", [["Cough", "DISEASE", 0, 5], ["fever", "DISEASE", 61, 66], ["expectoration", "DISEASE", 85, 98], ["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["Cough", "PROBLEM", 0, 5], ["fever", "PROBLEM", 61, 66], ["expectoration", "TEST", 85, 98]]], ["52.5% (1045/1992) of the patients were diagnosed with pneumonia by chest X-ray.", [["pneumonia", "DISEASE", 54, 63], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["pneumonia", "PROBLEM", 54, 63], ["chest X-ray", "TEST", 67, 78], ["pneumonia", "OBSERVATION", 54, 63], ["chest", "ANATOMY", 67, 72]]], ["Among all the cases, 9 children died during the study period, including 8 boys and 1 girl.Results of pathogen analysis ::: ResultsRespiratory viruses were analyzed in 1764 samples.", [["samples", "ANATOMY", 172, 179], ["children", "ORGANISM", 23, 31], ["girl", "ORGANISM", 85, 89], ["children", "SPECIES", 23, 31], ["boys", "SPECIES", 74, 78], ["girl", "SPECIES", 85, 89], ["pathogen analysis", "TEST", 101, 118], ["ResultsRespiratory viruses", "PROBLEM", 123, 149]]], ["HRV testing was added in 2012 and HRV was analyzed in 795 samples.", [["samples", "ANATOMY", 58, 65], ["HRV testing", "TEST", 0, 11], ["HRV", "TEST", 34, 37]]], ["One or more respiratory viruses were identified in 51.0% of the patients (Table 1).", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["more respiratory viruses", "PROBLEM", 7, 31], ["respiratory viruses", "OBSERVATION", 12, 31]]], ["HRV (23.0%, 183/795) and RSV (22.7%, 401/1764) were the most commonly identified viruses in hospitalized children, followed by PIV (13.4%, 236/1764), HBoV (8.4%, 149/1764) and ADV (6.2%, 110/1764).", [["HBoV", "DISEASE", 150, 154], ["ADV", "CHEMICAL", 176, 179], ["RSV", "ORGANISM", 25, 28], ["children", "ORGANISM", 105, 113], ["HBoV", "ORGANISM", 150, 154], ["children", "SPECIES", 105, 113], ["RSV", "SPECIES", 25, 28], ["HBoV", "SPECIES", 150, 154], ["ADV", "SPECIES", 176, 179], ["HRV", "TEST", 0, 3], ["RSV", "TEST", 25, 28], ["PIV", "TEST", 127, 130], ["HBoV", "TEST", 150, 154], ["ADV", "TEST", 176, 179], ["viruses", "OBSERVATION", 81, 88]]], ["Other viruses such as IFV (4.4%), HMPV (2.2%) and HCoV (0.6%) were identified in small proportions.", [["IFV", "GENE_OR_GENE_PRODUCT", 22, 25], ["HMPV", "ORGANISM", 34, 38], ["HCoV", "CANCER", 50, 54], ["IFV", "SPECIES", 22, 25], ["HMPV", "SPECIES", 34, 38], ["HCoV", "SPECIES", 50, 54], ["Other viruses", "PROBLEM", 0, 13], ["IFV", "TEST", 22, 25], ["HMPV", "TEST", 34, 38], ["HCoV", "TEST", 50, 54], ["viruses", "OBSERVATION", 6, 13], ["small proportions", "OBSERVATION", 81, 98]]], ["Multiple viral combinations in samples were found, including 223 dual, 37 triple and 3 quadruple combinations.", [["samples", "ANATOMY", 31, 38], ["samples", "CANCER", 31, 38], ["Multiple viral combinations", "PROBLEM", 0, 27], ["triple and 3 quadruple combinations", "TREATMENT", 74, 109], ["viral combinations", "OBSERVATION", 9, 27]]], ["Common combinations are listed in Table 2.Results of pathogen analysis ::: ResultsSix respiratory bacteria were analyzed among 1816 samples.", [["samples", "ANATOMY", 132, 139], ["pathogen analysis", "TEST", 53, 70], ["ResultsSix respiratory bacteria", "PROBLEM", 75, 106]]], ["One or more respiratory bacteria were identified in 26.2% (475/1816) of the patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["more respiratory bacteria", "PROBLEM", 7, 32], ["respiratory bacteria", "OBSERVATION", 12, 32]]], ["The most commonly detected bacteria were K. pneumoniae (11.5%, 209/1816), S. pneumoniae (9.5%, 173/1816) and S. aureus (4.0%, 73/1816), followed by H. influenzae (2.5%), P. aeruginosa (1.9%), and Group A streptococcus (0.4%).", [["K. pneumoniae", "DISEASE", 41, 54], ["S. pneumoniae", "DISEASE", 74, 87], ["S. aureus", "DISEASE", 109, 118], ["H. influenzae", "DISEASE", 148, 161], ["P. aeruginosa", "DISEASE", 170, 183], ["K. pneumoniae", "ORGANISM", 41, 54], ["S. pneumoniae", "ORGANISM", 74, 87], ["S. aureus", "ORGANISM", 109, 118], ["H. influenzae", "ORGANISM", 148, 161], ["P. aeruginosa", "ORGANISM", 170, 183], ["Group A streptococcus", "ORGANISM", 196, 217], ["K. pneumoniae", "SPECIES", 41, 54], ["S. pneumoniae", "SPECIES", 74, 87], ["S. aureus", "SPECIES", 109, 118], ["H. influenzae", "SPECIES", 148, 161], ["P. aeruginosa", "SPECIES", 170, 183], ["A streptococcus", "SPECIES", 202, 217], ["K. pneumoniae", "SPECIES", 41, 54], ["S. pneumoniae", "SPECIES", 74, 87], ["S. aureus", "SPECIES", 109, 118], ["H. influenzae", "SPECIES", 148, 161], ["P. aeruginosa", "SPECIES", 170, 183], ["Group A streptococcus", "SPECIES", 196, 217], ["bacteria", "PROBLEM", 27, 35], ["K. pneumoniae", "TEST", 41, 54], ["S. pneumoniae", "TEST", 74, 87], ["S. aureus", "TEST", 109, 118], ["H. influenzae", "TEST", 148, 161], ["P. aeruginosa", "TEST", 170, 183], ["Group A streptococcus", "TREATMENT", 196, 217], ["bacteria", "OBSERVATION", 27, 35], ["pneumoniae", "OBSERVATION", 77, 87], ["aureus", "OBSERVATION", 112, 118]]], ["Multiple bacterial combinations in samples were found, including 52 dual and 8 triple bacterial combinations.", [["samples", "ANATOMY", 35, 42], ["samples", "CANCER", 35, 42], ["Multiple bacterial combinations in samples", "PROBLEM", 0, 42], ["8 triple bacterial combinations", "TREATMENT", 77, 108], ["bacterial combinations", "OBSERVATION", 9, 31]]], ["K. pneumoniae/S. pneumoniae co-infection was the most frequent combination.", [["K", "CHEMICAL", 0, 1], ["S. pneumoniae co-infection", "DISEASE", 14, 40], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["pneumoniae", "ORGANISM", 3, 13], ["S. pneumoniae", "ORGANISM", 14, 27], ["pneumoniae", "SPECIES", 3, 13], ["S. pneumoniae", "SPECIES", 14, 27], ["pneumoniae", "SPECIES", 3, 13], ["S. pneumoniae", "SPECIES", 14, 27], ["K", "TEST", 0, 1], ["pneumoniae", "PROBLEM", 3, 13], ["S. pneumoniae co-infection", "PROBLEM", 14, 40], ["pneumoniae", "OBSERVATION_MODIFIER", 17, 27], ["co-infection", "OBSERVATION", 28, 40]]], ["Eight viruses and 6 bacteria were tested in 1728 samples, among which 883 (51.1%) were identified with at least one respiratory pathogen.", [["samples", "ANATOMY", 49, 56], ["Eight viruses", "PROBLEM", 0, 13], ["6 bacteria", "TEST", 18, 28], ["one respiratory pathogen", "PROBLEM", 112, 136], ["viruses", "OBSERVATION", 6, 13], ["respiratory pathogen", "OBSERVATION", 116, 136]]], ["240 (27.2%, 240/883) were viral/bacterial combination among positive cases.Results of pathogen analysis ::: ResultsAmong 9 death cases, 6 patients were identified with at least 1 respiratory pathogen, including 2 boys with single virus (IFV, HRV respectively), 2 boys with dual virus (PIV/HRV, PIV/HBoV respectively), 1 boy with triple virus (RSV/PIV/HRV) and 1 girl with both virus and bacteria (PIV/S.pneumoniae).", [["death", "DISEASE", 123, 128], ["patients", "ORGANISM", 138, 146], ["HBoV", "ORGANISM", 298, 302], ["boy", "ORGANISM", 320, 323], ["triple virus", "ORGANISM", 329, 341], ["RSV", "ORGANISM", 343, 346], ["girl", "ORGANISM", 362, 366], ["patients", "SPECIES", 138, 146], ["boys", "SPECIES", 213, 217], ["boys", "SPECIES", 263, 267], ["boy", "SPECIES", 320, 323], ["RSV", "SPECIES", 343, 346], ["girl", "SPECIES", 362, 366], ["IFV", "SPECIES", 237, 240], ["PIV", "SPECIES", 285, 288], ["HRV", "SPECIES", 289, 292], ["HBoV", "SPECIES", 298, 302], ["RSV", "SPECIES", 343, 346], ["PIV", "SPECIES", 347, 350], ["HRV", "SPECIES", 351, 354], ["viral/bacterial combination among positive cases", "PROBLEM", 26, 74], ["pathogen analysis", "TEST", 86, 103], ["1 respiratory pathogen", "PROBLEM", 177, 199], ["single virus", "PROBLEM", 223, 235], ["dual virus (PIV/HRV", "TREATMENT", 273, 292], ["PIV/HBoV", "TREATMENT", 294, 302], ["triple virus", "PROBLEM", 329, 341], ["RSV/PIV/HRV", "TREATMENT", 343, 354], ["both virus", "PROBLEM", 372, 382], ["bacteria", "PROBLEM", 387, 395], ["PIV/S.pneumoniae", "TREATMENT", 397, 413], ["respiratory", "ANATOMY", 179, 190], ["pathogen", "OBSERVATION", 191, 199], ["bacteria", "OBSERVATION", 387, 395]]], ["None of the pathogens was identified in the rest of 3 boys.Respiratory pathogens and clinical characteristics ::: ResultsA univariate analysis was conducted to find associations between demographic and clinical characteristics with infection (Table 3).", [["infection", "DISEASE", 232, 241], ["boys", "SPECIES", 54, 58], ["the pathogens", "PROBLEM", 8, 21], ["Respiratory pathogens", "PROBLEM", 59, 80], ["ResultsA univariate analysis", "TEST", 114, 142], ["infection", "PROBLEM", 232, 241], ["pathogens", "OBSERVATION", 12, 21], ["infection", "OBSERVATION", 232, 241]]], ["Infants tended to have a higher proportion of virus infection than older children (P < 0.001), with those from 6 to 12 months of age having the highest proportion (67.4%) (P < 0.001).", [["infection", "DISEASE", 52, 61], ["Infants", "ORGANISM", 0, 7], ["children", "ORGANISM", 73, 81], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 73, 81], ["virus infection", "PROBLEM", 46, 61], ["virus", "OBSERVATION", 46, 51]]], ["Infants identified with viruses had higher proportion of fever (P < 0.001), cough (P < 0.001), runny nose (P = 0.007), expectoration (P < 0.001) and diarrhea (P = 0.031) than infants that were not.", [["fever", "DISEASE", 57, 62], ["(P < 0.001), cough (P < 0.001), runny nose (P = 0.007), expectoration (P < 0.001) and diarrhea", "DISEASE", 63, 157], ["Infants", "ORGANISM", 0, 7], ["infants", "ORGANISM", 175, 182], ["Infants", "SPECIES", 0, 7], ["infants", "SPECIES", 175, 182], ["viruses", "PROBLEM", 24, 31], ["fever", "PROBLEM", 57, 62], ["cough", "PROBLEM", 76, 81], ["runny nose", "PROBLEM", 95, 105], ["P", "TEST", 107, 108], ["expectoration", "PROBLEM", 119, 132], ["diarrhea", "PROBLEM", 149, 157], ["viruses", "OBSERVATION", 24, 31]]], ["Older children with viral infections had a higher proportion of tachypnea (P = 0.007) than younger children (less than 1 year of age).", [["viral infections", "DISEASE", 20, 36], ["tachypnea", "DISEASE", 64, 73], ["children", "ORGANISM", 6, 14], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 6, 14], ["children", "SPECIES", 99, 107], ["viral infections", "PROBLEM", 20, 36], ["tachypnea", "PROBLEM", 64, 73], ["viral", "OBSERVATION_MODIFIER", 20, 25], ["infections", "OBSERVATION", 26, 36]]], ["In the virus-positive group, infants with viral co-infections had a significantly higher proportion of tachypnea (P = 0.033) than that with single viral infections.Respiratory pathogens and clinical characteristics ::: ResultsDemographic and clinical features for each analyzed respiratory virus were also examined.", [["viral co-infections", "DISEASE", 42, 61], ["tachypnea", "DISEASE", 103, 112], ["viral infections", "DISEASE", 147, 163], ["infants", "ORGANISM", 29, 36], ["infants", "SPECIES", 29, 36], ["viral co-infections", "PROBLEM", 42, 61], ["tachypnea", "PROBLEM", 103, 112], ["single viral infections", "PROBLEM", 140, 163], ["Respiratory pathogens", "PROBLEM", 164, 185], ["each analyzed respiratory virus", "PROBLEM", 264, 295], ["positive group", "OBSERVATION_MODIFIER", 13, 27], ["tachypnea", "OBSERVATION", 103, 112], ["viral", "OBSERVATION_MODIFIER", 147, 152], ["infections", "OBSERVATION", 153, 163], ["respiratory virus", "OBSERVATION", 278, 295]]], ["PIV and ADV were usually recognized in children aged from 6 to 12 months, whereas HBoV was mostly found in 1 to 3 years group, while HRV was found in all age groups (Table 1).", [["HBoV", "DISEASE", 82, 86], ["ADV", "ORGANISM", 8, 11], ["children", "ORGANISM", 39, 47], ["HBoV", "ORGANISM", 82, 86], ["children", "SPECIES", 39, 47], ["PIV", "SPECIES", 0, 3], ["ADV", "SPECIES", 8, 11], ["HBoV", "SPECIES", 82, 86], ["PIV", "TREATMENT", 0, 3], ["ADV", "TREATMENT", 8, 11], ["HBoV", "PROBLEM", 82, 86]]], ["PIV was associated with fever, cough and expectoration while HRV with cough, expectoration and diarrhea (Data not shown).Respiratory pathogens and clinical characteristics ::: ResultsAmong children tested for respiratory bacteria, older children had higher proportion of bacterial infections than infants (P = 0.010).", [["fever", "DISEASE", 24, 29], ["cough", "DISEASE", 31, 36], ["expectoration", "DISEASE", 41, 54], ["cough", "DISEASE", 70, 75], ["expectoration", "DISEASE", 77, 90], ["diarrhea", "DISEASE", 95, 103], ["bacterial infections", "DISEASE", 271, 291], ["children", "ORGANISM", 189, 197], ["children", "ORGANISM", 237, 245], ["infants", "ORGANISM", 297, 304], ["children", "SPECIES", 189, 197], ["children", "SPECIES", 237, 245], ["infants", "SPECIES", 297, 304], ["PIV", "SPECIES", 0, 3], ["PIV", "TREATMENT", 0, 3], ["fever", "PROBLEM", 24, 29], ["cough", "PROBLEM", 31, 36], ["expectoration", "PROBLEM", 41, 54], ["cough", "PROBLEM", 70, 75], ["expectoration", "PROBLEM", 77, 90], ["diarrhea", "PROBLEM", 95, 103], ["Respiratory pathogens", "PROBLEM", 121, 142], ["respiratory bacteria", "PROBLEM", 209, 229], ["bacterial infections", "PROBLEM", 271, 291], ["fever", "OBSERVATION", 24, 29], ["cough", "OBSERVATION", 31, 36], ["bacterial", "OBSERVATION_MODIFIER", 271, 280], ["infections", "OBSERVATION", 281, 291]]], ["K. pneumoniae was usually detected in infants and S. pneumoniae, H. influenzae were more common in older children.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["pneumoniae", "ORGANISM", 3, 13], ["infants", "ORGANISM", 38, 45], ["S. pneumoniae", "ORGANISM", 50, 63], ["H. influenzae", "ORGANISM", 65, 78], ["children", "ORGANISM", 105, 113], ["pneumoniae", "SPECIES", 3, 13], ["infants", "SPECIES", 38, 45], ["S. pneumoniae", "SPECIES", 50, 63], ["H. influenzae", "SPECIES", 65, 78], ["children", "SPECIES", 105, 113], ["pneumoniae", "SPECIES", 3, 13], ["S. pneumoniae", "SPECIES", 50, 63], ["H. influenzae", "SPECIES", 65, 78], ["K", "TEST", 0, 1], ["pneumoniae", "PROBLEM", 3, 13], ["S. pneumoniae", "PROBLEM", 50, 63], ["H. influenzae", "PROBLEM", 65, 78], ["pneumoniae", "OBSERVATION", 53, 63]]], ["Infants with bacterial infections had higher proportion of cough (P < 0.001) and expectoration (P = 0.048).Respiratory pathogens and clinical characteristics ::: ResultsAmong 1728 children (with complete viral and bacterial workups), infants identified with any pathogen (Table 4) had higher proportions of fever (P < 0.001), cough (P < 0.001), runny nose (P = 0.011), expectoration (P < 0.001) and diarrhea (P = 0.009) than infants that were not.", [["bacterial infections", "DISEASE", 13, 33], ["cough (P < 0.001) and expectoration", "DISEASE", 59, 94], ["fever", "DISEASE", 307, 312], ["cough", "DISEASE", 326, 331], ["runny nose (P = 0.011), expectoration (P < 0.001) and diarrhea", "DISEASE", 345, 407], ["Infants", "ORGANISM", 0, 7], ["children", "ORGANISM", 180, 188], ["infants", "ORGANISM", 234, 241], ["infants", "ORGANISM", 425, 432], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 180, 188], ["infants", "SPECIES", 234, 241], ["infants", "SPECIES", 425, 432], ["bacterial infections", "PROBLEM", 13, 33], ["cough", "PROBLEM", 59, 64], ["expectoration", "PROBLEM", 81, 94], ["Respiratory pathogens", "PROBLEM", 107, 128], ["bacterial workups", "TEST", 214, 231], ["fever", "PROBLEM", 307, 312], ["cough", "PROBLEM", 326, 331], ["runny nose", "PROBLEM", 345, 355], ["P", "TEST", 357, 358], ["expectoration", "PROBLEM", 369, 382], ["diarrhea", "PROBLEM", 399, 407], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["infections", "OBSERVATION", 23, 33], ["cough", "OBSERVATION", 59, 64]]], ["Pathogen-positive older children had a higher proportion of chest pain (P = 0.037).", [["chest", "ANATOMY", 60, 65], ["chest pain", "DISEASE", 60, 70], ["children", "ORGANISM", 24, 32], ["chest", "ORGANISM_SUBDIVISION", 60, 65], ["children", "SPECIES", 24, 32], ["chest pain", "PROBLEM", 60, 70], ["chest", "ANATOMY", 60, 65]]], ["In the pathogen positive group, infants with viral/bacterial co-infection had significantly higher proportions of cough (P = 0.007) and tachypnea (P = 0.025).Respiratory pathogens and clinical characteristics ::: ResultsConsidering diagnoses and etiology, pneumonia was taken into consideration.", [["viral/bacterial co-infection", "DISEASE", 45, 73], ["cough", "DISEASE", 114, 119], ["tachypnea", "DISEASE", 136, 145], ["pneumonia", "DISEASE", 256, 265], ["infants", "ORGANISM", 32, 39], ["infants", "SPECIES", 32, 39], ["viral/bacterial co-infection", "PROBLEM", 45, 73], ["cough", "PROBLEM", 114, 119], ["P", "TEST", 121, 122], ["tachypnea", "PROBLEM", 136, 145], ["Respiratory pathogens", "PROBLEM", 158, 179], ["pneumonia", "PROBLEM", 256, 265], ["bacterial co-infection", "OBSERVATION", 51, 73], ["cough", "OBSERVATION", 114, 119], ["pneumonia", "OBSERVATION", 256, 265]]], ["Older children had significantly higher proportion of pneumonia (P < 0.001) than infants, with the highest rate observed in children 1 to 3 years of age.", [["pneumonia", "DISEASE", 54, 63], ["children", "ORGANISM", 6, 14], ["infants", "ORGANISM", 81, 88], ["children", "ORGANISM", 124, 132], ["children", "SPECIES", 6, 14], ["infants", "SPECIES", 81, 88], ["children", "SPECIES", 124, 132], ["pneumonia", "PROBLEM", 54, 63], ["pneumonia", "OBSERVATION", 54, 63]]], ["Infants identified with bacterial had a higher proportion of pneumonia than older children, and S. aureus (P = 0.004) and S. pneumonia (P = 0.009) were associated with pneumonia.Seasonal distributions ::: ResultsSeasonal distributions of respiratory pathogens were estimated by admission dates for the included children.", [["pneumonia", "DISEASE", 61, 70], ["pneumonia", "DISEASE", 125, 134], ["pneumonia", "DISEASE", 168, 177], ["Infants", "ORGANISM", 0, 7], ["children", "ORGANISM", 82, 90], ["S. aureus", "ORGANISM", 96, 105], ["children", "ORGANISM", 311, 319], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 82, 90], ["S. aureus", "SPECIES", 96, 105], ["S. pneumonia", "SPECIES", 122, 134], ["children", "SPECIES", 311, 319], ["S. aureus", "SPECIES", 96, 105], ["bacterial", "PROBLEM", 24, 33], ["pneumonia", "PROBLEM", 61, 70], ["S. aureus", "PROBLEM", 96, 105], ["S. pneumonia", "PROBLEM", 122, 134], ["pneumonia", "PROBLEM", 168, 177], ["respiratory pathogens", "PROBLEM", 238, 259], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["pneumonia", "OBSERVATION", 61, 70], ["aureus", "OBSERVATION", 99, 105], ["pneumonia", "OBSERVATION", 125, 134], ["pneumonia", "OBSERVATION", 168, 177], ["respiratory pathogens", "OBSERVATION", 238, 259]]], ["The seasonal detection rates ranged from 7.4 to 79.7% with a mean rate of 49.5%.", [["The seasonal detection rates", "TEST", 0, 28], ["a mean rate", "TEST", 59, 70]]], ["Overall, viral infections were more likely to occur in winter months (December to February) with a decline in summer months (June to August) (Fig. 1).", [["viral infections", "DISEASE", 9, 25], ["viral infections", "PROBLEM", 9, 25], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["infections", "OBSERVATION", 15, 25]]], ["The same distribution was observed for ADV (Fig. 2).", [["ADV", "SPECIES", 39, 42]]], ["PIV and HRV were detected all year, with their detection peaks often in autumn.", [["PIV", "SPECIES", 0, 3], ["PIV", "TREATMENT", 0, 3], ["HRV", "TEST", 8, 11]]], ["HBoV infections showed a peak in the summer season of 2010 and 2012.", [["HBoV infections", "DISEASE", 0, 15], ["HBoV", "ORGANISM", 0, 4], ["HBoV", "SPECIES", 0, 4], ["HBoV infections", "PROBLEM", 0, 15], ["infections", "OBSERVATION", 5, 15], ["peak", "OBSERVATION_MODIFIER", 25, 29]]], ["No regular seasonal variations with IFV and HPMV were observed during the study period.DiscussionTo the best of our knowledge, this study is the first study to investigate the role of 8 respiratory viruses and 6 respiratory bacteria in ARIs among hospitalized children in Chengdu district, west China over a 5-year period.", [["respiratory viruses", "DISEASE", 186, 205], ["ARIs", "DISEASE", 236, 240], ["children", "ORGANISM", 260, 268], ["children", "SPECIES", 260, 268], ["IFV", "SPECIES", 36, 39], ["HPMV", "SPECIES", 44, 48], ["IFV and HPMV", "TREATMENT", 36, 48], ["the study", "TEST", 70, 79], ["this study", "TEST", 127, 137], ["the first study", "TEST", 141, 156], ["8 respiratory viruses", "PROBLEM", 184, 205], ["6 respiratory bacteria", "PROBLEM", 210, 232], ["regular", "OBSERVATION_MODIFIER", 3, 10], ["seasonal variations", "OBSERVATION", 11, 30], ["IFV", "OBSERVATION", 36, 39]]], ["Therefore, these findings may be useful nationally and internationally equally.DiscussionThe results confirmed a frequent viral etiology among 51% of children aged < 6 years presenting ARIs.", [["ARIs", "DISEASE", 185, 189], ["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["may be", "UNCERTAINTY", 26, 32]]], ["A review of studies on positive proportions of respiratory viruses among patients with ARIs in different parts of China, such as Beijing [14] Shanghai [11], Shenzhen [12], Wuhan [21], Lanzhou [22], indicated high variability.", [["respiratory viruses", "DISEASE", 47, 66], ["ARIs", "DISEASE", 87, 91], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["A review of studies", "TEST", 0, 19], ["respiratory viruses", "PROBLEM", 47, 66], ["ARIs", "PROBLEM", 87, 91], ["respiratory viruses", "OBSERVATION", 47, 66], ["high variability", "OBSERVATION", 208, 224]]], ["Different incidences may be attributed to different age groups, samples collected, inclusion criteria, diagnostic methods, target pathogens and seasonality.DiscussionIFV, RSV, HPMV and HRV were the most commonly detected viruses in most regions.", [["RSV", "ORGANISM", 171, 174], ["RSV", "SPECIES", 171, 174], ["HPMV", "SPECIES", 176, 180], ["diagnostic methods", "TEST", 103, 121], ["target pathogens", "PROBLEM", 123, 139], ["RSV", "PROBLEM", 171, 174], ["HPMV", "TEST", 176, 180], ["HRV", "PROBLEM", 185, 188], ["may be attributed to", "UNCERTAINTY", 21, 41], ["viruses", "OBSERVATION", 221, 228]]], ["HRV and RSV were equally predominant in our study period.", [["RSV", "ORGANISM", 8, 11], ["RSV", "SPECIES", 8, 11], ["HRV", "TEST", 0, 3], ["RSV", "PROBLEM", 8, 11], ["RSV", "OBSERVATION", 8, 11], ["predominant", "OBSERVATION_MODIFIER", 25, 36]]], ["RSV is a major respiratory virus that causes respiratory illness including bronchiolitis, pneumonia, and wheezing [23].", [["respiratory", "ANATOMY", 45, 56], ["RSV", "DISEASE", 0, 3], ["respiratory illness", "DISEASE", 45, 64], ["bronchiolitis", "DISEASE", 75, 88], ["pneumonia", "DISEASE", 90, 99], ["wheezing", "DISEASE", 105, 113], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["a major respiratory virus", "PROBLEM", 7, 32], ["respiratory illness", "PROBLEM", 45, 64], ["bronchiolitis", "PROBLEM", 75, 88], ["pneumonia", "PROBLEM", 90, 99], ["wheezing", "PROBLEM", 105, 113], ["respiratory virus", "OBSERVATION", 15, 32], ["respiratory illness", "OBSERVATION", 45, 64], ["bronchiolitis", "OBSERVATION", 75, 88], ["pneumonia", "OBSERVATION", 90, 99]]], ["RSV may bring about annual epidemics worldwide because of virus variability [24].", [["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["virus variability", "PROBLEM", 58, 75]]], ["It is reported that RSV epidemic was associated with the alternate circulation of multiple genotypes and with the change of G protein [25].", [["RSV", "DISEASE", 20, 23], ["RSV", "ORGANISM", 20, 23], ["G protein [25]", "GENE_OR_GENE_PRODUCT", 124, 138], ["G protein", "PROTEIN", 124, 133], ["RSV", "SPECIES", 20, 23], ["RSV epidemic", "PROBLEM", 20, 32], ["multiple genotypes", "PROBLEM", 82, 100], ["RSV", "OBSERVATION", 20, 23]]], ["HRV are usually associated with upper respiratory tract infections and are responsible for one half of all \u201ccommon colds\u201d [26].", [["upper respiratory tract", "ANATOMY", 32, 55], ["upper respiratory tract infections", "DISEASE", 32, 66], ["colds", "DISEASE", 115, 120], ["upper", "ORGANISM_SUBDIVISION", 32, 37], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["HRV", "PROBLEM", 0, 3], ["upper respiratory tract infections", "PROBLEM", 32, 66], ["usually associated with", "UNCERTAINTY", 8, 31], ["upper", "ANATOMY_MODIFIER", 32, 37], ["respiratory tract", "ANATOMY", 38, 55], ["infections", "OBSERVATION", 56, 66]]], ["The implementation of molecular methods has revealed HRV as an etiologic agent in lower respiratory tract infections (LRTI), associated with recurrent wheezing and asthma in infancy [26, 27].DiscussionClinical presentations of respiratory infections may be overlapping and could not discriminate between respiratory viruses.", [["lower respiratory tract", "ANATOMY", 82, 105], ["respiratory", "ANATOMY", 227, 238], ["lower respiratory tract infections", "DISEASE", 82, 116], ["LRTI", "DISEASE", 118, 122], ["wheezing", "DISEASE", 151, 159], ["asthma", "DISEASE", 164, 170], ["respiratory infections", "DISEASE", 227, 249], ["respiratory viruses", "DISEASE", 304, 323], ["lower respiratory", "ORGANISM_SUBDIVISION", 82, 99], ["tract", "ORGANISM_SUBDIVISION", 100, 105], ["molecular methods", "TEST", 22, 39], ["HRV", "PROBLEM", 53, 56], ["lower respiratory tract infections", "PROBLEM", 82, 116], ["recurrent wheezing", "PROBLEM", 141, 159], ["asthma", "PROBLEM", 164, 170], ["respiratory infections", "PROBLEM", 227, 249], ["respiratory viruses", "PROBLEM", 304, 323], ["lower", "ANATOMY_MODIFIER", 82, 87], ["respiratory tract", "ANATOMY", 88, 105], ["recurrent", "OBSERVATION_MODIFIER", 141, 150], ["wheezing", "OBSERVATION", 151, 159], ["asthma", "OBSERVATION", 164, 170], ["respiratory", "ANATOMY", 227, 238], ["infections", "OBSERVATION", 239, 249], ["viruses", "OBSERVATION", 316, 323]]], ["However, infants identified with respiratory virus tended to have more severe symptoms, particularly those in the 7\u201312 months of age group.", [["infants", "ORGANISM", 9, 16], ["infants", "SPECIES", 9, 16], ["respiratory virus", "PROBLEM", 33, 50], ["more severe symptoms", "PROBLEM", 66, 86]]], ["Age and exposure were two crucial factors for infection [8].", [["infection", "DISEASE", 46, 55], ["infection", "PROBLEM", 46, 55]]], ["Immune status of infants is different from adults, and the amount of maternal antibodies attenuate distinctly, which would make infants susceptible to respiratory viral infections.", [["respiratory viral infections", "DISEASE", 151, 179], ["infants", "ORGANISM", 17, 24], ["infants", "ORGANISM", 128, 135], ["maternal antibodies", "PROTEIN", 69, 88], ["infants", "SPECIES", 17, 24], ["infants", "SPECIES", 128, 135], ["maternal antibodies attenuate", "PROBLEM", 69, 98], ["respiratory viral infections", "PROBLEM", 151, 179], ["viral infections", "OBSERVATION", 163, 179]]], ["The onset of disease is an interplay of immune pathology and viral pathology and prevention measures need to be taken into account [28].DiscussionIt has been suggested that multiplex PCR techniques demonstrate a high detection rate of viral co-infections [29].", [["viral co-infections", "DISEASE", 235, 254], ["disease", "PROBLEM", 13, 20], ["immune pathology", "PROBLEM", 40, 56], ["viral pathology", "PROBLEM", 61, 76], ["prevention measures", "TREATMENT", 81, 100], ["multiplex PCR techniques", "TEST", 173, 197], ["viral co-infections", "PROBLEM", 235, 254], ["disease", "OBSERVATION", 13, 20]]], ["In this target population, mixed respiratory virus had a proportion of 14.9%, with RSV/PIV the most frequent combination.", [["RSV", "ORGANISM", 83, 86], ["RSV", "SPECIES", 83, 86], ["mixed respiratory virus", "PROBLEM", 27, 50], ["RSV/PIV", "TREATMENT", 83, 90], ["mixed", "OBSERVATION_MODIFIER", 27, 32], ["respiratory virus", "OBSERVATION", 33, 50]]], ["Previous research showed proportions of viral co-infection ranged from 4.0 to 24.7%, with RSV, IFV, HPMV the common viruses present in co-infections.", [["viral co-infection", "DISEASE", 40, 58], ["co-infections", "DISEASE", 135, 148], ["RSV", "ORGANISM", 90, 93], ["RSV", "SPECIES", 90, 93], ["IFV", "SPECIES", 95, 98], ["HPMV", "SPECIES", 100, 104], ["viral co-infection", "PROBLEM", 40, 58], ["RSV", "PROBLEM", 90, 93], ["IFV", "PROBLEM", 95, 98], ["HPMV the common viruses", "PROBLEM", 100, 123], ["co-infections", "PROBLEM", 135, 148], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["co-infection", "OBSERVATION", 46, 58], ["RSV", "OBSERVATION", 90, 93], ["IFV", "OBSERVATION", 95, 98], ["common", "OBSERVATION_MODIFIER", 109, 115], ["viruses", "OBSERVATION", 116, 123], ["co-infections", "OBSERVATION", 135, 148]]], ["Different incidence of co-infection may be due to high single infection rates of certain viruses, overlapping epidemic seasons, target pathogens as well as methodology.", [["co-infection", "DISEASE", 23, 35], ["infection", "DISEASE", 62, 71], ["co-infection", "PROBLEM", 23, 35], ["high single infection rates", "PROBLEM", 50, 77], ["certain viruses", "PROBLEM", 81, 96], ["overlapping epidemic seasons", "PROBLEM", 98, 126], ["target pathogens", "PROBLEM", 128, 144], ["co-infection", "OBSERVATION", 23, 35], ["may be due to", "UNCERTAINTY", 36, 49], ["high", "OBSERVATION_MODIFIER", 50, 54], ["infection", "OBSERVATION", 62, 71], ["epidemic", "OBSERVATION_MODIFIER", 110, 118]]], ["Evidence for increased clinical severity of viral single infections versus co-infections is controversial [30\u201333].", [["viral single infections", "DISEASE", 44, 67], ["co-infections", "DISEASE", 75, 88], ["increased clinical severity", "PROBLEM", 13, 40], ["viral single infections", "PROBLEM", 44, 67], ["co-infections", "PROBLEM", 75, 88], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["single", "OBSERVATION_MODIFIER", 50, 56], ["infections", "OBSERVATION", 57, 67]]], ["The impact of co-infection on clinical presentations may rely on the specific agent involved, as well as viral load [32, 33].", [["co-infection", "DISEASE", 14, 26], ["co-infection", "PROBLEM", 14, 26], ["viral load", "TEST", 105, 115], ["co-infection", "OBSERVATION", 14, 26]]], ["Experimental studies of simultaneous respiratory infections are scarce.", [["respiratory", "ANATOMY", 37, 48], ["respiratory infections", "DISEASE", 37, 59], ["Experimental studies", "TEST", 0, 20], ["simultaneous respiratory infections", "PROBLEM", 24, 59], ["simultaneous", "OBSERVATION_MODIFIER", 24, 36], ["respiratory infections", "OBSERVATION", 37, 59]]], ["However, one study showed by mathematical modeling, found that one virus can block replication of another due to competition for resources, which may have implications for the treatment regimens of simultaneous viral infections [34].DiscussionDespite vaccination, pneumonia still remains a serious public health issue in the world [35].", [["viral infections", "DISEASE", 211, 227], ["pneumonia", "DISEASE", 264, 273], ["one study", "TEST", 9, 18], ["one virus", "PROBLEM", 63, 72], ["the treatment regimens", "TREATMENT", 172, 194], ["simultaneous viral infections", "PROBLEM", 198, 227], ["vaccination", "TREATMENT", 251, 262], ["pneumonia", "PROBLEM", 264, 273], ["pneumonia", "OBSERVATION", 264, 273]]], ["In this study, children > 1 year seemed to suffer more from bacterial infections than younger children.", [["bacterial infections", "DISEASE", 60, 80], ["children", "ORGANISM", 15, 23], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 15, 23], ["children", "SPECIES", 94, 102], ["bacterial infections", "PROBLEM", 60, 80]]], ["The WHO reports that pneumonia is the forgotten killer of children and one of the main disease burdens worldwide [36].", [["pneumonia", "DISEASE", 21, 30], ["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66], ["pneumonia", "PROBLEM", 21, 30], ["pneumonia", "OBSERVATION", 21, 30], ["main", "OBSERVATION_MODIFIER", 82, 86], ["disease", "OBSERVATION", 87, 94]]], ["Pneumonia is the most serious result of ARIs and is often due to bacterial infection [37].", [["Pneumonia", "DISEASE", 0, 9], ["ARIs", "DISEASE", 40, 44], ["bacterial infection", "DISEASE", 65, 84], ["ARIs", "CANCER", 40, 44], ["Pneumonia", "PROBLEM", 0, 9], ["ARIs", "PROBLEM", 40, 44], ["bacterial infection", "PROBLEM", 65, 84], ["most serious", "OBSERVATION_MODIFIER", 17, 29], ["ARIs", "OBSERVATION", 40, 44], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["infection", "OBSERVATION", 75, 84]]], ["S. pneumoniae, H. influenzae type b are the leading causes of bacterial pneumonia in children worldwide [38, 39].", [["H. influenzae type b", "DISEASE", 15, 35], ["bacterial pneumonia", "DISEASE", 62, 81], ["S. pneumoniae", "ORGANISM", 0, 13], ["H. influenzae type b", "ORGANISM", 15, 35], ["children", "ORGANISM", 85, 93], ["S. pneumoniae", "SPECIES", 0, 13], ["H. influenzae", "SPECIES", 15, 28], ["children", "SPECIES", 85, 93], ["S. pneumoniae", "SPECIES", 0, 13], ["H. influenzae", "SPECIES", 15, 28], ["S. pneumoniae", "PROBLEM", 0, 13], ["H. influenzae type b", "PROBLEM", 15, 35], ["bacterial pneumonia", "PROBLEM", 62, 81], ["pneumoniae", "OBSERVATION", 3, 13], ["bacterial", "OBSERVATION_MODIFIER", 62, 71], ["pneumonia", "OBSERVATION", 72, 81]]], ["Under-nutrition, lack of breast-feeding, crowding, exposure to indoor air pollution, low birth weight and diarrhea have been identified as risk factors for pneumonia [40, 41].", [["breast", "ANATOMY", 25, 31], ["birth weight", "DISEASE", 89, 101], ["diarrhea", "DISEASE", 106, 114], ["pneumonia", "DISEASE", 156, 165], ["breast", "ORGANISM_SUBDIVISION", 25, 31], ["crowding", "PROBLEM", 41, 49], ["indoor air pollution", "PROBLEM", 63, 83], ["low birth weight", "PROBLEM", 85, 101], ["diarrhea", "PROBLEM", 106, 114], ["pneumonia", "PROBLEM", 156, 165], ["breast", "ANATOMY", 25, 31], ["pneumonia", "OBSERVATION", 156, 165]]], ["Etiologic studies could provide information on the prevalence of bacterial infections, which may help achieve a reduction in child mortality.DiscussionThe incidence of respiratory viral/bacterial co-infection in young children ranged from 1 to 44% [42].", [["bacterial infections", "DISEASE", 65, 85], ["respiratory viral/bacterial co-infection", "DISEASE", 168, 208], ["children", "ORGANISM", 218, 226], ["children", "SPECIES", 218, 226], ["Etiologic studies", "TEST", 0, 17], ["bacterial infections", "PROBLEM", 65, 85], ["a reduction in child mortality", "PROBLEM", 110, 140], ["respiratory viral/bacterial co-infection", "PROBLEM", 168, 208], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["infections", "OBSERVATION", 75, 85], ["reduction", "OBSERVATION_MODIFIER", 112, 121], ["respiratory", "ANATOMY", 168, 179], ["viral", "OBSERVATION", 180, 185], ["bacterial co-infection", "OBSERVATION", 186, 208]]], ["In the current study, we observed a respiratory viral/bacterial co-infection proportion of 13.9% (240/1728).", [["respiratory viral/bacterial co-infection", "DISEASE", 36, 76], ["the current study", "TEST", 3, 20], ["a respiratory viral/bacterial co-infection proportion", "TEST", 34, 87], ["respiratory", "ANATOMY", 36, 47], ["bacterial co-infection", "OBSERVATION", 54, 76]]], ["S.pneumoniae, S. aureus, H. influenzae and Pseudomonas species were common bacterial co-pathogens.", [["S.pneumoniae", "CHEMICAL", 0, 12], ["S. aureus", "ORGANISM", 14, 23], ["H. influenzae", "ORGANISM", 25, 38], ["Pseudomonas species", "ORGANISM", 43, 62], ["S. aureus", "SPECIES", 14, 23], ["H. influenzae", "SPECIES", 25, 38], ["S. aureus", "SPECIES", 14, 23], ["H. influenzae", "SPECIES", 25, 38], ["S.pneumoniae", "PROBLEM", 0, 12], ["S. aureus", "PROBLEM", 14, 23], ["H. influenzae", "PROBLEM", 25, 38], ["Pseudomonas species", "PROBLEM", 43, 62], ["common bacterial co-pathogens", "PROBLEM", 68, 97], ["aureus", "OBSERVATION", 17, 23], ["influenzae", "OBSERVATION", 28, 38], ["Pseudomonas species", "OBSERVATION", 43, 62], ["bacterial co-pathogens", "OBSERVATION", 75, 97]]], ["Influenza pandemics over the last 100 years have strengthened the association of bacterial super-infection and influenza infection [42, 43].", [["Influenza pandemics", "DISEASE", 0, 19], ["bacterial super-infection", "DISEASE", 81, 106], ["influenza infection", "DISEASE", 111, 130], ["Influenza pandemics", "PROBLEM", 0, 19], ["bacterial super-infection", "PROBLEM", 81, 106], ["influenza infection", "PROBLEM", 111, 130], ["bacterial super", "OBSERVATION_MODIFIER", 81, 96], ["infection", "OBSERVATION", 97, 106]]], ["There are mounting data indicating that virus infection can predispose to bacterial colonization and overgrowth, which adversely affect the pathogenesis of respiratory infections [44, 45].", [["respiratory", "ANATOMY", 156, 167], ["infection", "DISEASE", 46, 55], ["respiratory infections", "DISEASE", 156, 178], ["mounting data", "PROBLEM", 10, 23], ["virus infection", "PROBLEM", 40, 55], ["bacterial colonization", "PROBLEM", 74, 96], ["overgrowth", "PROBLEM", 101, 111], ["respiratory infections", "PROBLEM", 156, 178], ["virus", "OBSERVATION", 40, 45], ["bacterial", "OBSERVATION_MODIFIER", 74, 83], ["colonization", "OBSERVATION", 84, 96], ["overgrowth", "OBSERVATION", 101, 111], ["respiratory", "ANATOMY", 156, 167], ["infections", "OBSERVATION", 168, 178]]], ["Disruption of the epithelial barrier, up regulation of adhesion proteins, production of viral factors and alterations in immune responses are several known mechanisms [44, 45].", [["epithelial barrier", "ANATOMY", 18, 36], ["epithelial barrier", "TISSUE", 18, 36], ["adhesion proteins", "PROTEIN", 55, 72], ["viral factors", "PROTEIN", 88, 101], ["the epithelial barrier", "PROBLEM", 14, 36], ["adhesion proteins", "TREATMENT", 55, 72], ["viral factors", "PROBLEM", 88, 101], ["alterations in immune responses", "PROBLEM", 106, 137], ["epithelial", "ANATOMY_MODIFIER", 18, 28], ["adhesion proteins", "OBSERVATION", 55, 72], ["viral factors", "OBSERVATION", 88, 101]]], ["Increased morbidity with bacterial co-infections was found in children, leading to increased duration of mechanical ventilation, longer hospital stays and admission to pediatric intensive care units [42, 46].", [["bacterial co-infections", "DISEASE", 25, 48], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["Increased morbidity", "PROBLEM", 0, 19], ["bacterial co-infections", "PROBLEM", 25, 48], ["mechanical ventilation", "TREATMENT", 105, 127], ["morbidity", "OBSERVATION", 10, 19], ["bacterial co-infections", "OBSERVATION", 25, 48], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["mechanical ventilation", "OBSERVATION", 105, 127]]], ["However, the statistical association was weak and sporadic in some studies, and additional longitudinal cohort studies may be needed to reveal the contribution of bacterial to viral ARIs.DiscussionThere was a paucity of study that was conducted for etiologies of ARIs among hospitalized children in this area.", [["ARIs", "DISEASE", 263, 267], ["children", "ORGANISM", 287, 295], ["children", "SPECIES", 287, 295], ["weak", "PROBLEM", 41, 45], ["some studies", "TEST", 62, 74], ["additional longitudinal cohort studies", "TEST", 80, 118], ["bacterial to viral ARIs", "PROBLEM", 163, 186], ["study", "TEST", 220, 225], ["ARIs", "PROBLEM", 263, 267], ["bacterial", "OBSERVATION", 163, 172], ["viral ARIs", "OBSERVATION", 176, 186]]], ["Including 14 different respiratory pathogens (both viruses and bacteria), recruiting almost 2000 hospitalized children, over 5-year period, this current study revealed pathogens profiles, co-infection pattern, clinical features, and seasonality among hospitalized children with ARIs in Chengdu, west China.", [["respiratory pathogens", "DISEASE", 23, 44], ["co-infection", "DISEASE", 188, 200], ["ARIs", "DISEASE", 278, 282], ["children", "ORGANISM", 110, 118], ["children", "ORGANISM", 264, 272], ["children", "SPECIES", 110, 118], ["children", "SPECIES", 264, 272], ["14 different respiratory pathogens", "PROBLEM", 10, 44], ["bacteria", "PROBLEM", 63, 71], ["this current study", "TEST", 140, 158], ["pathogens profiles", "PROBLEM", 168, 186], ["co-infection pattern", "PROBLEM", 188, 208], ["ARIs", "PROBLEM", 278, 282], ["14 different", "OBSERVATION_MODIFIER", 10, 22], ["respiratory pathogens", "OBSERVATION", 23, 44]]], ["There are however some limitations in this study.", [["this study", "TEST", 38, 48]]], ["Outpatients were not recruited and the study lacked an asymptomatic control group.", [["the study", "TEST", 35, 44]]], ["Positive rates may be somewhat lower as other potential viral pathogens were not included (e.g. enteroviruses, HCoV NL63 and HKU1).", [["HCoV NL63", "GENE_OR_GENE_PRODUCT", 111, 120], ["HKU1", "GENE_OR_GENE_PRODUCT", 125, 129], ["HKU1", "PROTEIN", 125, 129], ["HCoV", "SPECIES", 111, 115], ["somewhat lower", "PROBLEM", 22, 36], ["viral pathogens", "PROBLEM", 56, 71], ["enteroviruses", "PROBLEM", 96, 109], ["may be", "UNCERTAINTY", 15, 21]]], ["In addition, virus genotyping and strain identification (such as HRV A/B/C) would be helpful for understanding viral epidemics and associated disease severity.ConclusionsIn conclusion, this 5-year consecutive surveillance research confirmed that respiratory viruses, especially RSV and HRV, were the leading potential cause of ARIs in hospitalized children in Chengdu, west China.", [["respiratory viruses", "DISEASE", 246, 265], ["ARIs", "DISEASE", 327, 331], ["RSV", "ORGANISM", 278, 281], ["ARIs", "CANCER", 327, 331], ["children", "ORGANISM", 348, 356], ["RSV", "SPECIES", 278, 281], ["children", "SPECIES", 348, 356], ["RSV", "SPECIES", 278, 281], ["virus genotyping", "TEST", 13, 29], ["strain identification", "TEST", 34, 55], ["HRV A/B/C)", "TEST", 65, 75], ["viral epidemics", "PROBLEM", 111, 126], ["associated disease severity", "PROBLEM", 131, 158], ["consecutive surveillance research", "TEST", 197, 230], ["respiratory viruses", "PROBLEM", 246, 265], ["RSV", "PROBLEM", 278, 281], ["ARIs", "PROBLEM", 327, 331], ["respiratory viruses", "OBSERVATION", 246, 265]]], ["Co-infections were associated with severity of illness in infants, who tended to have increased risks of ARIs.", [["Co-infections", "DISEASE", 0, 13], ["illness", "DISEASE", 47, 54], ["ARIs", "DISEASE", 105, 109], ["infants", "ORGANISM", 58, 65], ["infants", "SPECIES", 58, 65], ["Co-infections", "PROBLEM", 0, 13], ["illness", "PROBLEM", 47, 54], ["ARIs", "PROBLEM", 105, 109]]], ["This study gives us better information on the pathogen profiles, clinical association, co-infection combinations, and seasonal features of ARIs in hospitalized children in this area.", [["co-infection", "DISEASE", 87, 99], ["ARIs", "DISEASE", 139, 143], ["children", "ORGANISM", 160, 168], ["children", "SPECIES", 160, 168], ["This study", "TEST", 0, 10], ["the pathogen profiles", "TEST", 42, 63], ["co-infection combinations", "PROBLEM", 87, 112], ["ARIs", "PROBLEM", 139, 143]]], ["Moreover, future efforts in reducing the impact of ARIs will depend on a commitment to fund and implement programs to utilize available vaccines, especially vaccines on RSV, HRV and S. pneumoniae in in this region, and to develop new vaccines against common pathogens.", [["RSV", "ORGANISM", 169, 172], ["S. pneumoniae", "ORGANISM", 182, 195], ["S. pneumoniae", "SPECIES", 182, 195], ["RSV", "SPECIES", 169, 172], ["HRV", "SPECIES", 174, 177], ["S. pneumoniae", "SPECIES", 182, 195], ["available vaccines", "TREATMENT", 126, 144], ["vaccines", "TREATMENT", 157, 165], ["RSV", "PROBLEM", 169, 172], ["HRV", "PROBLEM", 174, 177], ["S. pneumoniae", "PROBLEM", 182, 195], ["new vaccines", "TREATMENT", 230, 242], ["common pathogens", "PROBLEM", 251, 267], ["pneumoniae", "OBSERVATION", 185, 195]]]], "99fa4397f1db8397a82fcc072f1593ae44a740d1": [["treated/processed leftover food or food-waste (swill feed) from various sources such as households, markets, factories, restaurants, or school canteens, which could contain contaminated pork products.", [["pork", "ORGANISM_SUBDIVISION", 186, 190], ["pork", "SPECIES", 186, 190]]], ["In China and Vietnam, more than 80% of pig farms are small-scale producers with very few large (industrial) farms.", [["pig", "ORGANISM", 39, 42], ["pig", "SPECIES", 39, 42], ["pig", "SPECIES", 39, 42], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["Moreover, the back-yard and industrial farms are frequently found in close proximity to each other.", [["back", "ANATOMY", 14, 18]]], ["This could be the major factor facilitating the faster spread of ASFV in Asian countries when compared with the European countries where wild boars play a major role in disease spread [2, 3] .", [["ASFV", "DISEASE", 65, 69], ["ASFV", "ORGANISM", 65, 69], ["boars", "ORGANISM", 142, 147], ["ASFV", "SPECIES", 65, 69]]]]}